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Abstract
This study set out to improve upon the quality of research addressing variation in cancer
outcomes amongst children and young adults (CYAs) through the novel application of
multiple imputation (MI) to the population based Yorkshire cancer register. The study
also sought to determine whether there were inequalities in disease severity according to
age, ethnicity or deprivation for CYAs with cancer for the first time in the UK and to
quantify cardiovascular late effects amongst survivors of CYA cancer based on a unique
data linkage approach to hospital admission data.
Key survival inequalities for CYAs with central nervous system (CNS) tumours (n=795),
leukaemia (n=912) and germ cell tumours (GCTs) (n=846) between 1990 and 2009 were
identified. Teenagers and young adults (TYA) compared to children across all three
groups and those of non-white and non-Asian ethnicity diagnosed with CNS tumours
had significantly poorer survival. Importantly, these survival inequalities could not
be explained by differences in the stage at diagnosis according to age, ethnicity or
deprivation. Survival rates from CNS tumours and leukaemia continued to improve over
time. These improvements only became evident after using MI to adjust for missingness,
which is often ignored by researchers. Despite no observed improvement for GCTs over
time, the number of advanced stage tumours at diagnosis decreased significantly for this
diagnostic group. For all cancers combined, the long term cardiovascular effects of cancer
exist not only for children, but also for TYAs surviving their cancer.
Continued efforts should be made to ensure equal access to clinical trials and improved
treatment protocols for TYAs. In addition, children as well as TYAs should be monitored
for early signs of cardiovascular disease to maximise cardiovascular health. Finally,
ignoring missing data can result in reduced study power and biased estimates, thus
researchers should strive to use advanced techniques such as MI to account for missing
data.
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1Chapter 1
Introduction
1.1 Motivation
Cancer is predominantly a disease seen in older people, with over a third of all cancer
diagnoses occurring in those aged over 75. In the UK, 40% of males and 37% of females
are expected to develop cancer at some stage during their life, and as such, cancer
has substantial public health implications [8]. Children and young adults (CYAs) with
cancer make up a small proportion of the overall cancer burden, with 0.5% and <1%
of all cancers being diagnosed amongst children and teenagers and young adults (TYAs)
respectively in the UK [5, 9, 10]. Despite being rare, CYA cancer remains an important
focus of research as it is the leading cause of death amongst children, contributing to 21%
of all deaths amongst 0-14 year olds, and TYAs, contributing to 9% and 15% of death
from disease for 15-24 year old males and females respectively [4, 5]. Furthermore, the
potential years of life lost for CYAs is much greater than for adults.
CYAs with cancer are a unique population for a number of reasons, and therefore warrant
research specifically focused on this population. Firstly, the types of cancer diagnosed
amongst CYAs differ substantially from adult cancers. Secondly, the clinical behaviour is
such that CYA cancers tend to grow more rapidly, but are also found to respond better to
chemotherapy than adult cancers [9]. Due to its rarity, the pathway to diagnosis for CYA
cancer tends to differ substantially than for adults. Presenting symptoms can be vague
and attributable to a range of different health issues, and in addition, a GP is likely to
encounter just one new case of CYA cancer once every 20 years [11, 12, 13].
Although cancer is the leading cause of death for CYAs, a high proportion of those
diagnosed with cancer survive more than 5-years (current figures range from 78% to
85% for children and TYAs [4, 5, 14]). This is in contrast to adults; 54% of whom
are said to survive beyond 5-years of diagnosis [15]. As the population of long term
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survivors increases, however, there is a growing concern over the risk of serious co-
morbidities experienced later in life as a result of intensive treatments received for cancer
[16]. Furthermore, results from a European wide study between 1995 and 2002 showed
that UK cancer survival for children was poorer than the European average (78% and
81% 5-year survival respectively) [17]. The same study also showed a difference for TYA
survival (85% and 87.5% for the UK and Europe respectively). Continued disparities in
survival across Europe are said to be due to late stage at presentation [18, 19, 20] which
could indicate delayed diagnosis and inequalities in access to healthcare.
The NHS outcomes framework, originally developed in 2010 and updated on a yearly
basis, highlights the importance of timely epidemiological research and reporting of
outcomes to improve the quality of care across all areas of the NHS [21]. Improving
survival and patient outcomes for cancer in the UK is a key priority across all age groups,
as evidenced by the Improving Outcomes: A Strategy for Cancer report [22] which sets
out the aim of saving an additional 5000 lives every year by 2015. The NHS outcomes
framework emphasizes the need for preventing premature mortality and reducing the
potential years of life lost. Following recommendations from the Children and Young
People’s Health Outcomes Forum [23], the NHS outcomes framework specifically
highlighted the need to focus on survival from childhood cancer for the first time in 2013,
by the introduction of a health indicator for 5-year survival from all cancers in children
under the age of 15 years. However, importantly, the report does not specify the need for
a similar indicator for teenagers and young adults (TYAs) with cancer, despite the TYA
population facing similar challenges as the childhood population.
The purpose of this research project was to improve upon the quality of information
available on cancer outcomes amongst CYAs within Yorkshire. The accuracy of
the conclusions drawn from such an analysis depend on the quality of data and
appropriateness of statistical techniques used. The problem of missing data is common
within health services research. Within cancer registration, the stage of the disease at
diagnosis is often poorly recorded, and as a result it is often not taken into account
when analysing survival patterns of cancer, despite it being a key prognostic factor.
Furthermore, historically in the UK, cancer registry data on ethnic group has not been
routinely, or accurately, collected, despite evidence from the US that childhood cancer
survival varies according to ethnic group based on detailed ethnic information held by
the Surveillance Epidemiology and End Results (SEER) cancer registries (for example,
in Kadan-Lottick et al. [24] and Linabery and Ross [25]). There are several available
methods for handling missing data within epidemiological research, including advanced
techniques such as imputation via the expectation maximization algorithm, multiple
imputation and inverse probability weighting. Despite this availability, these techniques
are not routinely used within medical research.
1. INTRODUCTION 3
1.2 Summary of Aims and Objectives
This project has 4 key aims:
1. To improve upon the quality of information available on cancer outcomes
amongst CYAs within Yorkshire.
Existing methods for handling missing data were researched, and the method(s)
which minimised bias and made most efficient use of the available data were applied
to data on CYAs with cancer. An assessment of the extent that missing data affects
the results and conclusions within the analysis was also determined.
2. To describe variation in cancer survival amongst CYAs within Yorkshire.
Variation in survival according to diagnostic group, disease severity, gender, year of
diagnosis, ethnicity and socioeconomic status was described for CYAs with cancer
in Yorkshire.
3. To describe variation in disease severity at presentation for CYAs with cancer
in Yorkshire.
The variation in disease severity at diagnosis was quantified for CYAs with cancer
in Yorkshire. In particular, potential inequalities in disease severity according to
deprivation, ethnicity and age were explored whilst adjusting for gender and year
of diagnosis.
4. To describe the long term health effects of treatment for long term survivors
of cancer amongst CYAs in Yorkshire.
The incidence and risk of long term health effects of treatment for long term
survivors of cancer were described using population-based cancer registry data
linked with national administrative data on hospital admissions.
1.3 Thesis Outline
To provide background information to the work presented in this thesis, Chapter 2
contains a critical review of the current literature on CYA cancer outcomes and provides
the evidence base for this thesis highlighting key gaps in the current literature. Chapter
3 contains a critical review of missing data techniques and the use of these methods
within the current literature inform the choice of missing data methods used throughout
this thesis to reflect aim 1 as listed above. The specific methods used throughout the
thesis are defined in Chapter 4 followed by detailed descriptive analysis of the cohort in
Chapter 5. The main results of the project are presented in three chapters focusing on
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variation in cancer survival (Chapter 6), inequalities in disease severity (Chapter 7) and
long term effects amongst survivors of cancer (Chapter 8) to achieve aims 2, 3 and 4 of
this study respectively. These results are then discussed in Chapter 9, highlighting the
main contributions of this work in the context of previous research and policy as well as
a discussion of the strengths and limitations and recommendations for future work.
5Chapter 2
Background and Epidemiology
2.1 Introduction
The aim of this chapter is to provide background information on cancer registration
processes and structures in the UK and describe the importance of such registration
systems for epidemiological research. This section will also include information on
the classification and staging of cancers in general as well as specific classification and
staging of childhood and young adult (CYA) cancers in addition to a discussion of missing
data problems within cancer registration.
Following this background information, the current literature and knowledge of CYA
cancer epidemiology is critically reviewed, focusing on variation in survival of CYA
cancer according to diagnostic group, age at diagnosis, gender, temporal changes, stage
at diagnosis, ethnicity, deprivation and geographical trends. The current evidence base
looking at variation in disease severity at diagnosis for CYA cancers is explored according
to ethnicity, deprivation and age at diagnosis, followed by a literature review on longer
term outcomes and co-morbidities for CYA cancer survivors.
Finally, the literature is summarised and key gaps in the knowledge are identified, forming
the basis of the analysis within this thesis.
Chapter 3 will go on to describe how missing data can have an impact upon statistical
analysis and describe in detail the methods which currently exist to deal with missing
data, and which of these methods is most suitable for use in population based research.
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2.2 Cancer Registration
Prior to critically reviewing the literature surrounding CYA cancer epidemiology (§2.3),
cancer registration processes and classifications in the UK are described to provide
relevant background information to the data sources from which the literature arises.
Cancer registration is “the process of maintaining a systematic collection of data on
the occurrence and characteristics of malignant neoplasms and certain non-malignant
tumours” [26]. Cancer registration is important to enable epidemiological research
to describe the degree of access to treatment services as well as for health planning
within a population; furthermore it can be used to identify specific targets for cancer
screening [27]. Cancer registration in England was previously covered by eight regional
registries which were all members of the UK Association of Cancer Registries (UKACR).
These regional registries collected data on all people diagnosed with cancer within their
geographical areas, adhering to a defined minimum dataset which was subsequently
collated into the national cancer registry. As of January 2013, the national registry was
replaced by the Cancer Outcomes Services Dataset (COSD) and the 8 regional registries
were replaced by lead cancer knowledge and information teams (KITs), each of which led
on one or more specific tumour site. The North West KIT is the lead KIT for all cancers
amongst children and TYAs.
2.2.1 Specialist Cancer Registries
In addition to the COSD, there are several specialist registers across the country. These
include the Manchester Childrens Cancer Registry which is the oldest childhood cancer
registry in the UK dating back to 1953, the Northern Region Young Persons’ Malignant
Disease Registry based at the University of Newcastle, dating back to 1968 and the
Yorkshire Specialist Register of Cancer in Children and Young People based at the
University of Leeds, dating back to 1974. The historical data in combination with
continued data collection makes these registers a great resource for large epidemiological
studies in differing parts of the country. These registers differ from the national cancer
register not only due to the level of detailed information they hold in addition to the core
data items such as treatment and relapse data, but also because cases are followed up for
a number of years making survival analysis a possibility.
The primary data source for this PhD is the Yorkshire Specialist Register of Cancer in
Children and Young People (the Yorkshire register from here on in). The Yorkshire
register is a regional population based register of cancer in CYAs. The register contains
detailed demographic and clinical information on children (0-14 years) diagnosed with
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cancer in Yorkshire since 1974. In 1998 the register expanded to include young adults
aged between 15 and 29 years, and data were retrospectively collected for cases diagnosed
since 1990 and prospectively from 1998. In 2006, there was a further expansion to include
all cases diagnosed in the current Yorkshire and Humber Strategic Health Authority which
previously did not include South Yorkshire. All cancer diagnoses on the Yorkshire register
are classified according to the International Classification of Childhood Cancer (ICCC)
[7] and cases are followed up every two years to determine whether or not they have
survived, have received any subsequent treatment, or if they have experienced any relapses
or secondary tumours. The core aim of the register is to conduct timely epidemiological
research examining patterns and causes of cancer amongst this cohort of under 30 year
olds in Yorkshire.
2.2.2 Classification of Cancer
Cancer is a term used to describe a collection of diseases which arise from mutated cells
exhibiting abnormal cell growth and division. A mass of tumour can form as a result
of abnormal cell behaviour, for example, if the cells do not die when they should or if
new cells grow unnecessarily. Tumours that do not spread around the body are known
as benign tumours, and although they can cause complications such as putting pressure
on other body organs, these are not cancerous. Malignant tumours, or neoplasms, are
those made up of cancerous cells that can spread to, and destroy, nearby tissues as well as
invade other body parts [28, 29]. Cancers that invade other organs or body parts are said
to have metastasised. There are over 200 types of cells in the human body; and as a result
there are over 200 different types of cancer [15].
Typically, cancers can be classified according to the primary tumour site, for example,
if bladder cancer metastasises to the lung, it will still be referred to as bladder cancer.
However, more accurately, the International Classification of Diseases for Oncology,
Third Edition (ICD-O-3), classifies cancer according to the primary site (topography)
and the type of tissue in which the cancer originated (morphology or histology) [30].
ICD-O-3 is an internationally recognised classification scheme used for coding tumours
in cancer registries and is widely used for cancers occurring in adults. However, the
types of cancer observed amongst CYAs differ substantially from those amongst adults.
These differences are described further in §2.3. Two classification schemes for children
and TYAs respectively were designed to group tumours according to their histological
similarities and reflect the common tumour groups observed amongst both age groups.
The ICCC was developed in 1996 to classify tumours amongst children according to their
histological similarities, as opposed to the site based scheme used for adult malignancies.
It has since been updated to its 3rd revision (ICCC-3) [7]. These histological groupings
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are a better reflection of the range of tumours more commonly seen amongst children.
The ICCC-3 contains 12 main diagnostic groups as shown below. The full classification
system is provided in Appendix A.
I. Leukaemia
II. Lymphoma and reticuloendothelial neoplasms
III. CNS and miscellaneous intracranial and intraspinal neoplasms
IV. Neuroblastoma
V. Retinoblastoma
VI. Renal tumours
VII. Hepatic tumours
VIII. Malignant bone tumours
IX. Soft tissue sarcomas
X. Germ-cell, trophoblastic and other gonadal neoplasms
XI. Carcinomas and other malignant epithelial neoplasms
XII. Other and unspecified malignant neoplasms
The Birch TYA Classification Scheme [31] was specifically designed for grouping cancers
which occur amongst TYAs. These malignancies tend to differ from tumours amongst
adults, and despite some similarities, also differ from childhood tumours (§2.3). The
Birch TYA Classification Scheme defines 10 main diagnostic groups as outlined below.
The full classification system is provided in Appendix B.
Group 1: Leukaemias
Group 2: Lymphomas
Group 3: CNS and other intracranial and intraspinal neoplasms
Group 4: Osseous and chondromatous neoplasms, Ewing sarcoma and other neoplasms
of bone.
Group 5: Soft tissue sarcomas
Group 6: Germ cell and trophoblastic neoplasms
Group 7: Melanoma and skin carcinoma
Group 8: Carcinomas
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Group 9: Miscellaneous neoplasms not elsewhere classified
Group 10: Unspecified malignant neoplasms not elsewhere classified
The Birch TYA classification scheme is similar to the ICCC with a focus on tumour
histology rather than tumour site. The slight differences in categories reflect those
tumours that are more common amongst TYAs compared to children, for example,
melanomas and carcinomas form separate groups within the Birch TYA Classification
as they are the second and third most common cancers amongst TYAs, however, amongst
children, melanomas and carcinomas are much less common. Due to TYAs bridging the
gap between childhood and adulthood, a mixture of childhood and adult cancers are seen
within this group.
2.2.3 Staging Mechanisms
Staging of cancer is an important concept in the classification of tumours. The stage
of a tumour defines the extent of the cancer and in general includes the location of the
primary tumour, the size of the tumour, whether or not cancer has spread to lymph nodes
and the presence or absence of metastases (the spread of the tumour to other body parts
or organs). The stage determines the management of the tumour, for example whether
surgery is appropriate or whether the patient is suitable for clinical trial enrollment. It
also determines prognosis and allows researchers to study relatively homogeneous tumour
groups. For the majority of tumours, staging mechanisms including the above elements
of size and spread, are easily defined. The tumour node metastasis (TNM) staging system
is used worldwide to classify stage of disease in terms of the primary tumour (T), whether
regional lymph nodes are affected (N) and whether or not the tumour has metastasized
(M). Although other staging mechanisms exist, TNM staging is said to be the most
clinically useful [32]. This staging mechanism was first created in the 1940s, and is now
maintained by the American Joint Committee on Cancer (AJCC) and the International
Union for Cancer Control. The TNM staging system constitutes multiple algorithms
specific to tumours of a particular anatomic site and histology. Once the TNM categories
have been determined, this information is then used to classify the tumour into a grouped
stage which generally ranges from stage I to stage IV. Table 2.1 gives an example of the
TNM staging mechanism for soft tissue sarcomas (STS), which additionally includes a G
code for the grade of the tumour. The grade of a tumour in this context refers to the degree
of differentiation of the tumour. The degree of differentiation refers to the similarity of
the cancer cells to normal cells, therefore, a well differentiated tumour is made up of cells
which are similar to normal cells (low grade) and a poorly differentiated tumour means
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the cells are less like normal cells (high grade). Table 2.2 shows how these individual
parts of the staging mechanism are grouped into a combined stage for STS.
Table 2.1: TNM Staging Definitions: Soft Tissue Sarcomas
Primary Tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour 5cm or less in greatest dimension
- T1a - Superficial tumour
- T1b - Deep tumour
T2 Tumour more than 5cm in greatest dimension
- T2a - Superficial tumour
- T2b - Deep tumour
Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph nodes
N1 Regional lymph node metastasis
Histologic Grade (G)
GX Grade cannot be assessed
G1 Grade 1
G2 Grade 2
G3 Grade 3
Table 2.2: Prognostic Groups based on TNM Staging: Soft Tissue Sarcomas
Grouped Primary Regional Lymph Distant Histologic
Stage Tumour (T) Nodes (N) Metastasis (M) Grade (G)
Stage IA
T1a N0 M0 G1, GX
T1b N0 M0 G1, GX
Stage IB
T2a N0 M0 G1, GX
T2b N0 M0 G1, GX
Stage IIA
T1a N0 M0 G2, G3
T1b N0 M0 G2, G3
Stage IIB
T2a N0 M0 G2
T2b N0 M0 G2
Stage III
T2a, T2b N0 M0 G3
Any T N1 M0 Any G
Stage IV Any T Any N M1 Any G
Due to the nature of some cancers, any of the T, N and M values may not be relevant
and sometimes alternative or additional measurements are required to stage a tumour. A
TNM staging algorithm exists for cancers of almost all sites and histology, however, the
AJCC staging manual does not include staging of CYA cancers specifically. As explained
further in §2.3.1, CYA cancers are vastly different from adult cancers. Furthermore, for
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some common CYA cancers, such as leukaemia and brain tumours, the size and spread are
not logical concepts and other measures of prognosis are required. For example, although
brain tumours can spread to other parts of the central nervous system (CNS) they do not
tend to spread to other organs. However, the growth of a brain tumour can have important
implications as it can put pressure on parts of the brain and potentially damage brain
function. Therefore, the WHO grade of a tumour is often used as a prognostic factor
instead of its stage [6]. A detailed exploration of staging mechanisms for all CYA cancers
is given in Chapter 5 alongside the descriptive data analysis.
2.2.4 Missing Data in Cancer Registration
This section focuses specifically upon the issue of missing data within cancer registration.
The statistical implications of missing data are discussed in Chapter 3. The Department of
Health’s Cancer Reform Strategy (CRS) highlighted the importance of the collection and
use of high quality data on cancer outcomes and survival to improve patient choice and
service quality. The CRS emphasizes that although there has been some improvement in
overall data collection, information on staging and co-morbidities, radiotherapy activity
and chemotherapy delivery is not consistently recorded across the UK [33]. Both the
2010 National Audit Office report on delivering the CRS and the Department of Health’s
‘Improving Outcomes: A Strategy for Cancer’ report of 2011 highlighted that incomplete
and inconsistent data on stage of disease at the time of diagnosis remains a key gap in
cancer intelligence [1, 22]. These data are not only vital for accurate analysis of cancer
outcomes across differing populations but also enables improved understanding of the
number of patients who are diagnosed late and whether this is an issue amongst particular
subgroups of patients [32].
As described in §2.2.3, the staging of a tumour is not a simple algorithm that can be
applied to all cancers, and the complicated nature of staging mechanisms has played
a large role in the missing data problem. Individual tumours require different staging
mechanisms, and some tumours, in particular amongst CYAs, do not have clearly defined
staging mechanisms. Poor understanding of these mechanisms can lead to a poor
translation of what is contained in the medical notes to cancer registry databases. For
example, in some cases, medical notes may contain data about the metastases of a tumour
which may imply directly that the tumour is stage IV, without explicitly stating the
stage. Therefore, missing data on stage can vary depending on the level of knowledge
and experience of the person responsible for collecting such data. The national cancer
intelligence network (NCIN) has identified a need to educate non-medical staff involved
in collecting and using cancer registry data within their report in 2009 [34]. Despite the
recognition of these issues by large national organisations, missing data of stage within
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cancer registries is still a large problem. Data from the NCIN shows that missing stage
data in the former regional English cancer registries ranged from around 30% to 85% in
2007 (Figure 2.1).
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Figure 2.1: Missing Stage Data in English Cancer Registries, 2007. Figure adapted from
Morse [1]
Another area of concern within cancer registration is missing data on ethnicity. Many
health outcomes, including cancer survival, are subject to inequalities based on ethnicity.
Complete and accurate information on ethnicity therefore plays an important role in health
services research. Historically, ethnicity data within the NHS has been both inaccurate
and incomplete as highlighted by the NCIN’s 2009 report on cancer incidence and survival
by major ethnic group [35]. NHS data sets such as hospital episode statistics (HES) data
contain multiple records per patient which can result in one person being assigned several
different ethnicities. Further issues in data quality can arise from differences between
ethnicity being determined by a health care professional to those that are self-reported. A
study in the U.S. showed that the level of agreement between administrative data sources
and self-reported ethnic groups could be as low as 15% and varied considerably by ethnic
group (60% for Hispanics, African Americans and Whites, but less than 40% for Asians
and Pacific Islanders) [36]. Several methods for improving the quality of data held on
ethnicity include cross referencing the data with other sources using data linkage methods
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and the use of name analysis programs [37].
2.3 Cancer Epidemiology
Cancer accounted for 7.6 million deaths in 2008, making it the leading cause of death
worldwide. Worldwide deaths from cancer are predicted to rise to over 11 million by
2030, with the most common types being lung, stomach, liver, colorectal and breast cancer
[38]. In the UK, incidence of cancer is higher amongst adult males than females, with the
European age standardised rate of all cancers combined being 417 and 366 per 100,000
for males and females respectively in 2008. The most common types of cancers in the
UK are breast, lung, colorectal and prostate cancer which account for over half of the
UKs cancer burden [15]. The prognosis of cancer in adults varies hugely according to the
type of cancer. For example, 5-year survival for people diagnosed with cancer in England
between 2003 and 2007 was 83.3% for women with breast cancer, 7.3% and 8.7% for
men and women respectively with lung cancer, 50.9% and 52.6% for men and women
respectively with colorectal cancer and 79.7% for men with prostate cancer [39]. The
variation in outcomes observed between different cancers is a reflection of the fact that
cancer is not one single disease but many.
2.3.1 Childhood and Young Adult Cancer
Children and TYAs with cancer form a distinct population from adults with cancer
due to a number of factors as outlined below. However, firstly, it is important to
define the childhood and TYA age range, which varies across the UK and worldwide.
The epidemiological definition of childhood cancer has been relatively consistent and
generally includes children diagnosed under the age of 15 (0-14 years inclusive). This age
range was adopted consistently by the former National Registry of Childhood Tumours
as well as in the European wide Automated Childhood Cancer Information System
(ACCIS) and EUROCARE projects [14, 17, 40]. Although this definition is used in cancer
epidemiology, it has been criticised as merely an arbitrary cut off which does not relate
to clinical aspects of cancer [41] and does not reflect the legal upper age boundary for
children which includes anyone up to the age of 16, or the World Health Organization
(WHO) definition which considers a child as an individual under 18 years of age. Age
boundaries and definitions are even less clearly defined for TYAs with cancer, and there
is a lot of variation in age limits between study groups within the UK, Europe and the
U.S.. TYAs were defined as those aged between 15-24 by large scale projects such as
the European wide EUROCARE-4 study [17], the NCIN report on survival of TYAs with
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cancer in the UK [42] and the NICE guidance on improving outcomes for children and
young people with cancer [43]. This age boundary is said to reflect clinical services and
bridges the gap between childhood and adult services, a TYA specific principal treatment
centres include patients up to the age of 25. However, many of the cancers common to
TYAs are still observed amongst older TYAs aged between 25 and 29, and as such the
upper age boundary could be feasibly extended to young adults as old as 29 [42, 43].
Several UK based studies, including Birch et al. [44] and Geraci et al. [45], define TYAs
as between the ages of 13 and 24, and the same authors also published data on TYAs
with cancer aged between 13 and 29 [46]. Individuals up to the age of 30 have also been
included in studies of cancer epidemiology in the U.S. [47] and those up to the age of 39
have been included in the definition of TYAs for two other U.S. studies [48, 49] as well as
in the UK TYA Cancer Survivor Study. Although justifications for age boundaries have
been provided, it can be argued that most of these age limits are arbitrary cut off points
as with childhood cancer definitions. The main data source for this thesis is the Yorkshire
register which contains data on cases of cancer up to the age of 30, and as such, TYAs for
the purposes of the analysis within this thesis will include those diagnosed between the
ages of 15 and 29 in line with several previous studies as highlighted above. In addition,
this age range provides equal 15-year age intervals for comparing children (0-14 years) to
TYAs (15-29 years).
The primary reason for CYAs with cancer being distinct from adults with cancer is
the distribution and type of cancers observed amongst CYAs. The most common
childhood cancers within the UK, in terms of their incidence rate per million person years
(IR/mpyears) are leukaemia (41/mpyears), CNS tumours (28/mpyears) and lymphomas
(11/mpyears) [10, 50]. For TYAs in England, lymphoma (45/mpyears), carcinoma
(31/mpyears) and germ cell tumours (GCTs) (25/mpyears) are most common [51]. The
percentage of cases for all diagnostic groups for children and TYAs are shown in Figure
2.2. Secondly, the incidence of CYA cancer is very rare compared to that of adults, as
childhood cancers account for less than 0.5% of cancers in the UK [9, 10] and TYA cancer
makes up less than 1% of cancers at all ages in the UK [5]. Despite being rare, cancer is
the leading cause of death for children with almost 21% of deaths in this age group being
attributed to cancer [4]. For TYAs cancer is the leading cause of death from disease,
contributing to 9% and 15% of deaths for 15-24 year old males and females respectively
[5]. Nonetheless, survival rates amongst CYAs are much higher in general compared to
that seen in adults, with almost 80% and over 80% of children and TYAs respectively
becoming long term survivors compared to only 54% of adults surviving cancer more
than 5 years [4, 5, 14] (§2.3.2 provides detailed information about CYA cancer survival).
Finally, CYA cancers also differ from adult cancers in terms of their clinical behaviour as
CYA cancers tend to grow much more rapidly, but also respond better to chemotherapy
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treatment when compared to adult tumours [9].
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Figure 2.2: Percentage of cancer diagnoses for (a) 0-14 year olds by diagnostic group
for diagnoses between 2001 and 2005 (Data Source: [2]) and (b) 15-24 year olds by
diagnostic group for diagnoses between 2005 and 2008 (Data Source: [3])
2.3.2 Survival
The literature on survival of CYA cancer in the UK between 1980 and 2014 was critically
reviewed to determine what is already known about variation in cancer survival amongst
CYAs. Full details of the search terms used are given in Appendix C. The search returned
1276 papers up until 2014 and a review of titles and abstracts resulted in final number of 18
papers assessing survival of CYA cancer in the UK, Britain or England [42, 44, 45, 52, 53,
54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66]. Variation in survival patterns according
to diagnostic group, age at diagnosis, sex, temporal trends, stage at diagnosis, deprivation
and ethnicity were evaluated focusing primarily on information contained within the 18
papers identified, however, additional reference was made to books including Little [9],
Stiller [14] and Estlin et al. [67], in addition to grey literature from websites containing
national statistics on CYA cancer which have not always been published in peer reviewed
journals [2, 4, 5]. In addition, publications on adult cancers and studies from outside of
the UK have been cited where appropriate for comparison.
2.3.2.1 Diagnostic Group
Changes and improvements in diagnostic tools and treatment protocols have led to overall
improvements in survival of CYA cancer (see §2.3.2.4 for further details). Despite these
improvements, survival varies significantly according to diagnostic group and subtype.
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For children, survival from embryonal CNS tumours (56%), osteosarcoma (54%) and
other glioma (44%) were substantially poorer than average (Figure 2.3). For TYAs,
survival for males with STS (55%), males and females with bone tumours (56%) and
males and females with acute myeloid leukaemia (AML) (58%) had a poorer prognosis
than average for males and females of the same age (Figure 2.4). These data were obtained
from the cancer research UK website and were based on national cancer registry data for
children and TYAs respectively [4, 5]. The data provide a useful overview of survival for
children and TYAs with cancer in the UK. However, the survival estimates are based on
univariable data and as such do not take into account other potentially important factors,
such as year of diagnosis, disease severity, ethnicity or deprivation. Furthermore, the data
covered only a selection of childhood and TYA cancers and were four years out of date
including only diagnoses up to 2005 with a maximum follow up period up until 2010.
The available literature focusing on survival differences among cancer subtypes for each
main ICCC diagnostic group is reviewed below.
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Figure 2.3: Five-year survival rates for selected childhood cancers, Great Britain,
diagnosed during 2001-2005. Data Source: [4]
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Figure 2.4: Five-year relative survival rates for teenage and young adult cancers by
diagnostic group and sex, ages 15-24, UK, 2001-2005. Data Source: [5]
Leukaemia
Leukaemias are cancerous blood cells which originate in the bone marrow and move
into the blood stream. The type of blood forming cell that leukaemia develops from
can be lymphoid or myeloid and it is these cells that determine the type of leukaemia.
ALL (ICCC Ia) is the most common form of childhood leukaemia, making up over
75% of all leukaemias diagnosed in England [2]. Other subtypes of leukaemia include
AML (ICCC Ib) and chronic myeloproliferative diseases (ICCC Ic). Approximately
90% of chronic myeloproliferative diseases are chronic myeloid leukaemias (CML),
and the remaining 10% are chronic myelomonocytic leukaemias [68]. For childhood
leukaemia, ALL is associated with the highest survival with almost 90% surviving at
least 5-years [4]. Survival for AML is much poorer compared to ALL amongst children
and TYAs, although the gap is much smaller for the latter due to poorer survival rates
of ALL for TYAs compared to children [5, 14]. Very little literature exists on survival
from childhood CML due to its extreme rarity of 8 cases diagnosed per year on average
in England [10], however, Gatta et al. [68] indicates that 1 and 5-year survival from
CML amongst children is 63% and 24% respectively. The large drop off in survival
between 1 and 5-years from diagnosis is due to CML developing much more slowly
compared to other leukaemias such as ALL and AML [68].
Lymphoma
Lymphoma is a type of cancer which evolves from abnormal white blood cells
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(WBC) within the lymph nodes (known as lymphocytes). Two main classifications
of lymphoma are HL and non-Hodgkin’s lymphoma (NHL), these classifications are
made based on the cell types within the tumour. Survival from lymphoma is high for
both HL and NHL amongst children (97% and 79% 5-year survival respectively) and
TYAs (93% and 72% 5-year survival respectively) [44, 63]. For childhood lymphoma,
survival rates of HL and NHL remain high even at 15-year survival (96% and 75%
respectively) [63]. Similar figures for TYAs at 10 and 15-years from diagnosis were
not available.
Central Nervous System Tumours
The most common type of CNS tumour amongst children is astrocytoma, accounting
for approximately 40% of cases. CNS tumour survival varies by diagnostic subgroup,
such that children with astrocytomas, have 81% 5-year survival compared to 67% for
ependymomas, 56% for intracranial and intraspinal embryonal tumours and 44% for
other gliomas [14].
Neuroblastoma
Neuroblastoma is the most common cancer in infancy, with a median age of diagnosis
of 18 months [69]. The oncogene MYCN has been identified as a major independent
prognostic factor [70], with 5-year survival at 85% in infants without the MYCN
amplification, compared to 25% for those with the MYCN amplification [69]. Only
3% of total neuroblastoma cases are diagnosed in children over the age of 10 [69].
Neuroblastoma in older cases has much slower progression and very poor survival
compared to other childhood tumours. Despite poor survival, the MYCN amplification
rarely occurs in tumours diagnosed within this age group. 5-, 10- and 15- year survival
for childhood neuroblastoma was 54%, 52% and 51% respectively for diagnoses
between 1991 and 1996 [63]. More recent results for diagnoses between 2001-2005
show 5-year survival has increased to approximately 65% [2, 64].
Retinoblastoma
Retinoblastoma is cancer of the eye, and is predominantly observed in children under
the age of 5. Children diagnosed with retinoblastoma have the best survival chance
compared to any other childhood cancer in England, with 5-year survival as high as
99% between 2001 and 2005 [2]. Retinoblastoma is extremely rare in TYAs or adults
with only 26 reported cases across the world between 1919 and 2013 [71].
Renal Tumours
The 5-year survival rate for renal tumours amongst children is 84% overall. The Wilm’s
tumour subgroup (also known as nephroblastoma), which accounts for approximately
90% of childhood renal tumours, has 85% 5-year survival [2, 72]. 77% of childhood
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Wilm’s tumours are diagnosed before the age of 5, and 15% are diagnosed before the
age of 1, however, there is no evidence that age is a prognostic factor for Wilm’s
tumours [14, 72]. Survival amongst the Rhabdoid renal tumour subgroup was much
lower compared to Wilm’s tumour, with 10-year survival being 25% [14].
Hepatic Tumours
Hepatic tumours are relatively rare in childhood, contributing to approximately 1.3%
of all childhood cancers. Due to its rarity, very few outcome studies exist focusing
specifically on hepatic tumours. Survival at 5-years for hepatic tumours diagnosed
between 2001 and 2005 was 66% [2].
Malignant Bone Tumours
In adults, bone tumours commonly arise from other tumours which have metastasized
and primary malignant bone tumours are rare amongst this age group. However,
amongst children they are the sixth most common cancer and the third most common
amongst TYAs. Osteosarcoma and Ewing sarcoma are the two most common
types of primary malignant bone tumours amongst CYAs [73]. 5-year survival for
Osteosarcoma and Ewing sarcoma in children was 54% and 64% overall respectively,
however, for tumours which had metastasized, survival was less than 25% [73].
Soft Tissue Sarcomas
STS are a group of cancers which originate from cells in soft tissues such as muscle,
fat, nerves or blood vessels. The most common form of STS amongst CYAs is
rhabdomyosarcoma, which has 5-year survival of just below 65% [2]. Approximately
20% of CYAs diagnosed with STS present with advanced stage tumours which have
metastasized, and survival for this group is less than 25% [74]. The histological subtype
of rhabdomyosarcoma has also been identified as an important prognostic factor, with
alveolar histology being a marker for poorer survival compared to embryonal histology
(73% and 39% 10-year survival respectively) [14, 74].
Germ Cell Tumours and Neoplasms of Gonads
GCTs occur amongst children as well as TYAs, however, it is much more common
for TYAs compared to children [75]. Survival at 5-years for GCTs in Britain is 86%,
however, this high survival was driven by the malignant gonadal GCT subgroup with
a 5-year survival of 96%. 5-year survival was considerably lower for the intracranial
and intraspinal GCT subgroup and the malignant extracranial and extragonadal GCT
subgroup at 79% each [14].
Carcinomas
Carcinomas are cancers which develop from epithelial tissue, it is the most common
form of cancer in adults, however, it is extremely rare amongst children (see Figure
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2.2). This is reflected in the classification of carcinomas in ICCC group XI - ‘Other
malignant epithelial neoplasms and malignant melanomas’. Although, still rare,
carcinomas are more common amongst TYAs than in children. Birch et al. [44]
document 5-year survival for TYAs with carcinomas according to site. The survival
rates were 97% for thyroid carcinoma, 83% for head and neck carcinomas excluding
thyroid carcinoma, 87% for ovarian carcinoma and 80% for cervical carcinoma, 70%
for colorectal carcinoma and 67% for lung carcinoma.
2.3.2.2 Age at Diagnosis
Age has been identified as an important prognostic factor in some but not all CYA
tumours, with varying patterns as described in Table 2.3. Marked improvements in
survival over time have been observed for children (see §2.3.2.4), however, despite
some improvements for TYAs, the survival benefit for this older age group have not
been observed to the same extent. Several papers have assessed variation in survival
according to age for CYAs, however, the literature largely focuses on survival amongst
children [14, 58, 63, 64, 65] separately to that amongst TYAs [44] with no data in the UK
comparing the survival differences between children and TYAs until a recent report by
the NCIN in 2012 [42].
Table 2.3 indicates that increasing age was associated with poorer prognosis for ALL,
AML, HL, NHL, astrocytoma, bone tumours, STS, extragonadal GCTs and breast cancer.
Poorer survival was observed between childhood and TYA age groups (ALL, AML, NHL,
bone tumours, STS and extra gonadal GCTs) as well as within the TYA age range (NHL
and STS). Furthermore, for some diagnostic groups, the evidence of poorer prognosis with
increasing age was restricted to within the TYA age range (astrocytoma, Ewing sarcoma
and breast cancer) and the effect of age for these tumours among children had not been
studied in detail. For ALL, differences according to age are thought to reflect differences
in disease biology, for example, the t[12, 21] translocation seen in 25% of children with B-
cell ALL is much rarer amongst adults and only seen in 3% of cases [76], and TYAs have
a higher ratio of T-cell compared to B-cell ALL compared to children [77, 78]. Despite
improved survival from ALL for children overall compared to TYAs, the age pattern of
prognosis amongst children with ALL is not linear, as those diagnosed under the age of 1
and over the age of 10 have poorer survival compared to those aged 1-9 years [53, 64, 65].
In contrast, survival rates have also been shown to improve with age for some diagnostic
groups (intracranial embryonal tumours, GCTs, intracranial GCTs, CNS tumours and
melanoma) (Table 2.3). For CNS tumours and melanoma, survival for TYAs was
significantly better when compared to children, however, there was no evidence of an
2. BACKGROUND AND EPIDEMIOLOGY 21
effect of age within the childhood or TYA age range for either CNS tumours or melanoma.
For GCTs overall, younger TYAs had poorer survival than older TYAs and evidence for
children was limited to intracranial GCTs which showed that those under the age of 5
had poorer survival compared to 5-14 year olds. However, in contrast, for extragonadal
GCTs, TYAs had poorer survival compared to children as highlighted in the previous
paragraph. Furthermore, age was not a significant predictor of survival for the ovarian
GCT subgroup.
Non-linear relationships with age have been observed for childhood ALL as indicated
above. Further non-linearities were observed for rhabdomyosarcoma, the most common
form of STS amongst children, with those under the age of 1 and over the age of 10 having
poorer survival compared to those aged 1-9. In addition, for neuroblastoma, there was a
sharp decline in survival for 1-4 year olds compared to those diagnosed under the age of
1, and a further, but smaller, decline for those aged 5-14 years old.
Finally, there was evidence to suggest that age was not a prognostic factor for some
diagnostic groups (retinoblastoma, renal tumours and hepatic tumours) obtained from
two national studies of children in Britain [14] and children in the UK [63]. The effect of
age for these tumours is unknown for TYAs. In addition, age was not a prognostic factor
within childhood AML, NHL, CNS tumours and bone tumours despite being identified as
a prognostic factor amongst TYAs and between children and TYAs (Table 2.3).
The age patterns in relation to prognosis were consistent between studies in general,
despite different time periods of study and differences between adjustment for
confounding factors. However, there were some conflicting results for HL. O’Hara
et al. [42] suggested there was no evidence of TYAs having poorer survival compared
to children for HL diagnosed between 2001 and 2005, however, data from two separate
studies indicated that TYAs with HL had a 5-year survival rate of 88% [44], which was
lower than that observed amongst children (98% for 1-9 year olds and 93% for 10-14)
[14]. Although the study by O’Hara et al. [42] only adjusted for age and sex, and did not
include other potentially important confounding factors (for example year of diagnosis,
deprivation, ethnicity or stage), the evidence comparing childhood and TYA survival for
HL was stronger than the individual evidence of childhood survival compared to another
study of TYA survival for several reasons. Firstly, the results from Stiller [14] and [44]
were not directly comparable as they cover different, although overlapping, time periods
(1991-2000 and 1979-2001). Finally, the results from Stiller [14] were unadjusted for
confounders whereas those from Birch et al. [44] were adjusted for age, sex, deprivation
and calendar year, thus again limiting their comparability.
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Table 2.3: Evidence of age as a prognostic factor for children and young adults with
cancer in England
Poorer prognosis with older age Age Survival Summary Reference(s)
Acute lymphoblastic leukaemia 0-14 88% 5yrS [44]
13-16 50% 5yrS [44]
17-20 44% 5yrS [44]
21-24 37% 5yrS [44]
0-14 vs 15-24 HR = 0.22 (0.18-0.28) [42]
Acute myeloid leukaemia 0-14 vs 15-24 HR = 0.71 (0.55-0.92) [42]
Hodgkin’s lymphoma 1-9 98% 5yrS [14]
10-14 93% 5yrS [14]
17-24 88% 5yrS [44]
Non-Hodgkin’s lymphoma 13-16 70% 5yrS [44]
17-20 65% 5yrS [44]
21-24 66% 5yrS [44]
0-14 vs 15-24 HR = 0.66 (0.0.49-0.89) [42]
Astrocytoma 13-16 71% 5yrS [44]
17-20 61% 5yrS [44]
21-24 47% 5yrS [44]
Bone Tumours 0-14 vs 15-24 HR = 0.79 (0.64-0.97) [42]
Ewing Sarcoma 13-16 44% 5yrS [44]
17-20 30% 5yrS [44]
21-24 38% 5yrS [44]
Soft tissue sarcoma 0-14 vs 15-24 HR = 0.79 (0.62-0.99) [42]
17-20 30% 5yrS [44]
21-24 25% 5yrS [44]
Extra gonadal germ cell tumours 0-14 vs 15-24 HR = 0.46 (0.23-0.94) [42]
Breast cancer 13-16 70% 5yrS [44]
21-24 58% 5yrS [44]
Improved prognosis with older age
Intracranial embryonal tumours <4 21% 5yrS [14, 58]
4-14 63% 5yrS [14, 58]
Germ cell tumours 13-16 80% 5yrS [44]
17-20 87% 5yrS [44]
21-24 90% 5yrS [44]
Intracranial germ cell tumours <5 61% 5yrS [14]
5-14 84% 5yrS [14]
Central nervous system tumours 0-14 vs 15-24 HR = 1.49 (1.28-1.77) [42]
Melanoma 0-14 vs 15-24 HR = 2.99 (1.61-5.54) [42]
Non-linear age patterns
Acute lymphoblastic leukaemia <1 vs 1-9 HR = 4.33, P <0.001 [53]
<1 vs 10-14 HR = 2.46, P <0.001 [53]
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10-14 vs 0-9 HR = 1.76 (1.35-2.30) [64]
<1 62.1% deaths [65]
1-9 21.0 % deaths [65]
10-14 40.6% deaths [65]
Rhabdomyosarcoma <1 53%, 66% 5yrS [14, 58]
1-9 72%, 70% 5yrS [14, 58]
10-14 51%, 48% 5yrS [14, 58]
Neuroblastoma <1 83% 5yrS [14]
1-4 46% 5yrS [14]
5-14 37% 5yrS [14]
No effects of age observed
Acute myeloid leukaemia 0-14 - [14, 63]
Retinoblastoma 0-14 - [14, 63]
Renal tumours 0-14 - [14, 63]
Hepatic tumours 0-14 - [14, 63]
Hodgkin’s lymphoma 0-14 vs 15-24 HR = 0.83 (0.50-1.37) [42]
Non-Hodgkin’s lymphoma 0-14 - [14, 63]
Ovarian germ cell tumours 0-14 vs 15-24 HR = 0.30 (0.03-3.38) [42]
Central nervous system tumours 0-14 - [14, 63]
Bone tumours 0-14 - [14, 63]
2.3.2.3 Sex
As with adult cancers, survival from cancer amongst CYAs is generally poorer for males
compared to females, however, associations vary according to diagnostic group. For
childhood ALL, survival was approximately 25% poorer amongst boys compared to girls,
however, this pattern was said to emerge 3 years post diagnosis [63, 65]. Stiller [14]
showed that survival was only poorer for males compared to females with precursor-
cell ALL and not for other immunophenotypes. However, Stiller [14] did not assess
the difference in sex at different time periods. Limited evidence from a European wide
study showed poorer survival for males compared to females with acute non-lymphocytic
leukaemia (ANLL), however this result was not significant [68]. Furthermore, Stiller [14]
and Johnston et al. [63] showed no evidence of a difference in survival between males and
females with AML, which make up 80% of ANLL cases.
Male TYAs with HL have poorer survival compared to females [44], however, there was
no evidence of difference by sex for childhood HL or for NHL amongst children or TYAs.
Amongst children, males with CNS tumours had poorer survival compared to females
[60], however, this effect was reversed for the intracranial embryonal tumour subgroup,
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in which females had a 37% increased risk of death compared to males [63]. Specifically,
Birch et al. [44] have shown that gender does not affect prognosis of CNS tumours
amongst TYAs. For children with neuroblastoma, survival overall was poor but
significantly better for females compared to males (59% and 52% 5-year survival
respectively) [14]. Female TYAs with osteosarcoma had improved survival compared to
males [44], however, no sex differences have been shown for any bone tumour subgroup
amongst children. Male TYAs with head and neck carcinoma and colorectal carcinoma
had poorer survival compared to females, however, no sex differences were observed for
thyroid or lung carcinomas [44].
There was no evidence of an effect of sex on survival for CYA renal or hepatic tumours
in the UK literature.
2.3.2.4 Temporal Trends
Survival of cancer for children improved significantly over time, with overall 5-year
survival for children in Britain having increased from 28% in the late 1960s to 77% in
the period 1996-2000 [14]. For TYAs, improvements over time have not been as great
as seen amongst children, with 5-year relative survival increasing from 63% in the late
1970s compared to 77% in the period 1996-2001 [44, 59]. However, data for TYAs did
not date back as far as the 1960s, therefore potential earlier sharp increases in survival
could not be determined.
National data showed improved survival over time for all diagnostic groups amongst
children, and for all cancers except STS amongst TYAs [14, 44, 45]. Although regional
evidence shows improved survival for TYAs with STS in the north of England (33% in
1968 to 67% in 2008) [64], and in the West Midlands (47% in 1971 to 69% in 2001)
[45]. Furthermore, a study from the south East of England was the only study to show a
decrease in survival for young adults with bone tumours in England (69% between 1968-
1972 to 36.6% between 1998-2002) [61]. This compared to an increase in survival for
children with bone tumours (23% in 1960s to 64% in 1990s) in Britain [14] and a 5%
increase in the North of England (1991-2001) [62]. For TYAs in England, there was a
modest survival improvement for those with osteosarcoma (41% in 1979 to 49% in 2001)
and a larger improvement (29% in 1979 to 46% in 2001) for those with Ewing’s sarcoma
[45].
For childhood leukaemia, survival improved from as low as 9% in the 1960s to 79% in
2000 [14]. The rate of increase for AML was similar to that of leukaemias overall (6% to
65%), and although the rate of increase for ALL was slower, overall survival of ALL was
higher in the latest period (83%) compared to AML. More recent data from the Cancer
2. BACKGROUND AND EPIDEMIOLOGY 25
Research UK website shows that survival from ALL increased further to 88% between
2001 and 2005, but for AML latest survival rates remained at 64% [4]. Improvements in
survival for ALL were likely due to the introduction of more intensive treatment protocols
after the UK medical research council trial in the 1980s [79]. For TYAs, survival from
ALL in England has improved from 41% in the late 1970s to 55% in the period 1996-
2001. For TYAs with AML, survival improved from 30% to 50% in the same period [45].
However, data from Birch et al. [44] showed that improvements were restricted to earlier
time periods (1979-1984 and 1985-1989) with no further survival improvements beyond
then. Despite improvements for both the childhood and TYA age ranges, survival for
TYAs with leukeamia remains poorer compared to children (see §2.3.2.2).
Sharp increases in survival were observed for HL (20% to 90% between 1968 and 1988),
however, little improvement has been observed after this period [64]. For NHL, a similarly
sharp increase in survival was observed ( 23% to 65% between 1978 and 1997), with a
further increase to 83% between 1998 and 2005 [64]. Large improvements in survival of
lymphoma were a result of improved treatment regimens and increased understanding of
tumour biology allowing for treatments to be more specifically targeted to specific tumour
subgroups. For NHL, treatment moved from involved field radiation and combined
chemotherapy which caused acute side effects, to a chemotherapy regimen derived from
a leukaemia treatment protocol [80]. For HL, initial improvements in survival were a
result of the introduction of extended field radiotherapy which involved radiotherapy
being administered to surrounding areas of the affected lymph nodes. For TYAs, survival
from HL was already high at 85% between 1979 and 1984 but improved further to 93%
for the period 1996-2001 [45]. For NHL, survival for TYAs improved from 55% to 71%
in the same respective periods [45]. Similar to trends for leukaemia, Birch et al. [44]
showed that improvements were restricted to earlier time periods (late 1970s and early
1980s) without further improvements beyond then.
Survival for children with CNS tumours improved significantly from 37% to 71% (1969-
2000) [14]. The most recently available data from the period 2001-2005 showed that
survival from CNS tumours amongst children had remained the same at 71% [4]. For
TYAs, survival had improved from 68% to 74% (1979-2001) [44, 45].
For GCTs, survival amongst TYAs has been consistently high, but despite already high
rates, survival has continued improving from 84% in 1979-1984 to 96% between 1996-
2001 [44, 45]. For childhood GCTs, survival was considerably poorer at 45% in the
mid 1970s [4] but latest figures show it to be comparable to TYA survival (92% between
2001-2005) [4].
Large improvements in survival have been made for hepatic tumours amongst children,
which have had historically poor survival (9%, 14% and 30% 5-year survival in the late
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1960s and mid 1970s and 1980s respectively) [14]. Survival increased to its current
rate of 66% in the early 1990’s and has remained the same since then [2]. Treatment
for hepatic tumours historically involved complete resection (removal of the tumour),
however, advances in treatment have improved outcomes as chemotherapy treatment
was introduced to shrink the tumour prior to its removal providing considerably better
prognosis [81, 82, 83].
2.3.2.5 Stage at Diagnosis
By definition, the stage of cancer defines the extent and severity of cancer and therefore
has strong bearing on the patients prognosis. Despite the importance of stage of disease
or other measures of disease severity at diagnosis, many epidemiological studies do not
include such measures within their survival analysis. Of the 18 key references in the UK
describing survival patterns of CYA cancers, the majority did not include measures of
disease severity within their analysis [14, 44, 45, 53, 54, 59, 61, 62, 63, 64, 65, 66]. Tseng
et al. [60] adjusted for WHO Grade as a measure of disease severity for CNS tumours and
Joshi et al. [58] adjusted for stage in their analysis of rhabdomyosarcoma. In addition,
studies by Oakhill and Mann [52], McKinney et al. [55], Powell et al. [57] and Stiller
et al. [56] included WBC count as a measure of disease severity for leukaemia, but the
latter three of these included a range of other childhood cancers in addition to leukaemia
for which disease severity was not studied. Lack of adjustment for the disease severity
implies that results showing differences between age groups, ethnic groups and other
variables could be confounded by casemix, therefore not showing the true effects of these
covariates.
2.3.2.6 Ethnicity
Data on ethnic differences for children and TYAs in England is sparse, with only four
studies of childhood cancer [52, 55, 56, 57] and just one recently published study looking
at breast cancer differences amongst those aged less than 40 years [84]. Amongst
the sparse childhood literature, few consistent patterns of ethnic differences in survival
exist. Powell et al. [57] showed evidence of poorer survival for south Asians with ALL
compared to white children which was similar to earlier findings of a small study (n=60)
in the 1980s using data from UK ALL clinical trials [52]. However, two further studies
[55, 56] showed no significant differences for south Asians with ALL compared to non-
south Asians. Although Stiller et al. [56] did observe a higher risk of death for non-white
children compared to white children with ALL. In the U.S., the overall 5-year cancer
survival rate of Hispanic children (72%) was found to be lower than for white children
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(84%), whilst black children with ALL had poorer survival than white children (75% vs.
85%) [24, 25]. There was some evidence from a UK wide study of poorer survival for
black children diagnosed with neuroblastoma compared to white children, with a hazard
ratio (HR) of 1.79 (P=0.047) [56], however, this analysis did not adjust for confounding
factors such as deprivation.
The four UK based papers were indicative of possible inequalities in survival between
ethnic groups, however the evidence was not convincing or consistent and was largely
restricted to ALL. In particular, comparability between studies was difficult because of
different methods of identifying ethnic groups. The study by Oakhill and Mann [52] was
based on clinical trial data, in which south Asian ethnicity seemed to based on country of
birth (India and Pakistan), although the method of identifying the country of birth was not
clear. Stiller et al. [56] used self reported ethnicity, whereas McKinney et al. [55] used
name analysis to identify south Asian vs. non-south Asian cases. Powell et al. [57] did
not mention the origin of ethnicity data. These differences lead to lack of comparability
as there could be discrepancies in the assignment or classification of ethnicity between
studies. In particular, the name analysis programme was used to identify those of Indian,
Pakistani or Bangladeshi origin, however, it is possible that non-south Asian people have
south Asian names through marriage for example, or vice versa. In addition, there was
no mention of any missing data for Oakhill and Mann [52] and Powell et al. [57], and it
is therefore assumed their analysis was a complete case only analysis, which could have
resulted in biased estimates (see Chapter 3 for further details). Both Stiller et al. [56] and
McKinney et al. [55] treated missing values as separate categories, which is considered
an inadequate method of handling missing data as described in Chapter 3, and the use
of multiple imputation could have improved estimates and may have resulted in different
outcomes.
2.3.2.7 Deprivation
Lightfoot et al. [65] document evidence of a survival gap in ALL according to
socioeconomic status (HR=1.29, 95% CI 1.05-1.57, P=0.034) for the most deprived
compared to least deprived cases. Importantly, this gap has been shown to widen
around 6-9 months post diagnosis, which coincides with the timing of treatment regimens
transferring to less intensive home-administered maintenance chemotherapy. This key
point highlights that the deprivation gap is not as a result of access to health care, and
perhaps explains why differences according to levels of deprivation for childhood cancer
survival have not been observed in earlier studies, [54], unlike those seen in the adult
population [85]. There is little evidence to suggest that survival of AML for children
differs according to socioeconomic status, however, a study in Yorkshire showed that
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deprivation does play a role in AML relapses, such that AML cases from the most
deprived areas were significantly less likely to relapse (OR=0.54, 95% CI=0.32-0.93)
[86].
For TYAs with leukaemia, Birch et al. [44] showed borderline evidence of poorer
survival for those in the most deprived group compared to least deprived (41% vs 45%;
P=0.048). The subgroup analysis revealed this difference was driven by ALL (42% vs
48%; P=0.066), with no differences in survival according to deprivation observed for
AML or CML subgroups. However, the evidence of a deprivation gap in survival for
TYAs with ALL is very weak compared to the evidence amongst children, as the former
difference was small with borderline significance, compared to a larger 30% significant
increase risk of death for more deprived children with ALL.
For lymphoma, there was some evidence that TYAs have poorer survival as deprivation
increased by 25% (95% CI 1.08-1.43) on average [66], however, this study was limited
to the north of England and similar effects were not observed for a larger study of TYAs
across England [44].
For CNS tumours, Tseng et al. [60] found no differences in survival according to
deprivation or region of residence in children in England, unlike amongst the adult group
for which higher socioeconomic status and living in southern England was associated
with better survival. This is in contrast to a study from the Yorkshire region, in which
the authors showed that children with CNS tumours from middle affluence were 62%
more likely to die than those from the most affluent area (P=0.020) [55]. This finding
was confirmed by a later study in the same region, again showing CNS tumour survival
for children from most affluent areas (quintile 1) was significantly worse compared to
survival from those in the 2nd and 4th quintiles of deprivation [12]. In addition, a study
from the North of England provided evidence of poorer survival for children with CNS
tumours from more affluent areas compared with more deprived areas [64]. Overall, the
evidence suggests that those from more affluent areas have poorer survival. However, the
difference has not been consistently shown between the most deprived and most affluent
areas, but instead, the significant difference appears to be between the most affluent and
the middle affluent areas. Furthermore, the evidence to date appears to be limited to the
Yorkshire and north of England region, with no effects observed nationally to date.
For neuroblastoma, a study from Yorkshire by McKinney et al. [55] show a reduced
risk of death from childhood neuroblastoma in the second most affluent deprivation
quintile compared to the most affluent area (HR=0.40, P=0.020). There were no national
studies looking at survival from neuroblastoma in relation to deprivation, thus it is unclear
whether or not this effect is consistently observed amongst other areas of the UK.
2. BACKGROUND AND EPIDEMIOLOGY 29
For TYAs, Birch et al. [44] provides evidence of poorer survival for carcinoma cases in
more deprived areas (69% vs. 73% in the most vs. least deprived areas respectively;
P=0.008). In particular, survival from head and neck carcinomas and colorectal
carcinomas was poorer in more deprived areas [44]. Survival for carcinoma of the thyroid,
lung, ovary and cervix did not vary according to deprivation level [44].
2.3.2.8 Geographical Variation
Differences in survival patterns have been observed within England and the UK and
regional differences in temporal changes in survival for bone tumours have been described
earlier in §2.3.2.4. For children with ALL, some evidence of regional variation in survival
trends have been observed in a national study by Schillinger et al. [54] which covers
diagnoses of ALL in the period 1971-1990. The authors describe that the North and
West NHS region have 5-year survival rates of ALL which are 4% and 7% lower than the
national average respectively. The authors do however make the overall conclusion that
there is no strong evidence of a north/south divide in terms of survival of ALL. For TYAs,
a study across all common cancer groups in England revealed that there was significant
variation in survival by government office region for GCTs, with 5-year survival ranging
from 87% in the south west compared to 95% survival in London [45]. In addition,
significant survival differences by region for colorectal cancer were observed in the same
study, with 5-year survival as low as 41% in the Yorkshire and Humber region compared
to 77% in the east of England. For both GCTs and colorectal cancer, the regional effects
remained significant after adjusting for socioeconomic deprivation per region.
2.3.2.9 Summary of variation in Cancer Survival Rates
Overall, childhood survival in each diagnostic group is well described within the literature
and most studies consistently use the 0-14 year age range making results comparable in
general. The literature portrays a positive message in terms of improvements in survival
over time. Despite certain subgroups having experienced significant improvements
historically, more recent figures show little improvement in the last 5 to 10 years. For
example, while NHL survival continues to improve, HL survival improved drastically in
the mid 1970s to 5-year survival of 90% with little or no improvement documented since
the late 1980s [64]. Large increases in survival were mainly a result of the development of
new treatment regimens and a better understanding of specific diagnostic groups, however,
perhaps the reason for no further improvements beyond those was because improvements
and refinements in treatment protocols were harder to make when survival was already
very high. Nevertheless, there were other diagnostic groups for which prognosis remained
30 2. BACKGROUND AND EPIDEMIOLOGY
poor. For example, survival from bone tumours amongst CYAs was between 50 and 60%,
and that of STS was 65% overall but less than 25% for those diagnosed with advanced
stage tumours.
Despite positive improvements overall, there are still gaps in survival according to gender,
age, deprivation and ethnicity. CYA cancer is more commonly diagnosed amongst males
than females, but survival rates are also poorer in many diagnostic groups for males
compared to females, including leukeamia, gliomas, neuroblastomas and osteosarcomas.
In terms of age, children under the age of 1 have significantly poorer survival of leukaemia
compared to children between 1 and 10 years of age, and the youngest astrocytoma cases
also have a very poor prognosis. Additionally, in general TYAs have poorer survival for
certain tumour groups compared to children. Reasons for TYAs having poorer outcomes
were unclear, however, it could be a result of later diagnosis of cancer amongst this
age group or due to differences in the precise types of tumours which occur in this age
group. In addition, access to effective treatments and clinical trials are also known to be
poorer for TYAs compared to children (19% and 51% of TYAs and children with cancer
respectively were enrolled onto clinical trials in 2006 [87]), which could result in poorer
survival for this age group.
There is strong evidence showing survival differences according to deprivation amongst
adults with cancer across the world [88], with many studies showing poorer survival for
people from more deprived areas for example for breast cancer [89, 90, 91], bowel cancer
[92, 93] and cervical cancer [94]. Similar evidence of differences in survival by ethnic
group [95, 96, 97] have been shown, and the effects of ethnicity and deprivation on health
care were often thought to be highly correlated. Moreover, ethnicity and deprivation have
both been shown to affect the severity of disease at presentation amongst adult cancers
[95, 96, 98, 99, 100, 101]. Section 2.3.2.5 discusses the severity of cancer at diagnosis and
its importance as a prognostic factor, however, inequalities in disease severity amongst
CYAs with cancer are unclear despite evidence of such inequalities amongst adults. For
example, for adult cancers in the U.S., African-American women with breast cancer
and black and Hispanic patients overall have been shown to have a significantly higher
proportion of advanced stage cancers compared to other ethnic groups [102, 103, 104].
However, there has been some suggestion that these differences by ethnic group can be
largely explained by deprivation [105]. In Scotland, poorer survival of breast cancer in
women from more deprived areas was attributed to these women presenting with more
advanced tumours compared to women from less deprived areas [106]. However, a study
in East Anglia concluded that stage only partly accounted for breast cancer survival
differences [98]. A recent study in the U.S. attempted to disentangle the effects of
ethnicity and deprivation on the effect of stage at diagnosis and concluded that ethnicity
was a stronger predictor of stage than socioeconomic status [107]. However, importantly,
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their analysis simply categorised missing data of stage at diagnosis as a separate level
which does not adequately account for missing data and could lead to biased results (as
discussed in Chapter 3).
Amongst CYAs with cancer, inequalities in survival according to deprivation or ethnic
group are less clearly described than for adults, however, results tended to differ between
studies which adjusted for stage or severity of disease at presentation and those that
did not. Tseng et al. [60] showed no difference in survival of childhood CNS tumours
according to deprivation after adjusting for WHO grade, whereas McKinney et al. [55]
showed that children from middle affluent areas in Yorkshire were at an increased
risk of death compared to those from affluent areas, however, data on WHO grade
was not included in this analysis. For leukaemia, Lightfoot et al. [65] showed that
children from more deprived areas had poorer survival with no adjustment for severity of
disease, whereas Schillinger et al. [54] did not observe significant differences according
to socioeconomic status for children with leukaemia. Although Schillinger et al. [54]
also did not adjust for disease severity at presentation, they excluded 10% of cases using
listwise deletion due to missing data, therefore calling into question the accuracy of these
results. In particular, they excluded all cases who were diagnosed on the same day as their
recorded date of death, which may have led to biased results as these were potentially the
cases with most advanced disease at presentation.
In terms of ethnicity, two previous studies have shown no difference in survival of
leukaemia amongst children according to ethnic group [55, 56] whereas Powell et al.
[57] showed that south Asian children with leukaemia had poorer survival compared to
non-south Asian children with the same diagnosis. The evidence of ethnic differences
was restricted to childhood cancers, predominantly focused on leukaemia and was out of
date (only including diagnosis up to the mid 1990s). Furthermore, missing data was not
handled adequately in any of the papers assessing childhood survival by ethnic group as
discussed in §2.3.2.6. The evidence base of ethnic differences for childhood cancers in
the UK is very weak, and for TYAs is limited to one study of breast cancer cases including
TYAs and older adults up to the age of 40 [84].
2.3.3 Long Term Effects Amongst Survivors of Cancer
The previous section on survival of CYA cancer in the UK shows that survival has
improved substantially since the 1960s and 70s and is high in general for children as
well as TYAs. This improvement in survival over time means there is a growing cohort
of long term survivors of childhood and TYA cancers within the UK, and a study of all
cancers in the UK at all ages shows increasing numbers of survivors by a rate of 3%
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per year on average [108]. Due to this increase in survivorship, focus is shifting from
simply improving overall survival towards the quality of that survival and minimising
occurrences of long term side effects of treatment. This is also reflected by the NHS
outcomes framework, which emphasizes the need to focus on reducing the potential years
of life lost [21]. In addition, the improving outcomes guidance for children and young
people [43] highlights that although many CYAs survive cancer, there is a substantial risk
of late effects (LEs) for survivors and therefore an increasing need for this group to be
monitored in long term follow up clinics.
There is a wealth of data on the long term effects amongst survivors of childhood
cancers, which have primarily arisen from two large scale retrospective cohort studies; the
North American Childhood Cancer Survivorship Study (CCSS) and the British Childhood
Cancer Survivorship Study (BCCSS). The CCSS includes cases diagnosed under the age
of 21 with cancer between 1970 and 1986, and the BCCSS includes cases of diagnosed
under the age of 16 between 1940 and 1991. Thus far, 346 publications since the 1980s
have emerged using CCSS and BCCSS data to describe the LEs amongst survivors
of childhood cancer which include an increased risk of second malignant neoplasms,
neurocognitive impairment, cardiotoxicity, fertility problems and psychological effects
[109, 110, 111, 112, 113, 114, 115, 116, 117, 118]. Oeffinger et al. [16] provides evidence
that approximately two-thirds of survivors of childhood cancer are expected to develop at
least one chronic health condition, and almost a third developing a severe, life threatening
or disabling condition. Reasons for this increased risk have largely been attributed to the
intensive treatment protocols which have helped improve overall survival rates of cancer
for CYAs but are also partially thought to be due to specific genetic predisposition [119].
Some specific examples of LEs are described below.
Survivors of childhood leukaemia are said to be at an increased risk of secondary cancers,
cardiovascular conditions, infertility and growth failure [120, 121, 122]. Mody et al. [122]
report that survivors of childhood leukaemia are at a 3-fold increased risk of developing
multiple chronic medical conditions compared to siblings and a 4-fold increased risk of
developing severe and life threatening conditions compared to siblings. The cumulative
incidence of developing a chronic medical condition for survivors of childhood leukaemia
was 13% at 25 years from diagnosis, but was as high as 21% for those who also received
radiation therapy as part of their treatment [122]. Increased exposure to anthracylines
(specific types of chemotherapy drugs) as well as treatment at a younger age are known
risk factors for developing cardiovascular LEs for survivors of childhood leukaemia [123,
124].
For HL, initial improvements in survival were a result of the introduction of extended field
radiotherapy which involves radiotherapy being administered to surrounding areas of the
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affected lymph nodes. LEs as a result of these intensive treatments include weakening
of the immune system, sterility, secondary tumours or cardiovascular complications
[125, 126]. The excess risk of cardiac death amongst children and adolescents who have
received intensive treatment for HL compared to the general population is 17.1 per 10,000
person years [126].
For childhood survivors of brain tumours, the relative risk for stroke is approximately 43
compared to healthy siblings, the relative risk for blood clots is almost 6-fold and the
relative risk for angina-like symptoms is two-fold [127].
For retinoblastoma survivors, the risk of developing secondary non-ocular tumours
(tumours not related to the eye) as late as 50 years post diagnosis is almost 50% (95%
CI 38-60%) for heritable retinoblastoma, however, this risk is dramatically lower for non-
heritable retinoblastoma cases (5%; 95% CI 2-12%) [128]. The most common types of
cancer following hereditary retinoblastoma are sarcomas, carcinomas, brain tumours and
melanoma [128, 129].
LEs following malignant bone tumours include cardiac complications due to
anthracycline treatment, as well as a risk of developing secondary tumours such as
leukaemia and lung cancer approximately 7.5 years after the end of treatment [130].
For rhabdomyosarcoma, effective treatment includes a combination of chemotherapy,
surgery and radiotherapy. However, the use of all three of these treatments can cause
adverse long term effects and there is an ongoing debate in the medical community around
whether radiotherapy is really required in all patients [131]. Recurrences or secondary
malignant neoplasms occur in approximately 9% of rhabdomyosarcoma cases 5-years
beyond treatment, and the risk of having a late event after treatment is highest in those
whose original diagnoses was for an advanced stage tumour, which is caused by the
increased level of therapy required in these patients [132].
In general, cardiovascular related events have been identified as one of the most important
LEs for survivors of CYA cancer due to the long term morbidity associated with it in
addition to the potential for early mortality in survivors when compared to the general
population [113, 114, 118]. The risk of cardiovascular related LEs are said to increase
with the dose of anthracyclines, ranging from approximately four- to 28-fold compared to
those not receiving anthracyclines and a 5-fold increased risk of cardiac disease is found
after radiation to the heart [112, 116]. Although high dose anthracyclines increase the
risk of cardiovascular LEs, cardiotoxicity is also observed in survivors who received low
dose anthracycline treatment [116]. The risk of cardiovascular LEs is said to be greatest
for patients receiving radiotherapy combined with chemotherapy [113, 118, 127].
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2.3.4 Key Gaps in the Knowledge
Continued research into the epidemiology and aetiology of all diagnostic groups and
subgroups is required with the aim of improving survival for all CYA cancers. The
main challenge that exists in this field of research is the small number of cases within
each diagnostic group and subgroup due to the rarity of cancer in children and TYAs.
This becomes even more of an issue in terms of statistical power when researchers
are interested in looking at survival within subgroups as well as by age, sex and other
demographic and medical related variables.
Despite 11 studies of childhood cancer survival and 7 studies of TYA cancer survival
across the UK, only 1 recent publication explicitly compares survival between childhood
and TYA cancer [42]. The results of this study were only adjusted for age and sex, and
although the research is broad and includes many diagnostic groups, the authors have
not included year of diagnosis, deprivation, ethnicity or stage, which are all potentially
important predictors of survival amongst children and TYAs. The authors do acknowledge
that stage is an important prognostic factor, but declare they were unable to assess this
due to the the high level of missing data. It is unclear whether variation in survival
observed in the UK for CYA cancer is due to differences in stage at diagnosis as very little
research exists for CYA survival which takes disease severity into account (see §2.3.2.5).
In addition, survival differences between ethnic groups for children in the UK remain
unclear, with few studies showing consistent results. There was only one study focusing
on differences by ethnic group amongst TYAs, however, this study only looked at breast
cancer diagnosis and their age range was not specific to TYAs as it included all cases
under the age of 40 [84]. One of the key issues for lack of data on the survival of CYA
cancer according to disease severity and ethnicity is missing data; the National Audit
Office report on delivering the CRS as well as the improving outcomes for CYAs with
cancer report recognises that stage at diagnosis remains a key gap in cancer intelligence
[1, 22].
This study aims to address the paucity of survival data in the UK across the CYA age range
which is adjusted for the risk factors identified from the current literature, including age,
sex, deprivation, ethnicity, year of diagnosis and stage or disease severity at diagnosis.
Adequate handling of missing data, through the use of multiple imputation, will allow for
partially observed variables to be included within the analysis as well as minimising the
chance of obtaining biased estimates (further details discussed in Chapter 3).
It remains unclear whether possible differences in survival by age, ethnicity or deprivation
are related to inequalities in disease severity at diagnosis for CYAs in the same manner as
for adults. The study by Lightfoot et al. [65] showed that the survival gap in deprivation
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arose around the same time as a change from hospital based chemotherapy administration
to home based chemotherapy treatment, thereby suggesting that the deprivation gap in
survival for leukaemia was more likely a result of differences in treatment adherence
according to deprivation rather than a result of delayed access to healthcare. To date,
no research in the UK has focused on the effects of ethnic group or deprivation on the
severity of cancer at diagnosis for CYAs. Furthermore, it is unclear whether there are
differences in disease severity between children and TYAs. In order to address this, the
effect of ethnic group, deprivation and age group on the severity of disease at diagnosis
was studied using multiply imputed data for partially observed variables (Chapter 7).
Despite a growing understanding of the risks of LEs amongst survivors of childhood
cancer, most studies rely on the CCSS and BCCSS for data. Despite these studies
providing a huge resource and long term follow up data, they only include cases diagnosed
up until 1986 and 1999. This means the long term effects of more modern treatment
modalities are not yet explored, in particular for the CCSS data on which the majority of
LEs papers are based. In addition, the BCCSS only includes data on childhood cancer
survivors up to the age of 16 at diagnosis, and although the CCSS includes cases up to
the age of 21 at diagnosis, this covers only a part of the TYA age range. The review
by Woodward et al. [133] highlights the paucity of information on the long term effects
of survivors of TYA cancer, despite hypothesised concerns over the risk of LEs amongst
this age group. The development of long term follow up services for TYA survivors with
cancer is under way in the UK [133], despite a lack of evidence about the burden of
LEs amongst TYA survivors. Further limitations of the CCSS and BCCSS data are that
they are retrospective cohort studies which rely on self-reported outcomes. Self-reported
outcomes can produce recall bias as, for example, people may be more likely to report
they have suffered from a heart problem, knowing that they are taking part in a survey
about possible LEs of their cancer treatment. Population based data on survivors of CYA
cancer are required to study LEs in an objective manor in order to improve intelligence
on the subject [134]. Hawkins [135] and Zhang et al. [136] identify the need for data
linkage of routine datasets in order to study LEs amongst survivors to provide timely
and objective data on the LEs experienced amongst CYA survivors of cancer. Many LEs
have been identified within the current literature, and it is outside of the scope of this
thesis to study them all in detail. As described in §2.3.3, cardiovascular LEs have been
identified as one of the most important co-morbidities amongst survivors of childhood
cancer. To date, there is limited data on cardiovascular disease sufficient to warrant
admission to hospital for childhood cancer survivors, for TYAs the paucity of information
on cardiovascular LEs is acknowledged [117, 133]. This study aims to use linked
routinely collected population-based cancer registry data with national administrative data
on hospital admissions (HES data), to quantify the incidence and risk of cardiovascular
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LEs amongst survivors of CYAs with cancer. The results of this analysis are provided in
Chapter 8.
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Chapter 3
Review of Missing Data Methodology
3.1 Introduction
This chapter provides a detailed evaluation of the effect missing data can have upon
statistical analyses, a review of the techniques currently available to handle missing data
problems as well as a critical evaluation of the use and accurate implementation of these
techniques within medical research.
Missing data arises frequently in medical research and could occur in the outcome of
interest or within the explanatory variables. Data can be missing as a result of never being
collected (by design or otherwise), being lost after collection or through being incorrectly
collected and therefore deleted. However, despite being common, researchers are often
not aware of the impact missing data can have upon their analysis. Furthermore, many
statistical techniques and packages are designed for complete data, and as such analyses
are often performed under the assumption that the data are complete [137].
Ignoring missing data could lead to inaccurate and biased estimates, as well as lack of
power and efficiency; missing data problems are discussed in detail in §3.4. However,
prior to this, an overview of the terminology commonly used within the missing data
literature is given §3.2.
There are a range of statistical methods which can be used to analyse incomplete
data, including ad-hoc methods (deletion methods and single imputation techniques)
as well as more advanced techniques (maximum likelihood estimation (MLE), multiple
imputation (MI) and inverse probably weighting (IPW)). Ad-hoc techniques are explored
in §3.5. More advanced techniques, including MLE, MI and IPW are explored in
more detail in §3.5.3, §3.5.4 and §3.5.5 as these are recognised as established and
advanced imputation techniques by key authors in the field of missing data techniques
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[138, 139, 140, 141, 142, 143, 144] and offer considerable advantages over the ad-
hoc techniques as is detailed in this Chapter. Furthermore, MLE, MI and IPW are
all methods which can be applied to population based datasets as used within this
thesis. Other advanced techniques for handling missing data include multiple imputation
by latent class analysis [145, 146] and non-parametric Bayesian multiple imputation
[147, 148]. Multiple imputation by latent class analysis and non-parametric Bayesian
multiple imputation methods were developed for high dimensional categorical datasets
(of the order of 80 or more categorical variables) and were therefore not applicable to this
study which included a small number of categorical and continuous variables.
The level of use of each of MLE, MI and IPW within the medical literature was assessed
by performing a critical review of the current literature. Searches were performed for
English language articles only within MEDLINE and Web of Science dating back to
the earliest known reference for each of the respective techniques to the present day.
The search strategies excluded subject categories from Web of Science that were not
medical related topics (for example economics and geography), however, mathematical
and statistical papers were retained within the search. Details of the exact search strategies
for imputation by MLE, MI and IPW are given in Appendices E, G and F respectively.
Finally, the chapter concludes with a detailed evaluation of the advanced missing data
techniques in order to determine which of these is most appropriate for the analysis within
this thesis (§3.6).
Missing data notation used throughout this chapter follows that as in Bartlett et al. [149].
3.2 Missing Data Mechanisms
There are several ways in which data can be missing, and in the presence of each of
these mechanisms a different technique for handling the missing data may be required
[150]. Missing data mechanisms, and their importance in determining the appropriate
missing data techniques, were generally overlooked until Rubin [151] in 1976 formalised
the concept. Rubin [151] developed the following three classifications of missing data;
missing completely at random (MCAR), missing at random (MAR) and missing not at
random (MNAR). In order to describe these three mechanisms, the following definitions
are required:
Fully Observed Outcome (Y )
Y is the fully observed outcome variable of interest within the analysis.
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Partially Observed Covariates (X)
The vectorX contains p partially observed covariates, such thatX = (X1, . . . , Xp).
Xmis and Xobs denote the missing and observed components of X for a given
subject, such that X = Xmis +Xobs.
Fully Observed Covariates (Z)
The vector Z contains q fully observed covariates, such that Z = (Z1, . . . , Zq).
Auxiliary Variables
Auxiliary variables are a subset of fully and partially observed variables within
the data which could aid the prediction of partially observed variables, but are not
themselves of primary interest in the analysis.
Complete Data
The complete data refers to all elements of the data that are either observed or were
intended to be observed, and thus includes Y , X and Z.
Missing Data Indicator R
The missing data indicator can be presented by a matrix of the same size as the
completed data which contains a value of zero when the corresponding value of X
is observed and a value of one when the corresponding value of X is missing.
3.2.1 Missing Completely at Random (MCAR)
Data are considered MCAR when the missing data are unrelated to either Xobs or Xmis,
conditionally on the covariates of interest. In other words there are no systematic
differences between the observed and missing data and information contained within
other variables in the dataset is unable to aid prediction of the missing data. MCAR
is represented by the following equation:
f(R|Y,X,Z,Φ) = f(R|Φ) for all Y,X,Z,Φ,
where Φ denotes unknown parameters.
For example, data are said to be MCAR if a laboratory sample is accidentally dropped.
If the data are MCAR, then they are a simple random sample of the complete data. This
implies that the analysis of a dataset with missingness under the MCAR assumption will
not result in biased estimates, provided the analysis of the data in the scenario in which
it was complete would also not result in bias [152]. However, a complete case analysis
under MCAR would result in a loss in precision.
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3.2.2 Missing at Random (MAR)
Data are MAR when the probability that the data are missing is independent of the
missing data itself conditionally on the observed data and the covariates of interest. This
is represented by the following equation:
f(R|Y,X,Z,Φ) = f(R|Y,Xobs, Z,Φ) for all Y,Xmis, Z,Φ.
In other words if any systematic differences between the observed and missing data
can be explained by differences in the observed data, then the data are considered
MAR. Therefore, the collection of as many covariates which can improve prediction
of the missing values as possible increases the plausibility of the MAR assumption
[153, 154, 155, 156]. These variables are known as the auxiliary variables. Missing
values of blood pressure data can be considered MAR if, for example, older patients were
more likely to have their blood pressure recorded. In this case, blood pressure would be
MAR with the missingness conditioned on the observed ages of the individuals as missing
blood pressure could be predicted from age.
MCAR is a special case of MAR, with the latter being an assumption which requires the
missing data to be a random sample of the observed data only and not of the complete
data [153]. Therefore, analyses under an MAR assumption would still be valid if the data
were MCAR [148].
3.2.3 Missing Not at Random (MNAR)
Data are MNAR when the probability of the data being missing is dependent upon the
missing values themselves after conditioning on the observed data and the covariates of
interest. This implies that when the data are MNAR, the missing data are related to
unobserved values of the partially observed variable. MNAR is also referred to as non-
ignorable or informative missing data [148]. For example, if blood pressure was less
likely to be recorded for those people who had low blood pressure and none of the other
observed variables could fully explain this relationship, then any missing values of blood
pressure would be MNAR. This implies that missing blood pressure could not be predicted
by any other observed data; unlike under the MAR assumption.
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3.3 How to Determine the Missing Data Mechanism
There are no definitive ways to test whether data are MCAR, MAR or MNAR. However, it
is possible to use the observed data in order to make informed decisions about the missing
data mechanism. Evidence against MCAR can be found by determining whether the
missing data pattern differs according to a variable within the data that is fully observed.
There is evidence against MCAR if for example age was related to whether or not blood
pressure was recorded. However, if no such relations are observed, it does not imply that
the data were necessarily MCAR, they could be MNAR. Despite this caveat, a test for
MCAR was developed by Jamshidian and Jalal [157] and has recently been implemented
in the R package MissMech [158]. The test determines whether subsets of data have
identical missing data patterns or not, by testing for homoscedasticity of the covariance
matrices of the missing data patterns using techniques described by Hawkins [159].
Although the MissMech test is useful for complex missing data problems, for simpler
scenarios with only one or two partially observed variables, logistic regression models
can be easily implemented to determine whether relationships between observed data and
the missing data patterns exist. In order to determine whether an MAR assumption is
plausible, a sensitivity analysis can be performed by analysing the data under an MNAR
assumption [160] (see Chapter 4 for further details of sensitivity analysis methods).
3.4 Missing Data Implications
As discussed in the introduction of this chapter, missing data is often overlooked by
researchers due to a lack of awareness or understanding of the impact missing data can
have upon their analysis. Missing data could undermine the validity of research as it
could lead to lack of power and inefficiency of the analysis as well as inaccurate and
biased estimates unless it is accounted for using advanced missing data techniques (see
§3.5 for further details).
Examples of ways in which missing data could lead to inaccurate results include excluding
a variable which has partially observed data or excluding all cases for which any
observations are missing (complete case analysis (CCA). These methods are discussed
in more detail in §3.5.1.1, however, are introduced here to enable a discussion of the
implications missing data can have on an analysis. If a partially observed variable is a
confounding variable within an analysis (that is to say, a variable which correlates with
the dependent and independent variables), then simply excluding this variable from the
analysis could generate misleading results. The need to adjust for confounding variables
is well known in statistical analysis in general to reduce the risk of false positive (Type
42 3. REVIEW OF MISSING DATA METHODOLOGY
I) errors. Moreover, if the missing data occurs in the outcome of interest, then excluding
this variable from the analysis is not a viable option.
More commonly, when researchers ignore missing data (knowingly or not), they tend to
perform a CCA in which all cases with any missing data are excluded from the analysis.
This has several implications on the analysis, including a loss of power and precision as
well as the potential to produce biased results. Power and efficiency of the analysis are
lost because CCA reduces the overall sample size included in the analysis, and although
each partially observed variable may only have a small percentage of missing data, a
large number of cases could be excluded from the analysis if there are many variables
with missing data [142]. Moreover, CCA does not only exclude the missing observations
themselves, but also excludes valuable recorded information in other variables for the
deleted cases. For example, if a person’s age was missing from the dataset, but all
other data were recorded, the whole record would be excluded from analysis. The
resulting estimates may be unable to detect statistical significance due to reduced power
and therefore important associations in the data could be missed, or the analysis may
lead to erroneous inferences due to increased standard errors by disregarding some of
the recorded data. As discussed earlier (§3.2), CCA will not lead to biased estimates if
the data are MCAR. However, if this assumption does not hold, then biased estimates
could occur. This is because the observed data are no longer a simple random sample of
the intended complete data. This implies there could be under-representation of certain
subgroups (selection bias) [161]. For example, if data are more likely to be missing in rare
subtypes of cancer then by excluding missing data, these rare subtypes would be under-
represented in the analysis. If in addition the survival rates of this particular cancer were
poorer compared to other more common subtypes, then the overall survival patterns of
the cohort would be overestimated in a CCA. Furthermore, if the subtype is already rare,
and data are also more likely to be missing for this subtype, a CCA could mean it is not
possible to estimate survival for this particular group as the potential of excluding 100%
or near 100% of these cases is high. In general, the presence of bias means that the results
may have limited validity and limited generalisability [162]. In medicine, presenting
inaccurate and invalid results could have serious consequences as the presented evidence
may be used to change clinical practice [163].
3.5 Techniques for Handling Missing Data
There are several ad-hoc methods for handling missing data including deletion methods
and a range of single imputation methods. These methods are described in this
section alongside their advantages and disadvantages. More advanced methods such
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as handling missing data by maximum likelihood estimation, multiple imputation and
inverse probability weighting are given towards the end of this section. These methods
are compared and contrasted and their use within the medical literature is reviewed.
3.5.1 Deletion Methods
3.5.1.1 Listwise Deletion
Listwise deletion (also referred to as CCA), is a method in which subjects with missing
data in any of the variables of interest are excluded. CCA is represented diagrammatically
in Figure 3.1.
Figure 3.1: Diagrammatic representation of complete case analysis.
This technique has the advantage of being a simple method of handling missing data as
no additional data manipulations are required prior to analysis. In a CCA the sample
of subjects remains the same for all variables which means that for several univariable
analyses on one dataset the results are directly comparable. In many statistical packages,
the default setting of statistical analysis such as regression analysis is to discard subjects
with any missing data, making it easy for the researcher to perform a CCA without
necessarily realising that in doing so they are making several assumptions about the
data which could lead to potential bias. Despite CCA being the default setting in many
statistical software packages, the technique is not accepted as an appropriate method for
handling missing data due to several disadvantages [161]. Unless the data are MCAR, a
CCA will produce biased results, increased standard errors and loss of power.
Nevertheless, a CCA can be justified if the data are deemed to be MCAR or if the amount
of missing data is relatively small. There are no specific rules for when a CCA is justified,
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and therefore the researcher has to make an informed decision contrasting the added
benefit of being able to complete a straightforward analysis to the loss of precision in
the final results [161]. Despite no general rules being available, Schafer [153] suggests
that when missing data occurs in less than 5% of cases, a CCA may be a reasonable
approach.
There were several examples of the use of CCA within the medical literature; however,
these techniques are often not fully justified within the journal articles. For example,
a paper published in the British Medical Journal reporting results from a randomised
control trial looking at the effect of acupuncture compared to standard treatment for
lower back pain used a CCA [164]. Data on participants of the trial were collected at
3, 12 and 24 months after commencement of treatment and missing data occurred in
24% of cases at the 24 month time period. The authors state that in addition to the
CCA, they also performed a sensitivity analysis by analysing the data using the ‘last
observation carried forward’ (LOCF) technique (see §3.5.2.1 for details of this method).
They concluded that there were no differences between the results between the CCA and
the LOCF analysis. Although the authors explored two options of handling missing data,
and concluded that there was no difference in the findings between the two methods, they
did not acknowledge that the two methods chosen could have led to biased results and
increased standard errors caused by the loss of information. The authors did not make
any statements with regards to the structure of the missing data, and as discussed above,
unless the missing data were MCAR, the CCA would have led to biased inferences.
3.5.1.2 Pairwise Deletion
Pairwise deletion (also referred to as available-case analysis) excludes cases for which the
variables in a particular sub analysis contain missing data as opposed to the cases which
have missing data in any variables within the whole dataset. For instance, if the researcher
has a dataset with age, gender, height and weight and aims to analyse the relationship
between height and weight, then only those cases for which height and weight data were
missing would be excluded, regardless of missing data in the age or gender variables (see
Figure 3.2).
In situations where the analysis is simple, and only performed on small subsets of the data,
this approach could be useful as there is less data loss in comparison to listwise deletion.
However, once regression analysis is required with even a small number of variables this
method can soon result in a similar amount of data loss as would be the case with listwise
deletion. A further disadvantage of pairwise deletion is that results on subsets of the data
will have different sample sizes and will therefore not be comparable [161]. As with all
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Figure 3.2: Diagrammatic representation of pairwise deletion analysis: example in which
the variables required for analysis are height and weight.
deletion methods, subgroups of the study population could be underrepresented within
each of the subset analyses, leading to selection bias and invalid estimates.
3.5.2 Single Imputation
Imputation is a method of filling in the missing data with alternative values, and then
analysing it as if it were the true complete data. In single imputation the missing
data are imputed with a single value. There are many types of single imputation,
including hot deck imputation, unconditional mean imputation, regression imputation
and stochastic imputation. These are discussed in more detail below. Single imputation
has the advantage of producing a complete dataset which can then be analysed using
standard statistical techniques and is superior to deletion methods as it does not exclude
any observed data. The drawbacks of single imputation are that, except for stochastic
imputation, the estimates are biased even when the data are MCAR. Furthermore, single
imputation leads to an underestimation of the variance as the uncertainty of the imputed
estimates is not taken into account, and therefore multiple imputation methods (§3.5.4)
supersede the more simplistic single imputation techniques.
3.5.2.1 Last observation carried forward
The LOCF method is commonly used for missing data within longitudinal studies
throughout the medical literature [165, 166]. The method simply replaces the missing
value at time t+ 1, Xmis(t+1), with the previously observed value, X
obs
(t) , at time t.
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The main flaw of this method is that it makes the assumption that the value of a certain
variable remains unchanged after dropout which is a strong and unrealistic assumption
in most situations [167]. Despite this known flaw, it is a method regularly used in
longitudinal studies, for example, in papers by Ginsberg and Lindefors [165] and Tariot
et al. [166].
3.5.2.2 Mean Imputation
The most basic form of mean imputation is referred to as unconditional mean imputation.
This is a method of single imputation in which missing values are replaced by the mean
of the observed values for that variable. Mean imputation dates back to 1932 [168], and
has been used throughout medical research since then despite some clear disadvantages.
Examples of mean imputation used within the literature include a recent paper published
by the Hammill Institute on Disabilities looking at the expectations employers have
of individuals with and without disabilities [169] and a study assessing major adverse
cardiac events in relation to anxiety and depression [170]. Ju et al. [169] excludes 20
cases due to incomplete data collection forms, with a further two cases for which “the
conventional data imputation method of substituting means for missing values” was used.
Despite mean imputation being implemented for only two cases, the authors show a lack
of understanding of missing data and the potential negative influence may have upon
their results by also excluding 20 incomplete cases from the analysis. Frasure-Smith
and Lesperance [170] use mean imputation to impute missing values of blood pressure
at baseline for 11 cases out of approximately 800. The authors also perform regression
imputation (see next section), but conclude that there was no difference in the results
between the two methods.
Unconditional mean imputation has been described as the worst method of imputation
which should always be avoided [141, 144], reasons for which are described below. The
papers published in recent years by Frasure-Smith and Lesperance [170] and Ju et al.
[169] indicate either a lack of understanding amongst the medical research community of
the implications incorrect imputation can have or a lack of willingness to implement more
complicated methods. Despite having identified only two such papers, there may be more
within the literature that were hard to identify as papers may have used this technique
of imputation without being fully aware of the fact that they were imputing data, and
therefore would not have used the terminology for mean imputation or explicitly stated
that they had missing data.
Mean imputation results in a distribution of X which has a spike at the mean and is
therefore more tightly centred on the mean than the true distribution of X. This implies
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that the variance of the true distribution of X is underestimated. Mathematically, this is
represented as follows:
If s2 is the sample variance of the observed available data, then the sample variance of
the imputed data combined with the observed data (s2imp) is described by the following
equation:
s2imp = s
2 (nobs − 1)
(n− 1) ,
where nobs is the number of subjects with observed data and n is the total number
of subjects. Under the MCAR assumption, s is an estimate of the true variance, so
the variance of the filled in data is underestimated by a factor of (nobs − 1)/(n − 1).
If subsequent analysis is performed under the assumption that the data are complete,
resulting estimates such as variances or percentiles will not be accurate, as the distribution
of the imputed and observed data is distorted from that of the true complete distribution.
Conditional mean imputation is a somewhat more refined approach of mean imputation in
which mean values are conditioned upon observed data items that are subsequently used to
replace missing values. For example in survey data, conditional mean imputation involves
splitting the data into respondents and non-respondents based on various categories
(referred to as classes in this context). The mean for the respondents in each of the classes
is then used as the value for the non-respondents in the same class.
3.5.2.3 Regression Imputation
Regression imputation is a method by which observed data is used to predict missing data
estimates. The method works by regressing all the observed cases of a partially observed
variable on other variables within the data set. This model is then used to generate
predictions for the missing values. For example, a regression line of the variableX2 onX1
will allow predictions to be made for the values of X2. This method can be applied using
a combination of variables within the data including continuous and categorical variables.
Regression imputation reduces down to conditional mean imputation in the situation
where the observed variables used in the prediction are dummy variables representing
a categorical variable. This is because the resulting predictions are equal to the mean
values within each class.
The disadvantage of regression imputation is that the imputed data values are highly
correlated as the imputed values lie directly on a straight line if the imputation model
is univariable or a flat surface if the imputation model is multivariable. This feature also
implies that the imputed values have less variability compared to if the data would have
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been fully observed. The attenuation of variances are not however to the same extent as
those resulting from unconditional mean imputation. Beale and Little [171] and Buck
[172] have developed adjustments that can be made to the results to ensure estimates are
unbiased, however, this is only valid if the data are MCAR. Regression imputation can be
unreliable if the missing data occurs for values of X1 which lie outside of the range of
X1 values corresponding to the observed X2 values. Furthermore, regression imputation
does not allow for missing data in the predictors of the variable being imputed. Therefore,
if such a situation arises, variables would be imputed based on a complete case analysis
of the other variables in the data and therefore could result in biased estimates as with any
complete case analysis.
3.5.2.4 Stochastic Regression Imputation
Stochastic regression imputation is similar to regression imputation as it imputes missing
values based upon predictions from a regression model. However, it has the additional
feature of including a normally distributed residual error. Instead of imputing the
conditional mean as described above, the imputation is based upon a draw out of the
set of observed values conditional upon the observed data (referred to as a conditional
draw). This draw includes a residual term to reflect the uncertainty of predicted values,
and is therefore an improvement upon regression imputation. Figure 3.3 gives a simple
diagram of how regression and stochastic imputation work for imputing missing values
of height based on weight.
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Figure 3.3: Diagrammatic representation of (a) regression imputation and (b) stochastic
regression imputation: example of imputing height based on weight
The inclusion of a residual error term eliminates the bias which standard regression
imputation suffers from and it is the only single imputation method which produces
unbiased estimates under the MAR assumption [144]. Despite these advantages,
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stochastic regression is still not recommended over multiple imputation or maximum
likelihood methods discussed in the following section. This is because the imputed data
are treated as the fully observed data when being analysed as with all single imputation
techniques, and therefore still retains the problem of attenuated standard errors. A
bootstrap sampling technique can be used to overcome this problem [167], however,
maximum likelihood and multiple imputation techniques are superior techniques which
negate the need to go through the effort of adding this extra step to the analysis.
3.5.2.5 Hot Deck Imputation
Hot deck imputation (also referred to as donor imputation) is a common type of
imputation used in survey data in which imputed values are obtained from survey
respondents with similar characteristics to those of the non-respondents. The method
of defining similarity varies from simply selecting respondents of the same age with the
same stage disease to complex and elaborate schemes involving a long list of variables. If
the data does not contain any donor respondents, then the search is repeated using a less
restrictive scheme (i.e. by trying to match fewer variables). Rao and Shao [173] stated that
the main advantage of hot deck imputation is that the distribution of the data is preserved.
However, it is the distribution of the available data that is maintained, and this is not
necessarily the same as the distribution of the data had it been complete. Nonetheless,
it is preferable to other single imputation techniques such as mean imputation in which
the distribution of the data is distorted with a spike at the mean. Furthermore, results
obtained from different analysis of the imputed data are comparable to each other as they
would be based on the same sample, unlike in an available-case analysis as described in
§3.5.1 [173]. As with all single imputation methods, the true variance is underestimated
as a direct result of treating the imputed values as the truly observed values and any
uncertainty introduced by the imputation is ignored.
3.5.3 Maximum Likelihood Estimation, Expectation-Maximization
(EM) Algorithm
Maximum likelihood estimation (MLE) is a common mathematical technique of
estimating unknown parameters given the data. Likelihood based methods can be used to
handle missing data problems by considering the missing data matrix, R, as an explicit
part of the data. If the data are MAR, then the missing data can be treated like unknown
random variables which are removed from the likelihood via summation or integration
[154]. Dempster et al. [174] give a detailed description of how to use a technique known
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as the Expectation-Maximization (EM) algorithm to find the MLE estimates when the
data are incomplete.
The likelihood function, L(θ|x) is a function of an unknown parameter θ given the data
x. For mathematical convenience, the log of the likelihood function, l(θ|x) is often
used to find the MLE instead of the likelihood function itself. The MLE is found by
maximising l(θ|x), and in the case of missing data, the EM algorithm is used to achieve
this in an iterative process. The expectation step (E-step) estimates the missing values
based on parameter estimates from the previous step by using the conditional expectation.
The maximisation step (M-step) is subsequently used to re-estimate the parameters by
maximising the log likelihood of θ given the observed data xobs as well as the estimated
values of xmis. Starting values for θ are required for the first step of the algorithm. The
likelihood is increased at each iteration of the algorithm, thus convergence is guaranteed
[174]. Despite this feature, one of the main disadvantages of the EM algorithm is that
convergence can be slow especially in situations where the amount of missing data is large
[167]. Furthermore, the asymptotic variance-covariance matrix is not directly available
from the EM algorithm for determining parameters such as standard errors. However, an
extension to the EM algorithm which allows for standard errors to be calculated has been
proposed by Meng and Rubin [175] as mentioned within the following section.
3.5.3.1 Applications of the EM Algorithm in the Medical Literature
Although the EM algorithm is well known within the mathematical and statistical
community, it is not commonly used within the medical literature. This is likely to
be due to its inaccessibility and the requirement of a good mathematical and statistical
background in order to fully understand and implement the method.
A literature search of the EM algorithm combined with missing data initially produced
179 results. After removing duplicates and irrelevant articles, 98 remained. Details of the
full search strategy can be found in Appendix E.
Most journal articles cite the EM algorithm back to Dempster et al. [174] in 1977, and
although this paper can be credited with formalising the algorithm, the earliest known
reference to the idea is that of McKendrick [176] in 1925. Further work exploring some
of the theory of the algorithm was done by Orchard and Woodbury [177] and Sundberg
[178] and specific examples were seen in Hartley [179] and Baum et al. [180].
The literature search returned many papers published within methodological journals
such as Statistics in Medicine, Biometrics and Lifetime Data Analysis, with only a third
of papers in various medical and epidemiological journals. This key point highlights
the limited uptake of the algorithm by medical researchers who may not necessarily
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have a good mathematical or statistical background. Many of the papers published
within statistical journals propose extensions to original EM algorithm and give specific
examples of how these methods can be applied to medical research. One key extension
to the EM algorithm is that given by Meng and Rubin [175]. The authors propose a
method named the supplemented EM algorithm (SEM) through which the asymptotic
sample variance-covariance matrices for point estimates such as standard errors can be
obtained. The SEM algorithm obtains the additional variability in the data caused by the
fraction of missing information and adds this to complete-data variance-covariance matrix
to obtain the sample variance-covariance matrix. This method builds on the simpler case
for one parameter in which the rate of conversion of the EM algorithm, r, connects the
sample data variance (i.e. the observed data variance), V , to the complete-data variance,
Vc, by the following relationship:
V =
Vc
(1− r) .
The same authors go on to propose another extension named the Expectation/Conditional
Maximization (ECM) algorithm in which the normal M-step of the algorithm is replaced
by several computationally simpler CM-steps based on the complete data conditional
maximum likelihood instead of the complete data maximum likelihood [181]. Enders
[182] describes an approach for calculating Cronbachs alpha with missing data (internal
consistency reliability estimates for scales) using the EM algorithm, and Claeskens and
Consentino [183] provide a method for determining the missing data Akaike’s information
criterion (AIC) for model selection after the EM algorithm.
Ibrahim [184] introduces a weighting method to handle data in which a categorical
covariate is missing. The method gives weights to the complete data log likelihood
within the E-step of the algorithm. The authors extend this weighting method further
to parametric survival models [185] as well as Cox proportional hazards models [186].
Further work by Ibrahim et al. [187] describe a method of applying the EM algorithm
to generalized linear models when the missing data are said to be non-ignorable. Non-
ignorable missing data refers to the scenario when non-response is related to the values of
the missing data itself [167]. The paper by Ibrahim et al. [187] in 1999 includes theoretical
discussions of complex situations in which data are missing in multiple variables which
can include a mixture of categorical and continuous variables. An additional paper in
the same year [138] gives an applied example using quality of life data in breast cancer
patients. The paper was published with the aim of aiding understanding of the more
complicated material presented in Ibrahim et al. [187], and thus includes data which
contained missing values in one covariate, the occurrence of which is rare in real life
data. Horton and Laird [139] describe the method of weights by Ibrahim [184], including
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its extensions, in detail and conclude that when the missing covariates are categorical the
method is straightforward, however, becomes much more complex when the number of
covariates is large.
Despite the use of specific examples within the methodological papers, the extension
methods rely on a good mathematical understanding and the sheer number of extensions
published highlight that the EM algorithm is not a simple approach that can be applied
in the same manner to each missing data problem. This makes the method unsuitable to
studies in which several different analyses of the same dataset are required, as individually
tailored techniques for imputation would be required each time.
Despite the complex theoretical background, the EM algorithm method of handling
missing data for a variety of data structures can be easily implemented in a range of
statistical software packages, details of which are provided in Collins et al. [154]. The
statistical package SPSS handles missing data problems via the EM algorithm, which is
a program widely used within the medical research community due to its simple user
interface. SPSS includes automatic settings such that the methods become incredibly
easy to implement, however, this can mean that researchers do not give adequate thought
to the assumptions required to produce unbiased results. Two papers published by
Jenkinson et al. in 2006 and 2007 [188, 189] use the EM algorithm to handle missing
data in questionnaires relating to Parkinsons disease and Amyotrophic Lateral Sclerosis
respectively. In both articles, the authors aimed to assess whether the EM algorithm was
a suitable method for handling missing data and if the results were reliable, the authors
do so by deliberately removing data from a complete set of data. The authors conclude
that the method produced satisfactory results in both cases, however, details of how the
algorithm was performed, except for a statement that states the analysis are performed
in SPSS, were not given. Nevertheless, the papers do discuss missing data patterns and
question the use of the methods if the missing data were not MAR which was indicative
of their understanding of the imputation process.
3.5.4 Multiple Imputation
Multiple imputation dates back to an idea developed by Rubin [190] in 1978, and is
documented in more detail in Rubin [191] in 1987. The technique is an extension to
stochastic regression imputation, however, instead of producing one set of imputed values,
the process is repeated several times to create M sets of imputed data. This process
ensures that the error variance lost with single imputation is accounted for. Once M
sets of imputed data have been obtained, each from the same regression model (referred
to as the imputation model), each set of data are then analysed individually according
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to standard statistical techniques. The parameter estimates from each of these analyses
are then combined to produce one final set of parameter estimates. The estimates are
combined according to Rubins rules [191], represented by the equation below:
θ¯M =
1
M
M∑
m=1
θˆm,
where θˆm is a scalar estimate of interest, for example a regression coefficient, obtained
from imputed data set m (for m = 1, 2, . . . ,M ).
There are two types of variance associated with this estimate; the within-imputation
variance
W¯M =
1
M
M∑
m=1
Wm,
where Wm is the variance associated with the estimate θˆm, and the between-imputation
variance
BM =
1
M − 1
M∑
m=1
(θˆm − θ¯M)2.
The total variance, TM can be calculated as follows
TM = W¯M +
M + 1
M
BM .
The process of multiple imputation can be represented by the following flow diagram
(Figure 3.4).
54 3. REVIEW OF MISSING DATA METHODOLOGY
Xobs 
X(1) 
X(2) 
X(m-1) 
X(m) 
···· 
 ···· 
 
𝜃 1 
𝜃 2 
Observed 
Data 
Imputed 
Data 
Analysis 
Results 
Combined 
Results 
Imputation Analysis Pooling 
𝜃 𝑀  
𝜃 𝑚−1 
𝜃 𝑚  
Figure 3.4: Diagrammatic Representation of the Multiple Imputation Process. Figure
adapted from short course materials on multiple imputation delivered by the MRC
Biostatistics Unit, Cambridge, 2011
3.5.4.1 Multiple Imputation for Multivariable Data
When the missing data occurs in more than one variable, there are a range of additional
complexities which can occur [192, 193]. Imputation of multivariable data was not
covered in the original literature by Rubin [191], however several methods have been
suggested since then [153, 193, 194, 195]. These methods fall into two broad categories
under the headings of joint modelling (JM) and fully conditional specification (FCS).
The JM approach, as proposed by Li [194], Rubin and Schafer [195] and Schafer [153]
involves specifying a joint distribution P (X,Z,R), where X = (X1, . . . , Xp) is a set of
p partially observed variables, Z = (Z1, . . . , Zq) is a set of q fully observed variables on
the same subjects and R is the missing data indicator matrix. The joint model P (X,Z,R)
encompasses both the analysis model and the imputation model, and in reality this model
is difficult to specify. Several problems are encountered during imputation by JM, which
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are listed below:
• The same type of modelling process may not be appropriate for each variable which
is to be imputed [193]. The variables in one data set can differ in terms of their type
(i.e. continuous, binary or categorical), therefore specifying one joint model could
end up creating unrealistic assumptions such as assuming normality of a binary
variable [193].
• The imputation models could be complicated if the relationship between the
variable which is to be imputed and the predictors is non-linear, contains
interactions or is dependent on censoring.
• Imputation by JM could create non-valid combinations such as ‘pregnant fathers’
[143].
• The data set could contain derived variables, and the JM approach does not
necessarily ensure that variables which are summed or transformed remain
consistent with their original parts.
The problems of imputation by JM can be overcome by specifying individual conditional
models for each variable with missing data (Xj) and treating this as a separate modelling
process from the final analysis model. In this case, each conditional model can be
represented by the conditional model in the form P (Xmisj |Y, Z,X−j, R), for each Xj ,
j = 1, . . . , q. Where Xmisj is the missing part of Xj and X−j refers to the set of X
variables excluding Xj . This process of specifying a conditional distribution for each
variable which is to be imputed is known as multiple imputation by fully conditional
specification (FCS). The FCS method consists of two parts, firstly, the set of conditional
models specified above, which are referred to as the imputation model, and secondly, the
analysis model (also known as the substantive model). Each model can be represented as
follows:
Imputation Model
f(Xmisj |Y, Z,X−j, R, ω), for parameter ω (ω ∈ Ω).
Analysis Model
f(Y |X,Z, θ), for parameter θ (θ ∈ Θ).
A widely used method of imputation by FCS is proposed by van Buuren et al. [160],
and is more commonly known as multiple imputation by chained equations (MICE).
Other terminologies used to refer to this process include variable by variable imputation,
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regression switching and sequential regressions [160, 196]. The main benefit of FCS over
a JM approach is that for categorical variables which contain missing data, a multinomial
logistic regression model can be applied whilst a linear regression model can be used
for imputing a continuous variable in the same dataset. Additional benefits include the
possibility of maintaining specific features of the data such as upper and lower boundaries
for specific variables, as well as the possibility of including constraints to ensure the
imputation process does not impute non-valid combinations [143].
MICE can be implemented in a range of statistical software. The MICE package by
van Buuren and Groothuis-Oudshoorn [192] is available in both S-Plus and R, the SPSS
module MVA is available in version 17 onwards and allows the user to perform multiple
imputation however it does not appear to be as flexible as the programs in S-Plus and R
which are command line driven. Royston [140] introduced the ‘ice’ software package to
Stata, implementing the same method as that in S-Plus and R. This package has since
been updated with additional flexibility around categorical variables [197].
3.5.4.2 Substantive model compatible fully conditional specification (SMC-FCS)
Despite MICE being a widely applied method in a range of medical applications, the
validity of the statistical properties underlying MICE are comparatively understudied
[145, 198]. The main question over the validity of the MICE method is the possibility of
specifying a set of imputation models in the case of multiple partially observed variables
which are not mutually compatible [198]. Two models are said to be incompatible if there
is no joint distribution for the corresponding set of conditional distributions. Furthermore,
there is concern that the imputation model is not always compatible with the analysis
model. The imputation and analysis models specified in the previous section are said to
be compatible if there exists a joint model:
f(Y,Xj|X−j, Z, ψ)
Recent work by Bartlett et al. [149] in 2014 indicated that incompatibility of the
imputation models and analysis models is particularly a problem when the analysis model
is non-linear, such as the Cox proportional hazards (PH) model. The Cox model is a non-
linear model as it does not belong to the family of generalized linear models (GLMs),
which are formed from a random component, a linear predictor and a link function.
Furthermore, Cox PH models cannot be evaluated using standard maximum likelihood
estimation as with GLMs, and instead rely on the partial likelihood. Although the log
hazard function is a linear function in the covariates, Cox PH models are considered
non-linear in relation to how partially observed variables are imputed using MICE. As
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discussed in more detail in §3.5.4.4, the outcome variable should be included in the
imputation model so that covariate-outcome associations are not diluted. For example,
for a continuous partially observed variable (X), the time to event variable (T ; or
more precisely, the Nelson-Aalen estimate of the hazard function of T ), is used to
generate imputations of X using a normal linear imputation model. The imputation
model therefore assumes linearity between X and the hazard function of T , which is
not compatible with the analysis model in which the relationship between the log hazard
function of T is linear with X [149]. The authors show that if the imputation and
analysis models are incompatible, then imputations will be drawn from the incorrect
distribution, and have therefore proposed an extension to the MICE method which
ensures compatibility between the analysis model and the conditional imputation models.
The method is known as Substantive Model Compatible Fully Conditional Specification
(SMC-FCS).
The MICE algorithm works by specifying a non-informative prior distribution for the
imputation model parameters (f(ω)). At the tth iteration, missing values for the t + 1th
iteration are imputed using parameters drawn from the posterior distribution (the product
of the prior and the likelihood of all observed data and the imputed values up to the tth
iteration). The SMC-FCS, instead specifies a non-informative prior distribution based on
the imputation model parameters (f(ω)) as well as the analysis model (f(θ)). At the tth
iteration, parameters are first drawn from the posterior distribution based on the analysis
model prior and likelihood, these parameters are then used to impute missing data by
drawing parameters from the posterior of the imputation model prior and likelihood. Thus
the t+ 1th iteration is imputed from a distribution which is proportional to the product of
the imputation and analysis models, which by definition is compatible with the analysis
model.
3.5.4.3 Number of Imputations
Early papers describing MI suggest that very few imputations (between 5 and 10) are
required to produce reliable results [160, 199]. Rubin [191] shows that the number of
imputations depends on the fraction of missing information, λ, and gives the following
equation for the relative efficiency of m imputations compared to 1 based on an infinite
number of them as:
(1 +
λ
m
)−1.
Schafer [199] uses this equation to show that by performing 5 imputations on a
dataset with 50% missing information, the standard deviation of the estimates is only
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approximately 5% wider than it would be if using an infinite number of imputations, since
(1 + 0.5
5
)−1 = 1.049. Schafer [199] therefore concludes that there is no added practical
benefit of performing more than 5 to 10 imputations.
Since these early methods have been implemented, several researchers have questioned
whether such a small number of imputations are sufficient, and simulation studies have
been performed to assess the optimum value form, weighing up the reproducibility of the
results and the computational time required [200, 201].
Graham et al. [201] recommends the use of m = 20,20,40,100 and > 100 for true λ =
0.10, 0.30, 0.50, 0.70 and 0.90 respectively as the simulations have shown a considerable
amount of loss of statistical power for detecting a small effect size when performing
fewer imputations than this. Bodner [200] also concludes that although the previous
suggestion of 5 to 10 imputations do not result in a great loss in efficiency compared
to using infinite imputations, the small number of imputations repeated independently
on the same dataset can result in substantial variability in important statistics such as P -
values and confidence intervals (CIs). This could have the important implication that
several researchers analysing the same data set could come to different conclusions.
This variability in results caused by the use of a finite value for m is referred to as the
imputation variance, as it is a measure of the variability obtained if the multiple imputation
process was repeated several times. The Monte Carlo (MC) error can be used to measure
this variability. The MC error is the standard deviation between several repetitions of
the same imputation model on the same dataset, this error tends to zero as the number
of imputations increases [202]. White et al. [202] also agree that reproducibility of the
analysis is important, and come to the same conclusion as Bodner [200] that this will be
achieved by choosing the number of imputations as approximately equal to the percentage
of missing data. MC errors can be calculated for all estimates obtained from multiple
imputed data, including parameter estimates, standard errors and P -values. Therefore,
the reproducibility of the analysis can be assessed after the analysis by checking whether
the MC error is sufficiently small so that the interpretation of the results remain the same
at the extreme ends of the MC error (i.e. by adding or subtracting the value of the MC
error to the parameter estimates and P -values).
3.5.4.4 Specifying the Imputation Model
Another important aspect of multiple imputation is correctly specifying the imputation
model, as an incorrectly specified model can result in inaccurate imputations. Several
papers describe methods for specifying the imputation model. The following general
principles apply;
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MAR Assumption
Including as many imputation predictors in the model as possible will make the MAR
assumption more plausible [153, 154, 155, 156], in general, MI will have minimal bias
if all available information is used [160]. Including all covariates from data sets is not
feasible within many medical research settings, as some data sets can contain over 100
variables. This would not only be computationally extensive, but would also create
problems with multicollinearity. van Buuren et al. [160] recommend that no more that
15 to 25 variables are to be included in the imputation model, as beyond this, an increase
in explained variance within the regression model becomes minor.
Congeniality
All variables which are to appear in the analysis model, including the outcome variable,
should also be included within the imputation model. An imputation model containing at
least the same variables as the analysis model is said to be congenial. If variables which
are used within the analysis are not included in the imputation model, then predictive
relationships within the imputed data will be incorrectly diluted [203]. Often, the outcome
variable is overlooked in the imputation process, however, the importance of its inclusion
was highlighted by Sterne et al. [142], who discuss a study published in the British
Medical Journal in which the authors claimed no association between cholesterol level
and cardiovascular risk [204]. The lack of association was a surprising result, and the
reason for this result was later found to be the exclusion of cardiovascular risk from the
imputation model for cholesterol level, which led to an underestimation of the association
between cholesterol and cardiovascular risk. Simulation studies have shown that in the
case of survival data, the outcome variable should be included in the form of the Nelson-
Aalen estimate of the hazard function in addition to including the censoring indicator
[205]. Previous to this, the log of survival time was commonly used in imputation of
survival data, however, White and Royston [205] and White et al. [202] show that this
tends to underestimate the covariate-outcome association.
Interaction Terms and Non-Linear Transformations
For the same reasons as described above, interaction terms and non-linear transformations
which may be of interest within the analysis should also be included as predictors in the
imputation model so any predictive relationships within the data are not falsely diluted.
Auxiliary Variables
Any additional variables available which may help predict the missing data, but are not
necessarily of interest in the main analysis should also be included in the imputation
model. Such variables are referred to as auxiliary variables.
Normality Assumption and Face Validity
Multiple imputation by chained equations assumes normality of any continuous variables
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to be imputed, and therefore it is important that this assumption is checked prior to
the imputation process. If a non-Normal continuous variable is imputed under the
assumption that the variable follows a Normal distribution, then the resulting set of
imputations will be closer to a Normal distribution than the original distribution of
the observed data, this is referred to as a lack of face validity [202]. For example,
if the variable x followed a bimodal distribution and was imputed under a Normal
assumption, then the resulting imputations are likely to contain values between the two
modes of the data, thus creating a distribution which does not represent the original
bimodal shape. There are several options for dealing with non-Normally distributed
continuous variables, these are transformation of the variable, the use of predictive mean
matching or multiple imputation by splitting. Non-Normally distributed variables can
often be transformed to an approximately Normal distribution prior to the imputation
process. The imputed values are then transformed back to their original scale prior to
using them within the analysis model. There are two main families of transformation,
include the log transformation, or more precisely, a shifted-log transformation, and a
Box-Cox transformation. Transformations of these types for a non-Normal variable x are
represented by the following formulae:
Shifted-Log Transformation
f(x) = ln(±x− c)
Where the sign of x is set to positive or negative if the distribution of x is positively or
negatively skewed respectively. The constant c is chosen such that (±x−c) > 0, to ensure
that the logarithm can be calculated.
Box-Cox Transformation
f(x) = (xλ − 1)/λ
Where the parameter λ can be estimated using maximum likelihood.
An alternative method for dealing with non-Normally distributed variables is predictive
mean matching. This method imputes values which are sampled from the observed values
of the variable that is to be imputed, this results in a set of imputed values which closely
follows the distribution of the observed data. However, the main downfall of this method
occurs when the observed values only form a small subset of the true distribution of that
variable, therefore the distribution of the imputed values would also be restricted to this
subset of the distribution.
Finally, when the variable to be imputed has a bimodal distribution it could be possible to
split this data into two Normally distributed variables according to some other variable.
For example, if height had a bimodal distribution, and this was because all males in the
dataset were taller than females, then imputation for males and females separately would
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allow height to be imputed under a Normal distribution in each case. This option avoids
complications of finding a transformation, and does not restrict the sample of imputed
values to those in the observed data, however, it depends heavily on whether or not such
an explanatory variable of the two modes is available within the dataset.
Imputation of the Outcome
Although multiple imputation is a modern method to produce unbiased and efficient
results in the presence of missing data, many applied researchers worry that the method
entails simply guessing missing data values. This concern is even more apparent, even
among those familiar with imputation, when it comes to imputing the dependent variable
of interest [206]. Due to this concern, a popular approach to handling missing outcome
data is a mixture of the CCA and MICE methods, in which all cases with missing outcome
data are excluded from the imputation and analysis, and then MICE is applied to all
independent variables. This method has been shown to produce unbiased estimates in the
situation where data are MCAR (as is the case for any CCA under MCAR) or if there
are no missing data in the independent variables (in which case no imputations would
be required) [207]. However, similarly to a CCA of independent variables, a CCA of the
outcome variable could result in underrepresentation of certain subgroups as well as a lack
of statistical power and efficiency. Moreover, there are many situations where a dataset is
to be used for several different research questions and it is not uncommon in this scenario
for a variable to be an independent variable for one analysis and a dependent variable for
a subsequent analysis. In this scenario it is not clear whether or not the variable of interest
should be imputed or not. Young and Johnson [206] argue that in fact there is no difference
between missing data within the independent or dependent variable and both should be
handled using multiple imputation techniques. Despite this, an alternative method for
imputing the outcome variable has been proposed, the multiple imputation then deletion
(MID) method. Using this terminology, the argument by Young and Johnson [206] can be
thought of as the multiple imputation and retention (MIR) approach as discussed below.
MID was proposed in 2007 by von Hippel [208] and involves including the outcome
variable in the imputation model, but then only retaining imputed values for the
independent variables for the subsequent analyses and deleting imputed values of the
outcome variable. This method ensures congeniality between the imputation and analysis
model. However, it removes the imputed values for the outcome variable, which are
argued to be simply adding random noise to the dataset. The MIR method, although used
commonly according to Young and Johnson [206], has not been labelled as a specific
‘new method’, but instead is simply considered as an approach which treats the outcome
variable as any other variable in the imputation process. Therefore, the imputed outcome
values are retained within the subsequent analysis as would be the case for imputation of
independent variables. This ensures congeniality of the imputation and analysis models as
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well as allowing variables to be used as outcome or independent variables across differing
analysis. Both Young and Johnson [206] and von Hippel [208] agree that there is little
difference between the MID and MIR analysis as the number of imputations increases
beyond 5. White et al. [202] in 2011 compared the MIR approach to a CCA for the
outcome variable and showed that MC errors were substantially reduced using the CCA
analysis. However, this was for a limited example which did not include any auxiliary
variables in the imputation process. If the imputation process were to include auxiliary
variables, especially those which are highly correlated with the outcome variable, then
imputing the outcome would result in an analysis which contains additional information
and would be preferable to an analysis which excluded this additional information
[202, 206].
3.5.4.5 Applications of Multiple Imputation in the Medical Literature
There have been several reviews of the use of MI in the medical literature including work
by Klebanoff and Cole [209], Sterne et al. [142] and Wood et al. [210]. These reviews
were used in combination with a full literature search as they only included searches on
restricted time periods and a restricted selection of medical journals. This search was
subsequently refined to applications of MI used within cancer survival research. Full
details of the search strategy used can be found in Appendix G.
The initial literature search returned 622 results, and there was a steady increase in the
use of MI within the medical literature in the last 10 years. The original publications
by Rubin in 1978 and 1987 [190, 191] resulted in fewer than 10 publications per year
until around 1996 when a few key publications were made. In 1995, Greenland and
Finkle [211] published a paper called ‘A Critical Look at Methods for Handling Missing
Covariates in Epidemiological Regression Analyses’. They reiterate the importance of
using more sophisticated methods instead of ad-hoc methods such as deletion methods
and single imputation techniques. Despite their recommendations, they acknowledged
that the reason these methods had not taken off within the medical literature was because
of the lack of understanding of the techniques and the lack of statistical software packages
to easily implement the more statistically sound methods for handling missing data. Rubin
[212] attempted to address the issues people have in their understanding of the method by
reviewing the important aspects of MI without going into much of the technical details
described in his earlier work in 1978 and 1987. However, again, concluding remarks were
that statistical software packages were urgently required and the authors concluded that
once these become available, MI would likely become the standard method of handling
missing data problems [212].
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Schafer [153] is often credited with popularising the method of MI because his book
published in 1997 describes the methods and their implementation in a much more
accessible manner compared to earlier work [212]. In combination with the publication
of this book, the availability of statistical software packages for the implementation of
MI, namely van Buuren’s MICE software in R and S-Plus first introduced in 1999 [192]
and the ice package for Stata by Royston [140] amongst others, are likely to have led to
the increase in the use of MI in recent years.
Papers by Klebanoff and Cole [209] and Sterne et al. [142] reviewed the use of MI within
the medical literature; the first focusing specifically on epidemiological journals and the
latter on major general medical journals. Both papers conclude that the use of MI is
sparse. More importantly, both papers highlight the variation in the reporting of MI and
attempt to provide guidelines for future use. These include;
• Reporting the number of missing values for each variable alongside possible
reasons for their missingness
• Providing details regarding potential differences between cases with complete and
incomplete data
• Describing the precise methods used for imputation (including software used,
variables included in the imputation model, the number of imputations, the use
of transformations of non-normal variables, any interactions used)
• Discussion of assumptions that are required for inferences to be valid
• Comparison of complete case analysis with MI analysis
Despite many methodological papers and several recent review papers, MI methods
are still uncommon within medical research and more specifically cancer research.
A literature search focusing specifically on MI within cancer research resulted in 60
publications between 1997 and 2014 (Appendix G). Although the number of publications
per year increased around 2008 (Figure 3.5), the use of multiple imputation remains
relatively uncommon. Moreover, those papers which did use imputation, the methods
were often not adequately described and implemented, with the most common problems
occurring around not accurately specifying the imputation model by excluding the
outcome variable and interaction terms as well as not performing an adequate number
of imputations for the amount of missing data.
Clark et al. [213] uses MI to impute missing values of prognostic factors of ovarian cancer
(including stage of cancer, grade of cancer, performance status, ascites and debulking) in
a data set of 1189 cases of ovarian cancer. The authors described in detail the pattern of
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Figure 3.5: Number of publications of multiple imputation per year within cancer survival
research
missing data and the level of missing data (17.2% missing in 69% of cases) and discussed
the plausibility of the MAR assumption. The authors used 10 imputations, but provide
no further discussion as to how they have arrived at this number. In light of recent papers
discussing the number of imputations, the recommended number of imputations for this
analysis would have been 20; approximately equal to the amount of missing data. Their
results show non-significant effects of interactions between several of their covariates
(stage and the tumour marker CA125, stage and grade and stage and histology), however,
it was not clear from the paper whether or not these interactions were included within
the imputation model. If they were excluded, the association between these variables
may have been falsely weakened as discussed in the previous section. The same authors
go on to publish a methodological paper using the same data as their case study [214].
This paper included step by step details on how the imputation was performed pointing
out important theoretical ideas along the way, in an attempt to demystify the imputation
process for other medical researchers. However, a few key points were not covered by
the authors. Namely, the authors referenced van Buuren et al. [160] and quoted: “all
variables that appear in a model constructed using complete cases should be included
in the imputation models.” Yet the authors appeared to fail to include interaction terms
within their imputation model, despite testing for interactions within their final analysis
model. The authors used 10 imputations in their analysis, again referencing van Buuren
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et al. [160]. As discussed in the previous section, the arbitrary figure of between 5 and
20 imputations is outdated, and papers by Graham et al. [201] and Bodner [200] indicate
that the number of imputations should be considerably higher than this, especially in the
case of large amounts of missing information. It is therefore important for the continued
publications of papers such as Clark and Altman [214] so that medical researchers who
rely on them to understand the MI methodologies are receiving the best possible and most
up to data advice as to their implementation.
More recent applications of MI within cancer survival research include Ferguson et al.
[215], Nur et al. [216] and Mandleblatt et al. [217]. Ferguson et al. [215] and Nur et al.
[216] both described the imputation models in detail and discussed the appropriateness
of the MAR assumption; Mandleblatt et al. [217] did not mention either of these points.
A small number of imputations was used in each of these papers; Ferguson et al. [215]
used 5 imputations on data which was missing in 32% in one variable and 17% in another,
Nur et al. [216] cite the use of 10 imputations quoting approximately 10% missing data
and Mandleblatt et al. [217] used 10 imputations quoting 5% of missing data in most
variables and two other variables with 17% missing data. The number of imputations
were too few for studies by Ferguson et al. [215] and Mandleblatt et al. [217] based on
the amount of missing information. The number of imputations used within Nur et al.
[216] were appropriate in relation to the amount of missing data, however, it was difficult
to determine whether or not this was a conscious decision or just by chance.
Although the use of MI within cancer survival research is not common practice, several
researchers have begun using the methods within their work over recent years. Despite
many methodological papers and several recent review papers the methods are not
adequately described and the most common pitfall is failing to specify the imputation
model adequately by including outcome variables and interactions in addition to the
choice of the number of imputations.
3.5.5 Inverse Probability Weighting
IPW is another technique for handling missing data which works very differently from
MI. It is similar to a CCA in that the analysis model is fitted only to the complete
cases. However, unlike in a CCA, the complete cases are weighted by the inverse of
their probability of being a complete case. IPW can remove the bias that results from a
CCA when the data are not MCAR [218]. The IPW analysis model estimates θˆ as the
solution to the following score equation:
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n∑
i=1
RiwiUi(θ) = 0
Where Ui(θ) is the first derivative with respect to θ of the log likelihood function and wi
is the weight given to individual i. This equation reduces down to a CCA in the case when
wi = 1 for all i.
As wi is unknown, it needs to be estimated, this is achieved by fitting a missingness
model. The missingness model is a logistic regression model using the missing data
indicator R as the outcome and variables from the set {X, Y, Z} as predictors (where
X and Y are the covariates and dependent variable from the analysis model respectively
and Z represents additional variables which are observed but not used in the analysis
model) [218, 219, 220]. The missingness model can be fitted provided the predictors in
the model are all fully observed, or if the missing data has a monotone pattern [218]. A
monotone missing pattern occurs when, for a set of variables X = (X1, . . . , Xk), Xk is
only observed for an individual if Xk−1 is observed for each k = 2, . . . , K. The Markov
randomised monotone missingness model can be used in the case of non-fully observed
variables [221], however, this model is more complicated to fit and is not described further
here as this would invalidate the main advantage IPW has over MI, which is its simplicity
as discussed in §3.6.
3.5.5.1 Applications of Inverse Probability Weighting in the Medical Literature
A literature search of IPW returned a total of 76 papers published between 2000 and
2014. However, the majority of these papers used IPW for the design and analysis of
surveys, without its application to dealing with missing data. In a refined literature search
combining IPW with missing data terminology, only 8 papers remained. Details of the
search strategy can be found in Appendix F. Applications of IPW included analyses of
missing data in surveys, clinical trials and longitudinal cohort studies. Reasons for the
lack of uptake of this method for handling missing data could be because IPW estimates
are known to be inefficient compared to likelihood based methods [222] as well as the
estimates being sensitive to the form of the probability response model [167]. The lack of
use of IPW as a method for handling missing data within the medical literature does not
seem to be an issue related to inaccessibility of the method to medical researchers. The
advantages and disadvantages of IPW as a missing data method compared to likelihood
based approaches and MI are discussed in §3.6.
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3.6 Comparison of Likelihood Based Approaches,
Multiple Imputation and Inverse Probability
Weighting
If the predictors in the missingness model are all fully observed, or if their missingness
pattern is monotone, IPW has the advantage of being easier to implement as there is less
technical sophistication compared to likelihood based approaches and MI. This makes
the method more accessible to researchers who are not necessarily experts in statistical
techniques. The increased availability of MI software has also made the use of MI more
accessible to researchers, however, methods are still largely inadequately handled as
shown earlier in §3.5.4.5. Many of the common pitfalls documented by Sterne et al. [142]
in 2009, including failure to specify the correct imputation model or using a sufficient
number of imputations, are still apparent in current applications of MI. Likelihood based
methods for handling missing data continue to be unpopular within applied medical
research as discussed in §3.5.3.1. This is largely due to the high level of mathematical
knowledge required to gain a detailed understanding of the method, as well as its many
extensions.
The desired imputation method depends not only on the ability of the researcher, but also
on the design of the study [161, 218, 223]. IPW is commonly used to handle survey
non-response or longitudinal studies, as missing data in these scenarios can often result
in large blocks of data being missing for each individual. The use of MI or likelihood
based methods to impute missing values for entire questionnaires, or for data collected at
a hospital visit which was not attended, are not recommended [218, 220]. However, for
registry based or routine population based data, MI and likelihood methods are preferred
as they are able to incorporate all of the available information within the datasets to
minimise bias and improve efficiency.
Although likelihood based methods, MI and IPW can all reduce bias compared to ad-
hoc methods and CCA, MI and likelihood based methods have a clear advantage over
IPW. Namely their efficiency, as likelihood based methods and MI do not solely rely
on information from complete cases, but additionally include partially observed cases
thereby allowing more information to be used within the final analysis [224, 225]. In
addition, imputation by both the EM algorithm and MI allow the researcher to account
for a degree of uncertainty within the final analysis [226], which ensures appropriate
estimates of standard errors and P -values are obtained [227].
MI has the additional advantage over IPW of allowing many statistical techniques to
be used and applied after the imputation process, provided the imputation process is
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completed in a thorough manner to ensure congeniality between the imputation process
and subsequent analysis. With the exception of methods for handling hierarchical
data structures after MICE; methodologies for which are still open for debate and in
development [223]. The data used within this study did not warrant the use of multilevel
modelling as, although patients were nested within hospitals, the data were not robust
enough in terms of their recorded principle treatment centres and therefore a clear
hierarchical structure could not be identified; methods used for imputation of multilevel
data were therefore not further explored in this thesis. As discussed in §3.5.3.1, there
are many extensions to the EM algorithm which are required for a range of different
missing data problems. The implication of this is that the method is not efficient for
scenarios in which multiple analyses are required from the same dataset, unlike with
MI. A further disadvantage of the EM algorithm is that with a large number of partially
observed variables and large amounts of missing data, convergence of the algorithm can
be slow and difficult to achieve [153].
Despite the clear advantages of MI over IPW and likelihood based approaches, MICE
(the most popular implementation of MI), is predominantly based on observational and
experimental evidence and lacks a strong theoretical basis [202, 228]. Another concern
raised over MICE is the possibility of incompatibility between the imputation and analysis
model which could result in imputations which are derived from the incorrect distribution,
in particular when the analysis model is non-linear [149]. van Buuren et al. [229] and
White et al. [202] agree there is little evidence to suggest that incompatibility is a concern
as it does not tend to have a real effect upon the analysis. Despite this, an extension to the
MICE algorithm, SMC-FCS, has recently been proposed by Bartlett et al. [149] in 2014
which recommends its use for non-linear models such as Cox PH modelling.
The analysis within this thesis is based on population based cancer registry data with a
moderate to high level of missing data (see Chapter 5 for a detailed description of missing
data specific to this thesis). The cancer registry dataset is used for many different analyses,
in particular, within this thesis, two analyses were completed based on multiply imputed
data. Firstly, a survival analysis based on imputed data of stage and ethnicity (Chapter 6)
and secondly, an analysis determining predictors of late stage diagnoses based on imputed
data of stage (as the outcome variable) and ethnicity (Chapter 7). Due to the nature of the
study design as well as the requirement of multiple analyses based on imputed data, MI
was the preferred imputation method within this thesis. MICE was used for both analyses,
however, results were also compared to SMC-FCS for the survival analysis which was
based on Cox PH modelling.
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3.7 Conclusion
The key implications of missing data are well understood in the statistical community.
Despite this, many applied health researchers fail to realise that the lack of an appropriate
statistical method to handle missing data does not only reduce the statistical power and
thereby the ability to identify potentially important factors, it can also result in invalid and
imprecise estimates. This can have serious consequences if the results are subsequently
used to determine clinical practice.
Despite the clear disadvantages of ad-hoc missing data methodologies, the uptake of
appropriate techniques within the medical literature remain limited. In particular, for
research focusing on survival of cancer including studies conducted worldwide covering
all age groups and cancer types, there were just 60 publications between 1997 and 2014
which implemented MICE. Moreover, the majority of the identified papers failed to satisfy
the full requirements for sound implementation of MICE through misspecification of the
imputation models and using an insufficient number of imputations to ensure validity of
the results.
As discussed in Chapter 2, missing data of stage and ethnicity is a common problem
within cancer registry data. In addition to the paucity of research on childhood and
TYA cancer survival which is adequately adjusted for stage of disease (Chapter 2), cancer
survival studies have not, in general, implemented adequate methods for handling missing
data. In particular, previous studies of survival of childhood leukaemia in the UK tended
to use either a CCA [52, 57] or the indicator method [55, 56] for missing data which
produces incorrect and biased estimates.
MICE and SMC-FCS were implemented in this thesis to produce efficient and reliable
results of CYA cancer survival following a detailed evaluation of the available methods
and discussion of the advantages and disadvantages of IPW, likelihood based approached
and MI (§3.6). Details of the specific methodology used throughout this thesis, including
a description of the imputation model specifications, are provided in Chapter 4, followed
by a description of the missing data patterns for the Yorkshire register in Chapter 5.
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Chapter 4
Methods
4.1 Introduction
This chapter includes a description of the datasets and methods used throughout the
thesis. The chapter begins with specific details of the Yorkshire Specialist Register of
Cancer in Children and Young People (Yorkshire register from here on in), which was
the main data source for this thesis. Additionally, inpatient hospital episodes statistics
(HES) data was used for analysing hospital activity amongst long term survivors of cancer
as well as allocating ethnicity codes. Several different types of HES data exist, which
are described within this chapter, before providing reasons for focusing specifically on
inpatient HES data. Both data sources contained detailed and identifiable information
on a person-by-person basis and these were therefore of a highly sensitive nature. The
ethical implications and required ethical approvals are discussed in §4.3. Following an
overview of the data sources, §4.4 focuses on the statistical methods used throughout the
thesis by initially describing the methods used for descriptive data analysis, followed by
the multiple imputation methods used within the thesis. Subsequently, methods for the
following three main analyses were described in turn;
i) Variation in Cancer Survival (results presented in Chapter 6)
ii) Inequalities in Disease Severity at Presentation (results presented in Chapter 7)
iii) Long Term Effects amongst Survivors of Cancer (results presented in Chapter 8)
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4.2 Data Sources
The importance of high quality cancer registration data in the use of large scale
epidemiological studies, as well as the structure of cancer registration in England has
been described in §2.2. This section focuses on the specific datasets used throughout the
thesis, namely the Yorkshire register and HES data. The Yorkshire register is appropriate
for research into both short and long term outcomes of CYA cancer due to the historical
nature of the database as well as its ongoing follow up of cases every two years beyond
their date of diagnosis. The dataset was used alongside HES data, which enabled research
into outcomes other than survival, such as late effects resulting from cancer treatment.
The Yorkshire register was linked to inpatient and outpatient HES data so that individual
cases could be identified in both datasets. Details of the data linkage process are given in
§4.2.4, following a general description of the Yorkshire register and HES datasets. The
percentage of linked cases as well as differences between linked and non-linked cases are
explored in Chapter 5.
4.2.1 Cancer Registry Data
The Yorkshire register is a regional population based dataset containing detailed
demographic and clinical information on CYAs aged 0-29 years inclusive at diagnosis.
Since 1974, cases of cancer were registered for children diagnosed under the age of 15
within the former Yorkshire regional health authority. Two expansions of the register
have occurred since then, the first was an extension of the age limit to include young
adults up to the age of 30 for diagnoses from 1990 onwards. This data was initially
collected retrospectively from 1999 and prospectively from that point forward. The
second expansion occurred in 2006 to align with the new definition of the Yorkshire
Strategic Health Authority, which consists of south Yorkshire in addition to the former
Yorkshire region. Data collection was extended to include cases diagnosed in south
Yorkshire from 1998 onwards.
Notifications of CYA cancer cases in the region were received from the Northern and
Yorkshire Knowledge and Intelligence Team (NYKIT) and East Midlands Knowledge
and Intelligence Team (EMKIT) (the regional cancer registry teams part of the National
Cancer Registration Service in the UK covering the Yorkshire Strategic Health Authority).
These notifications include data on the date of diagnosis as well as the morphology and
site of the tumour. Detailed data, including treatment information for each of these cases
is then obtained by a data collection officer via the medical records at relevant hospitals
in the area, and annual follow up of all cases takes place to ascertain data on any relapses
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or deaths.
Within this thesis, cases diagnosed under the age of 30 in the former Yorkshire regional
health authority (which excludes south Yorkshire) between 1990 and 2009 were included.
This time frame was chosen so that there was a consistent age range across the study
period. Although data collection is ongoing, the process of manually collecting data for
each case in the area is time consuming and thus at the time of analysis, complete data
was only available up to the end of 2009.
South Yorkshire data was not included within this analysis to avoid causing bias in
any results by a change in the inclusion criteria during the study period of interest.
Although survival analysis can account for differences in the entry point to the study
(the date of diagnosis in this case), a change in the underlying cohort over time could
introduce unknown biases. For example, there could be differences in the types of cancers
which are diagnosed in south Yorkshire compared to the former Yorkshire region due to
differences in the expertise or specialist services offered by these two areas. If survival
was generally higher or lower in south Yorkshire compared to the former Yorkshire region,
then including this cohort part way through the study period (from 1998 onwards) would
mean that survival rates would appear to be improving or worsening over time due to
the structure of the data. Without detailed research into any potential differences between
these two areas in terms of the population demographics, the clinical practices and clinical
coding procedures it was not possible to determine whether such a bias would exist, what
size this may be and in which direction it would occur.
Additionally, the south Yorkshire region is covered by EMKIT, whereas the former
Yorkshire region is covered by NYKIT. Differences in the procedures for notifying the
Yorkshire register as well as the process of data collection could lead to differences in case
ascertainment within these areas, and therefore has the potential to introduce information
or ascertainment bias. Ascertainment bias can lead to biased estimation of survival rates,
the bias will be towards improved survival rates should the cases which were missed
in data collection have poorer survival than those that have been collected and towards
poorer survival rates if those that were missed had better survival. There will be no bias if
the missing cases are MCAR as the collected cases will be a random sample of the total
cases, however, without in depth analysis and examination of the potential differences
between the two regions it is not possible to determine the potential size of the bias
introduced.
One possibility to avoid the types of biases described above would be to only include
data from 1998 onwards covering both the south Yorkshire region and the former
Yorkshire region. Any potential differences between these two areas could then be
adjusted for within the analysis by including a variable to indicate which region the
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data is from. However, restricting the analysis to diagnosis from 1998 onwards has
several disadvantages. Firstly, the ability to analyse longer term outcomes would be
lost as there would be a reduction in the maximum follow up time of cases by 8 years.
Secondly, although the size of the study region would be increased, south Yorkshire is
geographically much smaller than the former Yorkshire region, thus excluding 8 years of
data from this larger region in favour of including data from an additional small region
would inevitably lead to an overall reduction in the number of cases within the study and
therefore result in a loss of statistical power.
4.2.2 Hospital Episode Statistics Data
HES is the national statistical data warehouse for England containing data on all national
health service (NHS) care in England and is managed by the Health and Social Care
Information Centre (HSCIC). Data on private patients treated within NHS hospitals are
also included (approximately 11% of the UK population have private health insurance).
There are six datasets within the HES data warehouse, including inpatient, outpatient,
accident and emergency (A&E), patient reported outcome measures (PROMs), adult
critical care and mortality data.
4.2.2.1 Inpatient Data
Of the six datasets that comprise the full HES data warehouse, the most established is
HES inpatient data (also referred to as admitted patient data). Inpatient data dates back
to the 1st of April 1989, however, the level of completeness and quality of data was not
considered adequate for large scale statistical analysis until 1st April 1996, and the Pseudo
HES ID field used to link records from individual cases across the HES data warehouse
was not introduced until after this point [230]. Inpatient HES data contains details of all
admissions to NHS hospitals in England; additionally it includes private patients treated in
NHS hospitals. Within inpatient HES, data are recorded by individual episodes, referred
to as a finished consultant episode (FCE). This term often gets confused with a hospital
admission, however, one hospital admission can comprise one or more FCEs if a patient
is cared for by more than one consultant during their admission. An admission can
therefore be defined as a continuous inpatient spell (CIPS) which can be constructed for
each patient. A detailed algorithm for the construction of these CIPS is given in Lakhani
et al. [231], the implementation of which is described in Chapter 5. As well as having a
data structure in which multiple FCEs make up a single CIPS, each FCE can also contain
up to 20 diagnoses and up to 24 operation codes which are classified according to the
International Classification of Diseases (ICD-10) and the Office of Population Censuses
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and Surveys Classification of Interventions and Procedures (OPCS-4.5) [30, 232]. A
summary of the inpatient HES data used within this thesis is provided in Chapter 5.
4.2.2.2 Outpatient Data
Outpatient data contains individual level data on all outpatient hospital appointments in
England since the 1st of April 2003. This dataset is less well established and in its data
dictionary, the introduction describes this data as ‘experimental due to known problems’.
The main problem with outpatient HES data was the incompleteness of clinical codes,
since collection of this data was not mandatory for outpatient appointments, unlike for
inpatient admissions. However, the specialty of the consultant under which the patient was
seen was recorded consistently within outpatient HES data. A summary of an outpatient
data extract is given in Chapter 5.
4.2.2.3 Accident and Emergency Data
In the 2007/08 financial year, HES expanded its database to include an A&E dataset
containing diagnosis, investigation and treatment codes on all A&E hospital visits in
England. As with outpatient data, the A&E dataset is listed as an experimental one, with
many data items not being mandatory. Although the inpatient and outpatient datasets
contain admission method codes so that patients who came into hospital via A&E could
be identified, any activity which occurred prior to referral to a specific department was
recorded within the A&E dataset, and was not available from inpatient data.
4.2.2.4 Mortality Data
Although inpatient HES data contains mortality data for those who died during an
inpatient admission, this does not cover those who died outside of hospital or additional
data such as the underlying cause of death. The mortality dataset was constructed using
the Office for National Statistics (ONS) mortality data linked to any patient within the
HES data warehouse. This linkage provides data on those who died in and out of hospital
as well as providing their cause of death. However, mortality data was only available
for patients who have had at least one hospital record in one of the three main datasets
mentioned above.
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4.2.2.5 Patient Reported Outcomes Measures (PROMs) Data
The PROMs data covers patient reported outcomes for four elective surgical procedures,
including groin hernia operations, hip replacements, knee replacements and varicose vein
operations for the whole of England since 2009.
4.2.2.6 Adult Critical Care Data
The critical care dataset comprises all records for adults who have had critical care
hospital stays. Individuals may be associated with more than one critical care stay which
could either be for the same or a different condition, and may be during the same or a
different time period.
4.2.3 HES data and Cancer Epidemiology
Each of the HES datasets as described above have complicated structures, their own
limitations and cover different time periods. Therefore careful consideration into which
of the datasets was most useful in supplementing the Yorkshire register data was required.
Inpatient HES data could not be used as a stand alone dataset for the purposes of cancer
epidemiology. Although cancer diagnoses codes were recorded within inpatient data, the
data was not sufficient to accurately determine the number of cases of cancer in England,
as only those in hospital care at the time of their diagnosis would be included. Therefore,
a cohort of cancer cases obtained solely from HES data could be biased towards a more
‘unhealthy’ cohort. Furthermore, some non-specific cancer diagnoses codes could be
recorded within an episode before a definitive diagnosis had been made. There was
also the possibility of duplication of diagnostic codes in which a cancer diagnosis was
recorded each time a person with cancer had a hospital admission regardless of it being
the admission in which the diagnosis was made. However, inpatient data linked to cancer
registry data can provide a powerful tool for cancer epidemiology analysis, with examples
including Pollock and Vickers [233], Morris et al. [234] and Maddams et al. [235].
Detailed information on the definitive diagnosis of cancer and related specialist oncology
data such as treatment and staging can be supplemented with detailed hospital admissions
and all possible clinical diagnoses both before and after the diagnosis of cancer.
Within this thesis, linked cancer registry and inpatient HES data was used to obtain
additional information about the patients’ demographics, namely, their ethnicity, as well
as to describe and quantify late effects of cancer treatment such as cardiovascular disease
within this cohort. As described in the literature review in Chapter 2, there was a paucity
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of objective data of this kind to accurately quantify the incidence of cardiovascular late
effects within long term survivors of CYA cancer. The details of this analysis can be
found in Chapter 8.
Inpatient data, however, only portrays a subset of a patients hospital activity and a
more complete picture would be seen when also considering outpatient appointments.
In the example of cardiovascular late effects, the incidence of such late effects could
be underestimated by simply assessing inpatient appointments as a proportion of heart
problems could be dealt with entirely within outpatient appointments. As mentioned
within the description of outpatient data, the dataset was not sufficient for this type of
analysis due to the lack of clinical diagnostic coding within the data. Although specialty
codes were included within the outpatient data, this information would not be sufficient
to determine the frequency of cardiovascular late effects within outpatient appointments.
For example, you cannot assume that someone who was seen under the ‘Cardiology’
specialty had a heart problem, as they may have been referred there by an oncologist as a
precaution.
The other HES datasets mentioned will not be used within this thesis due to their
irrelevance to CYA cancer (Adult Critical Care and PROMs data) and their limited time
frame (A&E data). Mortality data for the cohort was available via the Yorkshire register,
obtained through the follow up of patients and notifications received via NYKIT. Both
the mortality dataset held by the HES data warehouse and the data held by NYKIT were
obtained from death certificates. There was therefore no need to obtain duplicate mortality
data via HES.
4.2.4 Data Linkage Methods
Inpatient HES data between 1996 and 2011 was linked to specialist cancer registry data
including diagnosis from 1974 to present. Only those cases who were alive in 1996 were
eligible for linkage, as those who died before this time would not be present within
the inpatient dataset. NHS number, date of birth, sex and postcode at diagnosis for
all eligible cases were extracted from the Yorkshire register and sent to the HSCIC for
linkage, alongside a detailed application form containing all required HES data fields.
The linkage process was performed by the HSCIC trusted data linkage service, who
performed deterministic matching (also known as exact matching) in combination with
fuzzy matching using the above identifiers. Deterministic matching requires all identifiers
to match exactly. In fuzzy matching, exact matching is performed on part of the identifier
(for example, matching exactly on month and year of birth, instead of full date of birth).
The matching process was completed in several stages (referred to as passes) as outlined
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below.
1st Pass Matching on NHS number, sex, date of birth and postcode
2nd Pass Matching on NHS number, sex and date of birth
3rd Pass Matching on NHS number, sex, postcode and partial date of birth
4th Pass Matching on NHS number, sex, and partial date of birth
5th Pass Matching on NHS number, postcode
6th Pass Matching on sex, date of birth and postcode, where NHS number does not
contradict the match, date of birth is not the 1st January and postcode is not on the
ignore list (a list of postcodes that have a dense population such as Army Bases)
7th Pass Matching on sex, date of birth and postcode, where NHS number does not
contradict the match and date of birth is not the 1st January
Details of the number of cases which successfully linked to the register, as well as
differences between linked and non-linked cases are explored in §5.2.1.
4.3 Ethical Approval and Data Security
The University of Leeds requires ethical review of any research which involves human
participants - this includes the use of their data or their tissue. For example, the collection
and use of data obtained via interviews or questionnaires, as well as via observations
or testing. Any research involving human participants from the NHS (including their
personal data or tissue) requires ethical review by the National Research Ethics Service.
A research project which has obtained NHS ethical approval does not require University
of Leeds approval in addition. Throughout this thesis, personal data on NHS patients as
collected by the Yorkshire register as well as HES data was used. Ethical approval for the
collection and use of this data for research purposes has been granted by the Northern and
Yorkshire Research Ethics Committee, reference: MREC/00/3/001. This ethical approval
covers the work set out within the study protocol for the Yorkshire register, of which this
thesis is one element. Original approval was obtained in May 2000, with the most recent
update being approved in April 2014.
Most research involving individuals requires informed consent from each participant
involved in the study according to the Data Protection Act 1998, the Human Rights Act
1998 and the common law. However, any member of the UKACR, which included the
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Yorkshire register, was exempt from having to obtain informed patient consent for the
holding of personal data. This exemption was granted under Section 251 of the NHS Act
2006 to all members of UKACR, and was conditional upon annual reports to the National
Information Governance Board (NIGB) outlining the fulfillment of the conditions on the
retention and disposal of personal information. As of 2009, the NIGB became responsible
for issuing Section 251 approval and following national cancer registration structural
change, the Yorkshire register was required to obtain individual Section 251 approval
through the Confidentiality Advisory Group (CAG). The application was approved in
August 2014, reference: CAG 1-07(b)/2014.
The data held by the Yorkshire register is of a highly sensitive nature as it identifies all
individuals in Yorkshire diagnosed with a malignancy under the age of 30. The data
held are fully identifiable, including names, dates of birth, addresses and unique NHS
number alongside detailed clinical data. This data is only accessed by those covered
under the ethical approval, and data security is therefore very important. As stated within
the registers protocol, all data is held in a secure room on a University of Leeds secure
area network, which can only be accessed by authorised members of staff via password
authentication. The following additional conditions of the data are also in place;
• No information is ever published in which individuals can be identified.
• No individuals on the Yorkshire register are ever approached directly.
• Data are only released according to the requirements of the security policy which
specifies the circumstances for data release.
All work within this thesis will abide by the ethical and data security conditions as
outlined here. In particular, the publication of any data from the Yorkshire register will
not contain identifiable patient data (such as NHS number), or potentially identifiable data
(such as the publication of fewer than five individuals in any one group).
4.4 Statistical Analysis
The main analysis within this thesis was performed in Stata, version 13 [236]. R was used
to perform the sensitivity analysis for multiple imputation [237] (§6.6.1).
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4.4.1 Descriptive Data Analysis
A detailed description of the cohort is given in Chapter 5, including the number of cases
by age group and gender for each diagnostic group, exploration of cancer registry and
HES data linkage rates and an overview of missing data patterns.
To determine diagnostic groups, morphology and site codes for each diagnosis were
initially allocated to ICCC classification as well as Birch TYA classification schemes
(see §2.2.2), and results compared. The cohort covered two age groups for which
separate classification schemes were devised, however, using two classification schemes
in the same analysis would make comparisons by age group difficult. The classification
scheme which minimised the number of cases allocated to the ‘other’ categories was used
throughout the analysis (see Chapter 5). For ICCC, groups XI and XII contain ‘other
malignant epithelial neoplasms’ and ‘other and unspecified neoplasms’ respectively,
whereas for Birch TYA, groups 9 and 10 contain ‘miscellaneous neoplasms not elsewhere
classified’ and ‘unspecified malignant neoplasms not elsewhere classified’ respectively.
Each scheme also resulted in a number of cases which could not be classified, such cases
were described and labelled as ‘unknown.’ Unknown classifications could have resulted
from poor data quality, for example, not all site codes are valid for all morphology codes.
Further exploratory analysis included a detailed description of the number of cancer
registry cases which successfully linked to at least one HES record, and differences
between linked and non-linked cases were explored using the appropriate statistical test
for demographic and clinical variables (including Pearson χ2 test, McNemar’s test, t-test
or Mann-Whitney U-test).
Following detailed descriptions of the cohort, the level of missing data was explored per
variable in which missingness occurred (stage/disease severity and ethnicity). This was
completed on a diagnostic group basis, which was of particular importance for the stage or
disease severity measure due to the fact that each diagnostic group has their own measure
of stage or disease severity. Once the missingness for each variable was explored in detail,
missing data patterns by diagnostic group were assessed.
The diagnostic groups taken forward for imputation and detailed analysis were determined
based on the overall amount of missing data discovered in the descriptive data analysis.
There are no standard rules or cut off points for how much missing data is too much
missing data, with very little research addressing this point specifically. Statements on
the topic of the amount of missing data in research papers are vague and include for
example “if the extent of missing data is not too great” [238], “the potential for bias
usually increases with the extent of missing data” [239], and “70% missing [data] may
require more imputations” [240]. However, a paper by Barzi and Woodward [241] looking
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at different imputation methods at different levels of missing data stated that multiple
imputation was acceptable for studies with up to 60% missing data, after which none
of the tested imputation methods (including multiple imputation and the EM algorithm)
produced satisfactory results. Although indicative of a level at which missing data
may become problematic, the research by Barzi and Woodward [241] was a single
paper comparing a specific set of datasets in which cholesterol level was imputed. The
results found by Barzi and Woodward [241] could be specific to the exact missing data
mechanism of cholesterol level and was not necessarily generalisable to other studies. The
general consensus between researchers appeared to be that with large amounts of missing
data (60/70/80% or higher), any errors made within the imputation process would lead to
greater inaccuracies in the results compared to situations in which the level of missing data
was small. Extra thought, therefore, needs to be put into the exact methods of imputation,
the number of imputations and correctly specifying the imputation model(s) in situations
where the amount of missing data is large.
Based on the available information, only diagnostic groups for which the overall level
of missing data was below 60% were considered for imputation and subsequent survival
analysis. These were central nervous system (CNS) tumours, leukaemia and germ cell
tumours (GCT). WHO Grade (four level ordered categorical variable), white blood cell
(WBC) count (continuous measure) and stage (four level ordered categorical variable)
were the disease severity measures to be imputed for each diagnostic group respectively
and ethnicity (three level categorical variable) was imputed for all three diagnostic groups
(see Chapter 5 for a detailed description of the missing data for all diagnostic groups).
4.4.2 Multiple Imputation
Missing data for disease severity and ethnic group was imputed to allow for the
inclusion of these variables in the ‘Variation in Cancer Survival’ analysis (Chapter 6) and
‘Inequalities in Disease Severity at Diagnosis’ analysis (Chapter 7). This section contains
specific methods used for imputation purposes, §4.4.3, §4.4.4 and §4.4.5 contain details
of the main analysis methods. As discussed in Chapter 3, multiple imputation was the
preferred method of handling missing data within this thesis. Two multiple imputation
techniques, MICE and SMC-FCS, were compared to a complete case analysis (CCA) in
Chapter 6. The SMC-FCS method was only applicable to survival analysis due to the use
of Cox PH modelling which is a non-linear model. For the access to healthcare analysis,
which is based on logistic regression modelling (a form of generalised linear modelling),
only MICE was used for imputation. The final analysis in Chapter 8 did not include any
imputation, thus all methods relating to that chapter are provided in §4.4.5.
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Prior to any imputation process, the missingness mechanism was explored. As described
in Chapter 3, there is no definitive way to determine from the observed data whether the
missing data are MCAR, MAR or MNAR. A distinction between MCAR and MAR can be
made by assessing whether any of the non-missing variables within the observed dataset
can predict missingness. This was determined with the use of logistic regression models,
where a binary indicator variable for missingness of a particular variable was treated as
the outcome measure, and the non-missing variables within the dataset were entered into
the model as independent variables. One such model was produced for each variable
which was to be imputed (i.e. disease severity and ethnicity for CNS tumours, leukaemia
and GCT). The variables included in these missingness predictor models included all
variables of interest in the main survival analysis (see §4.4.3 for variable choice), as
well as any additional variables available within the Yorkshire register data, namely three
binary variables for initial treatment modalities (chemotherapy, radiotherapy or surgery)
and a binary variable to indicate whether a relapse had occurred. Furthermore, Kaplan-
Meier survival curves for cases with missing data compared to cases without missing
data were plotted in order to further explore the missing data mechanism. The presence
of significant differences between cases with missing data compared to cases without
missing data implies that the data are not MCAR, however, the absence of such differences
is not sufficient to conclude that the data are MCAR. Evidence for MNAR cannot be
obtained from the observed data alone, however, a sensitivity analysis can be performed
(see §4.4.2.2).
4.4.2.1 Imputation Model Specification
Imputation models were specified for CNS tumours, leukaemia and GCTs individually
due to their individual measures of disease severity. The imputation models included all
variables of interest in the main survival analysis, including interaction terms (see §4.4.3),
the Nelson-Aalen survival estimate and the censoring indicator. Any variables which were
shown to be significant predictors of missingness based on the results of the missingness
predictor models described above were included in the imputation models as auxiliary
variables. Any continuous variables which could be categorised, such as age, year of
diagnosis and deprivation were all included as continuous variables within the imputation
models. Tests for linearity (see §4.4.3) for each of these variables were subsequently
performed at the analysis stage.
The same imputation model specifications were used for the ‘Inequalities in Disease
Severity at Diagnosis’ analysis. The outcome variables for survival analysis (Nelson-
Aalen estimate and censoring indicator) were also retained in the imputation models as
disease severity and survival were highly correlated as demonstrated in the results section
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of Chapter 6. The outcome measure for the inequalities analysis was disease severity
(see §4.4.4 for details), which was also a variable to be imputed. Chapter 3 contains a
discussion of the literature surrounding imputation of the outcome variable. Based on
this discussion the outcome variable was imputed and observed and imputed data were
included within the analysis as firstly, auxiliary variables were used within the imputation
process thereby providing additional information in the imputed outcome variable and
secondly, the power of the analysis was substantially increased using this method due to
the amount of missing disease severity data.
Collinearity of variables was checked using Spearman correlation coefficients between
variable pairs. All imputation models for ethnicity were based on multinomial logistic
regression models as this was an unordered categorical variable. Imputation of WHO
grade for CNS tumours and stage for GCTs was based on ordered logistic regression due
to the natural ordering of the variables (high grade/stage represents more severe disease
at presentation). For leukaemia, WBC count was imputed using linear regression. As
described in §3.5.4.4, it is important to check the normality assumption for any continuous
variable which is to be imputed. The distribution of WBC count was checked graphically
using a histogram with a Normal density curve overlay. WBC count was transformed
using a natural logarithmic transformation due to evidence of non-Normality (§6.3.2).
4.4.2.2 Imputation Assessment and Sensitivity Analysis
In order to determine the quality of the imputations, stacked bar charts were plotted for the
observed cases compared to each imputation number for all imputed categorical variables.
For WBC count, a histogram showing observed and imputed data was produced. These
graphics provided a visual method of assessing the general pattern of imputed values.
Additionally, pooled parameter estimates obtained from the multiple imputation analysis
models were compared to those obtained via a CCA as suggested by good practice
guidelines [142]. In order to determine the number of imputation iterations required,
the method suggested by Royston [242] of running one imputation with a large number of
iterations and assessing the point at which the imputations became stationary was used.
The point at which imputations became stationary was determined visually using trace
plots. For categorical variables, convergence was difficult to assess using trace plots of
the mean, however, the literature provides no alternative suggestions and were therefore
still used. The recommended number of cycles used for multiple imputation was between
10 and 20 according to van Buuren and Groothuis-Oudshoorn [192], thus 20 cycles were
used for tumour groups in which there was no evidence of later convergence.
For imputation models in which there was reason to believe the MAR assumption could
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be violated, the data was analysed under plausible MNAR assumptions by allowing the
underlying missingness probability to differ systematically. For example, by assuming
that those with missing stage data had poorer survival compared to those with completed
stage data. For continuous variables, the method is described in detail by van Buuren
and Oudshoorn [193], in which a constant, referred to as the δ−adjustment, is added
to the imputed values. For categorical variables, the method is more complicated as it
requires adjustment of the probability that the missing data takes a specific value, rather
than adjustments of the values themselves. This method can be implemented in the
sens.mice package in R, where parameters of θ are specified to allow a percentage
increase or decrease in the missingness probability in relation to the outcome. The
resulting imputations are analysed using the same techniques as for imputations under
the MAR assumption and results compared. The data are deemed to be robust to
deviations from the MAR assumption if the results obtained under the MNAR assumption
do not differ substantially from those obtained under an MAR assumption (i.e. the
magnitude, direction and significance of effect sizes are similar). van Buuren [243] states
that sensitivity analysis should only be performed in situations where there is a good
idea of different plausible missing data scenarios, and a careful imputation procedure
is considered more important than conducting a poorly informed sensitivity analysis.
Furthermore, van Buuren [243] state that it is sufficient to make adjustments to one
imputation variable within the model, rather than all imputed variables. The reason for
this is that the effect of changing the imputed values of one variable will change the
imputations of the other imputed variables due to the cyclical nature of imputation by
chained equations.
A sensitivity analysis using the δ−adjustment method was performed for the missing
WBC variable within the leukaemia diagnostic group analysis. For CNS tumours
and GCTs, sensitivity analysis for WHO grade and stage were performed using the
sens.mice package. The missingness probability adjustments were set at 50% and
80% respectively.
Further sensitivity analysis to determine whether or not the number of imputations was
sufficient for repeatability of the analysis was conducted by assessing Monte Carlo errors
(as described in §3.5.4.3). The number of imputations were deemed to be sufficient if
the Monte Carlo error was sufficiently small so that the addition or subtraction of this
error to the parameter estimates and P -values of the survival analysis did not change their
interpretation. Initial choices for the number of imputations were set to be approximately
equal to the amount of missing data, thus these are specified in Chapter 5.
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4.4.3 Variation in Cancer Survival
Survival patterns of the cohort were initially described in a univariable analysis, and were
summarised by one, three and five-year survival estimates alongside 95% confidence
intervals. For imputed variables, it was initially thought that pooled estimates of the
survivor function and the standard error could be obtained by manually calculating these
according to Rubin’s rules. However, after initial calculations, it became clear that
although the pooled estimates were sensible, the associated standard errors taking into
account the within and between imputation variance (see §3.5.4) produced confidence
intervals outside of the range zero to one. The combining of estimates and their related
standard errors across imputed dataset relied on the assumption that the estimates follow
a normal distribution, which was not the case for the survivor function. Although
transformations of the data could have been applied, research by Marshall et al. [244]
suggests that despite such transformations it is unclear how to produce sensible pooled
standard errors for measures which are bound by zero and one, and instead the authors
suggest that providing the full range of estimates across all imputed datasets provides a
more appropriate representation of the variability within the data.
In order to represent the univariable survival estimates for imputed variables, Kaplan-
Meier (K-M) plots of the pooled estimates were overlayed onto a K-M plot showing the
range of survival estimates at each time point over all imputations. However, several
complications arose during this process. K-M curves could be obtained for each single
imputation, however, these tended to overlap with each other and therefore simply
selecting the minimum and maximum lines out of all the imputations was not possible.
Instead, initially, the maximum and minimum value at each time point was selected.
However, by doing so, the sequence of increasing time corresponding to a decrease in
the proportion of people survived was not necessarily maintained. This was because for
each single imputation of stage for example, one person could be assigned a different
stage to the subsequent imputation(s). This implies that each K-M curve associated with
each imputation contained different people and therefore different times at which events
(deaths) occurred. Therefore, in order to obtain sensible K-M curves which maintained
the standard pattern of decreasing proportion survived over time, whilst highlighting the
variability across all imputations, individual K-M curves for each imputation were plotted
in a light background colour, with the average over all imputations overlayed on to this
plot in a dark foreground colour. As Stata has a maximum number of plot options (70),
lines could not be coloured via the command line. Therefore, they were instead coloured
using schemes written via the ‘record’ option in the Stata Graphics editor. Details of the
Stata code required to implement this technique are given in Appendix H.
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4.4.3.1 Model Selection Process
A multivariable Cox PH model was implemented for each imputed dataset for
CNS tumours, leukaemia and GCTs and the resulting parameter estimates were
combined using Rubin’s rules [191], which were implemented in Stata by use of the
mi estimate, hr: prefix. The model selection procedure for the Cox PH model
followed the method described in Collett [245], pages 80-89, however, instead of testing
significant improvements to model fit using a likelihood ratio test, model improvements
were checked using the Wald test, which is asymptotically equivalent to the likelihood
ratio test [246]. Model comparisons using an approximation of likelihood ratio testing
[247] after imputation is possible for models in which the log-likelihood function is fully
specified, and the package milrtest in Stata can be used for such tests in linear and
logistic regression models. However, likelihood ratio testing after multiple imputation
was not possible for Cox PH models as these models use the partial log-likelihood rather
than the full log-likelihood function due to the baseline hazard ratio not being specified.
Furthermore, White et al. [202] suggests that although likelihood ratio tests are often
used to compare models for CCA, the Wald test is generally recommended for comparing
models after imputation as there is no evidence to suggest that the approximation of the
likelihood ratio test for multiple imputed estimates offers an advantage over the Wald test.
The model selection procedure recommended by Collett [245] involved identifying a
set of explanatory variables for potential inclusion in the model alongside any potential
interaction terms of interest based on the literature review provided in Chapter 2 and
clinical input from Dr DP Stark. Subsequently, each explanatory variable was fitted
individually in a univariable Cox PH model and compared to the null model to determine
which variables had individual predictive power. All variables with individual predictive
power were then sequentially added to the model, and only those that continued to
improve model fit were retained in the model in addition to those of specific clinical
interest in the study. Explanatory variables that were not individually predictive were
then added to the model one at a time, as they may become important in combination
with other variables. Again, only those that improved the model were retained. Once all
main effects in the model were determined, interactions were added to the main effects
model and individually tested against the nested main effects model. Main effects which
formed part of interaction terms of interest were retained in the model even if they did not
improve model fit so that the corresponding interaction could be tested and the hierarchic
principle remained intact. If subsequently, the interaction term was not significant, then
this was removed from the model alongside the non-significant main effect term. Linearity
was checked for continuous variables which could be categorised (specified below) and
were tested individually by adding a categorical variable to the full model containing the
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corresponding continuous variable, a significant improvement in model fit gave evidence
against linearity and would result in the categorical variable being chosen in favour of the
continuous form.
Collett [245] highlights the importance of using clinical knowledge alongside sensible
model checking procedures and therefore recommends a lenient significant value of
10% while selecting variables for inclusion or exclusion from the model. Alternative
approaches to the procedure outlined above include automated stepwise procedures or
the use of Directed Acyclic Graphs (DAGs). The reason for not choosing an automated
forward, backward or stepwise model selection procedure is that the final model obtained
can depend on the procedure used (for example, forward elimination could result in a
different final model than backward elimination) and they depend on a pre-specified
significance level which does not allow for clinical knowledge, or variables of key interest
in a study to be included. DAGs can be helpful in determining the intricate causal
pathways between explanatory variables and any sources of bias within a multivariable
analysis. However, the use of DAGs to inform model selection, is more suited to an
analysis in which there is one main exposure for a given outcome. Although it may
be possible to select one variable as the main exposure, the purpose of this research
was primarily to discover where variations in survival may arise due to a number of
demographic and clinical factors, with no single most important exposure. Therefore, the
analysis models presented in Chapters 6 and 7 are mutually adjusted multivariable models,
which can be used to predict the survival for a particular person with characteristics of all
the variables included in the model (for example a south Asian person, aged 25 diagnosed
with a certain type of cancer in a particular year). Without the use of DAG, care must be
taken to not make any causal inferences based on the analysis results as the effect of each
variable includes both direct and indirect effects. Nevertheless, the approach of using
mutually adjusted variables is arguably more applicable to a clinical scenario in which a
doctor can determine the prognosis of a patient according to a full range of patient and
clinical characteristics in combination.
Variables considered for inclusion in the Cox PH models were based upon those which
were previously used within the CYA cancer survival literature. These were diagnostic
subgroup, age, sex, deprivation, stage or severity of disease, ethnicity and year of
diagnosis [40, 64, 248]. Deprivation was measured using the 2007 Index of Multiple
Deprivation (IMD) [249], assigned to the lower super output area associated with the
postcode at diagnosis. IMD 2007 is a measure of seven domains, which include income,
employment, health and disability, education, skills and training, barriers to housing and
services, living environment and crime. This data was obtained from GeoConvert, which
is a web based tool run by the UK Data Service Census Support and allows extraction of
geographical data based on postcodes. The IMD is an area based measure of deprivation
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and is routinely used within epidemiological research in cases where individual based
deprivation data is not available. Lower super output areas (LSOA) are confined to a
population of approximately 1500 people, and there are a total 32,482 of these areas in
England. The deprivation fifth for each lower super output area in England has been
shown to remain relatively stable over a 25 year study period [250]. Despite IMD being
the measure of socioeconomic status of choice by the UK government and its common
use for public health research, the inclusion of a health domain has been criticised
as it could lead to a statistical phenomenon known as mathematical coupling [251].
Mathematical coupling occurs when one variable contains all or part of another variable,
and therefore when analysing relationships between these variables they will inevitably be
highly correlated [252], thus potentially causing spurious results. However, Adams and
White [253] assessed the impact of analysing health outcomes using IMD by comparing
such an analysis to one in which the health domain was removed. Quintiles based on the
full IMD score and the score without the health domain had a high level of agreement
(92%). Furthermore, although the study showed that there were some differences in
the relationship between health outcomes and the two IMD measures (with and without
the health domain), these differences were very small and the authors concluded the
inclusion of the health domain was of little practical importance. The IMD score was
chosen in favour of other more historical area based deprivation scores (including the
Townsend Deprivation Score [254] and Carstairs Index [255]) as it was updated using
routine data collected in inter-census years, rather than being confined solely to census
data. Furthermore, IMD assigns weights to each of its domains, compared to the equal
weighting used in the Townsend deprivation score. The latest version of the 2007 IMD
score includes postcodes from the most up to date National Statistics Postcode Products
at time of analysis (2010), which is a directory of all postcodes in England. IMD 2007 is
a contemporary measure of deprivation which falls within the period of diagnosis covered
in this thesis.
The linearity of age, deprivation and year of diagnosis were all tested, if there
were retained as explanatory variables in the modelling selection procedure, using the
categorisation method. The problems of using categorisation within epidemiological
studies are well described [256, 257, 258, 259] as discussed below, however, this
method was adopted in favour of more advanced methods to account for non-linear
relationships such as splines, fractional polynomials and generalized additive models
(GAMs) [260, 261, 262] due to ease of interpretation of results by a clinical, non-
statistical, audience. The disadvantages of categorisation include the assumption of
homogeneity between the categorised groups of data and the introduction of multiple
hypotheses testing through pairwise comparisons [257]. Furthermore, comparing results
across studies can become problematic if categorisation is done based on data driven cut
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off points such as quantiles [256]. Although other methods of testing for linearity are
available (such as splines, fractional polynomials and GAMs), these methods are prone to
over fitting which could lead to spurious findings and are known to hinder communication
of results to a non-statistical audience [256, 259]. The results of this study were intended
for a clinical audience and to be published in clinical journals, therefore, the ease of
interpretation by clinical audiences and the translation of the results into practice was key.
Moreover, the use of this approach compared with other methods allowed for straight
forward quantification of the effect of imputation on the coefficients. Whereas quantifying
the effect of imputation on coefficients of spline functions or fractional polynomials
is not immediately obvious, although these could be described, rather than quantified,
graphically.
For age at diagnosis, data was considered in 5-year age bands (0-4, 5-9, 10-14, 15-19,
20-24 and 25-29) as well as two main age groups (0-14 and 15-29). For leukaemia, the
following age grouping was additionally checked (< 1, 1-10, 11-14, 15-29 years). For
year of diagnosis, 5-year periods (1990-1994, 1995-1999, 2000-2004, 2005-2009) were
considered and linearity of deprivation was checked against deprivation fifths, which were
generated using the following quintiles of LSOA: 6496.4, 12992.8, 19489.2 and 25985.6.
These quintiles were based on splitting the total number of LSOA in England into fifths,
rather than by splitting the deprivation values for the cohort into fifths to ensure groups
were relative to the whole of England rather than Yorkshire to ensure generalisability of
results across England.
Age and sex were known to have an impact upon survival for certain diagnostic groups, for
example, TYAs with acute lymphoblastic leukaemia (ALL) had poorer survival compared
to children with the same diagnosis. The effect of age on survival could vary by sex
[263]. In particular, as the cohort in this thesis spanned two main age groups (children
< 15 years of age and TYAs aged 15-29), gender differences in survival could exist for
childhood tumours for example, but not for TYAs. Therefore, interaction terms between
age and sex as well as between age and diagnostic subgroup were considered for analysis.
Furthermore, year of diagnosis could have a direct effect upon survival through changes in
treatment regimens and protocols over time, and improvements in survival of CYA cancer
over time are well documented (see §2.3.1). In order to determine whether potential
improvements over time were restricted to specific diagnostic subgroups, an interaction
between year of diagnosis and diagnostic subgroup was also considered for analysis.
Interactions were only included within the imputation and survival analysis if there were
a sufficiently large number of events per interaction level. A minimum of 10 events per
variable (EPV) have been shown to be required to ensure sufficient power in any survival
analysis [264, 265, 266], thus for each tumour group, the number of deaths per interaction
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level were summarised (§6.2.1) to determine whether interactions were to be included in
the analysis. Further work by Vittinghoff and McCulloch [267] in 2007 highlights that
the use of 10 EPV may be too conservative, therefore, 10 EPV was simply used as a guide
to inform whether further subgroup analysis and interactions were to be studied, but was
not used at the expense of including important confounding effects and variables of key
interest in the analysis (such as ethnicity and disease severity). In cases where there was
sufficient data, interactions were included within the imputation models in addition to the
analysis models so that any potential interaction effects were not diluted by the imputation
process as described in §3.5.4.4. Interaction terms were specified by creating dummy
variables for each interaction level. The interactions of interest (as mentioned above) only
included fully observed variables, thus special methods for interactions such as the ‘just
another variable’ method (whereby a new variable representing the interaction is created
and it is included in the imputation model as an ordinary main effects variable) or passive
imputation (whereby the main effects within the interaction are imputed individually, and
the interaction term is derived post-imputation analysis based on the imputed main effects)
were not required. If including interactions with partially observed variables, the ‘just
another variable’ method would be preferred, as this has been shown to perform better
than passive imputation [207, 268].
4.4.3.2 Model Assessment
The PH assumption was checked graphically using log cumulative hazard plots for each
variable in the final model of each diagnostic group across all imputations. Continuous
variables were categorised as follows prior to plotting: year of diagnosis - 1990–1998 and
1999–2009 and WBC count - standard risk (< 50, 000µ/L) and high risk (≥ 50, 000µ/L).
Goodness of fit (GOF) was assessed by plotting deviance residuals against risk scores
(predicted values) for all imputations. Deviance residuals were chosen in favour of
Martingale residuals as deviance residuals have been shown to detect residuals at the
extreme negative (observed deaths occurred later than predicted by the model) as well
as the extreme positive (observed deaths occurred earlier than predicted by the model)
end of the scale, whereas Martingale residuals are not sensitive to extreme positive
residuals [269, 270]. Therefore, lack of model fit was indicated by extreme outlying
residuals on the deviance residual plots. Harrell’s C-index of discrimination was used to
assess the predictive performance of each model [271], which was obtained via Stata’s
post estimation command estat concordance.Harrell’s C-index of discrimination
cannot be combined using Rubin’s rules [244], and therefore the range of values was
described over all imputation models rather than providing one pooled estimate and CI.
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4.4.4 Inequalities in Disease Severity at Diagnosis
In order to assess inequalities in disease severity at diagnosis, the analysis focused
around three main factors of interest as identified in the literature (Chapter 2), these
were ethnicity, deprivation and age. Missing data for disease severity and ethnicity were
imputed using MICE (see §4.4.2 above for detailed imputation methods). In order to
describe the imputed data, the average percentage over all imputations of cases by age
group (0-14 vs. 15-29), ethnicity (White, Asian, other) and deprivation (1-5, where 1 was
least deprived and 5 was most deprived) were summarised.
The effects of ethnicity and deprivation on disease severity were modeled using ordinal
logistic regression for WHO grade of tumour for CNS tumours (grade I-IV) and stage
for GCTs (stage I-IV). For leukaemia, the effects of ethnicity and deprivation on disease
severity were modelled using logistic regression according to standard risk and high risk
leukaemia based on WBC count measures of < 50, 000µ/L and ≥ 50, 000µ/L.
4.4.4.1 Model Selection Process
Initially, the effects of age, ethnicity and deprivation on disease severity were modelled
individually using ordinal logistic regression for WHO grade of tumour for CNS tumours
(grade I-IV) and stage for GCTs (stage I-IV) whilst adjusting for sex and year of
diagnosis. Similarly, for leukaemia, the effects of age, ethnicity and deprivation on
disease severity were modelled using logistic regression according to standard risk and
high risk leukaemia based on WBC count measures of < 50, 000µ/L and ≥ 50, 000µ/L
respectively, again, adjusting for sex and year of diagnosis. After assessing the
independent effects of age, ethnicity and deprivation, a multivariable model was fitted
which included mutual adjustments for age, ethnicity and deprivation in addition to sex
and year of diagnosis.
4.4.4.2 Model Assessment
The GOF for the logistic regression model (i.e. the leukaemia analysis) was tested using
the Hosmer-Lemeshow (HL) test for each imputation [272]. The HL-GOF test was
chosen in favour of assessing the Pearson or Deviance residuals as continuous variables
were included in the model (year of diagnosis), implying that there could be as many
covariate patterns as subjects. This condition has been shown to lead to incorrect P -
values for model fit tested using Pearson or Deviance residuals [273], which the HL-GOF
test overcomes by grouping data according to values of the estimated probabilities (i.e.
the estimated probability of having high risk compared to low risk leukaemia based on
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values of the independent variables). The HL-GOF tests the null hypothesis that the
observed probability of the event (high risk leukaemia) and expected probability of the
event obtained from the model are the same, therefore, a non-significant result provides
no evidence against model fit. The recommended number of 10 subgroups was used for all
HL-GOF tests. The discriminatory power (i.e. the sensitivity versus 1 minus specificity)
for logistic regression models can be assessed using a receiver operator (ROC) curve,
however, as the discriminatory power needed to be assessed for all imputations models,
the area under the ROC curve (AUROC) values for each model were calculated and the
mean and 95% CI of these values were summarised. This process was performed in Stata
using the following commands, as described in the mim: Stata help file:
mim: logit x1 x2 x3, or
mim: predict xb
mim, cat(combine) byvar est(r(area)) se(r(se)) : roctab y xb
where x1,x2 and x3 are independent variables and y is the dependent variable.
In order to test the model fit of the ordered logistic regression models for the CNS tumour
and GCT analysis, a series of logistic regression models were tested using the HL-GOF
and AUROC methods described above per imputation. Although methods have been
developed based on extensions of the HL-GOF test [274], these are not readily available
or easily applied in current software, therefore Hosmer and Lemeshow [273] recommends
use of the individual logistic regression method by Begg and Gray [275]. Furthermore,
this method could be easily repeated for each imputation model as described above. The
outcomes WHO grade and stage each have four ordered categories, therefore, model
fit and predictive power was assessed for the set of logistic regression models with the
following binary outcomes, whilst retaining the ordered structure of the data:
i) Grade/stage I compared to grade/stage II-IV,
ii) Grade/stage I-II compared to grade/stage III-IV,
iii) Grade/stage I-III compared to grade/stage IV.
4.4.5 Long Term Effects amongst Survivors of Cancer
In order to describe the risk of cardiovascular LEs amongst long term survivors of CYA
cancer, a subset of the linked cancer registry and inpatient HES data was studied. A
long term survivor of cancer was defined as anyone having survived a minimum of 5
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years post diagnosis of cancer and a LE was defined as a co-morbidity (in this case a
cardiovascular hospital event; see detailed definition below) occurring a minimum of
5 years post diagnosis. As described earlier in this chapter, inpatient HES data was
available from 1996 to 2011, therefore, cases diagnosed between 1991 and 2006 who
survived a minimum of 5 years were included in the subset of cancer registry linked HES
data. This ensured that inpatient HES data for identification of late effects was available
for all linked cases from 5 years of diagnosis. A summary of the linkage rates for this
subset of the cohort are provided in §5.2.1. In order to determine whether the rate of
cardiovascular LEs amongst survivors of CYA cancer differed to the rate of cardiovascular
hospital events amongst the background population, record level inpatient HES data were
obtained for the whole population resident within the former Yorkshire Regional Health
Authority between 1996 and 2011 and matched on age and sex. The cohort of survivors
were aged between 0 and 29 years at diagnosis and were diagnosed between 1991 and
2006. To ensure comparability of admission rates amongst the survivor cohort and the
general population, the age at hospital admission was used to match the survivor cohort to
the general population cohort. In 1996, the first year of available HES data, the possible
age range at hospital admission for the survivor cohort was 5-34 years old, in 1997,
the possible age range was 5 to 35 years old and so forth up until 5 to 49 year olds
in 2011. Table 4.1 shows the age structure by diagnosis and hospital admission year.
Any admissions for the general population outside of the highlighted age ranges in each
year of hospital admission were excluded from the general population based HES data to
ensure the overall age range included in the general population matched that of the cancer
survivor cohort.
Table 4.1: Age structure at hospital admission by year of diagnosis (1991-2006) and
year of hospital admission (1996-2011). Highlighted age ranges for each year of hospital
admission were selected from the general population HES data as comparator data.
Year of Diagnosis Year of Hospital Admission1996 1997 1998 1999 . . . 2008 2009 2010 2011
1991 5-34 6-35 7-36 8-37 . . . 17-46 18-47 19-48 20-49
1992 4-33 5-34 6-35 7-36 . . . 16-45 17-46 18-47 19-48
1993 3-32 4-33 5-34 6-35 . . . 15-44 16-45 17-46 18-47
1994 2-31 3-32 4-33 5-34 . . . 14-34 15-44 16-45 17-46
1995 1-30 2-31 3-32 4-33 . . . 13-42 14-34 15-44 16-45
1996 0-29 1-30 2-31 3-32 . . . 12-41 13-42 14-34 15-44
1997 0-28 0-29 1-30 2-31 . . . 11-40 12-41 13-42 14-34
1998 0-27 0-28 0-29 1-30 . . . 10-39 11-40 12-41 13-42
1999 0-26 0-27 0-28 0-29 . . . 9-38 10-39 11-40 12-41
2000 0-25 0-26 0-27 0-28 . . . 8-37 9-38 10-39 11-40
2001 0-24 0-25 0-26 0-27 . . . 7-36 8-37 9-38 10-39
2002 0-23 0-24 0-25 0-26 . . . 6-35 7-36 8-37 9-38
2003 0-22 0-23 0-24 0-25 . . . 5-34 6-35 7-36 8-37
2004 0-21 0-22 0-23 0-24 . . . 4-33 5-34 6-35 7-36
2005 0-20 0-21 0-22 0-23 . . . 3-32 4-33 5-34 6-35
2006 0-19 0-20 0-21 0-22 . . . 2-31 3-32 4-33 5-34
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Cardiovascular LEs were defined using inpatient diagnoses and operations fields as
recorded in HES and grouped as follows: hypertension, cardiomyopathy and heart failure,
coronary artery disease, pulmonary heart disease, pericardial and endocardial disease,
valvular heart disease, conduction disorders, cerebrovascular disease and operations &
procedures requiring hospitalisation. Expert advice from a cardiologist (Dr Chris Gale)
was sought to form these groups and identify specific codes used to categorise the
diagnoses codes and operations and procedure codes (classified according to ICD-10
and OPCS-4.5 respectively; see §4.4.5) and specific codes in each group are given in
Table 4.2. A patient was identified as having a cardiovascular LE if they experienced
at least one hospital admission containing any diagnoses or procedure in the above
categories occurring exclusively five or more years after the diagnosis of cancer. Those
who had either no reported cardiovascular LEs, or who had any cardiovascular hospital
admission prior to, or within five years of, cancer diagnosis were defined as having had no
cardiovascular LE as the latter could be an indication that the cardiovascular admission
was related to a pre-existing or underlying condition, and not as a result of their cancer.
The number of cases with a cardiovascular admission prior to or within five years of
diagnosis was small and occurred in less than 1% of the cohort. Events were identified
from all diagnosis and procedure fields, however, only the first occurrence of a particular
event was included in the analysis so that ongoing conditions, which could be recorded
multiple times, were not duplicated. It was important to include the primary diagnoses
and all subsequently recorded diagnoses codes within the HES data to compare to the
general population, as for the cohort of survivors, the majority of primary diagnoses were
recorded as a neoplasm (see §5.2.2 for a data summary). Again, ongoing conditions, such
as cancer, are sometimes recorded within diagnoses fields despite not being the diagnoses
related to that specific hospital episode. Therefore, by only assessing primary diagnoses
codes compared to the general population, the true rate of cardiovascular LEs could be
underestimated.
Table 4.2: Diagnoses and operations classification codes (ICD-10 and OPCS-4.5
respectively) used to identify cardiovascular late effects and grouped into 9 categories
Cardiovascular Category and ICD-10 Code Description
Hypertension
I10 Essential (primary) hypertension
I11 Hypertensive heart disease
I12 Hypertensive renal disease
I13 Hypertensive heart and renal disease
I15 Secondary hypertension
Cardiomyopathy and Heart Failure
I42 Cardiomyopathy
I43 Cardiomyopathy in diseases classified elsewhere
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I50 Heart Failure
I51 Complications and illdefined descriptions of heart disease
I52 Other heart disorders in diseases classified elsewhere
Coronary Artery Disease
I20 Angina pectoris
I21 Acute myocardial infarction
I22 Subsequent myocardial infarction
I23 Certain current complications following acute
myocardial infarction
I24 Other acute ischaemic heart diseases
I25 Chronic ischaemic heart disease
Pulmonary Heart Disease
I26 Pulmonary embolism
I27 Other pulmonary heart diseases
I28 Other diseases of pulmonary vessels
Pericardial disease
I30 Acute pericarditis
I31 Other diseases of pericardium
I32 Pericarditis in diseases classified elsewhere
Valvular Heart Disease
I08 Multiple valve diseases
I34 Nonrheumatic mitral valve disorders
I35 Nonrheumatic aortic valve disorders
I36 Nonrheumatic tricuspid valve disorders
I37 Pulmonary valve disorders
I33 Acute and subacute endocarditis
I38 Endocarditis, valve unspecified
I39 Endocarditis and heart valve disorders in diseases
classified elsewhere
Conduction Disorders
I44 Atrioventricular and left bundle-branch block
I45 Other conduction disorders
I46 Cardiac arrest
I47 Paroxysmal tachycardia
I48 Atrial fibrillation and flutter
I49 Other cardiac arrhythmias
Cerebrovascular Disease
I60 Subarachnoid haemorrhage
I61 Intracerebral haemorrhage
I62 Other non traumatic intracranial haemorrhage
I63 Cerebral Infarction
I64 Stroke, not specificied as haemorrhage or infarction
I65 Occlusion and stenosis of precerebral arteries, not
resulting in cerebral infarction
I66 Occlusion and stenosis of cerebral arteries, not resulting
in cerebral infarction
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I67 Other cerebrovascular diseases
I68 Cerebrovascular disorders in diseases classified
elsewhere
I69 Sequelae of cerebrovascular disease
G45 Transient cerebral ischeamic attacks and related
syndromes
Operations and Procedures1
K02 Other Transplantation of heart
K13 Transluminal repair of defect of septum
K14 Other open operations on septum of heart
K16 Other therapeutic transluminal operations on septum of
heart
K23 Other operations of wall of heart
K25 Plastic repair of mitral valve
K26 Plastic repair of aortic valve
K27 Plastic repair of tricuspid valve
K28 Plastic repair of pulmonary valve
K29 Plastic repair of unspecified valve of hear
K30 Revision of plastic repair of valve of heart
K31 Open incision of valve of heart
K32 Closed incision of valve of heart
K33 Operations on aortic root
K34 Other open operations on valve of heart
K35 Therapeutic transluminal operations on valve of heart
K36 Excision of valve of heart
K38 Other operations on structure adjacent to valve of heart
K40 Saphenous vein graft replacement of coronary artery
K41 Other autograft replacement of coronary artery
K42 Allograft replacement of coronary artery
K43 Prosthetic replacement of coronary artery
K44 Other replacement of coronary artery
K45 Connection of thoracic artery to coronary artery
K46 Other bypass of coronary artery
K47 Repair of coronary artery
K48 Other open operations on coronary artery
K49 Transluminal balloon angioplasty of coronary artery
K50 Other therapeutic transluminal operations on coronary
artery
K51 Diagnostic transluminal operations on coronary artery
K52 Open operations on conducting system of heart
K53 Other incision of heart
K54 Open heart assist operations
K55 Other open operations on heart
K56 Transluminal heart assist operations
K57 Other therapeutic transluminal operations on heart
K58 Diagnostic transluminal operations on heart
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K59 Cardioverter defibrillator introduced through vein
K60 Cardiac pacemaker system introduced through vein
K61 Other cardiac pacemaker system
K62 Therapeutic transluminal operations on heart
K63 Contrast radiology of heart
K65 Catherisation of heart
K67 Excision of pericardium
K68 Drainage of pericardium
K69 Incision of pericardium
K71 Other operations on pericardium
K75 Percutaneous transluminal ballon angioplasty and
insertion of stent into coronary
K77 Transluminal drainage of pericardium
K78 Transluminal operations on internal mammary artery side
branch
1OPCS-4.5 Coding
4.4.5.1 Statistical Methods for Long Term Effects amongst Survivors of Cancer
The number of cardiovascular LEs amongst the cancer survivor cohort was summarised
by age group at cancer diagnosis (0-14 year olds and 15-29 year olds) and the number
of distinct cardiovascular LEs per survivor was described. Furthermore, the time to
first cardiovascular hospital admission per survivor was described using the median and
interquartile range (IQR). The cumulative incidence for cardiovascular LEs was estimated
as a function of years since diagnosis whilst death without experiencing a cardiovascular
LE was treated as a competing risk.
In order to compare the survivor cohort to the general population, the number and crude
incidence (per 10,000 person-years) of cardiovascular hospital admissions amongst the
survivor cohort and the general population were summarised by cardiovascular diagnosis
and age group. For the cancer survivor cohort, total person-years (PYs) was calculated by
summing up the exposure time of all cancer survivors, where exposure time was taken as
the time to first cardiovascular event for all cases classified as having had a cardiovascular
LE. For those who did not experience a cardiovascular LE, PYs was taken as the time
until the end of the study period (31st December 2011) or the date of death. Time zero
was taken as 5 years beyond cancer diagnosis, the point at which the patient became
classified as a long term survivor. For the general population, the PYs were calculated as
the sum of the total age-sex matched population of Yorkshire following the age and year
structure highlighted in Table 4.1.
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The excess risk of cardiovascular hospitalisation amongst the survivor cohort compared
to the general population was described by calculating hospitalisation rate ratios (HRR)
overall and by age group using the indirect standardisation method [276]. This method
compares the rate of cardiovascular hospital admissions in the survivor cohort (study
population) to the rate of cardiovascular admissions in the general population (reference
population). HRRs were standardised to the general population by single year of attained
age (age at hospital admission), year of event and sex.
To determine the risk factors for cardiovascular LEs amongst the survivor cohort Royston-
Parmar relative survival modelling was implemented, which allowed for adjustment of the
risk of a cardiovascular event in the general population by attained age, year of event and
sex (Royston & Lambert, 2006). Explanatory variables included gender, age and year
at diagnosis, diagnostic group, deprivation [249] and initial treatment type. In order to
further assess the risk factors for cardiovascular LEs, two further models were fitted to
the following subgroups:
i) Cases who received chemotherapy to examine the effect of the number of different
anthracycline drugs administered (in the absence of accurate dose information).
ii) Cases who received radiotherapy (excluding cerebrovascular LEs) to examine the
effect of radiation to the chest.
Models were fitted for all cancers combined and no further subgroup analyses for specific
diagnoses was possible due to the low number of cardiovascular events in the cohort
(n=119). As diagnostic groups were not studied individually, the impact of stage or
disease severity was not assessed as disease severity was specific to each individual
diagnostic group and individual analyses would be required.
4.4.5.2 Model Assessment for Long Term Effects amongst Survivors of Cancer
As the flexible parametric RP survival models rely on cubic splines to estimate the
baseline hazard function, the scale and the complexity of the splines need to be determined
[277]. Models were compared using the AIC and BIC for the proportional hazards (PH)
model, proportional odds (PO) model and probit model between 1 and 5 degrees of
freedom (df). The optimal (lowest) AIC and BIC values determined which combination
of model scales and df provided the most appropriate model fit to the data. The PH
assumption for PH models was checked using the log cumulative hazard plot for each
variable included in the final model. Finally, sensitivity to the choice of model was
assessed by plotting relative survival curves and 95% CI’s at varying df for each of the
PH, PO and probit models.
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Chapter 5
Descriptive Data Analysis
5.1 Introduction
This chapter includes general descriptive statistics of the Yorkshire register and HES
datasets. The cohort is described according to diagnostic group, age group (children and
TYAs) and gender. Prior to a detailed description of the cohort, the ICCC and TYA Birch
Classification schemes were applied to the data and compared to determine the suitability
of each scheme for the analysis within this thesis. The number of cases which successfully
linked to HES data are described in detail, and any differences between linked and non-
linked cases were also explored. A summary of inpatient and outpatient hospital episodes
is provided, alongside summary statistics for the cohort subgroup used within the analysis
of cardiovascular LEs amongst survivors of CYA cancer. In addition, this chapter focuses
on the level of missing data of stage (disease severity) and ethnicity. However, specific
missing data mechanisms (described in §3.2) were considered in Chapter 6 alongside the
main imputation analysis. The chapter concludes with a strategy for imputation within
the thesis (§5.4).
5.2 Study Population
There were a total of 4852 cases diagnosed between 1990 and 2009 inclusive in the former
Yorkshire regional health authority and registered on the specialist register. After applying
the ICCC and Birch TYA classification schemes to the morphology and topography data
within the Yorkshire register, 0.1% (n=7) and 2.0% (n=95) of cases were classified as
unknown for each scheme respectively (Figure 5.1). Furthermore, the ICCC resulted
in fewer allocations to the ‘other’ categories (ICCC XI - other malignant epithelial
neoplasms, ICCC XII - other and unspecified neoplasms) compared to the Birch TYA
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scheme (Birch Group 9 - Miscellaneous neoplasms not elsewhere classified and Birch
Group 10 unspecified malignant neoplasms not elsewhere classified), with 6.4% (n=312)
and 7.5% (n=365) for ICCC and Birch respectively. The ICCC scheme minimised the
number of cases allocated to the ‘other’ and unknown categories, thus resulting in a larger
number of cancers being allocated to a detailed classification. Therefore, the ICCC was
used throughout the thesis in favour of the Birch TYA scheme.
Table 5.1 shows that amongst the cohort, the most commonly diagnosed cancers were
leukaemia, lymphoma and GCTs. There were approximately one and a half times as
many males as females in the cohort and the largest number of cases were diagnosed aged
0-4 years, 20-24 years and 25-29 years. Diagnoses of neuroblastoma, hepatic tumours and
other and unspecified malignant neoplasms had poorest 5-year survival (54%, 57% and
54% respectively), compared to retinoblastoma and GCTs with much better survival at 5-
years (98% and 94% respectively). There was little variation in 5-year survival according
to gender or age group, averaging at 77%.
Cases of leukaemia, neuroblastoma, retinoblastoma and renal tumours tended to be
diagnosed in younger children, with a peak in the number of leukaemia cases diagnosed
around the age of 2 and 6 (Figure 5.1). Lymphomas, GCTs and other malignant
epithelial neoplasms more commonly occurred amongst older TYAs. However, there
was an incidence peak in GCTs for those diagnosed under the age of 1. The number of
cases diagnosed with ‘other specified malignant neoplasms’ increased with age, which
reflects the choice of a childhood specific classification scheme. This diagnostic group
predominantly included tumours more commonly diagnosed amongst TYAs, consisting
of 55% ‘other and unspecified carcinomas’ and 35% ‘thyroid carcinomas’. CNS tumours
and STS were diagnosed across the whole 0-29 year age range in roughly equal numbers,
and malignant bone tumours was most common amongst 10-19 year olds and less
common in very young children.
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Figure 5.1: Age at diagnosis by (a) the international classification of childhood cancer
(ICCC) and (b) the Birch teenage and young adult (TYA) diagnostic group classification
for cases of cancer diagnosed in Yorkshire between 1990 and 2009
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Table 5.1: Cases of childhood and young adult cancer diagnosed in the former Yorkshire
regional health authority, 1990-2009
Variable Cases (N) Percentage 5-yearsurvival (%)
Diagnostic group
Leukaemia 912 18.8 72
Lymphoma 981 20.2 85
CNS tumours 795 16.4 69
Neuroblastoma 157 3.2 54
Retinoblastoma 58 1.2 98
Renal tumours 143 2.9 86
Hepatic tumours 37 0.8 57
Bone tumours 212 4.4 64
Soft tissue sarcomas 392 8.1 66
Germ cell tumours 846 17.4 94
Other malignant epithelial neoplasms 299 6.2 69
Other unspecified malignant neoplasms 13 0.3 54
Unknown ICCC group 7 0.1 86
Gender
Male 2905 59.9 77
Female 1947 40.1 76
Age group (years)
0-4 932 19.2 76
5-9 510 10.5 79
10-14 533 11.0 76
15-19 692 14.3 76
20-24 918 18.9 77
25-29 1267 26.1 78
Total 4852 - 77
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5.2.1 Summary of Data Linkage
Of the 4852 cases diagnosed between 1990 and 2009, 382 cases died before 1st of April
1996 and were therefore not eligible for linkage to HES (which was available from this
date forward). A total of 4113 (92%) of the cases eligible for linkage were successfully
linked to at least one inpatient HES record (Figure 5.2).
Diagnoses 1990-2009 
N=4852 
Alive on 1st April 1996 
N=4470 
Linked to at least one 
inpatient HES record 
N=4113 (92%) 
Not linked to inpatient 
HES record 
N=357 (8%) 
Figure 5.2: Number of linked and non-linked cases of cancer registry patients diagnosed
between 1990 and 2009 to inpatient hospital episode statistics (HES) data for admissions
between 1996 and 2011
Of the 4113 successful matches, 82% matched at the 1st pass, 16% were matched after
the 2nd pass and fewer than 1% were matched at each of the remaining passes (Table 5.2).
Table 5.2: Match Rank for Linked Cases
Pass Number of Cases Percentage
1st Pass 3378 82%
2nd Pass 641 16%
3rd Pass 38 1%
4th Pass 5 <1%
5th Pass 12 <1%
6th Pass 0 0%
7th Pass 39 1%
Total 4113 100%
Outpatient data was available for 89% (n=3669) of the linked HES cases for outpatient
appointments between 2003 and 2011. Outpatient data was initially obtained in addition
to inpatient HES data to assess the number of cardiovascular LEs experienced by long
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term survivors of cancer. For reasons outlined in §5.2.2.1 below, outpatient data were not
used in any analysis.
5.2.2 Summary of Inpatient HES Data Admissions
There were a total of 83,614 FCEs for the 4,113 Yorkshire register cases who successfully
linked to one or more inpatient HES record. Of these, the majority were single episode
CIPS (n=71,653, 91%). Overall, the median number of admissions per case was 11,
with an IQR of 4-27 (Table 5.3). Leukaemia patients had the highest median number of
admissions per person (33, IQR=10-52), which could be a reflection of the number of
day case admissions which are also recorded within inpatient HES data. The majority
of primary HES diagnosis codes were neoplasms (67%), followed by ‘symptoms, signs
and abnormal clinical and laboratory findings’ (6.0%) and ‘factors influencing health
status’ (5.9%) (Table 5.4), although the latter were much more commonly seen amongst
secondary diagnoses (14.3% and 27.6%). Other relatively frequent primary diagnoses
included ‘diseases of the blood and blood-forming organs’ (2.9%), ‘diseases of the
digestive system’(2.7%) and ‘injury, poisoning and certain consequences of external
causes’ (2.9%). The majority of neoplasms were recorded as the primary diagnosis,
a relatively large proportion of neoplasms were recorded in secondary (9.9%), tertiary
(6.6%) and quaternary (2.9%) diagnoses fields. The percentage of missing data increased
rapidly for subsequent diagnoses fields, with 25%, 64% and 82% blank diagnoses fields
for secondary, tertiary and quaternary diagnoses. This was an expected finding, as not
every admitted patient is expected to have multiple diagnoses.
Table 5.3: Median and interquartile range (IQR) for the number of admissionsa by main
diagnostic group
Diagnostic Groupb Median IQR
Leukaemia 33 10-52
Lymphoma 15 5-25
CNS Tumours 7 3-17
Other Solid Tumours 8 3-18
Overall 11 4-27
aAdmissions were defined as continuous inpatient spells (CIPS)
bBased on the international classification of childhood
cancer groups I, II, III and IV-XI respectively.
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5.2.2.1 Cardiovascular Late Effects Dataset
As described in §4.4.5 of Chapter 4, a subset of the cohort was used to analyse
cardiovascular LEs among survivors of cancer (see Chapter 8 for main results). The
linkage chart applicable to this subset is given in Figure 5.3. There were 3939 diagnoses
of cancer between 1991 and 2006 registered on the Yorkshire register. Of these, 3,306
had survived a minimum of 5-years and were alive on the 1st of April 1996. A total of
3247 (98%) of cases linked to at least one inpatient HES record. Outpatient data were
available for 74% (n=2412) of those successfully linked to inpatient HES data. In order
to successfully use outpatient data to identify cardiovascular LEs, diagnoses code data
were required. However, 99.5% of primary diagnoses codes in the available outpatient
data were in the ‘Symptoms, signs and abnormal clinical and laboratory findings not
elsewhere classified’ ICD-10 chapter, almost all of which were the specific code for
‘unknown and unspecified causes of morbidity’ (Table 5.5). The remaining 0.5% of
outpatient records contained more specific diagnoses information from a range of ICD-10
chapters. For subsequent diagnoses, the outpatient data became even more sparse with
just over 1% of secondary diagnoses codes being recorded as ‘unknown and unspecified
causes of morbidity’ and 99% of missing data. For tertiary and quaternary diagnoses,
there was virtually 100% missing data. In addition to the diagnoses fields for outpatient
appointments, the main specialty under which the patient was seen was also recorded.
This data showed that the majority of outpatient appointments for long term survivors of
CYA cancer were with paediatric (21%) and medical oncology (14%) specialists. In total,
0.9% of appointments were recorded as being with ‘cardiology’ or ‘paediatric cardiology’
specialists. However, these data could not be used reliably to determine whether a survivor
of cancer had experienced a cardiovascular LE or not, as the person could be referred to
a cardiologist as a precautionary measure. Without data on the diagnosis made during
an outpatient appointment it is not possible to confidently attribute a cardiovascular LE
to someone who had attended an outpatient appointment under a cardiovascular specialty
code. Outpatient data were therefore not used to analyse cardiovascular LEs, and the
main analysis focused instead on cardiovascular LEs experienced in inpatient admissions
(Chapter 8).
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Diagnoses 1991-2006 
N=3939 
Survived 5 years post 
diagnosis 
N=3306 
Linked to at least one 
inpatient HES record 
N=3247 (98%) 
Not linked to an 
inpatient HES record 
N=59 (2%) 
Figure 5.3: Number of linkages and non-linkages of cancer registry patients diagnosed
between 1991 and 2006 to inpatient hospital episode statistics (HES) data for admissions
between 1996 and 2011
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5.2.3 Comparison of Linked and Non-Linked Cases
There were more cases of leukaemia and fewer cases of other solid tumours in those that
linked compared to those that did not, there was a 3:2 male to female ratio compared to
a 7:3 ratio for linked and non-linked cases respectively and the median age at diagnosis
was significantly lower in linked cases (18.2 years) compared to non-linked cases (22.2
years) (Table 5.6).
Table 5.6: Distribution of cases for linked and non-linked Yorkshire registry and hospital
episode statistics (HES) data
Variable Linked Not Linked Total P-valueN Col % N Col % N
Diagnostic groupa
Leukaemia 774 18.8 48 13.4 822
Lymphoma 838 20.4 83 23.2 921
0.019b
CNS Tumours 667 16.2 48 13.4 715
Other solid tumours 1834 44.6 178 49.8 2012
Gender
Male 2424 58.9 257 72.0 2681
< 0.001b
Female 1689 41.1 100 28.0 1789
Median IQR Median IQR
Age at diagnosis (years) 18.2 17.6 22.2 17.4 < 0.001c
Total (N) 4113 - 357 - 4470
aBroad diagnostic groupings were used to avoid small numbers
bBased on Pearson χ2 test
cBased on Mann-Whitney U-test due to non-normal distribution of age at
diagnosis
5.3 Missing Data
This section assesses missing data structures of stage and disease severity from the
Yorkshire register and ethnicity data from the linked HES data. Missing data was
described for each variable separately initially, after which missing data patterns across
both variables were described for the whole dataset as well as by year of diagnosis to
determine whether there were any changes over time in the level of completeness. Missing
data was assessed overall as well as by diagnostic group and a strategy for imputation is
given at the end of this chapter (§5.4).
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5.3.1 Stage and Disease Severity
Table 5.7 summarises the available stage data by each of the 12 ICCC diagnostic
groups. The table includes all recorded and raw values within the stage field of the
Yorkshire register, which is a single field for all diagnostic groups combined. The data
includes many values which appear to be invalid, as they are outside of the standard
staging range of 1 to 4. However, validity cannot be assessed in detail for all cancers
combined, as different staging mechanisms apply for each diagnostic group (discussed
below). Nonetheless, the high number of cases for which a ‘9’ was recorded suggests this
value may have been entered to indicate missing data, despite the correct procedure for
missingness in the Yorkshire register being to leave the field blank. Counting missing
data as only those cases for which the stage was blank shows that other malignant
epithelial neoplasms and other and unspecified neoplasms have the highest levels of
missing data (93.3% and 100% respectively), whereas GCTs have the lowest level of
missing data (40%). However, when additionally including ‘9’ as a missing value, the
level of missingness was very high (over 90%) for the majority of diagnostic groups,
including leukaemia, retinoblastoma, hepatic tumours, bone tumours, other malignant
epithelial neoplasms and other and unspecified neoplasms.
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The following sections explore the level of missing stage data per diagnostic group in
detail by taking into consideration the validity of recorded values.
5.3.1.1 I - Leukaemia
Leukaemia is a haematological tumour which means that a stage, in terms of its traditional
definition which includes a measure of the physical size of the tumour, does not apply.
The AJCC does not include a TNM stage for leukaemia, nor does it mention another
staging mechanism for this cancer. The French-American-British (FAB) classification
is sometimes considered to stage leukaemia, as it classifies leukaemias in terms of cell
type, with classifications ranging from M1 to M7 for myeloid leukaemia and L1 to L3
for lymphocytic leukaemia [278]. The values recorded in the stage field for leukaemia
were likely to be based on this system (Table 5.7). However, the FAB classification is
not related to the prognosis or severity of disease and will therefore not be used within
this thesis as a staging mechanism. Many studies use WBC count as a prognostic factor
for leukaemia, with high levels of white cells in the blood indicating poorer outcomes
[279, 280, 281]. This measure was used throughout this thesis to measure disease severity
at diagnosis for leukaemia.
Just over half (51%) of WBCs were missing for leukaemia overall, with a higher than
average level of missing data for AML (64%) (Table 5.8). Despite there being roughly
50% fewer leukaemia cases amongst TYAs compared to children, TYAs had a much
higher level of missing WBC data (69% compared to 42%).
WBC is commonly measured for cases diagnosed with leukaemia, and should therefore
be available within the medical notes. Issues relating to missing data of stage due to its
complexity therefore do not apply. Due to the unexpected high level of missing data for
WBC amongst cases of leukaemia, efforts were made to retrieve this data from paper
records held by the register as well as electronic records held by the paediatric oncology
department at the Leeds General Infirmary, where the majority of childhood cancers in
the region were treated. The level of missingness amongst children was minimised to
3% overall (Table 5.9). However, the level of missing WBC was still high (58%) for
15-29 year olds. The reason for this was that data on WBC was electronically stored
for childhood leukaemias at the paediatric oncology department, however, data for TYAs
around the region was not available in this format, therefore despite retrieving some of
the data, there was still a high level of missingness of WBC for the TYA cohort.
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Table 5.8: Summary of missing white blood cell (WBC) count for Leukaemia by age
group at diagnosis. Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded WBC Missing WBC Total
Children (0-14 year olds)
a) Lymphoid leukaemias 290 (60%) 195 (40%) 485
b) Acute myeloid leukaemias 46 (46%) 55 (55%) 101
c) Chronic myeloproliferative diseases 7 (54%) 6 (46%) 13
d) Myelodysplastic syndrome # (75%) # (25%) #
e) Unspecified and other leukaemias # (83 %) # (17%) #
a-e) All leukaemias 351 (58%) 258 (42%) 609
Teenagers and Young Adults (15-29
year olds)
a) Lymphoid leukaemias 40 (36%) 70 (64%) 110
b) Acute myeloid leukaemias 42 (29%) 104 (71%) 146
c) Chronic myeloproliferative diseases 9 (24%) 28 (76%) 37
d) Myelodysplastic syndrome # (40%) # (60%) #
e) Unspecified and other leukaemias # (0%) # (100%) #
a-e) All leukaemias 93 (31%) 210 (69%) 303
All Ages (0-29 year olds)
a) Lymphoid leukaemias 330 (55%) 265 (45%) 595
b) Acute myeloid leukaemias 88 (36%) 159 (64%) 247
c) Chronic myeloproliferative diseases 16 (32%) 34 (68%) 50
d) Myelodysplastic syndrome # (56%) # (44%) #
e) Unspecified and other leukaemias # (45%) # (55%) #
a-e) All leukaemias 444 (49%) 468 (51%) 912
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Table 5.9: Summary of white blood cell count (WBC) data for leukaemia after retrieval
of additional data from medical notes. Sensitive data on fewer than 5 cases were replaced
by #
Diagnostic Subgroup Recorded WBC Missing WBC Total
Children (0-14 year olds)
a) Lymphoid leukaemias 472 (97%) 13 (3%) 485
b) Acute myeloid leukaemias 96 (95%) 5 (5%) 101
c) Chronic myeloproliferative diseases # (92%) # (8%) #
d) Myelodysplastic syndrome # (100%) # (0%) #
e) Unspecified and other leukaemias # (100%) # (0%) #
a-e) All leukaemias 590 (97%) 19 (3%) 609
Teenagers and Young Adults (15-29
year olds)
a) Lymphoid leukaemias 51 (46%) 59 (54%) 110
b) Acute myeloid leukaemias 60 (41%) 86 (59%) 146
c) Chronic myeloproliferative diseases 14 (38%) 23 (62%) 37
d) Myelodysplastic syndrome # (60%) # (40%) #
e) Unspecified and other leukaemias # (0%) # (100%) #
a-e) All leukaemias 128 (42%) 175 (58%) 303
All Ages (0-29 year olds)
a) Lymphoid leukaemias 523 (88%) 72 (12%) 595
b) Acute myeloid leukaemias 156 (63%) 91 (37%) 247
c) Chronic myeloproliferative diseases 26 (52%) 24 (48%) 50
d) Myelodysplastic syndrome # (78%) # (22%) #
e) Unspecified and other leukaemias # (55%) # (45%) #
a-e) All leukaemias 718 (79%) 194 (22%) 912
5. DESCRIPTIVE DATA ANALYSIS 115
5.3.1.2 II - Lymphoma
Similarly to leukaemia, lymphoma is a haematological tumour and cannot be staged
according to the TNM system. However, the AJCC Staging Manual suggests the use
of the Ann Arbor Staging System for HL and NHL to determine the disease severity at
diagnosis. The Ann Arbor Staging System classifies lymphoma similarly to a grouped
TNM stage, with levels I-IV (Table 5.10). Each stage is further accompanied with an A or
B classification which refers to the absence or presence respectively of the following three
symptoms; unexplained fever, night sweats and unexplained weight loss. Additionally,
optional staging information based on the presence of extra nodal involvement can be
recorded, which is indicated by an ‘E’. The recorded values of stage for lymphoma cases
show inconsistencies with the Ann Arbor staging system (Table 5.11). The value ‘9’
is not valid, and stages recorded as ‘1’, ‘2’, ‘3’ or ‘4’ should be accompanied by an A
or B. As discussed earlier, we can assume that the value of ‘9’ indicates missingness.
The symptoms (A or B codes) and extranodality (E code) provide additional information
to main staging levels I-IV, and can therefore be considered as separate data items.
Missingness is described in further detail by counting any values of I-IV, regardless of
an additional A, B or E code, as complete data.
Overall, there was 70% missing stage data, which did not vary by age (76% and 68% for
childhood and TYA cases respectively) (Table 5.12). Amongst the two largest subgroups
(HL and NHL), there was a higher level of missingness for NHL compared to HL in both
age groups (75% vs. 67% and 84% vs. 61% for childhood and TYA cases respectively).
Table 5.10: The Ann Arbor Classification System
Stage Description
I Involvement of a single lymphatic site
II Involvement of two or more lymph node regions on the same side of the
diaphragm
III Involvement of lymph node regions on both sides of the diaphragm
IV Diffuse or disseminated involvement of one or more extralymphatic organs1
1Extralymphatic organs are those that are outside of the
lymphatic system, such as the liver, lungs or brain.
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Table 5.11: Recorded values of stage for lymphoma cases diagnosed between 1990 and
2009. Sensitive data on fewer than 5 cases were replaced by #
Recorded value CasesN Percentage
1 23 6.7
1A 31 9.1
1B 5 1.5
1E # #
2 34 10.0
2A 60 17.6
2B 59 17.3
3 12 3.5
3A 18 5.3
3B 17 5.0
4 19 5.6
4A # #
4B 15 4.4
9 43 12.6
Total 341 100
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Table 5.12: Summary of missing stage for lymphoma by age group at diagnosis. Sensitive
data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
Children (0-14 year olds)
a) Hodgkin lymphomas 31 (33%) 62 (67%) 93
b) Non-Hodgkin lymphomas 16 (25%) 48 (75%) 64
c) Burkitt lymphoma # (3%) # (97%) #
d) Miscellaneous lymphoreticular
neoplasms
0 (0%) 10 (100%) 10
e) Unspecified lymphomas # (26%) # (74%) #
a-e) All lymphomas 53 (24%) 164 (76%) 217
Teenagers and Young Adults (15-29
year olds)
a) Hodgkin lymphomas 213 (39%) 332 (61%) 545
b) Non-Hodgkin lymphomas 21 (16%) 114 (84%) 135
c) Burkitt lymphoma # (0%) # (100%) #
d) Miscellaneous lymphoreticular
neoplasms
# (0%) # (100%) #
e) Unspecified lymphomas 11 (16%) 56 (84%) 67
a-e) All lymphomas 245 (32%) 519 (68%) 764
All Ages (0-29 year olds)
a) Hodgkin lymphomas 244 (38%) 394 (62%) 638
b) Non-Hodgkin lymphomas 37 (19%) 162 (81%) 199
c) Burkitt lymphoma # (2%) # (98%) #
d) Miscellaneous lymphoreticular
neoplasms
# (0%) # (100%) #
e) Unspecified lymphomas 16 (19%) 70 (81%) 86
a-e) All lymphomas 298 (30%) 683 (70%) 981
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5.3.1.3 III - Central nervous system tumours
There is no TNM stage for CNS tumours, as the key factor relating to prognosis of CNS
tumours is the growth of the tumour, which can damage brain functioning due to pressure
on other parts of the brain. Furthermore, the N and M parts of the staging mechanism do
not apply to CNS tumours as there are no lymph nodes within the brain or spinal cord,
and CNS tumours tend to move around the CNS but do not tend to metastasize to other
parts of the body [32]. The AJCC recommends the use of the WHO Grading of Tumours
of the Central Nervous System scheme ([6], see Appendix D). This classification scheme
assigns certain tumour morphologies to a specific grade (I to IV). The grading system
does not align to the ICCC classification scheme, as for example, ICCC group III(b)
is ‘Astroyctoma’ which includes WHO grade I tumours such as pilocytic astrocytoma
and subependymal giant cell astrocytomas, as well as WHO grade IV tumours such as
glioblastoma and gliosarcoma. The WHO grading system is a different type of grade to
that mentioned in the TNM staging of STS in the example in Chapter 2, Table 2.1, where
grade was used to supplement the stage, and refers to the level of differentiation of cells.
Table 5.13 gives the values for grade recorded by the Yorkshire register for this cohort.
Those with a ‘9’ and a number followed by the letter ‘A’ do not correspond with valid
values for the WHO grading system. Both instances were treated as missing.
There was 46% missing data on the grade of CNS tumours overall, which did not vary by
age (43% and 49% for children and TYAs respectively) (Table 5.14). The level of missing
data varied according to diagnostic subgroup. Amongst children, the level of missing
data was much lower for ependymomas, astrocytomas and intracranial and intraspinal
embryonal tumours (34%, 38% and 24% respectively) compared to other gliomas, other
specified and unspecified intacranial and intraspinal neoplasms (80%, 65% and 100%
respectively). The variation in the level of missingness did not appear to be related to
how rare the cancer was. Ependymomas made up less than 10% of all childhood CNS
tumours, but had a similar level of missingness to astrocytomas, which account for almost
half of CNS tumours. For the TYA age range the overall level of missingness was similar
compared to children, however, there was less variation in the level of missing grade data
according to diagnostic subgroup. Nevertheless, the pattern was similar to that of children
in that other gliomas and unspecified intacranial and intraspinal neoplasms had the highest
level of missingness (62% and 100% respectively).
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Table 5.13: Recorded grade values for central nervous system tumours diagnosed between
1990 and 2009. Sensitive data on fewer than 5 cases were replaced by #
Recorded value CasesN Percentage
1 160 31.7
1A 12 2.4
2 98 19.4
2A # #
3 41 8.1
3A # #
4 135 26.7
9 49 9.7
Total 505 100
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Table 5.14: Summary of missing grade for central nervous system tumours by age group
at diagnosis. Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Grade Missing Grade Total
Children (0-14 year olds)
a) Ependymomas and choroid plexus tumour 25 (66%) 13 (34%) 38
b) Astrocytoma 119 (62%) 74 (38%) 193
c) Intracranial and intraspinal embryonal
tumours
78 (76%) 24 (24%) 102
d) Other gliomas 9 (20%) 37 (80%) 46
e) Other specified intracranial and intraspinal
neoplasms
18 (35%) 34 (65%) 52
f) Unspecified intracranial and intraspinal
neoplasms
0 (0%) 5 (100%) 5
a-f) All CNS tumours 249 (57%) 187 (43%) 436
Teenagers and Young Adults (15-29 year
olds)
a) Ependymomas and choroid plexus tumour 15 (52%) 14 (48%) 29
b) Astrocytoma 110 (58%) 81 (42%) 191
c) Intracranial and intraspinal embryonal
tumours
# (41%) # (59%) #
d) Other gliomas 20 (38%) 32 (62%) 52
e) Other specified intracranial and intraspinal
neoplasms
28 (48%) 30 (52%) 58
f) Unspecified intracranial and intraspinal
neoplasms
# (0%) # (100%) #
a-f) All CNS tumours 184 (51%) 175 (49%) 359
All Ages (0-29 year olds)
a) Ependymomas and choroid plexus tumour 40 (60%) 27 (40%) 67
b) Astrocytoma 229 (60%) 155 (40%) 384
c) Intracranial and intraspinal embryonal
tumours
89 (69%) 40 (31%) 129
d) Other gliomas 29 (30%) 69 (70%) 98
e) Other specified intracranial and intraspinal
neoplasms
46 (42%) 64 (58%) 110
f) Unspecified intracranial and intraspinal
neoplasms
0 (0%) 7 (100%) 7
a-f) All CNS tumours 433 (54%) 362 (46%) 795
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Although the level of missing WHO grade data was 46%, the WHO grading system can
be used to infer the grade of tumour where it is missing, as the grading system is based
upon the exact morphology of a tumour. Table 5.15 gives the level of missing data by
subgroup after WHO grades were assigned based on morphology. This process was only
completed for cases in which grade was missing, as it was assumed that data available via
the data collection procedures had a higher degree of accuracy as additional information
other than the morphology code may have helped determine the grade in those instances.
After this process, 9% of missing grade data remained (Table 5.15). The reason for this
was that some morphology codes were associated with multiple grades, and therefore the
morphology code alone did not provide sufficient information to assign a unique grade.
In these instances, the grade could not be inferred from the morphology code and were
therefore imputed (Chapter 6).
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Table 5.15: Missing grade for central nervous system tumours after assigning grades
based on morphology using the WHO grading scheme [6]. Sensitive data on fewer than 5
cases were replaced by #
Diagnostic Subgroup Recorded Grade Missing Grade Total
Children (0-14 year olds)
a) Ependymomas and choroid plexus tumour 38 (100%) 0 (0%) 38
b) Astrocytoma 177 (92%) 16 (8%) 193
c) Intracranial and intraspinal embryonal
tumours
102 (100%) 0 (0%) 102
d) Other gliomas 15 (33%) 31 (67%) 46
e) Other specified intracranial and intraspinal
neoplasms
# (94%) # (6%) #
f) Unspecified intracranial and intraspinal
neoplasms
# (0%) # (100%) #
a-f) All CNS tumours 372 (85%) 64 (15%) 436
Teenagers and Young Adults (15-29 year
olds)
a) Ependymomas and choroid plexus tumour # (93%) # (7%) #
b) Astrocytoma # (99%) # (1%) #
c) Intracranial and intraspinal embryonal
tumours
27 (100%) 0 (0%) 27
d) Other gliomas 44 (85%) 8 (15%) 52
e) Other specified intracranial and intraspinal
neoplasms
# (93%) # (7%) #
f) Unspecified intracranial and intraspinal
neoplasms
# (50%) # (50%) #
a-f) All CNS tumours 338 (94%) 21 (6%) 359
All Ages (0-29 year olds)
a) Ependymomas and choroid plexus tumour # (97%) # (3%) #
b) Astrocytoma 367 (96%) 17 (4%) 384
c) Intracranial and intraspinal embryonal
tumours
1129 (100%) 0 (0%) 129
d) Other gliomas 59 (60%) 39 (40%) 98
e) Other specified intracranial and intraspinal
neoplasms
103 (94%) 7 (6%) 110
f) Unspecified intracranial and intraspinal
neoplasms
# (14%) # (86%) #
a-f) All CNS tumours 710 (89%) 71 (9%) 795
5.3.1.4 IV - Neuroblastoma
Neuroblastoma is a disease which predominantly occurs amongst children, and as such,
there was no TNM staging mechanism for neuroblastoma. There were two alternative
staging systems in place for neuroblastoma, the International Neuroblastoma Staging
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System (INSS) [282] and The International Neuroblastoma Risk Group (INRG) staging
system [283]. The former was established in 1986, however, staging according to this
system is dependent on surgery. Table 5.16 gives a full description of the INSS staging
system. Dependency on surgery means that comparisons of staging between different
centres is difficult as the same tumour could be Stage I or Stage III depending on the
extent of surgical excision, which could vary between surgeons [284, 285]. These issues
have led to the development of a pre-treatment staging system by the INRG, published
by Cohn et al. [283]. The cancer register used the original INSS mechanism for staging
tumours as the INRG system was relatively new, however, a recommendation to adopt
the use of the new INRG staging system was made. This will depend on the uptake of
the system by clinicians and upon which system is recorded within the medical notes.
In addition to the INRG staging system, the same authors also developed an INRG risk
group which is a pre-treatment risk group system in which patients were identified as very
low, low, intermediate and high risk [283]. These data are not currently collected by the
cancer register, however, it was recommended for future data collection.
Table 5.17 gives the values for stage contained within the cancer register for this cohort.
All values except for the 27 cases of ‘9’ were valid. The level of missing stage data was
high (72%) overall, despite the data being relatively clean compared to stage data in other
diagnostic groups (Table 5.18). Neuroblastoma is extremely rare in TYAs compared to
amongst children, making up just over 10% of cases. All stage data for these cases was
missing, possibly a result of its rarity. Particularly, if patients in this age range were treated
within an adult clinic environment (as opposed to receiving paediatric care) the medical
team were not necessarily aware of how to stage this particular tumour given that it does
not have a TNM staging mechanism. Amongst children, stage was missing in 68% of
the more common subgroup ‘neuroblastoma and ganglioneuroblastoma’, and missingness
was as high as 78% for the less common ‘other peripheral nervous cell tumours’ subgroup.
124 5. DESCRIPTIVE DATA ANALYSIS
Table 5.16: The International Neuroblastoma Staging System (INSS)
Stage Description
I The tumour can be removed completely during surgery. Lymph nodes
removed during surgery may or may not contain cancer, but other lymph
nodes near the tumour do not.
II-A The tumour is located only in the area it started and cannot be completely
removed during surgery. Nearby lymph nodes do not contain cancer.
II-B The tumour is located only in the area where it started and may or may not
be completely removed during surgery, but nearby lymph nodes do contain
cancer.
III The tumour cannot be removed with surgery. It has spread to regional lymph
nodes (lymph nodes near the tumour) or other areas near the tumour, but not
to other parts of the body.
IV The original tumour has spread to distant lymph nodes (lymph nodes in
other parts of the body), bones, bone marrow, liver, skin, and/or other organs
(except for those listed in stage 4S, below).
IV-S The original tumour is located only where it started (as in stage I, IIA, or
IIB), and it has spread only to the skin, liver, and/or bone marrow (in infants
younger than one). The spread to the bone marrow is minimal (usually less
than 10% of cells examined show cancer).
Table 5.17: Recorded stage values for neuroblastoma cases diagnosed between 1990 and
2009. Sensitive data on fewer than 5 cases were replaced by #
Recorded value CasesN Percentage
1 # #
2 # #
3 # #
4 34 47.9
4S # #
9 27 38.0
Total 71 100
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Table 5.18: Summary of missing stage for neuroblastoma by age group at diagnosis.
Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
Children (0-14 year olds)
a) Neuroblastoma and
ganglioneuroblastoma
# (32%) # (68%) #
b) Other peripheral nervous cell tumours # (22%) # (78%) #
a-b) All Neuroblastomas 44 (31%) 97 (69%) 141
Teenagers and Young Adults (15-29
year olds)
a) Neuroblastoma and
ganglioneuroblastoma
0 (0%) 5 (100%) 5
b) Other peripheral nervous cell tumours 0 (0%) 11 (100%) 11
a-b) All Neuroblastomas 0 (0%) 16 (100%) 16
All Ages (0-29 year olds)
a) Neuroblastoma and
ganglioneuroblastoma
# (31%) # (69%) #
b) Other peripheral nervous cell tumours # (20%) # (90%) #
a-b) All Neuroblastomas 44 (28%) 113 (72%) 157
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5.3.1.5 V - Retinoblastoma
Survival for retinoblastoma is very high compared to other childhood cancers, with 5-
year survival reaching 99% in England (§2.3.1). As such, the main priority in treating
retinoblastoma is that of saving the sight of the patient. There are two staging systems
in place, both on a scale of 1 to 5. These are the Reese-Ellsworth staging system [286]
and the International Classification for Intraocular Retinoblastoma [287]. Both staging
mechanisms were designed for intraocular tumours (tumours within the eye), as most
retinoblastoma tumours are diagnosed before they spread outside of the eye. As staging
of retinoblastoma concerns saving of the patients eye sight rather than being related to
the patients prognosis, staging of retinoblastoma was not included in the analysis for
this thesis which focuses on survival, and therefore, imputation for this variable or a
description of missingness was not completed.
5.3.1.6 VI - Renal Tumours
Renal tumours can be staged using the TNM Staging Mechanism [32]. The grouped
stage contains levels I, II, III and IV and does not include any additional subgrouping.
The only non-valid value recorded on the register for renal tumours was ‘9’, which was
treated as missing (Table 5.19). The level of missingness by diagnostic subgroup and
age group was given in Table 5.20. Despite renal tumours having a relatively simple
staging mechanism, there was still a high level of missing data (82% overall). Table 5.20
highlights differences between children and TYAs in terms of which type of renal tumour
they were more likely to have (nephroblastoma and renal carcinomas for children and
TYAs respectively), however, the pattern of missingness did not appear to differ by age
group.
Table 5.19: Recorded stage values for renal tumours diagnosed between 1990 and 2009.
Sensitive data on fewer than 5 cases were replaced by #
Recorded value CasesN Percentage
1 7 12.1
2 9 15.5
3 # #
4 # #
9 32 55.2
Total 58 100
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Table 5.20: Summary of missing stage for renal tumours by age group at diagnosis.
Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
Children (0-14 year olds)
a) Nephroblastoma and other nonepithelial renal
tumours
21 (19%) 92 (81%) 113
b) Renal carcinomas # (67%) # (33%) #
c) Unspecified malignant renal tumours # (#) # (#) #
a-c) All renal tumours 23 (20%) 93 (80%) 116
Teenagers and Young Adults (15-29 year olds)
a) Nephroblastoma and other nonepithelial renal
tumours
# (0%) # (100%) #
b) Renal carcinomas # (12%) # (88%) #
c) Unspecified malignant renal tumours 0 (-) 0 (-) 0
a-c) All renal tumours # (11%) # (89%) #
All Ages (0-29 year olds)
a) Nephroblastoma and other nonepithelial renal
tumours
21 (18%) 93 (82%) 114
b) Renal carcinomas 5 (17%) 24 (83%) 29
c) Unspecified malignant renal tumours 0 (-) 0 (-) 0
a-c) All renal tumours 26 (18%) 117 (82%) 143
5.3.1.7 VII - Hepatic Tumours
Although a TNM staging system exists for liver tumours amongst adults, this only
includes hepatic carcinomas and not hepatoblastoma. For paediatric hepatic tumours,
the PRETEXT Staging System for Hepatoblastoma and Hepatocellular Carcinomas exists
(Table 5.21).
There were a total of 37 hepatic tumours within this cohort (hepatoblastoma - n=16,
hepatic carcinomas and unspecified malignant hepatic tumours - n=21), of these,<5 cases
had a recorded value of ‘9’, which were treated as missing. No other data on stage was
available for these hepatic tumours, thus stage was missing in 100% of cases.
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Table 5.21: The PRETEXT staging system for Hepatoblastoma and Hepatocellular
Carcinomas
Stage Description
PRETEXT 1 Tumour involves only one liver sector; three adjoining liver sectors are
free of tumour.
PRETEXT 2 Tumour involves one or two liver sectors; two adjoining liver sectors
are free of tumour.
PRETEXT 3 Tumour involves three liver sectors and one liver sector is free of
tumour or tumour involves two liver sectors and two non-adjoining
liver sectors are free of tumour.
PRETEXT 4 Tumour involves all four liver sectors; there is no liver sector free of
tumour.
5.3.1.8 VIII - Malignant Bone Tumours
Malignant bone tumours can be staged using the TNM staging mechanism, with
additional subgrouping for stages I, II and IV (Tables 5.22 and 5.23).
The majority of recorded values were ‘9’, which was invalid and treated as missing (Table
5.24). There were 6 further recorded values out of 212 bone tumour cases, however, these
were not consistent with the TNM staging system as the A and B codes which supplement
stages I, II and IV were not present. As with lymphoma, these were treated as separate
data items and therefore, stages I, II and IV were counted as complete data. Any recorded
values of ‘3A’ were invalid and counted as missing as it was unclear whether the recorded
stage should have been III, or any of IA, IIA and IVA. Overall bone tumour staging was
missing in 98% cases. By age, there was 100% missing data for children with bone
tumours. Table 5.25 gives the breakdown of recorded and missing stage by diagnostic
subgroup (age group breakdown is not provided due to small numbers). There was no
indication of any pattern of missing data, however, this could be because of the limited
number of cases which had a recorded stage.
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Table 5.22: Prognostic groups based on TNM staging for bone tumours
Grouped Primary Regional Lymph Distant Histologic
Stage Tumour (T) Nodes (N) Metastasis (M) Grade (G)
Stage IA T1 N0 M0 G1,2 GX
Stage IB T2 N0 M0 G1,2 GX
T3 N0 M0 G1,2 GX
Stage IIA T1 N0 M0 G3, G4
Stage IIB T2 N0 M0 G3, G4
Stage III T3 N0 M0 G3, G4
Stage IVA Any T N0 M1a Any G
Stage IVB Any T N1 Any M Any G
Any T Any N M1b Any G
Table 5.23: TNM staging definitions for bone tumours
Primary Tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour 8cm or less in greatest dimension
T2 Tumour more than 8cm in greatest dimension
T3 Discontinuous tumours in the primary bone site
Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
M1a Lung
M1b Other distant sites
Histologic Grade (G)
GX Grade cannot be assessed
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated
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Table 5.24: Recorded values of stage for malignant bone tumours diagnosed between
1990 and 2009. Sensitive data on fewer than 5 cases were replaced by #
Recorded value CasesN Percentage
1 # #
2 # #
3A # #
4 # #
9 22 78.6
Total 28 100
Table 5.25: Summary of missing stage for malignant bone tumours by age group at
diagnosis. Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
All Ages (0-29 year olds)
a) Osteosarcomas 0 (0%) 103 (100%) 103
b) Chondrosarcomas # (10%) # (80%) #
c) Ewing tumour and related sarcomas of
bone
# (3%) # (97%) #
d) Other specified malignant bone
tumours
0 (0%) 20 (100%) 20
e) Unspecified malignant bone tumours # (25%) # (75%) #
a-e) All soft tissue sarcomas 5 (2%) 207 (98%) 212
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5.3.1.9 IX - Soft Tissue and Other Extraosseuous Sarcomas
STS can be staged using the TNM staging mechanism, with additional subgroups ‘A’ and
‘B’ for stages I and II (See Tables 2.1 and 2.2, Chapter 2). There were 52 cases with the
value of ‘9’ recorded, all of which were classed as missing (Table 5.26). There was one
value of ‘4A’ recorded which is inconsistent with the staging mechanism in Table 2.2 and
was treated as missing. The overall level of missingness of stage was very high at 96%.
The high level of missingness occurred consistently across diagnostic subgroups as well
as by age group (Table 5.27).
Table 5.26: Recorded stage values for soft tissue sarcomas. Sensitive data on fewer than
5 cases were replaced by #
Recorded value CasesN Percentage
1 8 11.4
2 5 7.1
4 # #
4A # #
9 52 74.3
Total 70 100
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Table 5.27: Summary of missing stage for soft tissue sarcomas by age group at diagnosis.
Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
Children (0-14 year olds)
a) Rhabdomyosarcomas # (3%) # (97%) #
b) Fibrosarcomas, peripheral nerve
sheath tumours, and other fibrous
neoplasms
0 (0%) 23 (100%) 23
c) Kaposi sarcoma # (0%) # (100%) #
d) Other specified soft tissue sarcomas # (7%) # (93%) #
e) Unspecified soft tissue sarcomas # (17%) # (83%) #
a-e) All soft tissue sarcomas 7 (4%) 159 (94%) 166
Teenagers and Young Adults (15-29
year olds)
a) Rhabdomyosarcomas # (6%) # (94%) #
b) Fibrosarcomas, peripheral nerve
sheath tumours, and other fibrous
neoplasms
6 (7%) 75 (93%) 81
c) Kaposi sarcoma 0 (0%) 9 (100%) 9
d) Other specified soft tissue sarcomas # (3%) # (97%) #
e) Unspecified soft tissue sarcomas 0 (0%) 26 (100%) 26
a-e) All soft tissue sarcomas 10 (4%) 216 (96%) 226
All Ages (0-29 year olds)
a) Rhabdomyosarcomas # (3%) # (97%) #
b) Fibrosarcomas, peripheral nerve
sheath tumours, and other fibrous
neoplasms
6 (6%) 98 (94%) 104
c) Kaposi sarcoma 0 (0%) 10 (100%) 10
d) Other specified soft tissue sarcomas 7 (5%) 142 (95%) 149
e) Unspecified soft tissue sarcomas # (3%) # (97%) #
a-e) All soft tissue sarcomas 17 (4%) 375 (96%) 392
5.3.1.10 X - Germ Cell Tumours
Staging of GCTs is complex as different staging mechanisms exist depending on which
subgroup the tumour belongs to. However, these subgroups do not align to the ICCC GCT
subgroups. The ICCC subgroups for GCTs include the following categories;
Xa) Intracranial and intraspinal germ cell tumours
Xb) Malignant extracranial and extragonadal germ cell tumours
Xc) Malignant gonadal germ cell tumours
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Xd) Gonadal carcinomas
Xe) Other and unspecified malignant gonadal tumours
The most commonly occurring GCT in this cohort were malignant gonadal GCTs (Xc).
This diagnostic subgroup includes both ovarian and testicular GCTs, each of which have
their own TNM staging system, which also apply to subgroups Xd and Xe for the same
topographies. In addition to the TNM staging system, ovarian GCTs can be staged
according to the International Federation of Obstetricians and Gynaecologists (FIGO)
staging system. The FIGO and TNM staging systems have the same number of groups
and subgroups (see Table 5.28), however, there are differences in terms of how these are
defined [32]. There was also an additional staging mechanism for testicular GCTs, known
as the Royal Marsden staging system [288].
Malignant extracranial and extragonadal GCTs (Xb) were staged using the International
Germ Cell Cancer Collaborative Group (IGCCCG) Classification, using a basic four
stage system. The more complex GCTs classified in group Xa do not have a universally
accepted staging mechanism [289], however, they are sometimes staged according to the
Chang TM staging system for medulloblastoma, which is a CNS tumour [290, 291].
Table 5.28 shows the main staging systems in place for different types of GCTs alongside
an indication of which ICCC subgroups align to these systems. In total, there are
five staging systems for GCTs covering most of the diagnostic subgroups. Each
staging system has their own subgroups but are broadly speaking on a four level scale.
Additionally, there was no applicable staging mechanism for intracranial and intraspinal
GCTs. The implications on the analysis caused by these complications are discussed in
Section 5.4.
The Yorkshire register does not record the staging mechanism alongside the stage value,
therefore, it was difficult to ascertain which values were valid or not. As a consequence,
any value of stage which matched to any of the possible stages indicated in Table 5.28
was deemed valid. Blank or recorded values of ‘9’ were classified as missing.
Missingness is presented by age and diagnostic subgroup, excluding group Xa for which
no staging mechanism applied (Table 5.29). Despite GCTs being a complex group of
tumours to stage, the level of missingness was 43% overall, which was much lower
compared to other diagnostic groups. The overall level of missingness was lower amongst
the TYA age group (36% missing) which made up the biggest proportion of GCTs (91%
of GCTs in this cohort were diagnosed amongst TYAs). Overall and amongst TYAs, the
group which had the lowest level of missing stage data was Xc (<40% missing) which was
associated with clearly defined TNM staging systems for ovarian and testicular tumours.
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However, the same pattern was not seen amongst children, which despite being subject to
the same TNM staging mechanisms, had 82% missing stage for group Xc.
Table 5.28: Germ cell tumour staging systems
Name Stage Values ICCC Subgroup
TNM Staging for Ovarian
Germ Cell Tumours
I, IA, IB, IC, II, IIA, IIB, IIC,
III, IIIA, IIIB, IIIC, IV
Xc, Xd, Xe (provided site is
ovary)
FIGO Staging for Ovarian
Germ Cell Tumours
I, IA, IB, IC, II, IIA, IIB, IIC,
III, IIIA, IIIB, IIIC, IV
Xc, Xd, Xe (provided site is
ovary)
TNM Staging for Testicular
Germ Cell Tumours
0, I, IA, IB, IS, II, IIA, IIB,
IIC, III, IIIA, IIIB, IIIC
Xc, Xd, Xe (provided site is
testis)
The Royal Marsden System
for Testicular Germ Cell
Tumours
Xc, Xd, Xe (provided site is
testis)
IGCCCG Classification
for Extracranial and
Extragonadal Germ Cell
Tumours
I, II, III, IV Xb (any site)
5. DESCRIPTIVE DATA ANALYSIS 135
Table 5.29: Summary of missing stage for germ cell tumours by age group at diagnosis.
Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
Children (0-14 year olds)
b) Malignant extracranial and extragonadal germ
cell tumours
# (6%) # (94%) #
c) Malignant gonadal germ cell tumours 7 (18%) 32 (82%) 39
d) Gonadal carcinomas # (0%) # (100%) #
e) Other and unspecified malignant gonadal
tumours
# (0%) # (100%) #
b-e) Germ Cell Tumours (exlcuding
Intracranial and Intraspinal GCTs)
9 (12%) 66 (88%) 75
Teenagers and Young Adults (15-29 year olds)
b) Malignant extracranial and extragonadal germ
cell tumours
7 (30%) 16 (70%) 23
c) Malignant gonadal germ cell tumours 435 (64%) 241 (36%) 676
d) Gonadal carcinomas # (28%) # (72%) #
e) Other and unspecified malignant gonadal
tumours
# (25%) # (75%) #
b-e) Germ Cell Tumours (exlcuding
Intracranial and Intraspinal GCTs)
451 (62%) 281 (38%) 732
All Ages (0-29 year olds)
b) Malignant extracranial and extragonadal germ
cell tumours
9 (16%) 46 (84%) 55
c) Malignant gonadal germ cell tumours 442 (62%) 273 (38%) 715
d) Gonadal carcinomas # (27%) # (73%) #
e) Other and unspecified malignant gonadal
tumours
# (18%) # (82%) #
b-e) Germ Cell Tumours (exlcuding
Intracranial and Intraspinal GCTs)
460 (57%) 347 (43%) 807
5.3.1.11 XI - Other Malignant Epithelial Neoplasms
Age structures for each diagnostic group were explored at the beginning of §5.2, which
highlighted that most tumours within ICCC group XI occurred primarily in the older TYA
age range. This implied that the types of tumours classified within this ‘other’ category,
tended to be those more commonly seen in older adults and could be seen according to
the subgroups of XI which were predominantly ‘other and unspecified carcinomas’ and
‘thyroid carcinomas’. Staging mechanisms are difficult to define for a diagnostic group
which contains a range of different tumours, especially when the majority of those were
‘other and unspecified carcinomas’. Therefore the validity of stage data was difficult to
determine. Values of ‘9’ were counted as missing and the remaining values I, IB, II,
IIB, III and IV were all considered complete (Table 5.30). Stage was missing for all 44
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childhood cases, as well as for all cases in diagnostic subgroups XIa, XIb, XIc and XId.
For XIf, the level of missing data was high (100% and 92%) amongst 0-14 and 15-29 year
olds respectively. Overall, stage was missing in 96% of cases.
Table 5.30: Summary of missing stage for other malignant epithelial neoplasms by age
group at diagnosis. Sensitive data on fewer than 5 cases were replaced by #
Diagnostic Subgroup Recorded Stage Missing Stage Total
Children (0-14 year olds)
a) Adrenocortical carcinomas 0 (0%) 14 (100%) 14
b) Thyroid carcinomas 0 (0%) 18 (100%) 18
c) Nasopharyngeal carcinomas 0 (0%) # (100%) #
d) Malignant Melanomas 0 (0%) # (100%) #
f) Other and unspecified malignant
neoplasms
0 (0%) 6 (100%) 6
a-d, f) Other Malignant Neoplasmsa 0 (0%) 44 (100%) 44
Teenagers and Young Adults (15-29
year olds)
a) Adrenocortical carcinomas 0 (0%) # (100%) #
b) Thyroid carcinomas 0 (0%) 87 (100%) 87
c) Nasopharyngeal carcinomas 0 (0%) 16 (100%) 16
d) Malignant Melanomas 0 (0%) # (100%) #
f) Other and unspecified malignant
neoplasms
13 (8%) 145 (92%) 158
a-d, f) Other Malignant Neoplasmsa 13 (5%) 252 (95%) 265
All Ages (0-29 year olds)
a) Adrenocortical carcinomas 0 (0%) 7 (100%) 7
b) Thyroid carcinomas 0 (0%) 105 (100%) 105
c) Nasopharyngeal carcinomas 0 (0%) 10 (100%) 10
d) Malignant Melanomas 0 (0%) 13 (100%) 13
f) Other and unspecified malignant
neoplasms
13 (8%) 151 (92%) 164
a-d, f) Other Malignant Neoplasmsa 13 (4%) 286 (96%) 299
aCategory e) ‘Skin Carcinomas’ was excluded as tumours in this category were not
registered on the Yorkshire register.
5.3.1.12 XII - Other and Unspecified Malignant Neoplasms
It is not possible to stage tumours which were of an unknown or unspecified nature, and
therefore no stage data were available for these tumours.
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5.3.1.13 Summary of Missing Stage Data
The above detailed descriptions of stage per tumour group highlight the problems which
arise for staging of CYA cancers. Firstly, there were a number of different mechanisms
for staging across diagnostic groups as well as across subgroups. Furthermore, stage does
not relate to prognosis in all cases (for example, leukaemia and retinoblastoma) and no
staging mechanism existed for some tumour types (for example, malignant extracranial
and extragonadal GCTs). For the purposes of this thesis, the term stage and disease
severity will be used interchangeably to refer to the extent and severity of disease at
diagnosis. The term stage will be used generally throughout this thesis to refer to a
measure of disease severity. For clarity, Table 5.31 provides the measures of disease
severity used for each diagnostic group.
Table 5.31: Stage and disease severity by diagnostic group for cancer in children and
young people
Diagnostic Group Measure of Stage/Disease Severity
I - Leukaemia White blood cell (WBC) count
(continuous, 103µ/L)
II - Lymphoma Stage (Ann Arbor Staging Classification,
I-IV)
III - CNS Tumours Grade (WHO Grade, I-IV)
IV - Neuroblastoma Stage (INSS, I-IV)
V - Retinoblastoma Not Applicable
VI - Renal Tumours Stage (TNM, I-IV)
VII - Hepatic Tumours Stage (PRETEXT, I-IV)
VIII - Malignant Bone Tumours Stage (TNM, I-IV)
IX - Soft Tissue Sarcomas Stage (TNM, I-IV)
X - Germ Cell Tumours Stage (TNM ovarian, I-IV; TNM
testicular, 0-III; FIGO I-IV; Royal
Marsden, I-IV and IGCCCG I-IV)
XI - Other Epithelial Neoplasms Stage (unspecified systems, I-IV)
XII - Other and Unspecified Neoplasms Not Applicable
The level of missing stage data was very high in most diagnostic groups (Figure 5.4). For
leukaemia, CNS tumours and GCTs, the level of missing data was below 50%. However,
for all other diagnostic groups, the level of missing stage data was above 70% and close
to 100% in a few cases.
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Figure 5.4: Level of missing disease severity by diagnostic group
The Yorkshire register database was unable to accurately capture staging data of this
nature due to a single field for stage which was applicable for all tumours. This meant
that there was no validation upon data entry of the values recorded, which has resulted
in a large amount of missing or invalid recordings of stage. A detailed scheme for each
diagnostic group has been developed (Appendix I) including all the information on stage
and disease severity detailed in this chapter as well as additional data items in relation
to prognosis for some tumour groups. This information formed part of the development
of the Yorkshire register’s electronic database system, which is currently ongoing. The
implementation of accurate and up to date staging information on the data collection and
storage system for the Yorkshire register is anticipated to improve the completeness and
importantly, the quality of data on stage and disease severity.
5.3.2 Ethnicity
Detailed ethnicity data was obtained from linked HES records. These data were coded
according to an 11 category system until April 2001, after which a more detailed 18
category system based on 2001 census classifications was adopted. In order to analyse
these data, pre-2001 ethnicity codes and post-2001 ethnicity codes were mapped into one
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system of broad ethnic groups, as shown in Table 5.32.
Table 5.32: Ethnicity coding schemes contained in hospital episode statistics (HES) data
pre- and post-2001 alongside suggested broad grouped categories
Pre-2001 Census Coding 2001 Census Coding Grouped Categories
0 = White A = British (White)
WhiteB = Irish (White)
C = Any other White
background
D = White and Black Caribbean
(Mixed)
Mixed
E = White and Black African
(Mixed)
F = White and Asian (Mixed)
G = Any other Mixed
background
4 = Indian H = Indian (Asian or Asian
British)
Asian
5 = Pakistani J = Pakistani (Asian or Asian
British)
6 = Bangladeshi K = Bangladeshi (Asian or
Asian British)
L = Any other Asian
background
1 = Black - Caribbean M = Caribbean (Black or Black
British) Black
2 = Black - African N = African (Black or Black
British)
3 = Black - Other P = Any other Black
background
7 = Chinese R = Chinese (other ethnic
group)
Chinese
8 = Any other ethnic group S = Any other ethnic group Other
X = Not known X = Not known
Unknown
9 = Not given Z = Not stated
HES data can contain multiple episodes (FCEs) per patient, and patient demographic data
is entered and recorded separately for each such FCE rather than being carried forward
from a previous FCE. This has the implication that one patient can be associated with
multiple ethnicity codes. Furthermore, some records associated with one person could
have missing ethnicity codes, whilst other ethnicity codes for that person are recorded.
In order to overcome this, an initial imputation scheme, selecting the most commonly
recorded ethnicity code (the ethnicity mode) for each person, was implemented. Missing
values were not included when determining the most common code. For example, one
person with 10 FCEs of which three had been recorded as ‘White’ ethnicity and the
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remaining 7 ethnicity codes were missing, was assigned to ‘White’ ethnicity. This was
done to avoid the loss of valuable ethnicity information. In some cases, it was not possible
to identify the most commonly recorded ethnicity value either because all were missing
or because there were multiple codes recorded an equal number of times. The former
scenario was treated as an ordinary missing data problem and accounted for using multiple
imputation techniques (results in Chapter 6), the latter was determined using the method
described below.
Figure 5.5 provides the missing data structure for ethnicity, which indicates that there
were 8 individuals in the dataset with multiple modes of ethnicity. Each of these records
was reviewed manually to determine the ethnicity. Another option would be to treat
these cases as having missing ethnicity, however, that would disregard potentially useful
data. The assignment of ethnicity was based on the record which contained the most
detailed information. For example, if one of the modes was white, and the other mode
was mixed then the latter was the assigned ethnicity as this was a more detailed ethnic
category. In cases where the two modes were white and other, white was allocated as
this was more detailed than ‘other’. In cases where there was conflicting information
such as white and black or white and Chinese, a cross check with the full name of the
person was made where this was available. If the name was not available or did not
provide further indications of ethnicity, the non-white categories were chosen as white
could have been incorrectly entered as a default value. Lastly, if there were cases with
conflicting information between categories, where neither category was white, and where
no mixed category existed for those two ethnicities then this would have been assigned
to missing, however, no such cases occurred in this data. There were no cases with more
than two modes. Table 5.33 shows all combinations of multiple modes of ethnicity that
were observed alongside their final assignments.
5. DESCRIPTIVE DATA ANALYSIS 141
Linked HES Data 
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N Cases = 4113 
Complete Ethnicity 
Codes* 
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Missing Ethnicity Codes** 
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Complete Ethnicity 
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N Cases = 3556 (86.5%) 
Multiple Modes 
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*Includes HES records with complete ethnicity data and cases with multiple ethnicity codes per person with on distinct mode. 
**Include HES records for patients for which all records had missing ethnicity, and patients for which there were multiple modes. 
Figure 5.5: Ethnicity Data Chart
Table 5.33: Ethnicity assignment for observed scenarios of multiple ethnicity modes
Scenario Mode 1 Mode 2 Assigned Ethnicity
1 White Mixed Mixed
2 White Other White
3 White Black Black
4 White Chinese Chinese
5 Mixed Asian Mixed
After individual review of these 8 cases, there were a total of 3556 (86.5%) cases with
recorded ethnicity and a remaining 557 (13.5%) with missing ethnicity data. However,
there were an additional 739 cases which did not link to HES data and as such also
had missing ethnicity. Therefore, ethnicity was missing in 1297 (26.7%) cases overall.
The majority of the cohort was White (64.2%), and the second largest group were Asian
(6.4%) (Figure 5.6). There was little variation in the level of missing ethnicity data by
diagnostic groups (Figure 5.7), ranging from 20% to 40% on average. Missing data
appeared high for 0-14 year olds in ICCC group XII (50%), however, this group was
very small with fewer than 5 cases in total.
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Figure 5.6: Distribution of ethnic groups amongst children and young adults with cancer
in Yorkshire, 1990-2009
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Figure 5.7: Percentage of Missing Ethnicity Data by Diagnostic Group and Age at
Diagnosis
5.3.3 Missing Data Patterns
In order to fully understand the overall amount of missing data within the cohort, the
missing data for individuals across multiple variables was assessed as well as missing
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data trends over time. This section continues to focus on missing disease severity and
ethnicity data as the remaining variables of interest within the Yorkshire register did not
contain any missing data.
Figure 5.8 shows that complete data was available for over 60% of cases of leukaemia
(I), CNS tumours (III), retinoblastoma (V), other and unspecified neoplasms (XII) and
for those with unknown ICCC group. For GCTs (X), the level of complete data was
approximately 40% and for the remaining diagnostic groups, complete data was available
for less than 20% of cases. The level of completeness was high for retinoblastoma, other
and unspecified neoplasms (XII) and for those with unknown ICCC group as stage was
not applicable for these diagnostic groups, and thus only missing data for ethnicity was
counted towards the overall percentage of missing data. For leukaemia, additional efforts
were made to retrospectively collect WBC count and for CNS tumours, the WHO grading
system was used to assign a grade according to morphological code which had resulted in
higher levels of completeness for these tumour groups.
Figure 5.9 shows the percentage of missing disease severity and ethnicity data by year of
diagnosis. For disease severity, the overall average level of missing data appears stable
over the study period, between 40 and 60% missingness (univariable incidence rate ratio
(IRR) = 0.99, 95% CI 0.99-1.01, P -value=0.630). For ethnicity, the percentage of missing
data decreased significantly over time by 12% on average (univariable IRR=0.88 (95% CI
0.88-0.89, P -value<0.001). There was a large drop in missingness of ethnicity around
the mid 1990s (Figure 5.9), which was due to linkage to HES data (available from 1996/7
onwards). After a small increase in the level of missing data, there was a further drop in
the level of missing ethnicity between 2002 and 2009 which is indicative of improvements
in HES data over time.
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Figure 5.8: Percentage of missing disease severity and ethnicity by international
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Figure 5.9: Percentage of missing disease severity and ethnicity by year of diagnosis for
children and young adults with cancer in Yorkshire, 1990-2009
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5.4 Imputation Strategy
The overall level of missing data within this cohort was very high (over 80%) in most
diagnostic groups. Based on the results described within this chapter and the discussion
of an acceptable level of missingness for imputation (§4.4.1), the diagnostic groups
considered for imputation and further analysis were leukaemia, CNS tumours and GCTs
as their overall levels of missingness was below 60%. Disease severity and ethnicity were
imputed for each of these diagnostic groups, using individual imputation models specific
to each diagnostic group due to differences in disease severity measures.
For leukaemia, WBC count was used as a proxy measure for stage at diagnosis as
discussed in §5.3.1.1. WBC count is a continuous measure, therefore the imputation
model was a linear regression model. However, WBC count cannot be negative, and it is
possible that the imputation model could impute negative values. Therefore, the logarithm
of WBC count was imputed instead to ensure only positive values of WBC were obtained.
For CNS tumours, missing values for WHO grade were imputed. The WHO classification
scheme contained values on a four level scale, from grade I-IV, and therefore the
imputation model was based on an ordered logistic regression model.
As described in §5.3.1, GCTs were staged using multiple systems per subgroup. In
addition, there was no known staging mechanism for intracranial and intraspinal GCTs,
which could be considered as missing by design. The staging mechanisms available for
the other subgroups of GCTs all had four main levels, with additional subgroups in each
category. For the purposes of imputing these values, only the four main stages were
considered and subcategories were not imputed. Despite no known staging mechanism
for intracranial and intraspinal GCTs, values of stage were still imputed on a scale of I
to IV. The purpose of imputation was to model the distribution of disease severity, rather
than to impute a specific value for a single persons disease severity. Therefore, imputing
values of disease severity for this subgroup allowed stage to be adjusted for within the
final survival analysis for all GCT subgroups. As suggested by von Hippel [292], the main
focus of multiple imputation is to obtain a set of values which behave like the complete
data if these values had not been missing rather than to obtain a set of values which
look like those in the observed data. Using four main levels of stage gave a measure of
increasing disease severity, whether including additional subcategories or not.
Detailed considerations of the assumptions required for multiple imputation as well as the
missing data mechanisms and the imputation models are given in Chapter 6 alongside the
analysis of variation in survival from CYA cancer.
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5.5 Conclusion
This chapter provides a detailed scrutiny of the linked Yorkshire register and HES datasets
used for analysis in Chapters 6, 7 and 8. Overall, there were 4852 diagnoses of CYA
cancer in the former Yorkshire region between 1990 and 2009, of whom 92% (n=4113)
successfully linked to at least one inpatient HES record. Specifically, for the sub-cohort
used for assessing cardiovascular LEs amongst long term survivors of CYA cancer (results
provided in Chapter 8), the linkage rate was 98%. This linkage enabled the capturing of
inpatient hospital activity for the vast majority of the cohort. Despite available outpatient
records for 3669 cases, these data were found to be unsuitable for identifying specific
diagnoses or conditions due to 99% of data being recorded as ‘unknown and unspecified
causes of morbidity’.
The analysis revealed that both the quantity and quality of data on disease severity within
the Yorkshire register was poor, with more than 50% missing data for most tumour groups.
Based on the evidence given in §4.4.1, detailed survival analysis for CYA cancers within
Yorkshire was performed for CNS tumours, leukaemia and GCTs in which missing data
levels were deemed suitable for multiple imputation techniques.
Importantly, the level of missing stage data did not decrease over the 20 year study
period. The results within this chapter were used to develop and compile a detailed
staging scheme (Appendix I) for all CYA cancers to be implemented into the Yorkshire
registers electronic database system. The successful implementation of this scheme is
hoped to improve the quality of data through validation of data upon entry, implying
that data loss due to recording errors would be minimised. Furthermore, an electronic
data collection system which contains detailed information about staging mechanisms
may provide a level of additional information to the data collection officer, which was
previously inaccessible.
Linkage to a routine dataset, inpatient HES data, has enabled data on ethnicity for CYAs
with cancer in Yorkshire to be identified in a more objective manor than the previous
method of relying on name analysis programs. Despite a 92% overall linkage rate and
improvement in data completeness over time, ethnicity was missing in 26.7% of cases
overall and was therefore imputed for use within the analysis (Chapters 6 and 7).
The main results of the thesis are presented in three chapters focusing on variation in
cancer survival (Chapter 6), inequalities in disease severity at diagnosis (Chapter 7)
and long term effects amongst survivors of cancer (Chapter 8) followed by a detailed
discussion of these results in Chapter 9.
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Chapter 6
Variation in Cancer Survival
The following publications have arisen from the analysis and results in this chapter:
1 van Laar, M., P.A. McKinney, D.P. Stark, A. Glaser, S.E. Kinsey, I.J. Lewis, S.V.
Picton, M. Richards, P.D. Norman, and R.G. Feltbower. (2012). Survival trends of
cancer amongst the south Asian and non-south Asian population under 30 years of
age in Yorkshire, UK. Cancer Epidemiology 36(1): e13-e18.
2 van Laar, M., D. Greenwood, D. Stark, R.G. Feltbower. (2014). Missing data
and survival analysis of central nervous system tumours amongst children and
adolescents in Yorkshire, UK, 1990-2009. Pediatric Blood & Cancer. 61:
S293-S293. Conference Abstract.
3 van Laar, M., D. Greenwood, D. Stark, R.G. Feltbower. (2013). Missing data and
survival analysis of central nervous system tumours amongst children and young
people in Yorkshire, 1990-2009. European Journal of Cancer. 60:3-3. Conference
Abstract.
4 van Laar, M., D. Greenwood, D. Stark, R.G. Feltbower. (2011). Multiple
imputation and survival analysis: an example using cancer registry data. Journal of
Epidemiology and Community Health 65:A395-A395. Conference Abstract.
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6.1 Introduction
The analysis presented in this chapter focuses on survival patterns for CYAs with CNS
tumours, leukaemia and GCTs. Missing data for disease severity (WHO grade, WBC
count and stage respectively) and ethnicity (white, Asian and other) were imputed using
the SMC-FCS method (see §4.4.2). Preliminary results focusing on survival analysis
after multiple imputation for CYAs with cancer in Yorkshire were published in 2012 in
van Laar et al. [263], however, the work in this chapter includes more detailed analysis
for three main tumour groups using the more advanced SMC-FCS imputation method
and extends the analysis from 2005 up to 2009. This chapter includes the imputation
analysis results and survival analysis results in detail, and therefore focuses on two types
of models:
1. Imputation models - including predictor, outcome and auxiliary variables to impute
partially observed variables, and
2. Analysis models - including predictor variables after multiple imputation to model
overall survival.
The structure of this chapter follows the analysis order as follows; proposed survival
analysis models were specified prior to the imputation process (§6.2) to ensure
congeniality between the analysis and imputation. Subsequently, §6.3 details the
imputation analysis, including missing data mechanism exploration, imputation model
specification and imputation results. Although §6.3 includes analysis model results, these
were presented for the purpose of comparing CCA, MICE and SMC-FCS methods; full
consideration of the survival models is given in §6.4 including 1, 3 and 5-year survival
estimates, K-M plots for imputed data, multivariable model selection, and pooled Cox PH
model results for the final analysis models. Survival model diagnostics are summarised
in §6.5, and sensitivity to the missing data mechanism assumption is explored in §6.6.
6.2 Analysis Model Specification
Partially observed variables were imputed separately for each tumour group and analysed
according to tumour specific analysis models, however, the initial model specification
was the same for all tumour groups, with the exception of the disease severity variable.
Table 6.1 shows the Spearman correlation coefficients for all variables to be included in
the analysis (variables were identified in §4.4.3). The correlation coefficients between
ethnicity and deprivation were higher than for any other variable pairs, however,
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all correlation coefficients were < |0.3|, thus providing no concern for collinearity.
Therefore, all variables were considered in the model selection process for the final
analysis models (§6.4).
Table 6.1: Spearman Correlation Coefficients by Tumour Group
Central Nervous System Tumours
Variable WHO Ethnic Sex Age Diagnostic Year of DeprivationGrade Group Subgroup Diagnosis
WHO Grade 1
Ethnic Group -0.0061 1
Sex -0.0732 0.0179 1
Age -0.0538 0.0219 0.0115 1
Diagnostic
Subgroup
0.0257 0.0115 0.0193 -0.0086 1
Year of Diagnosis -0.0486 0.1505 0.0357 0.0694 0.0066 1
Deprivation -0.0494 0.2947 -0.0116 0.0001 0.0152 0.0452 1
Leukaemia
Variable WBC Ethnic Sex Age Diagnostic Year of DeprivationCount Group Subgroup Diagnosis
WBC Count 1
Ethnic Group -0.0052 1
Sex -0.0147 -0.0105 1
Age -0.0628 -0.0205 0.0345 1
Diagnostic
Subgroup
0.1848 -0.0417 0.0718 0.2081 1
Year of Diagnosis 0.0144 -0.0946 -0.0038 0.1295 0.0841 1
Deprivation -0.0606 0.2402 -0.0529 -0.0497 0.0813 -0.0027 1
Germ Cell Tumours
Variable Stage Ethnic Sex Age Diagnostic Year of DeprivationGroup Subgroup Diagnosis
Stage 1
Ethnic Group 0.0778 1
Sex 0.0956 0.0388 1
Age -0.1364 -0.0856 -0.1753 1
Diagnostic
Subgroup
-0.1610 0.0056 0.0592 0.0639 1
Year of Diagnosis -0.0443 0.1630 -0.0401 -0.0165 0.0376 1
Deprivation -0.0056 0.2115 -0.1017 0.1282 -0.0414 0.1163 1
6.2.1 Interactions
As discussed in §4.4.3, interactions were only included in the imputation and analysis
models if there was sufficient power (greater than 10 deaths per interaction level) [264,
265, 266]. Interaction terms considered for analysis were age at diagnosis by sex, age at
diagnosis by diagnostic subgroup and year of diagnosis by diagnostic subgroup (§4.4.3)
and were summarised according to the number of deaths (Table 6.2). The variables to be
considered for analyses and the overall events per variable (EPV) are given in Table 6.3.
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For CNS tumours, fewer than 10 deaths occurred for ‘other specified CNS’ and ‘other
unspecified CNS’ subgroups, which were therefore combined to allow for the year
by diagnostic subgroup interaction to be considered for analysis. Despite combining
these groups, there remained too few events for the age group by diagnostic subgroup
interaction which was therefore excluded. The age group by sex interaction was included
as the number of events was sufficient. Table 6.3 indicates that the overall EPV for the
proposed CNS tumour analysis model was sufficiently large at 14.5. For leukaemia, the
number of events was sufficiently large for the age group by sex interaction, however,
there was not enough power to study the effects of a year- or age- by diagnostic subgroup
interaction for leukaemia. The overall EPV for leukaemia was sufficiently large at 19.8.
For GCTs, there were an insufficient number of events for all proposed interaction terms,
therefore no interactions were included. Furthermore, the proposed analysis model,
despite excluding interactions, had insufficient power with EPV of 4.8. The final analysis
models for each diagnostic group were determined in §6.5 and the low EPV value for
GCTs was addressed simultaneously.
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Table 6.2: Number of deaths by tumour group for proposed interaction terms; diagnostic
subgroup by year, diagnostic subgroup by age group and sex by age group. Sensitive data
on fewer than 5 deaths were replaced by #
Central Nervous System Tumours
Year of Diagnosis Age at Diagnosis0-14 years 15-29 years
Diagnostic Subgroup
Ependymoma 18 # #
Astrocytoma 144 41 103
Embryonal 63 51 12
Other Gliomas 57 30 27
Other specified CNS 17 10 7
Other unspecified CNS 6 # #
Sex
Male N/A 88 95
Female N/A 61 61
Leukaemia
Year of Diagnosis Age at Diagnosis0-14 years 15-29 years
Diagnostic Subgroup
Lymphoid Leukaemia 140 91 49
Acute Myeloid Leukaemia 114 38 76
Chronic Myeloproliferative disaeases 17 # #
Meylodysplastic syndrome # # #
Unspecified Leukaemia # # #
Sex
Male N/A 80 73
Female N/A 55 69
Germ Cell Tumours
Year of Diagnosis Age at Diagnosis0-14 years 15-29 years
Diagnostic Subgroup
Malignant Gonadal GCTs 37 0 37
Intracranial and Intraspinal GCTs 9 # #
Malignant extracranial and extragonadal GCTs 8 # #
Gonadal Carcinomas # # 6
Other and unspecified GCTs # # #
Sex
Male N/A # 45
Female N/A # 11
154 6. VARIATION IN CANCER SURVIVAL
Table 6.3: Proposed variables for analysis by tumour group including the number of levels
for each variable, the number of dummy variables associated with each variable and the
number of events per variable
Central Nervous System Tumours
Variable Levels (N) Dummy Variables (N)
WHO grade 4 3
Ethnic group 3 2
Sex 2 1
Age at diagnosis 1 1
Diagnostic subgroup 5 5
Year of diagnosis 1 1
Deprivation 1 1
Year by diagnostic subgroup 5 4
Age by sex 4 3
Totals N
Total dummy variables 21
Total cases 795
Total deaths 305
Events per variablea 14.5
Leukaemia
Variable Levels (N) Dummy Variables (N)
WBC count 1 1
Ethnic group 3 2
Sex 2 1
Age at diagnosis 1 1
Diagnostic subgroup 5 4
Year of diagnosis 1 1
Deprivation 1 1
Age by sex 4 3
Totals N
Total dummy variables 11
Total cases 912
Total deaths 277
Events per variablea 19.8
Germ Cell Tumours
Variable Levels (N) Dummy Variables (N)
Stage 4 3
Ethnic group 3 2
Sex 2 1
Age at diagnosis 1 1
Diagnostic subgroup 5 4
Year of diagnosis 1 1
Deprivation 1 1
Totals N
Total dummy variables 13
Total cases 846
Total deaths 62
Events per variablea 4.8
aEvents were deaths
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6.3 Imputation Analysis
6.3.1 Missing Data Mechanism Assessment
There were significant differences between survival curves for cases with observed and
missing disease severity and ethnicity for CNS tumours and leukaemia but not for GCTs
(Figure 6.1).
For CNS tumours, grade was 7% less likely to be missing per single yearly increase in age
at diagnosis and 95% less likely to be missing for those who received surgery compared
to those who did not (Table 6.4). Cases diagnosed later in the study period as well as
those who received chemotherapy were 10% and 3-fold more likely to have missing
grade respectively. Grade was more likely to be missing for those with other gliomas
and unspecified intracranial and intraspinal tumours compared to astrocytomas. Missing
ethnicity was 44% more likely for males compared to females, however, missing ethnicity
became less likely over the study period. Furthermore, those who received surgery and
radiotherapy were less likely to have missing data on ethnicity.
For leukaemia, WBC count was more likely to be missing for older cases of leukaemia and
those who had received radiotherapy. WBC count became less likely to be missing over
the study period and was less likely to be missing for those who had relapsed or received
chemotherapy. Missingness of ethnicity was also less likely over the study period as well
as for those who received chemotherapy or radiotherapy. CYAs with AML were 80%
more likely to have missing ethnicity data compared to those with ALL.
For GCTs, missingness of stage was 4% less likely to be missing per single yearly increase
in age at diagnosis. Cases diagnosed with extracranial & extragonadal GCTs and gonadal
carcinomas were over 3.5- and 3- times respectively more likely to have missing stage
compared to those with gonadal GCTs. Cases who received any of the three treatment
modalities (chemotherapy, radiotherapy or surgery) were all significantly less likely to
have missing data on stage. Ethnicity was less likely to be missing by an average of 10%
per year over the study period. There were no differences in the missingness of ethnicity
between diagnostic subgroups, however, cases who experienced a relapse were less likely
to have missing data on ethnicity.
For CNS tumours and leukaemias, it was evident from K-M survival curves that the data
were not MCAR, due to evidence of a systematic difference in the outcome between
missing and observed cases. For GCTs, although survival did not differ overall between
those with missing and observed stage or ethnicity, there were systematic differences in
missingness according to other clinical and demographic variables as described above and
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therefore the MCAR assumption could also not be made for GCTs. All data were assumed
to MAR, however, a sensitivity analysis to this assumption is presented in §6.6.1.
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Figure 6.1: Kaplan-Meier curves for central nervous system (CNS) tumours by observed
and missing grade (a) and ethnicity (b), for leukaemia by observed and missing white
blood cell (WBC) count (c) and ethnicity (d) and for germ cell tumours by observed and
missing stage (e) and ethnicity (f)
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Table 6.4: Predictors of missingness for disease severity (WHO grade, white blood cell
(WBC) count and stage) and ethnicity amongst children and young adults by tumour
group
Central Nervous System Tumours
Variable Odds Ratios
a
WHO Grade Ethnicity
Age (years) 0.93∗∗ 1.02
Sex (Female vs. Male) 1.31 0.66∗
Year of Diagnosis 1.10∗∗ 0.77∗∗
Deprivation Scoreb 1.05 0.95
Diagnostic Subgroup
Astrocytomas 1 1
Ependymomas 1.60 0.94
Intracranial and intraspinal embryonal tumours 1.00 1.00
Other gliomas 21.58∗∗ 1.15
Other specified intracranial and intraspinal neoplasms 2.92 1.07
Unspecified intracranial and intraspinal neoplasms 88.49∗∗ 1.94
Relapse (Yes vs. No) 0.42 0.79
Surgery (Yes vs. No) 0.05∗∗ 0.43∗∗
Chemotherapy (Yes vs. No) 3.05∗∗ 1.01
Radiotherapy (Yes vs. No) 0.71 0.57∗
Leukaemia
WBC Count Ethnicity
Age (years) 1.22∗∗ 1.02
Sex (Female vs. Male) 0.87 0.71
Year of Diagnosis 0.87∗∗ 0.80∗∗
Deprivation Scoreb 0.99 1.00
Diagnostic Subgroup
Lymphoid leukaemias 1 1
Acute myeloid leukaemias 1.40 1.81∗∗
Chronic myeloproliferative diseases 1.66 0.69
Myelodysplastic syndrome 0.38 3.35
Unspecified and other leukaemias 2.43 2.14
Relapse (Yes vs. No) 0.54∗ 0.83
Surgery (Yes vs. No) 1.23 0.81
Chemotherapy (Yes vs. No) 0.09∗∗ 0.50∗
Radiotherapy (Yes vs. No) 2.69∗∗ 0.30∗∗
Germ Cell Tumours
Stage Ethnicity
Age (years) 0.96 ∗∗ 1.00
Sex (Female vs. Male) 1.48 0.64
Year of Diagnosis 1.02 0.90 ∗∗
Deprivation Scoreb 1.01 1.00
Diagnostic Subgroup
Malignant Gonadal GCTs 1 1
Malignant extracranial and extragonadal GCTs 3.65 ∗∗ 0.84
Gonadal carcinomas 3.02 ∗ 1.03
Other and unspecified malignant gonadal tumours 4.05 0.85
Relapse (Yes vs. No) 0.61 0.45 ∗
Surgery (Yes vs. No) 0.09 ∗∗ 1.05
Chemotherapy (Yes vs. No) 0.58 ∗∗ 0.78
Radiotherapy (Yes vs. No) 0.47 ∗∗ 1.06
aOdds ratios were obtained from a multivariable logistic regression models for missing
data by disease severity (WHO Grade, white blood cell (WBC) count and stage) and ethnicity
b2007 Index of Multiple Deprivation (IMD)
∗Significant at 5% level, ∗∗Significant at 1% level.
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6.3.2 Imputation Model Specification
WBC count was the only continuous variable to be imputed, and it was therefore checked
for normality. Figure 6.2 shows that WBC count was highly positively skewed, and was
transformed to an approximately normal distribution using a log transformation. The
log transformation was also convenient in this case to restrict imputations to positive
values, as negative values of WBC count are not possible. Table 6.5 contains the
imputation model specifications for each tumour group based on the predictors for the
proposed analysis model, outcome variables and interactions which were based on clinical
relevance in addition to study power. Furthermore, the auxiliary variables identified
within the previous section as predictors of missing values were also included. The
number of imputations were m = 40 for CNS tumours and leukaemia, and m = 60
for GCTs, according to the overall level of missing data (justified in §3.5.4). Suitability
of the number of imputations in each case was checked by assessing MC errors (see
§6.3.3). The number of cycles used for each imputation model was 20 after checking for
convergence using 500 cycles for m = 1 (Figure 6.3). There were no clear patterns of
non-convergence, thus the default of 20 cycles was used for all analysis. The primary
imputation method was SMC-FCS, however, CCA and MICE analyses are also presented
for comparison.
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Figure 6.2: Histogram and Normal density curve for white blood cell count (a) and
logarithm of white blood cell count (b)
6. VARIATION IN CANCER SURVIVAL 159
Ta
bl
e
6.
5:
Im
pu
ta
tio
n
m
od
el
sp
ec
ifi
ca
tio
ns
sh
ow
in
g
pa
rt
ia
lly
ob
se
rv
ed
va
ri
ab
le
s,
fu
lly
ob
se
rv
ed
pr
ed
ic
to
rs
,i
nt
er
ac
tio
n
te
rm
so
fi
nt
er
es
t,
ou
tc
om
e
va
ri
ab
le
s
an
d
au
xi
lia
ry
va
ri
ab
le
s
by
tu
m
ou
rt
yp
e
Pa
rt
ia
lly
O
bs
er
ve
d
Va
ri
ab
le
s
Pr
ed
ic
to
rs
In
te
ra
ct
io
ns
O
ut
co
m
e
Va
ri
ab
le
s
A
ux
ili
ar
y
Va
ri
ab
le
s
C
en
tr
al
N
er
vo
us
Sy
st
em
Tu
m
ou
rs
G
ra
de
(O
rd
er
ed
L
og
is
tic
)
A
ge
(C
on
tin
uo
us
)
A
ge
by
Se
x
N
el
so
n-
A
al
en
E
st
im
at
es
C
he
m
ot
he
ra
py
(B
in
ar
y)
E
th
ni
c
G
ro
up
(M
ul
tin
om
ia
lL
og
is
tic
)
Se
x
(B
in
ar
y)
Y
ea
rb
y
D
ia
gn
os
tic
Su
bg
ro
up
C
en
so
ri
ng
In
di
ca
to
r
Su
rg
er
y
(B
in
ar
y)
D
ep
riv
at
io
n
(C
on
tin
uo
us
)
R
ad
io
th
er
ap
y
(B
in
ar
y)
Y
ea
r(
C
on
tin
uo
us
)
D
ia
gn
os
tic
Su
bg
ro
up
(C
at
eg
or
ic
al
)
L
eu
ka
em
ia
L
og
W
B
C
C
ou
nt
(L
in
ea
rR
eg
re
ss
io
n)
A
ge
(C
on
tin
uo
us
)
A
ge
by
Se
x
N
el
so
n-
A
al
en
E
st
im
at
es
C
he
m
ot
he
ra
py
(B
in
ar
y)
E
th
ni
c
G
ro
up
(M
ul
tin
om
ia
lL
og
is
tic
)
Se
x
(B
in
ar
y)
C
en
so
ri
ng
In
di
ca
to
r
R
el
ap
se
(B
in
ar
y)
D
ep
riv
at
io
n
(C
on
tin
uo
us
)
R
ad
io
th
er
ap
y
(B
in
ar
y)
Y
ea
r(
C
on
tin
uo
us
)
D
ia
gn
os
tic
Su
bg
ro
up
(C
at
eg
or
ic
al
)
G
er
m
C
el
l
Tu
m
ou
rs
St
ag
e
(O
rd
er
ed
L
og
is
tic
)
A
ge
(C
on
tin
uo
us
)
N
el
so
n-
A
al
en
E
st
im
at
es
C
he
m
ot
he
ra
py
(B
in
ar
y)
E
th
ni
c
G
ro
up
(M
ul
tin
om
ia
lL
og
is
tic
)
Se
x
(B
in
ar
y)
C
en
so
ri
ng
In
di
ca
to
r
Su
rg
er
y
(B
in
ar
y)
D
ep
riv
at
io
n
(C
on
tin
uo
us
)
R
ad
io
th
er
ap
y
(B
in
ar
y)
Y
ea
r(
C
on
tin
uo
us
)
R
el
ap
se
(B
in
ar
y)
D
ia
gn
os
tic
Su
bg
ro
up
(C
at
eg
or
ic
al
)
160 6. VARIATION IN CANCER SURVIVAL
2.
1
2.
14
2.
18
M
ea
n
G
ra
de
 C
at
eg
or
y
0 100 200 300 400 500
Iteration Number
WHO Grade
1.
11
1.
13
1.
15
M
ea
n
Et
hn
ic
 C
at
eg
or
y
0 100 200 300 400 500
Iteration Number
Ethnic Group
(a)
2
2.
4
2.
8
3.
2
M
ea
n 
Lo
g
W
BC
 C
ou
nt
0 100 200 300 400 500
Iteration Number
Logarithm of WBC Count
1
1.
16
1.
32
M
ea
n
Et
hn
ic
 C
at
eg
or
y
0 100 200 300 400 500
Iteration Number
Ethnic Group
(b)
1.
45
1.
65
1.
85
2.
05
M
ea
n
St
ag
e 
Ca
te
go
ry
0 100 200 300 400 500
Iteration Number
Stage
1.
08
1.
1
1.
12
1.
14
M
ea
n
Et
hn
ic
 C
at
eg
or
y
0 100 200 300 400 500
Iteration Number
Ethnic Group
(c)
Figure 6.3: Trace plots of the mean value of partially observed variables over 500
iterations (imputation cycles) based on one imputation for central nervous system tumours
(a), leukaemia (b) and germ cell tumours (c).
6.3.3 Imputation Results
Imputations were generally stable with no obvious outliers, showing only expected
variation between imputations for each tumour group (Figure 6.4 for CNS tumours,
Figure 6.5 for leukaemia and Figure 6.6 for GCTs). Imputations of stage for GCTs
varied more than for other imputation models by imputation number, this additional
uncertainty between imputations was a reflection of the larger amount of missing data for
this variable. Amongst CNS tumours, there was a slightly higher proportion of grade II
tumours and lower proportion of grade IV tumours amongst the imputed cases compared
to the observed cases, however, the overall distribution of completed data matched the
observed data very closely (Figure 6.7). For leukaemia, it was evident that the complex
pattern at the centre of the logarithm of WBC count distribution was not fully replicated
by the imputation model, which had a normal distribution (Figure 6.7). Nonetheless, the
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distribution of the imputed values was close to that of the observed values outside of this
central area, and the observed and completed distributions were very similar. In addition,
the imputation model for leukaemia predicted more cases into to the ‘other’ than ‘white’
ethnic category compared to the observed data, however the observed and completed data
ethnic distributions were very similar. For GCTs, there were slightly more stage III and IV
imputed values and fewer stage II values compared to observed data. The distribution of
ethnic groups between the observed, imputed and completed data for GCTs did not vary
(Figure 6.7). MC errors for each HR and associated P -value were sufficiently small so
that neither the direction of significant variables nor the significance level of any variable
were affected at the extreme boundaries of the error for all three tumour groups (Table
6.6).
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Figure 6.4: The percentage of central nervous system tumour cases by grade (a) and
ethnicity (b) within the observed data and each imputed dataset
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Figure 6.5: The distribution of the logarithm of white blood cell (WBC) count for
leukaemia cases (a) and the percentage of leukaemia cases by ethnicity (b) for the
observed data and each imputed dataset
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Figure 6.6: The percentage of germ cell tumour cases by stage (a) and ethnicity (b) within
the observed data and each imputed dataset
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Figure 6.7: Distribution of observed, imputed and completed cases for central nervous
system tumours by WHO grade (a) and ethnicity (b), leukaemia by logarithm of white
blood cell (WBC) count (c) and ethnicity (d) and germ cell tumours by stage (e) and
ethnicity (f)
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Table 6.6: Monte Carlo (MC) errors of pooled hazard ratios (HRs) and P−values
obtained from survival analysis models after multiple imputation for central nervous
system tumours, leukaemia and germ cell tumoursa
Central nervous system tumours
Variable HR MC Error HR P -value MC Error P -value± MC Error ± MC Error
Age 1.01 0.0002 1.0141-1.0146 0.036 0.0030 0.0330-0.0690
Sex (Female vs. Male) 0.84 0.0042 0.8322-0.8406 0.149 0.0100 0.1390-0.2880
Year 0.96 0.0004 0.9632-0.9639 0.001 < 0.0001 0.0010-0.0020
Deprivation 1.00 0.0002 1.0002-1.0005 0.912 0.0400 0.8720-1.7840
Diagnostic subgroup
Astrocytoma 1
Ependymoma 0.60 0.0035 0.5921-0.5990 0.047 0.0020 0.0450-0.0920
Embryonal 0.38 0.0033 0.3739-0.3805 < 0.001 < 0.0001 < 0.0001-< 0.0001
Other gliomas 1.51 0.0212 1.4929-1.5353 0.023 0.0070 0.0160-0.0390
Other CNS 0.80 0.0044 0.7916-0.8005 0.340 0.0120 0.3280-0.6680
Ethnicity
White 1
Asian 1.43 0.0358 1.3897-1.4614 0.216 0.0380 0.1780-0.3940
Other 2.22 0.0759 2.1443-2.2962 0.032 0.0100 0.0220-0.0540
Grade
I 1
II 3.64 0.0403 3.6027-3.6833 < 0.001 < 0.0001 < 0.0001-< 0.0001
III 6.31 0.0815 6.2259-6.3888 < 0.001 < 0.0001 < 0.0001-< 0.0001
IV 11.02 0.1194 10.903-11.142 < 0.001 < 0.0001 < 0.0001-< 0.0001
Leukaemia
Age 1.04 0.0003 1.0428-1.0435 < 0.001 < 0.0001 < 0.0001-< 0.0001
Sex (Female vs. Male) 0.97 0.0041 0.9664-0.9745 0.811 0.0270 0.7840-0.8380
Year 0.94 0.0004 0.9400-0.9409 < 0.001 < 0.0001 < 0.0001-< 0.0001
Deprivation 1.00 0.0001 1.0034-1.0037 0.331 0.0180 0.3131-0.3491
Diagnostic subgroupb
Ia 1
Ib 1.79 0.0099 1.7843-1.8041 < 0.001 < 0.0001 0.0001-0.0001
Ic 0.65 0.0087 0.6424-0.6597 0.216 0.0050 0.2112-0.2212
Id 0.33 0.0075 0.3255-0.3406 0.280 0.0090 0.2713-0.2893
Ie 2.34 0.0420 2.2994-2.3835 0.067 0.0060 0.0611-0.0731
Ethnicity
White 1
Asian 1.25 0.0331 1.2157-1.2820 0.438 0.0520 0.3861-0.4901
Other 1.52 0.0733 1.4464-1.5929 0.347 0.0640 0.2828-0.4108
Log WBC Count 1.21 0.0060 1.2077-1.2197 < 0.001 < 0.0001 < 0.0001-< 0.0001
Germ Cell Tumours
Age 1.04 0.0017 1.0355-1.0389 0.158 0.0190 0.1390-0.1770
Sex (Female vs. Male) 0.64 0.0251 0.6178-0.6680 0.408 0.0420 0.3660-0.4500
Year 1.01 0.0017 1.0063-1.0097 0.775 0.0450 0.7300-0.8200
Deprivation 1.01 0.0005 1.0069-1.0080 0.376 0.0370 0.3390-0.4130
Diagnostic subgroupc
Xc
Xa 18.24 1.6397 16.5976-19.8771 0.001 0.0010 < 0.0001-0.0020
Xb 1.72 0.0681 1.6489-1.7852 0.334 0.0380 0.2960-0.3720
Xd 13.31 0.9252 12.3875-14.2378 0.002 0.0010 0.0010-0.0030
Xe 15.20 1.2187 13.9813-16.4186 0.009 0.0040 0.0050-0.0130
Ethnicity
White
Asian 1.55 0.0662 1.4802-1.6126 0.441 0.0470 0.3940-0.4880
Other 2.65 0.2175 2.4294-2.8645 0.296 0.0440 0.2520-0.3400
Stage
I
II 5.27 0.2869 4.9781-5.5520 0.014 0.0040 0.0100-0.0180
III 18.87 1.0537 17.8181-19.9254 < 0.001 < 0.001 < 0.0001-< 0.0001
IV 32.77 2.2626 30.5098-35.0349 < 0.001 < 0.001 < 0.0001-< 0.0001
aFull model results including confidence intervals and standard errors are provided in Tables 6.7, 6.8 and 6.9
bIa - Lymphoid leukaemias; Ib - Acute myeloid leukaemias; Ic - Chronic myeloproliferative diseases; Id - Myelodysplastic
syndrome and other myeloproliferative diseases; Ie - Unspecified and other specified leukaemias
cXa - Intracranial and Intraspinal GCTs; Xb - Malignant extracranial and extragonadal GCTs; Xc - Malignant Gonadal
GCTs; Xd - Gonadal carcinomas; Xe - Other and unspecified malignant gonadal tumours
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The CCA, MICE and SMC-FCS methods were compared by assessing estimates from the
Cox PH model for CNS tumours, leukaemia and GCTs (Tables 6.7, 6.8 and 6.9). A basic
analysis model including only main effects was used to compare results between CCA
and imputation methods; an assessment of the most appropriate analysis model (including
interactions and testing for linearity) is provided in the survival analysis section (§6.4).
For GCTs, the proposed imputation model did not work using the SMC-FCS method,
therefore imputations generated using the MICE method were used for further analysis
of GCTs. A detailed description providing reasons for this is provided in the following
subsection (§6.3.3.1).
6.3.3.1 Exploration of Germ Cell Tumour Substantive Model Compatible Fully
Conditional Specification (SMC-FCS) Analysis
There were several complications when imputing and analysing stage and ethnic group for GCTs.
The SMC-FCS imputation method for GCTs did not run using the proposed imputation model
specification (Table 6.5), and the below paragraph contains a detailed description exploring the
possible reasons. The SMC-FCS method required the imputation model and the analysis model
to be specified at the imputation stage to ensure an imputation model that is compatible with the
analysis model can be derived. This meant that any problems could arise in either the imputation
or analysis part, and identifying the model which was not working was not immediately obvious
from the Stata output. In terms of potential problems with the imputation model, the GCT
analysis differed from other tumour groups due to the large amount of missing data (60% overall).
Furthermore, as there was no known staging mechanism for the intracranial and intraspinal
GCT subgroup, this subgroup had a 100% missing stage data. In addition, perfect prediction
arose for some variables as all observed cases of intracranial and intraspinal GCTs were of
white ethnicity, and all observed cases diagnosed between 5 and 9 years of age were of white
ethnicity and had stage III tumours. In addition, there were only 9 cases of unspecified malignant
gonadal tumours, 2 of which had a non-missing stage which were both stage I. In terms of the
problems encountered for the survival analysis of GCTs, there was a much higher overall 5-year
survival rate for GCTs (94% 5-year survival) compared to CNS tumours (59% 5-year survival)
and leukaemia (72% 5-year survival). This meant that the EPV value for the proposed analysis
model was too low (EPV = 4.7) to provide the required power for a Cox PH model. Initially,
SMC-FCS using the full proposed imputation and analysis models were implemented, resulting
in the following error messages “valid imputations have not been generated” and “convergence
was not achieved”. The default number of imputation cycles (c=20) and the default rejection
sampling limit (rjlimit=5000) were increased by 50 and 1000 respectively at a time, however,
even at c=1000 and rjlimit=500000 respectively, convergence and valid imputations for each
subject were not achieved. Subsequently, the imputation model was constructed in a stepwise
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manner by adding a single variable at a time whilst keeping the basic analysis model constant
(including only stage and ethnic group as explanatory variables). The algorithm converged and
generated valid imputations for each subject based on a model including all proposed imputation
variables (age, sex, year of diagnosis, deprivation, relapse status, surgery status, chemotherapy
status and radiotherapy status) except diagnostic subgroup. Subsequently, the analysis model
was constructed in a stepwise manner whilst maintaining the aforementioned imputation model
constant throughout. The algorithm produced successful imputations for an analysis model
containing all variables in the proposed analysis model (age, sex, year of diagnosis, stage,
ethnicity and diagnostic subgroup) except for deprivation. The diagnostic subgroup variable
had two main features (100% missing stage for one subgroup and perfect prediction) which
were likely to lead to the SMC-FCS method failing to converge and produce valid imputations
whilst including this variable. Being unable to include diagnostic subgroup in the imputation
model led to uncertainty over the imputation validity and the strength of the MAR assumption
as diagnostic subgroup was a significant predictor of missingness of stage as shown in Table
6.4. For this reason, further analysis of GCTs were performed using imputations produced by
MICE for which the proposed imputation model was successfully implemented. It was unclear
why inclusion of the deprivation variable in the analysis model caused the SMC-FCS algorithm
to fail, however, SMC-FCS required more power than MICE due to its attempt to find a complex
compatible imputation and analysis model, therefore it was likely to be a combination of the low
EPV value for GCT tumours and the high level of missing data which were causing a problem.
The remainder of §6.3.3 focuses on comparing the CCA, MICE and SMC-FCS methods for all
three tumour groups, however, for GCTs, the MICE and SMC-FCS results compared were based
on different imputation models as described here.
Tables 6.7, 6.8 and 6.9 contain multivariable survival estimates based on CCA, MICE
and SMC-FCS methods. The results show, for the first time in CYA cancer survival, that
ignoring missingness can lead to serious bias and incorrect inferences as discussed in
detail for each tumour group below. The final analysis models and clinical interpretation
of these are discussed later in §6.4.
For the CNS tumour analysis, despite very similar HRs, both the MICE and SMC-FCS
analysis resulted in significant differences in survival for age, other ethnicity compared to
white ethnicity as well as ependymoma and other gliomas compared to astrocytmas which
were not observed amongst the CCA (Table 6.7). This showed that without the use of an
imputation technique, the study was underpowered to detect these significant differences.
The HR for year of diagnosis reversed direction, moving from an increased risk of death in
the CCA (HR=1.02, 95% CI 0.99-1.05, P=0.294), compared to a decreased risk of death
in the MICE and SMC-FCS analysis (HR=0.96, 95% CI 0.94-0.98, P=0.001 for MICE
and SMC-FCS). Furthermore, the CCA indicated a significant difference in survival for
the other CNS tumour subgroup compared to astrocytomas (HR=0.41, 95% CI 0.19-
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0.86, P=0.019), whereas in the MICE and SMC-FCS methods there was no difference
in the survival of this subgroup compared to astrocytomas (HR=0.79, 95% CI 0.50-
1.27, P=0.335 and HR=0.80, 95% CI 0.50-1.27, P =0.340 for MICE and SMC-FCS
respectively). The missing data, if ignored, would have caused incorrect inferences to be
drawn about the ‘other CNS tumour’ subgroup, which appeared to have poorer survival
rates in the CCA, however, survival was similar to that of astrocytomas after imputation.
The availability of grade data for diagnoses which are not well defined, such as those in
the ‘other CNS tumour’ group was poor (discussed in §5.3.1.3). However, imputation
allowed for all information related to cases within this subgroup to be included within the
analysis, regardless of whether grade was missing or not, thereby providing more accurate
results. These important differences between CCA and imputation techniques indicate
how ignoring missingness can cause bias in terms of the direction, size and significance
of survival effects.
The significant difference in survival between embryonal tumours compared to
astrocytomas as well as between grades II, III and IV compared to grade I were evident in
all three analyses, and their effect sizes were comparable. The standard error was either
reduced or of similar magnitude for all variables in the MICE and SMC-FCS analyses
compared to the CCA except for those associated with ethnicity. Overall, imputation led
to an increase in efficiency resulting from including all available data within the analysis.
For the leukaemia, the HR for year of diagnosis was not significant (HR=1.00, 95%
CI 0.96-1.04, P=0.999) in the CCA, compared to a decreased risk of death observed
using MICE and SMC-FCS methods (HR=0.94, 95% CI 0.92-0.96, P <0.001 for MICE
and SMC-FCS) (Table 6.8). A similar change between HRs in the CCA and imputation
analysis for year of diagnosis was also observed in the CNS tumour analysis. Estimates
for diagnostic subgroup Id - ‘Myelodysplastic syndrome and other myeloproliferative
disease’ were not available in the CCA as this group was small (n=6) and contained no
deaths when using listwise deletion. The use of imputation techniques allowed estimates
of survival for this subgroup to be obtained, although CIs around these estimates remained
large. MICE and SMC-FCS resulted in an increase in HRs and borderline significant
evidence of increased risk of death of subgroup Ie -‘Unspecified and other specified
leukaemias’ compared to Ia - ‘lymphoid leukaemias’ compared to CCA.
HRs under CCA, MICE and SMC-FCS were very similar for those variables which
displayed significant effects in the CCA, including HRs for age, diagnostic subgroup
Ib and log WBC count. The HRs for other ethnicity compared to white ethnicity
gave conflicting information between the MICE and SMC-FCS results in terms of the
direction of effect (HR=0.90 and HR=1.52 respectively). However, both effects were not
significant (P=0.814 and P=0.347 respectively), indicating that there was no certainty of
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the direction of effect for this estimate. Furthermore, the percentage of cases and deaths
within this category were very small (3.2% and 5.1% respectively) thereby highlighting
the uncertainty and unstable nature of these results.
For the GCT analysis, the CCA showed a worrying significant increase in the risk of
death by 18% on average per year of diagnosis (HR=1.18, 95% CI 1.04-1.33, P=0.008),
however, after imputation using MICE and SMC-FCS, no significant increase in the risk
of death was observed (HR=1.01, 95% CI 0.95-1.06, P=0.775 and HR=1.02, 95% CI
0.97-1.08, P=0.448 for MICE and SMC-FCS respectively) (Table 6.9). Estimates for
diagnostic subgroup Xa - ‘Intracranial and intraspinal GCTs’ were not available as stage
was missing in 100% of cases, causing the variable to be automatically excluded from
the CCA through listwise deletion. The MICE and SMC-FCS methods both showed an
increased risk of death for this subgroup compared to Xc - ‘Malignant gonadal GCTs’
(HR=18.24, 95% CI 3.33-99.99, P=0.001 and HR=7.51, 95% CI 2.70-20.88, P <0.001
for MICE and SMC-FCS respectively). In addition, estimates for Xe - ‘Other and
unspecified malignant gonadal GCTs’ were not available in the CCA as there were no
observed deaths in this subgroup after listwise deletion. MICE and SMC-FCS again
showed a significant increased risk of death for this diagnostic subgroup compared to Xc
- ‘Malignant gonadal GCTs’ (HR=15.20, 95% CI 1.97-117.09, P=0.009 and HR=7.24,
95% CI 1.26-41.68, P=0.027 for MICE and SMC-FCS respectively). For Xb - ‘Malignant
extracranial and extragonadal GCTs’ CCA showed a significant 7-fold increased risk
of death compared to Xc - ‘Malignant gonadal GCTs’, however, this effect was much
smaller and non-significant (HR=1.72, 95% CI 0.57-5.15, P=0.334 and HR=2.27, 95%
CI 0.82-6.28, P=0.113) using the MICE and SMC-FCS methods respectively. Although
the increased risk of death for Xd - ‘Gonadal carcinomas’ was evident in CCA, MICE
and SMC-FCS, the standard error of this estimate reduced from 85.14 to 17.07 and 6.45
for each method respectively. No significant effect of ethnicity on survival was observed
in the CCA or MICE despite increased HRs for Asian and other ethnic groups compared
to white ethnicity. However, there was a significant 5-fold increased risk of death for the
other ethnic group compared to white ethnicity after using the SMC-FCS method. The
risk of death increased significantly for stage II, III and IV tumours compared to stage I
tumours across all analyses. The standard errors of these estimates reduced substantially
by approximately 4- and 5-fold for MICE and SMC-FCS respectively. The SMC-FCS
models differ from the MICE models as the former method excluded diagnostic subgroup
from the imputation model (see §6.3.3.1). Standard errors for SMC-FCS were smaller
on average than MICE, however, due to the inability to specify the proposed imputation
model, the validity of the SMC-FCS results was uncertain.
Overall, important differences between CCA and each of the imputation methods were
observed, however results between MICE and SMC-FCS were very similar. HRs were
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identical or within< 0.1 of each other for each of the fully observed variables between the
latter two methods for CNS tumours and leukaemia. For the partially observed variables,
there was a slightly larger difference between HRs when comparing MICE and SMC-
FCS for CNS tumours and leukaemia, however, the largest difference was still very small
(|0.11|). For GCTs, the differences were larger (up to 10.7 difference in HRs of fully
observed variables and up to 4.1 difference in HRs for partially observed variables),
however, this was expected as the imputation models differed for each method. There
was no change in the significance for any of the variables between the MICE and SMC-
FCS methods. Standard errors were very similar for fully observed as well as partially
observed variables between the MICE and SMC-FCS methods, except for the significant
affect of other ethnicity compared to white ethnicity in the SMC-FCS analysis for GCTs.
There was no consistent pattern in terms of the direction of the small differences observed
between MICE and SMC-FCS, although on average, effect sizes were smaller using the
SMC-FCS method compared to MICE (i.e. HRs tended to be closer to 1 using the SMC-
FCS method compared to MICE), however this was not the case for all estimates.
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6.4 Survival Analysis
This section contains details of the survival analysis following multiple imputation of
partially observed variables, including 1, 3 and 5-year survival estimates and multivariable
Cox PH models. The analysis for CNS tumours, leukaemia and GCTs are summarised in
§6.4.1, §6.4.2 and §6.4.3 respectively. An assessment of each analyses model is provided
in §6.5.
6.4.1 Central Nervous System Tumours
For CNS tumours, 1 and 3-year survival was similar for children and TYAs, however,
by 5-years, survival was poorer for TYAs (65%, 95% CI 60-70%) compared to children
(73%, 95% CI 68-77%) although not significantly so (Table 6.10). A similar pattern
was observed for males and females with CNS tumours, whereby there was little or no
difference in 1 and 3-year survival, but by 5-years, males had poorer survival compared to
females (66%, 95% CI 62-71% vs. 73%, 95%CI 68-77%). Across deprivation quintiles,
survival decreased steadily between 1, 3 and 5-years, however, this decline was slightly
steeper for the three most deprived fifths compared to the two least deprived fifths.
Survival was highest for the ‘other CNS’ tumour subgroup and ependymomas and was
poorest for ‘other gliomas’ and ‘unspecified CNS tumours.’ Of note was the particularly
poor 5-year survival for those in the unspecified CNS tumour subgroup, with only 29%
survival. K-M curves for grade of CNS tumour showed that those with grade I tumours
had a much improved prognosis compared to any other grade of tumour (Figure 6.8). Of
note, there was little difference between grade III and grade IV tumours, with a slight
indication that survival for those with grade III tumours was poorer compared to those
with grade IV tumours, particularly beyond approximately 6-years from diagnosis. K-M
curves for ethnicity showed very little difference between survival amongst Asian and
other ethnicities, whereas the white ethnic group indicated better survival compared to
the Asian and other ethnic category.
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Table 6.10: 1, 3 and 5-year survival estimates for central nervous system tumours
(displayed as percentages of cases survived)
Variable 1 year (95% CI) 3 year (95% CI) 5 year (95% CI)
Age
0-14 84 (81-87) 75 (70-79) 73 (68-77)
15-29 82 (78-86) 74 (69-78) 65 (60-70)
Sex
Male 82 (78-85) 72 (67-76) 66 (62-71)
Female 85 (81-88) 77 (72-81) 73 (68-77)
Deprivation
Least deprived (1) 82 (75-88) 75 (67-81) 71 (62-78)
2 80 (74-86) 70 (63-77) 67 (59-73)
3 88 (81-92) 80 (73-86) 73 (65-80)
4 86 (79-91) 77 (69-83) 71 (63-78)
Most deprived (5) 82 (76-86) 71 (65-77) 66 (59-72)
Diagnostic sugroups
Astrocytoma 85 (81-89) 76 (72-80) 70 (65-74)
Ependymoma 91 (81-96) 82 (71-89) 77 (65-86)
Embryonal 79 (71-85) 65 (56-73) 61 (52-69)
Other gliomas 69 (59-77) 55 (45-64) 51 (41-60)
Other CNS 92 (85-96) 92 (85-96) 90 (82-94)
Unspec. CNS 43 (10-73) 43 (10-73) 29 (04-51)
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Figure 6.8: Kaplan-Meier (K-M) survival curves for central nervous system tumours for
each imputation, superimposed with the mean K-M curve averaged over all imputations
by grade (a) and ethnic group (b)
In order to determine a final analysis model, the method recommended by Collett
[245] was implemented (discussed in §4.4.3.1 in detail) and results given in Table
6.11. Importantly, this method relies on clinical knowledge and considers variables of
key interest (as identified from previous literature) rather than relying on an automated
forward, backward or stepwise model selection procedure. A lenient significant cut off of
10% was used for guidance on individual explanatory power and evidence of interactions
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and linearity while selecting variables for inclusion or exclusion from the model.
WHO grade and diagnostic subgroup both had individual explanatory power on survival
which was significant at the 1% level. Age, sex and year of diagnosis all had explanatory
power at the 5% significance level and ethnicity had explanatory power at the 10%
significance level. The single effect of deprivation was not significant and was therefore
excluded from the final model. Sex did not significantly improve the model containing
WHO grade and diagnostic group, however, it was initially retained in the model to allow
the age by sex interaction to be tested. There was no significant evidence against linearity
of age (P=0.582 for 5-year age bands and P=0.313 for 15 year age bands), and year of
diagnosis (P=0.148 for 5-year periods), therefore these variables were initially retained
in the model as continuous variables. However, upon assessment of the PH assumption,
a model with 15 year age groups was deemed more appropriate than one with continuous
age (see §6.5 below). There was no evidence of an interaction between year and diagnostic
subgroup (P=0.408) or age and sex (P=0.286), therefore these interactions were excluded
from the final model. In addition, the non-significant main effect of sex was also excluded
from the final model.
Table 6.11: Model selection process for central nervous system tumours using P -values
of overall model fit obtained from Wald tests to guide selection of the analysis model
Variables in model P -value
None -
Age 0.0030
Sex 0.0263
Ethnicity 0.0941
Year 0.0016
Grade < 0.001
Deprivation 0.6316
Diagnostic subgroup < 0.001
Diagnostic subgroup + Grade < 0.001
Diagnostic subgroup + Grade + Age 0.0924
Diagnostic subgroup + Grade + Sex 0.1037
Diagnostic subgroup + Grade + Year 0.0025
Diagnostic subgroup + Grade + Ethnicity 0.0765
Diagnostic subgroup + Grade + Year + Age 0.0339
Diagnostic subgroup + Grade + Year + Age + Sex 0.1559
Diagnostic subgroup + Grade + Year + Age + Sex + Ethnicity (Full Model) 0.0272
Linearity Tests
Full model + Age Group (0-14, 15-29 years) 0.3131
Full model + Age Group (0-4, 5-9, 10-14, 15-19, 20-24, 25-29 years) 0.5818
Full model + Period (1990-1994, 1995-1999, 2000-2004, 2005-2009) 0.1475
Interactions
Year x Diagnostic subgroup 0.4075
Age x Sex 0.2856
Final Model
Diagnostic subgroup + Grade + Year + Age + Ethnicity
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6.4.1.1 Survival analysis results for central nervous system tumours
Survival for CNS tumours was significantly worse for older cases, with a 34% increase in
the risk of death for those diagnosed aged 15-29 years compared to 0-14 year olds (Table
6.12). There was a two-fold increased risk of death for other ethnicity compared to white
ethnicity, and an increased risk for those of Asian ethnicity compared to white ethnicity
(HR=1.50) although the latter was not significant. Survival worsened significantly with
increasing WHO grade at presentation by 3.5-fold, almost 6.5-fold and 10-fold for grade
II, III and IV tumours respectively compared to grade I tumours. Over the study period,
survival rates of CNS tumours improved by 4% on average per year, and survival for
ependymomas and embryonal tumours was significantly better compared to astrocytomas.
In the univariable analysis, survival of ependymomas was significantly worse compared to
survival of astrocytomas (Table 6.10), however, after adjusting for WHO grade, this effect
was reversed as all embryonal tumours were WHO grade IV, compared to only 1.8% of
astrocytoma cases at WHO grade IV. Those with other gliomas had a 51% increased risk
of death compared to astrocytomas and those with unspecified CNS tumours had a 3-fold
increased risk of death compared to astrocytomas, as reflected by the univariable 1, 3 and
5-year survival rates.
Table 6.12: Pooled Cox proportional hazards model estimates based on 40 imputations
for CNS tumours amongst children and young adults in Yorkshire, 1990-2009
Variable HR 95% CI SE P -value
Age Group
0-14 years 1
15-29 years 1.34 1.04-1.71 0.169 0.022
Year 0.96 0.94-0.98 0.011 < 0.001
Diagnostic Subgroup
Astrocytoma 1
Ependymoma 0.58 0.35-0.96 0.150 0.035
Embryonal 0.40 0.27-0.61 0.083 < 0.001
Other gliomas 1.51 1.06-2.16 0.273 0.022
Other CNS 0.60 0.35-1.01 0.160 0.055
Unspecified CNS 2.97 1.17-7.50 1.401 0.021
Ethnicity
White 1
Asian 1.50 0.89-2.53 0.399 0.128
Other 2.25 1.12-4.52 0.797 0.023
Grade
I 1
II 3.53 2.41-5.18 0.690 < 0.001
III 6.41 3.95-10.41 1.585 < 0.001
IV 10.10 6.72-15.20 2.103 < 0.001
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6.4.2 Leukaemia
For leukaemia, survival for those diagnosed under the age of 1 was very poor compared to
other age groups and continued to decline from 55% to 37% and 29% at 1-, 3- and 5-years
respectively (Table 6.13). Children diagnosed between the age of 1 and 14 experienced
better survival compared to all other age groups, and although 1-year survival for TYAs
aged 15-29 years was good, survival declined from 78% to 62% and 55% at 3 and 5-years
respectively. Survival did not vary by gender or deprivation and remained stable over all
three time points. Diagnostic subgroup Ib - Acute myeloid leukaemias displayed a similar
survival pattern as that for TYAs, which was reflected by the fact that AML occurred more
commonly amongst TYAs compared to children. Survival amongst diagnostic subgroup
Ie - Unspecified and other specified leukaemias was poor at 55% survival by 1-year,
but remained the same for 3 and 5-year survival. K-M curves for log WBC count were
categorised according to standard and high risk, and these risk classifications accurately
represented survival differences with clear separation between curves (Figure 6.9). The
graph also showed there was less between-imputation variation for those with standard
risk compared to high risk cases. K-M curves for ethnicity showed no difference between
survival amongst white, Asian and other ethnic categories.
0.
00
0.
25
0.
50
0.
75
1.
00
Pr
op
or
tio
n 
Su
rv
ive
d
0 5 10 15 20 25
Survival Time (Years)
Standard Risk High Risk
(a)
0.
00
0.
25
0.
50
0.
75
1.
00
Pr
op
or
tio
n 
Su
rv
ive
d
0 5 10 15 20 25
Survival Time (Years)
White Asian
Other
(b)
Figure 6.9: Kaplan-Meier (K-M) survival curves for leukaemia for each imputation,
superimposed with the mean K-M curve averaged over all imputations by standard
(< 50, 000µ/L) and high risk (≥ 50, 000µ/L) WBC count (a) and ethnic group (b)
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Table 6.13: 1, 3 and 5-year survival estimates for leukaemia (displayed as percentages of
cases survived)
Variable 1 year (95% CI) 3 year (95% CI) 5 year (95% CI)
Age (years)
< 1 51 (35-65) 37 (22-51) 29 (16-43)
1-10 95 (93-97) 90 (87-92) 87 (84-90)
11-14 89 (80-94) 78 (68-85) 75 (61-80)
15-29 78 (72-82) 62 (56-67) 55 (49-61)
Sex
Male 88 (84-90) 78 (74-81) 73 (68-76)
Female 86 (82-89) 76 (72-80) 72 (68-76)
Deprivation Quintile
Least deprived (1) 89 (82-93) 80 (72-86) 76 (68-83)
2 89 (83-93) 80 (73-85) 74 (67-80)
3 85 (78-89) 78 (70-83) 74 (67-80)
4 88 (82-92) 75 (68-81) 69 (61-76)
Most deprived (5) 85 (80-89) 74 (69-79) 71 (65-75)
Diagnostic subgroupa
Ia 93 (90-94) 84 (81-87) 80 (76-83)
Ib 72 (66-77) 59 (53-65) 55 (49-61)
Ic 94 (83-98) 84 (71-92) 72 (57-82)
Id 100 (100-100) 89 (43-98) 89 (43-98)
Ie 55 (23-78) 55 (23-78) 55 (23-78)
aIa - Lymphoid leukaemias; Ib - Acute myeloid leukaemias; Ic - Chronic myeloproliferative
diseases; Id - Myelodysplastic syndrome and other myeloproliferative diseases;
Ie - Unspecified and other specified leukaemias
Table 6.14 shows the model selection process for the Cox PH model for survival of
leukaemia, following the same process as for CNS tumours. Age, year of diagnosis,
logarithm of WBC count and diagnostic subgroup all had individual explanatory power
on survival which was significant at the 1% level. The addition of each of these variables
individually to the model continued to improve the model fit, therefore all were included
in the final model. The single effects of sex, ethnicity and deprivation were not significant.
Deprivation was excluded from the final model, however, ethnicity was retained within
the model as it was of primary interest in the analysis. In addition, sex was initially
retained in the model in order to study the interaction of age and sex. There was significant
evidence against linearity of age when tested against children and TYA age groupings (0-
14 and 15-29 years), 5-year age groupings (0-4, 5-9, 10-14, 15-19, 20-24, 25-29 years)
as well as clinically relevant age groups (< 1, 1-10, 11-14, 15-29 years). The latter was
chosen to be included in the model due to its clinical relevance in addition to the observed
differences in survival by age groups in the univariable 1, 3 and 5-year survival estimates.
The interaction between age group and sex was not significant (P <0.124), therefore the
non-significant main effect of sex was also excluded from the final model.
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Table 6.14: Model selection process for leukaemia using P -values of overall model fit
obtained from Wald tests to guide selection of the analysis model
Variables in model P -value
None -
Age < 0.001
Sex 0.875
Ethnicity 0.301
Year < 0.001
log WBC Count 0.006
Deprivation 0.248
Diagnostic subgroup < 0.001
Diagnostic subgroup + Ethnicity 0.4701
Diagnostic subgroup + Ethnicity + Sex 0.6118
Diagnostic subgroup + Ethnicity + Sex + Year < 0.001
Diagnostic subgroup + Ethnicity + Sex + Year + Age < 0.001
Diagnostic subgroup + Ethnicity + Sex + Year + Age + log WBC count (Full Model) < 0.001
Linearity Tests
Full model + Age Group (0-14, 15-29 years) 0.001
Full model + Age Group (0-4, 5-9,10-14,15-19,20-24,25-29 years) 0.001
Full model + Age Group (< 1, 1-10, 11-14, 15-29 years) < 0.001
Full model + Period (1990-1994, 1995-1999, 2000-2004, 2005-2009) 0.773
Interactions
Age Group (< 1, 1-10, 11-14, 15-29 years) by Sex 0.124
Final Model
Diagnostic subgroup + Ethnicity + Year + Age Group (< 1, 1-10, 11-14, 15-29 years) + log
WBC count
6.4.2.1 Survival analysis results for leukaemia
Survival was significantly better for all age groups compared to those diagnosed under
the age of 1 (Table 6.15). Furthermore, survival improved significantly over the study
period by 7% on average per year (P <0.001). Survival of AML was 44% poorer
compared to lymphoid leukaemias (P=0.009), and there was a 2.3-fold increased risk of
death for unspecified and other specified leukaemias compared to lymphoid leukaemias,
however, this effect was not significant (P=0.087). Those diagnosed with chronic
myeloproliferative diseases had better survival compared to lymphoid leukaemias by 50%
(P=0.013), and despite a low HR for those with myelodysplastic syndrome (HR=0.30,
95% CI 0.04-2.22) there was no significant difference in survival compared to lymphoid
leukaemias. There was no significant difference for survival of leukaemia by ethnic
group, despite large HRs of 1.34 and 1.38 for Asian and other ethnicity compared to
white ethnicity, and survival worsened significantly by 18% on average per increase in
the logarithm of WBC count (P=0.001).
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Table 6.15: Pooled Cox proportional hazards model estimates based on 40 imputations
for leukaemia amongst children and young adults in Yorkshire, 1990-2009
Variable HR 95% CI SE P -value
Age Group
< 1 year 1
1-10 years 0.16 0.10-0.25 0.04 < 0.001
11-14 years 0.34 0.19-0.59 0.10 < 0.001
15-29 years 0.63 0.41-0.97 0.14 0.037
Year 0.93 0.91-0.95 0.01 < 0.001
Diagnostic Subgroup
Lymphoid leukaemias 1
Acute myeloid leukaemias 1.44 1.09-1.90 0.20 0.009
Chronic myeloproliferative diseases 0.49 0.28-0.86 0.14 0.013
Myelodysplastic syndrome 0.30 0.04-2.22 0.31 0.240
Unspecified and other specified leukaemias 2.26 0.89-5.73 1.07 0.087
Ethnicity
White 1
Asian 1.34 0.80-2.26 0.36 0.266
Other 1.38 0.56-3.34 0.63 0.481
Log white blood cell (WBC) count 1.18 1.07-1.30 0.06 0.001
6.4.3 Germ Cell Tumours
For GCTs, survival was very high overall and in all cases remained high even at 5-years
from diagnosis (Table 6.16). Changes between 1 and 3 year survival did occur amongst
the smaller diagnostic subgroups, with intracranial and intraspinal GCTs decreasing from
87% to 82%, malignant extracranial and extragonadal GCTs from 91% to 85%, gonadal
carcinomas from 96% to 85% and other and unspecified malignant gonadal tumours
from 100% to 82%. However, no further deaths were observed between 3 and 5 years
beyond diagnosis. The largest diagnostic subgroup, malignant gonadal GCTs, had a 1-
year survival rate of 98%, which dropped only slightly to 96% at 3 and 5-years.
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Table 6.16: 1, 3 and 5-year survival estimates for germ cell tumours (displayed as
percentages of cases survived)
Variable 1 year (95% CI) 3 year (95% CI) 5 year (95% CI)
Age
0-14 96 (89-98) 95 (88-98) 95 (88-98)
15-29 97 (96-98) 94 (92-95) 94 (92-95)
Sex
Male 97 (96-98) 94 (92-96) 94 (92-96)
Female 97 (91-99) 92 (85-95) 92 (85-95)
Deprivation Quintile
Least Deprived (1) 97 (92-99) 94 (88-97) 94 (88-97)
2 97 (93-99) 95 (91-98) 95 (90-97)
3 99 (96-100) 96 (92-98) 96 (92-98)
4 96 (92-98) 92 (87-95) 92 (86-95)
Most Deprived (5) 96 (93-98) 93 (89-96) 93 (89-96)
Diagnostic subgroupa
Xa 87 (72-94) 82 (66-91) 82 (66-91)
Xb 91 (80-96) 85 (73-92) 85 (73-92)
Xc 98 (97-99) 96 (94-97) 96 (94-97)
Xd 96 (76-99) 85 (64-94) 85 (64-94)
Xe 100 (-) 82 (45-95) 82 (45-95)
aXa - Intracranial and Intraspinal GCTs; Xb - Malignant extracranial and extragonadal GCTs;
Xc - Malignant Gonadal GCTs; Xd - Gonadal carcinomas;
Xe - Other and unspecified malignant gonadal tumours
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Figure 6.10: Kaplan-Meier (K-M) survival curves for germ cell tumours for each
imputation, superimposed with the mean K-M curve averaged over all imputations by
stage (a) and ethnic group (b)
Stage and diagnostic subgroup both had individual explanatory power on survival which
was significant at the 1% level (Table 6.17). Sex had individual explanatory power at
the 5% level, however, the addition of sex to a model containing stage and diagnostic
subgroup did not provide a significant improvement in model fit. Despite age not
having individual explanatory power, a model containing age group, stage and diagnostic
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subgroup significantly improved the model. This was not observed when adding
continuous age, or any other variable individually to the model.
Table 6.17: Model selection process for germ cell tumours using P -values of overall
model fit obtained from Wald tests to guide selection of the analysis model
Variables in model P -value
None -
Age 0.720
Sex 0.049
Ethnicity 0.163
Year 0.646
Stage < 0.001
Deprivation 0.181
Diagnostic subgroup < 0.001
Diagnostic subgroup + Ethnicity 0.1841
Diagnostic subgroup + Ethnicity + Stage < 0.001
Diagnostic subgroup + Ethnicity + Stage + Sex 0.1567
Diagnostic subgroup + Ethnicity + Stage + Age Group (0-14, 15-29 years) 0.0219
Final Model
Diagnostic subgroup + Ethnicity + Stage + Age Group (0-14, 15-29 years)
6.4.3.1 Survival analysis results for germ cell tumours
Table 6.18 shows estimates from the final Cox PH model for survival of GCTs. Those
diagnosed aged 15 to 29 years had a significant 4-fold increased risk of death compared
to children diagnosed aged 0-14 years (P=0.022). Survival was poorer for all diagnostic
subgroups compared to gonadal GCTs, although the effect was not significant for
extracranial and extragonadal GCTs. There was no significant difference by ethnic group
despite the large HRs (HR=1.68, 95% CI=0.59-4.82 and HR=2.85, 95% CI 0.50-16.32 for
Asian and other ethnicity respectively). This may be a result of the low EPV for the final
model (EPV=6.2) in addition to the small number of cases diagnosed with GCT within
these ethnic groups as reflected by the wide confidence intervals. Survival worsened
significantly by 5-fold, 16-fold and 32-fold for stage II, III and IV tumours respectively.
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Table 6.18: Pooled Cox proportional hazards model estimates based on 60 imputations
for germ cell tumours amongst children and young adults in Yorkshire, 1990-2009
Variable HR 95% CI SE P -value
Age Group
0-14 years 1
15-29 years 3.92 1.22-12.60 2.33 0.022
Diagnostic subgroup
Malignant gonadal GCTs 1
Intracranial and Intraspinal GCTs 19.88 4.19-94.43 15.67 < 0.001
Malignant extracranial and extragonadal GCTs 1.67 0.58-4.81 0.90 0.342
Gonadal carcinomas 10.09 2.55-39.97 7.05 0.001
Other and unspecified GCTs 15.21 1.84-125.93 16.34 0.012
Ethnicity
White 1
Asian 1.68 0.59-4.82 0.90 0.333
Other 2.85 0.50-16.32 2.53 0.238
Stage
I 1
II 5.18 1.38-19.41 3.48 0.015
III 15.63 4.34-56.27 10.18 < 0.001
IV 31.59 8.11-122.96 21.75 < 0.001
6.5 Analysis Model Assessment
Figures 6.11, 6.12 and 6.13 show log cumulative hazard plots for all variables included in
the CNS tumour, leukaemia and GCT models. In cases where the data was sparse, most
notably in the GCT analysis for diagnostic subgroup and ethnicity between -6 and 0 log
survival time, the log cumulative hazard plots cross for certain subgroups (Xb - Malignant
extracranial and extragonadal GCTs crosses Xa - Intracranial and Intraspinal GCTs and
the plot for Asian ethnicity crosses the white ethnicity group). However, despite this, for
all tumour groups and variables, the lines do not cross in the most concentrated area of the
graph and therefore, there is no strong evidence against the PH assumption for the CNS
tumour, leukaemia or GCT analysis.
The deviance residuals plots shown in Figures 6.14, 6.15 and 6.16 show that there were no
extreme outlying residuals for any tumour group. There were two clear groups of residuals
in each individual plot; the residuals associated with censored observations forming a
dense scatter, and the residuals associated with the observed failure events forming a
curved pattern. For all three tumour groups, the censored observations appeared to be
randomly scattered and there were no extreme outliers for the observed failure events in
any tumour group. The lack of extreme outliers indicated an overall adequate model fit
as the model predicted events close to the time of observed events for all three tumour
groups. Furthermore, the predictive power of all models was high, with Harrell’s C
statistic ranging between 74% and 76% over all imputations for CNS tumours, 74% and
75% for leukaemia and 81% to 92% for GCTs.
184 6. VARIATION IN CANCER SURVIVAL
0
1
2
3
4
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
     Aged
0-14 years
     Aged
15-29 years
Age at Diagnosis
0
1
2
3
4
5
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
Diagnosed
1990-1998
Diagnosed
1999-2009
Year of Diagnosis
0
1
2
3
4
5
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
Astrocytoma Ependymoma
Embryonal Other Gliomas
Other CNS
Diagnostic Subgroup
0
1
2
3
4
5
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
White Asian
Other
Ethnicity
0
2
4
6
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
Grade I Grade II
Grade III Grade IV
WHO Grade
Figure 6.11: Log cumulative hazard plot for one imputation by age group at diagnosis,
year of diagnosis, diagnostic subgroup, ethnicity and WHO grade for central nervous
system tumours based on the final analysis model (see Table 6.12)
6. VARIATION IN CANCER SURVIVAL 185
0
2
4
6
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
Aged <1 year Aged 1-10years
Aged 11-14
years
Aged 15-29
years
Age at Diagnosis
1
2
3
4
5
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
1990-1998 1999-2009
Year of Diagnosis
0
2
4
6
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
Ia 1b
Ic Id
Ie
Diagnostic Subgroup
0
1
2
3
4
5
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
White Asian
Other
Ethnicity
1
2
3
4
5
Lo
g 
Cu
m
ul
at
ive
 H
az
ar
d
-6 -4 -2 0 2 4
Log Survival Time (Years)
Standard
Risk1
High
Risk2
Log WBC Count
Figure 6.12: Log cumulative hazard plot for one imputation by age group at diagnosis,
year of diagnosis, diagnostic subgroup, ethnicity and logarithm of white blood cell (WBC)
count for leukaemia based on the final analysis model (see Table 6.15).
Diagnostic subgroups: Ia - Lymphoid leukaemias; Ib - Acute myeloid leukaemias;
Ic - Chronic myeloproliferative diseases; Id - Myelodysplastic syndrome and other
myeloproliferative diseases; Ie - Unspecified and other specified leukaemias. 1 Standard
Risk:< 50, 000µ/L, 2 High Risk: ≥ 50, 000µ/L
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Figure 6.13: Log cumulative hazard plot for one imputation by diagnostic subgroup,
ethnicity, stage and age group at diagnosis for germ cell tumours based on the final
analysis model (see Table 6.18).
Diagnostic subgroups: Xa - Intracranial and Intraspinal GCTs; Xb - Malignant
extracranial and extragonadal GCTs; Xc - Malignant Gonadal GCTs; Xd - Gonadal
carcinomas; Xe - Other and unspecified malignant gonadal tumours
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Figure 6.14: Deviance residual plots for each of the 40 Cox Proportional Hazards models
based on individual imputations for central nervous system tumours
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Figure 6.15: Deviance residual plots for each of the 40 Cox Proportional Hazards models
based on individual imputations for leukaemia
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Figure 6.16: Deviance residual plots for each of the 60 Cox Proportional Hazards models
based on individual imputations for germ cell tumours
6.6 Sensitivity Analysis
6.6.1 Deviations from MAR Assumption
Deviations from the MAR assumption were assessed by adjusting the probability of
imputed values by a factor of θ=0.5 and θ=0.8 to assess sensitivity to the assumption that
tumours with a higher grade, higher WBC measures or higher stage for CNS, leukaemia
and GCT respectively, were associated with poorer survival. Figures 6.17, 6.18 and 6.19
show the HRs and standard errors obtained under the MAR assumption, compared to
those obtained under an MNAR assumption by adjusting the imputed values by a factor
of θ as indicated. The graph indicated that the multiple imputation process was robust
to any deviations from the MAR assumption, as changes in the HRs were minimal and
the 95% CIs for θ=0, 0.5 and 0.8 overlapped in all instances indicating that there were
no significant differences to results when adjusting the probability of imputing disease
severity. The greatest variation in HRs was seen amongst GCTs, with larger pooled HRs
for stage IV tumours under the MNAR assumption, however, both CIs overlapped with the
CI for the MAR assumption, showing that the assumption remained robust to deviations
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from this assumption.
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Figure 6.17: Hazard ratios and 95% confidence intervals obtained under the MAR
assumption (θ=0) and the MNAR assumption θ=0.5 and θ=0.8, where θ was the
adjustment factor of the probability of imputing higher grade central nervous system
tumours
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Figure 6.18: Hazard ratios and 95% confidence intervals obtained under the MAR
assumption (θ=0) and the MNAR assumption θ=0.5 and θ=0.8, where θ was the
adjustment factor of the probability of imputing higher WBC counts for leukaemia
192 6. VARIATION IN CANCER SURVIVAL
0
5
10
15
20
25
30
35
40
45
P
o
o
le
d
 H
a
z
a
rd
 R
a
ti
o
 a
n
d
 9
6
%
 C
o
n
fi
d
e
n
c
e
 I
n
te
rv
a
l 
Covariate 
MAR (Theta = 0)
MNAR (Theta = 0.5)
MNAR (Theta = 0.8)
A
g
e
 
S
e
x
 
Y
e
a
r o
f 
D
ia
g
n
o
s
is
 
D
e
p
riv
a
tio
n
 
D
ia
g
n
o
s
tic
 
G
ro
u
p
 
IC
C
C
 - X
a
 
D
ia
g
n
o
s
tic
 
G
ro
u
p
 
IC
C
C
 - X
b
 
D
ia
g
n
o
s
tic
 
G
ro
u
p
 
IC
C
C
 - X
d
 
D
ia
g
n
o
s
tic
 
G
ro
u
p
 
IC
C
C
 - X
e
 
E
th
n
ic
ity
 
A
s
ia
n
 
E
th
n
ic
ity
 
O
th
e
r 
S
ta
g
e
 - II  
 
S
ta
g
e
 - III 
S
ta
g
e
 - IV
 
Figure 6.19: Hazard ratios and 95% confidence intervals obtained under the MAR
assumption (θ=0) and the MNAR assumption θ=0.5 and θ=0.8, where θ was the
adjustment factor of the probability of imputing higher stage germ cell tumours.
Upper confidence limits not shown on the plot were as follows: diagnostic group Xd
- 68.1 (θ=0), 47.6 (θ=0.5) and 46.1 (θ=0.8); diagnostic group Xe - 117.1 (θ=0), 118.1
(θ=0.5) and 126.9 (θ=0.8); Stage III - 56.6 (θ=0.5) and 58.2 (θ=0.8); Stage IV - 130.2
(θ=0), 118.1 (θ=0.5) and 124.4 (θ=0.8)
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6.7 Summary
The results presented in this chapter provide an important contribution to CYA cancer
epidemiology, as well as the wider adult cancer epidemiology research field, showing
important differences between the results from CCA and multiple imputation analyses and
their effect upon conclusions drawn. Exploratory analyses revealed that the univariable
survival curves for CNS tumours and leukaemia were significantly poorer for those cases
which had missing data compared to those with complete data. Therefore, performing a
CCA would result in overestimation of the true survival for CNS tumours and leukaemia.
Furthermore, based on CCA, there were some variable levels for which HRs could not
be estimated as there were instances in which some variable levels contained either no
cases or events after listwise deletion. Specifically, there were no observed deaths for the
myelodysplastic syndrome subgroup of leukaemia or the intracranial and intraspinal GCT
subgroup and there were no cases of the other and unspecified subgroup of GCTs after
listwise deletion. These subgroups were therefore excluded from the CCA, whereas the
use of multiple imputation allowed these subgroups to be retained in the analysis.
Multiple imputation improved study power, as more cases were included in the analysis
after imputation. There were several examples of increased study power to detect a
significant difference, including effects of age, year of diagnosis, diagnostic subgroup
and ethnicity for CNS tumours which were significant in the multiple imputation analysis
but not in the CCA. For leukaemia, year of diagnosis and diagnostic subgroup were
significant only after multiple imputation. These effects were not apparent amongst
the GCT analysis, because power remained poor even after imputation due to the low
number of deaths within this diagnostic group. Related to an improvement in the power
of the analysis after multiple imputation, the precision of estimates was also improved
and therefore smaller CIs were obtained, this occurred consistently across tumour groups.
SMC-FCS has been identified as a superior method to MICE when imputing for a
non-linear model such as a Cox PH model, however, when results were compared
to imputation under the MICE algorithm, any differences observed were negligible.
Furthermore, the desired SMC-FCS analysis was not possible for the GCT tumour
analysis, and a correctly specified imputation model using MICE was favoured compared
to an incorrectly specified imputation model using SMC-FCS.
A summary of the survival analysis results per tumour group is provided below, with
further in depth discussion of these results given in Chapter 9 as part of the main thesis
discussion.
For CNS tumours, univariable analysis indicated very little difference in survival for
children compared to TYAs at 1 and 3 years post diagnosis, however, a difference
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began to emerge for longer term survival (5-years post diagnosis). The multivariable
results confirmed a significant difference between children and TYAs, with 34% poorer
survival for TYAs compared to children. There was a significant 2-fold increase in the
risk of death for other ethnicity compared to white ethnicity, however, there was no
difference in survival between Asian and white ethnic groups. The univariable analysis
indicated poorest survival occurred for unspecified CNS tumours (29% 5-year survival),
followed by other gliomas (51%) and embryonal tumours (61%). Improved survival was
observed for other CNS tumours (90%), ependymomas (77%) and astrocytomas (70%).
The multivariable analysis was consistent with the univariable analysis for other gliomas
and unspecified CNS tumours which had a significant 50% and 3-fold increased risk of
death compared to astrocytomas respectively. However, after adjustment for casemix, the
embryonal tumours had a 60% improved chance of survival compared to astrocytomas
which was not evident from the univariable analysis. Finally, the risk of death increased
exponentially by 4, 6 and 10-fold for grade II, III and IV tumours respectively compared
to grade I tumours. Importantly, survival improved by 4% per year on average over the
study period, and there was no evidence against linearity of this effect. Neither deprivation
or sex had significant effects on the survival for cases of CNS tumours.
For leukaemia, age was a strong predictor of survival, with those diagnosed under the
age of 1 having very poor survival (29% 5-year survival). With the exception of those
aged under 1, survival worsened with age which was observed in the univariable as well
as multivariable analyses. Survival of leukaemia varied by diagnostic subgroup, with
5-year survival rates being highest for lymphoid leukaemia (80%) and myelodysplastic
syndrome (89%) and poorer for AML (55%) and other and unspecified leukaemias
(55%). This was confirmed in the univariable and multivariable analysis. The univariable
results indicated slightly poorer 5-year survival of chronic myeloproliferative disease
(72%), however, after adjustment for age, year, ethnicity and WBC count, those with
chronic myeloproliferative disease were 50% less likely to die compared to those with
lymhoid leukaemia. Survival became significantly poorer with the increase of WBC
count, however, there was an improvement in survival overall of 7% per year on average
during the study period. Ethnicity, deprivation and sex did not have an impact on the
survival of leukaemia cases.
For GCTs, TYAs were at a 4-fold increased risk of death compared to children under
the age of 15. In general, survival of GCTs was very high, ranging from 82% 5-year
survival for intracranial and intraspinal GCTs and other and unspecified GCTs, to 96% 5-
year survival for malignant gonadal GCTs. The multivariable model results indicated
significant differences in the risk of death according to diagnostic subgroup, with a
20-fold, 10-fold and 15-fold increase in the risk of intracranial and intraspinal GCTs,
gonadal carcinomas and other and unspecified GCTs compared to malignant gonadal
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GCTs. However, these estimates were inflated and have very wide CIs due to the small
number of deaths occurring across the whole diagnostic group, thus there was a large
amount of uncertainty associated with the size of these estimates. The stage of tumour
increased the risk of death exponentially, with a 5-fold, 16-fold and 32-fold increased risk
of death for stage II, III and IV tumours respectively compared to grade I tumours. Again,
the CIs surrounding these estimates were very wide. There was no significant effect of
ethnicity on survival for GCTs, however, the non-significant increase in the risk of death
was 70% and almost 3-fold for Asian and other ethnicity compared to white ethnicity.
Although these effects were not significant, the size of the HRs suggest that there could
be differences in survival according to ethnicity for GCTs which were not identified due
to a lack of study power for this analysis. There were no effects of year of diagnosis, sex
or deprivation on the survival of GCTs.
In conclusion, these results show the importance of multiple imputation through
highlighting the serious errors in inferences which can occur from ignoring missing
data. The novel application of this method to CYA cancer in Yorkshire has highlighted
that results from this regional cancer registry could have been misrepresenting important
patterns and changes in survival unless missing data was properly accounted for. Although
the benefits of imputation were clear, the choice of imputation method was less obvious
and this study showed there was limited benefit in using the recently developed SMC-
FCS method compared to the more established MICE method. This study has, for the
first time, produced survival estimates of CYA cancer which take into account disease
severity as well as adequately handling missing data.
Survival for TYAs was poorer compared to that of children for CNS tumours, leukaemias
(excluding survival of those aged under 1) and GCTs. There were large and significant
decreases in survival according to disease severity for all three tumour groups as expected,
highlighting the importance of this prognostic factor, which should not be excluded
from survival analyses. There was a significant increase in the risk of death for other
ethnicity compared to white ethnicity for CNS tumours, and despite effects not being
significant, there was evidence of increased risk of death for Asian and other ethnic groups
compared to white ethnicity amongst leukaemia and GCT cases. There were significant
improvements in survival over the study period for CNS tumours and leukaemia, however,
survival of GCTs did not change significantly over time. Finally, there were no significant
differences between males and females or according to deprivation for any of the tumour
groups studied.
Despite survival of CYA cancer being high in general, survival for certain subgroups of
society remain poor even after adjustment for disease severity. Moreover, those with
advanced disease at diagnosis were at a significant survival disadvantage. Ethnicity and
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deprivation have both been shown to affect the severity of disease at presentation amongst
adult cancers [95, 96, 98, 99, 100]. However, very little is known about the factors
affecting disease severity at diagnosis for the CYA population and whether these are the
same as seen amongst adults. Chapter 7 uses multiply imputed data arising from this
chapter to determine, for the first time, whether age, ethnicity and deprivation play a role
in the disease severity at diagnosis for CYAs in Yorkshire. Evidence of inequalities in
disease severity at diagnosis could highlight potential inequalities in the quality of access
to healthcare which could ultimately affect the survival of CYAs diagnosed with cancer.
In addition, as survival has been shown to improve consistently for most tumour groups in
Yorkshire, Chapter 8 focuses on one aspect of the quality of that survival, by quantifying
the long term cardiovascular effects for a cohort of long term survivors of CYA cancer.
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Chapter 7
Inequalities in Disease Severity at
Diagnosis
7.1 Introduction
Advanced stage disease at diagnosis has clear survival implications for CYAs with cancer
as evidenced by the analyses presented in Chapter 6. Furthermore, despite continued
improvements in survival over time, outcomes remain significantly poorer for TYAs
compared to children and for non-white ethnicity (Chapter 6).
For adults with cancer, ethnicity and deprivation have both been shown to be associated
with disease severity at presentation as described in detail in Chapter 2 [95, 96, 98, 99,
100].
To date, no research in the UK has focused on the effects of ethnic group or deprivation
on the stage or severity of cancer at diagnosis for CYAs. The results presented in this
chapter aimed, for the first time, to determine whether inequalities in disease severity
exist for the CYA cancer population in Yorkshire by assessing the impact of ethnicity
(white, Asian, other) and deprivation (IMD quintile) upon disease severity at diagnosis.
In addition, the impact of age group at diagnosis (children vs. TYAs) upon disease severity
was also determined. The analysis presented here was based on multiply imputed data for
missing values of ethnicity and disease severity for CNS tumours, leukaemia and GCTs
as described in detail in Chapter 6. A detailed description of the methods used for this
analysis is given in Chapter 4.
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7.2 Disease Severity by Age, Ethnicity and Deprivation
Disease severity was missing in 9%, 22% and 46% of CNS tumour, leukaemia and GCT
cases (Table 7.1). After imputation, the majority of CNS tumours, leukaemias and GCTs
were low grade, standard risk or early stage respectively across the cohort (Table 7.1).
The pattern mirrored that of the observed data prior to imputation.
For CNS tumours, there was little difference in the proportion of low grade tumours
(grades I and II) between children and TYAs (Table 7.2). However, TYAs tended to
have relatively more grade III tumours and fewer grade IV tumours compared to children.
Similarly, there was little difference in the proportion of low grade tumours between
ethnic groups, however, those of Asian ethnicity tended to be diagnosed with a higher
proportion of grade IV tumours and fewer grade III tumours compared to white and
other ethnic groups. There was little deviation from the average grade distribution by
deprivation level for CNS tumours.
For leukaemia, there was no difference in the distribution of standard and high risk cases
according to age group, with approximately 75% of cases being diagnosed with standard
risk leukaemia (WBC of < 50, 000µ/L) (Table 7.3). There was a smaller proportion of
more advanced malignancies (high risk WBC count) amongst the ‘other’ ethnic group
(13%) compared to white and Asian ethnic groups (24% and 21% respectively). There
was little variation in disease severity according to deprivation level, although there was
a slight increase in the proportion of high risk leukaemias in the least deprived group
(quintile 1).
For GCTs, children were diagnosed with twice as many advanced stage tumours
compared to TYAs (10% and 23% compared to 5% and 11% stage III and IV tumours
for children and TYAs respectively) (Table 7.4). Furthermore, there was a higher than
average proportion of advanced tumours amongst the Asian ethnic group (9% and 25%
vs. 6% and 12% for stage III and IV tumours respectively). Similarly, there was a higher
than average proportion of stage III tumours amongst ‘other’ ethnicity (13% vs. 6%),
and only a small increase in stage IV tumours (14% vs. 12%). According to deprivation
level, there appeared to be a decreasing proportion of stage III tumours with increasing
deprivation, and a similar pattern (although not as clear) was observed amongst stage IV
tumours.
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Table 7.1: Number and percentage of observed and imputed cases of disease severity at
diagnosis by tumour group
Disease Severity Observed Imputed1
Central nervous system tumours
Grade N (%) N (%)
I 319 (40.1) 354.0 (44.5)
II 163 (20.5) 178.9 (22.5)
III 46 (5.8) 53.8 (6.8)
IV 196 (24.7) 208.3 (26.2)
Missing 71 (8.9) -
Total 795 795
Leukaemia
WBC Count
< 50, 000µ/L 543 (59.5) 695.3 (76.2)
≥ 50, 000µ/L 171 (18.8) 216.7 (23.8)
Missing 198 (21.7) -
Total 912 912
Germ cell tumours
Stage
I 296 (35.0) 539.4 (63.8)
II 91 (10.8) 152.9 (18.1)
III 22 (2.6) 48.2 (5.7)
IV 51 (6.0) 105.6 (12.5)
Missing 386 (45.6) -
Total 846 846
1Average number of cases over all imputations (m=40 for central
nervous system tumours and leukaemia, m=60 for germ cell
tumours)
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Table 7.2: The distribution of WHO grade for central nervous system (CNS) tumours by
age group at diagnosis, ethnicity and deprivation after multiple imputation by chained
equations
WHO Grade
I II III IV TotalAge at Diagnosis Na % Na (%) Na (%) Na (%)
0-14 years 191.4 43.9 83.4 19.1 28.2 6.5 133.1 30.5 436.0
15-29 years 162.6 45.3 95.6 26.6 25.7 7.1 75.2 20.9 359.0
Ethnicity
White 318.4 44.3 165.4 23.0 48.7 6.8 186.1 25.9 718.6
Asian 17.7 36.5 11.3 23.3 1.6 3.3 17.8 36.9 48.3
Other 18.0 63.8 2.3 8.3 3.5 12.4 4.4 15.5 28.1
Deprivation
1 (Least Deprived) 51.8 38.4 32.7 24.2 9.2 6.8 41.4 30.6 135.0
2 74.6 44.1 35.5 21.0 14.8 8.8 44.2 26.1 169.0
3 57.5 43.2 38.7 29.1 6.5 4.9 30.4 22.8 133.0
4 65.9 47.7 28.1 20.4 6.4 4.6 37.7 27.3 138.0
5 (Most Deprived) 104.3 47.4 44.1 20.0 17.0 7.7 54.7 24.9 220.0
Total 354 44.5 179 22.5 54 6.8 208 26.2 795
aAverage number of cases over m=40 imputations for partially observed variables WHO grade and ethnicity.
Table 7.3: The distribution of low and high risk white blood cell (WBC) count for
leukaemia by age group at diagnosis, ethnicity and deprivation after multiple imputation
by chained equations
White Blood Cell Count
Standard Risk High Risk
Total< 50, 000µ/L ≥ 50, 000µ/L
Age at Diagnosis Na % Na (%)
0-14 years 465.3 76.4 143.7 23.6 609.0
15-29 years 230.0 75.9 73.0 24.1 303.0
Ethnicity
White 615.2 75.7 197.5 24.3 812.7
Asian 60.5 78.9 16.1 21.1 76.6
Other 19.7 86.7 3.0 13.3 22.8
Deprivation
1 (Least Deprived) 88.3 71.8 34.7 28.2 123.0
2 129.1 75.5 42.0 24.5 171.0
3 124.1 79.0 33.0 21.0 157.0
4 135.3 81.0 31.7 19.0 167.0
5 (Most Deprived) 218.6 74.3 75.4 25.7 294.0
Total 695.3 76.2 216.7 23.8 912
aAverage number of cases over m=40 imputations for partially observed variables
white blood cell count and ethnicity.
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Table 7.4: The distribution of stage for germ cell tumours (GCTs) by age group at
diagnosis, ethnicity and deprivation after multiple imputation by chained equations
Stage
I II III IV TotalAge at Diagnosis Na % Na (%) Na (%) Na (%)
0-14 years 46.9 49.9 15.9 16.9 9.4 10.0 21.7 23.1 94.0
15-29 years 492.5 65.5 137.0 18.2 38.7 5.1 83.8 11.1 752.0
Ethnicity
White 499.3 64.7 143.2 18.5 40.7 5.3 88.9 11.5 772.0
Asian 30.3 53.5 6.9 12.2 5.2 9.2 14.2 25.1 56.6
Other 9.9 56.6 2.9 16.4 2.2 12.6 2.5 14.4 17.4
Deprivation
1 (Least Deprived) 65.9 56.8 23.6 20.3 8.1 7.0 18.4 15.9 116.0
2 103.9 62.9 30.9 18.7 12.3 7.4 18.0 10.9 165.0
3 104.6 61.9 34.8 20.6 9.4 5.5 20.3 12.0 169.0
4 117.9 69.8 21.5 12.7 7.6 4.5 22.0 13.0 169.0
5 (Most Deprived) 147.2 64.8 42.1 18.6 10.9 4.8 26.9 11.8 227.0
Total 326.3 64.9 87.2 17.3 29.2 5.8 60.3 12.0 846
aAverage number of cases over m=60 imputations for partially observed variables stage and ethnicity.
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7.2.1 Predictors of Advanced Stage Disease for CYAs with Cancer
The independent models of age group, ethnicity and deprivation (adjusted for sex and
year of diagnosis) showed that there was no significant effect of these three factors upon
disease severity at presentation for CNS tumours, leukaemias or GCTs (Table 7.5). This
finding remained consistent after mutual adjustment of age, ethnicity and deprivation in
the fully adjusted model (Table 7.5). For GCTs, the proportion of late stage tumours
amongst children was double that of TYAs (Table 7.4, §7.2). Furthermore, there was a
non-significant 40% decrease in the likelihood of being diagnosed with a late stage tumour
for TYAs compared to children in the age model (OR = 0.57, 95% CI 0.23-1.40, P=0.220)
and the fully adjusted model (OR = 0.60, 95% CI 0.24-1.49, P=0.268) (Table 7.5). The
non-significant effect may be a reflection of the age group distribution for GCTs, as just
11% of GCTs were diagnosed amongst children and the remaining 89% amongst TYAs.
There was evidence of a decrease in the number of later stage diagnoses of GCTs by
4% on average over the study period (OR = 0.96, 95% CI 0.92-1.00, P=0.033), but
similar patterns for CNS tumours and leukaemias were not observed. Finally, there
was borderline significant evidence to suggest that females were 22% less likely to be
diagnosed with higher grade CNS tumours compared to males (OR = 0.78, 95% CI 0.59-
1.02, P=0.069 in the fully adjusted model). Model diagnostic checks for the fully adjusted
models were performed in the next section (§7.2.2).
7. INEQUALITIES IN DISEASE SEVERITY AT DIAGNOSIS 203
Ta
bl
e
7.
5:
Po
ol
ed
od
d
ra
tio
s
(O
R
)a
nd
95
%
co
nfi
de
nc
e
in
te
rv
al
s
(C
I)
fo
rb
ei
ng
di
ag
no
se
d
w
ith
hi
gh
er
W
H
O
gr
ad
e
ce
nt
ra
ln
er
vo
us
sy
st
em
(C
N
S)
tu
m
ou
rs
,h
ig
h
ri
sk
w
hi
te
bl
oo
d
ce
ll
(W
B
C
)
co
un
t
or
la
te
r
st
ag
e
ge
rm
ce
ll
tu
m
ou
rs
(G
C
T
s)
by
ag
e
at
di
ag
no
si
s,
et
hn
ic
ity
an
d
de
pr
iv
at
io
n
fo
r
ch
ild
re
n
an
d
yo
un
g
ad
ul
ts
w
ith
ca
nc
er
in
Y
or
ks
hi
re
,1
99
0-
20
09
M
od
el
C
N
S
tu
m
ou
rs
L
eu
ka
em
ia
G
C
T
O
R
a
C
I
P
-v
al
ue
O
R
b
C
I
P
-v
al
ue
O
R
a
C
I
P
-v
al
ue
A
ge
c
A
ge
at
D
ia
gn
os
is
0-
14
ye
ar
s
1
1
1
15
-2
9
ye
ar
s
0.
81
(0
.6
0-
1.
08
)
0.
15
3
1.
00
(0
.6
6-
1.
53
)
0.
98
4
0.
57
(0
.2
3-
1.
40
)
0.
22
0
E
th
ni
ci
ty
c
E
th
ni
ci
ty
W
hi
te
1
1
1
A
si
an
1.
54
(0
.8
4-
2.
82
)
0.
16
1
0.
81
(0
.4
2-
1.
56
)
0.
52
8
1.
82
(0
.7
6-
4.
32
)
0.
17
5
O
th
er
0.
53
(0
.2
2-
1.
28
)
0.
15
8
0.
41
(0
.0
7-
2.
28
)
0.
30
7
1.
31
(0
.2
4-
7.
19
)
0.
75
3
D
ep
ri
va
tio
nc
D
ep
riv
at
io
n
1
(L
ea
st
D
ep
riv
ed
)
1
1
1
2
0.
82
(0
.5
3-
1.
25
)
0.
35
1
0.
84
(0
.4
8-
1.
48
)
0.
54
8
0.
77
(0
.4
3-
1.
38
)
0.
37
6
3
0.
76
(0
.4
9-
1.
20
)
0.
23
8
0.
67
(0
.3
6-
1.
25
)
0.
21
0
0.
78
(0
.4
2-
1.
44
)
0.
42
8
4
0.
70
(0
.4
4-
1.
12
)
0.
14
0
0.
60
(0
.3
3-
1.
11
)
0.
10
4
0.
57
(0
.3
0-
1.
08
)
0.
08
4
5
(M
os
tD
ep
riv
ed
)
0.
75
(0
.5
0-
1.
12
)
0.
15
4
0.
89
(0
.5
4-
1.
48
)
0.
65
7
0.
74
(0
.4
1-
1.
34
)
0.
31
3
Fu
lly
A
dj
us
te
d
A
ge
at
D
ia
gn
os
is
0-
14
ye
ar
s
1
1
1
15
-2
9
ye
ar
s
0.
79
(0
.5
9-
1.
06
)
0.
12
2
1.
02
(0
.6
7-
1.
57
)
0.
91
7
0.
60
(0
.2
4-
1.
49
)
0.
26
8
E
th
ni
ci
ty
W
hi
te
1
1
1.
00
A
si
an
1.
69
(0
.8
9-
3.
21
)
0.
10
9
0.
76
(0
.3
9-
1.
50
)
0.
43
1
1.
93
(0
.8
0-
4.
66
)
0.
14
1
O
th
er
0.
56
(0
.2
3-
1.
35
)
0.
19
5
0.
43
(0
.0
8-
2.
41
)
0.
33
5
1.
37
(0
.2
4-
7.
71
)
0.
72
1
D
ep
riv
at
io
n
1
(L
ea
st
D
ep
riv
ed
)
1
1
1
2
0.
82
(0
.5
3-
1.
26
)
0.
36
2
0.
84
(0
.4
7-
1.
49
)
0.
55
0
0.
77
(0
.4
3-
1.
39
)
0.
38
7
3
0.
75
(0
.4
8-
1.
18
)
0.
21
4
0.
69
(0
.3
7-
1.
28
)
0.
23
5
0.
77
(0
.4
2-
1.
43
)
0.
41
4
4
0.
69
(0
.4
3-
1.
10
)
0.
12
0
0.
62
(0
.3
3-
1.
13
)
0.
11
9
0.
56
(0
.2
9-
1.
06
)
0.
07
4
5
(M
os
tD
ep
riv
ed
)
0.
70
(0
.4
6-
1.
08
)
0.
10
5
0.
93
(0
.5
6-
1.
56
)
0.
79
0
0.
68
(0
.3
7-
1.
24
)
0.
20
5
Se
x
M
al
e
1
1
1
Fe
m
al
e
0.
78
(0
.5
9-
1.
02
)
0.
06
9
1.
00
(0
.7
0-
1.
43
)
0.
98
7
1.
40
(0
.7
7-
2.
55
)
0.
27
0
Y
ea
ro
fD
ia
gn
os
is
0.
99
(0
.9
6-
1.
01
)
0.
23
4
1.
03
(0
.9
9-
1.
03
)
0.
11
3
0.
96
(0
.9
2-
1.
00
)
0.
03
3
a P
oo
le
d
O
R
ba
se
d
on
or
de
re
d
lo
gi
st
ic
re
gr
es
si
on
fo
rg
ra
de
/s
ta
ge
of
tu
m
ou
r(
I-
IV
)o
ve
r4
0
an
d
60
im
pu
ta
tio
ns
fo
rC
N
S
tu
m
ou
rs
an
d
G
C
T
s
re
sp
ec
tiv
el
y
b P
oo
le
d
O
R
ba
se
d
on
lo
gi
st
ic
re
gr
es
si
on
fo
rh
ig
h
vs
.s
ta
nd
ar
d
ri
sk
W
B
C
ri
sk
st
ra
tifi
ca
tio
n
ov
er
40
im
pu
ta
tio
ns
.
c I
nd
iv
id
ua
lm
od
el
s
fo
ra
ge
,e
th
ni
ci
ty
an
d
de
pr
iv
at
io
n
w
er
e
ad
di
tio
na
lly
ad
ju
st
ed
fo
rs
ex
an
d
ye
ar
of
di
ag
no
si
s
204 7. INEQUALITIES IN DISEASE SEVERITY AT DIAGNOSIS
7.2.2 Model Assessment
As described in §4.4.4.2, all fully adjusted models presented in Table 7.5 were checked
for model fit using the HL-GOF test averaged over all imputations. For all three
tumours groups, the HL-GOF test provided no evidence to suggest poor model fit (P
>0.05) overall. There was some suggestion of poor model fit for some of the individual
imputations, with 1 out of 40 models for CNS tumours (P=0.025) and 1 out of 40 models
for leukaemias showing poor fit (P=0.007). For GCTs, out of 60 imputations, 3 models
displayed poor fit (P=0.022, P=0.028 and P=0.029), however this was not an unexpected
finding over a large number of imputations and therefore there was no concern over lack
of overall model fit for any of the tumour groups.
The mean discriminative power over all imputations was tested for individual components
of the ordered logistic regression models for CNS tumours and GCTs (see methods
§4.4.4.2) and were approximately 60% and 40% for CNS tumours and GCTs respectively
(Table 7.6). For leukaemia, the model was a logistic regression model with binary
outcome, therefore the mean discriminative power was calculated directly for the model
of interest, and was 57%. These results indicate poor discriminative power for all three
models, highlighting that the variables studied (age, ethnicity, deprivation, sex and year
of diagnosis) were not strongly predictive of the disease severity levels and that there
were other, unknown or unmeasured variables which may have a greater impact on the
disease severity at diagnosis for CYAs with CNS tumours, leukaemias and GCTs. This
was consistent with the model results which showed that age, ethnicity, deprivation, sex
and year of diagnosis were not, in general, predictive of disease severity.
Table 7.6: Discriminative power (displayed as a percentage) for a logistic regression
model for leukaemia risk and for component parts of ordered logistic regression models
for disease severity for CNS tumours and GCTs (see Table 7.5)
Model Discriminative Power (%)Mean 95% CI
CNS tumours
Binary outcome: Grade I vs. Grade II-IV 59% (55%-63%)
Binary outcome: Grade I-II vs. Grade III-IV 59% (53%-63%)
Binary outcome: Grade I-III vs. Grade IV 61% (56%-65%)
Leukaemia
Binary outcome: standard risk vs. high risk 57% (52%-62%)
GCT
Binary outcome: Stage I vs. Stage II-IV 39% (33%-44%)
Binary outcome: Stage I-II vs. Stage III-IV 40% (34%-46%)
Binary outcome: Stage I-III vs. Stage IV 42% (33%-51%)
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7.3 Summary
The results presented here form the first study in the UK to assess inequalities in disease
severity at diagnosis for CYAs diagnosed with cancer. The use of advanced missing data
techniques applied to a comprehensive population based cancer register allowed for a
detailed analyses of the effects of age, ethnicity and deprivation upon the severity of
disease at diagnosis for CYAs diagnosed with cancer in Yorkshire between 1990 and
2009.
Overall, the proportion of early stage tumours was higher across all three tumour groups
when compared to advanced stage tumours. There was some evidence in the univariable
analysis of an inverse relationship between disease severity and deprivation for leukaemia
and GCTs such that more advanced tumours tended to occur in the least deprived groups.
In addition, the univariable analysis indicated that despite poorer survival for the ‘other’
ethnic group amongst CNS tumours, they tended to be diagnosed with less advanced
tumours compared to those of white or Asian ethnicity. A similar pattern was observed
for leukaemia.
After adjusting for sex and year of diagnosis there was no evidence of a difference in
disease severity at diagnosis according to ethnic group or deprivation for CNS tumours,
leukaemia or GCTs. Importantly, the results indicate that in contrast to adults with cancer,
ethnicity and deprivation did not appear to influence inequalities in disease severity for
CYAs with cancer. This is supportive of the findings by Lightfoot et al. [65], which
focused on childhood leukaemia, in which differences in survival by deprivation for
children were thought to be attributed to treatment adherence rather than to inequalities
in disease severity.
Furthermore, the Yorkshire register provided the unique opportunity to assess, for the
first time, whether there were any differences in disease severity at diagnosis between
children and TYAs. For CNS tumours and leukaemia, there was no evidence to suggest
that children and TYAs differed in terms of their disease severity at diagnosis with cancer.
Despite a two-fold increase in the proportion of children with advanced stage GCTs
compared to TYAs, there was no significant evidence of later stage diagnoses for children
compared to TYAs in the multivariable analyses. This was likely to be due to the small
proportion of children diagnosed with GCTs compared to TYAs, and further larger scale
studies are required to provide conclusive evidence of inequalities in disease severity
for children and TYAs who develop GCTs. Importantly, there was significant evidence
of a reduction in the chance of later stage diagnoses by 4% on average between 1990
and 2009 for GCTs. However, similar advances were not observed for CNS tumours
or leukaemias. Finally, there was borderline significant evidence that males tended to
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be diagnosed with more advanced grade CNS tumours compared to females, however,
further study is required to determine the strength of this evidence.
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Chapter 8
Long Term Effects amongst Survivors
of Cancer
The following publications have arisen from the analysis and results in this chapter:
1 van Laar, M., R.G. Feltbower, C.P. Gale, D.T. Bowen, S.E. Oliver, and A. Glaser.
(2014). Cardiovascular sequelae in long-term survivors of young peoples’ cancer:
a linked cohort study. British Journal of Cancer 110(5) 2014:1338-1341.
2 Simms A.D., M. van Laar, R.J. Birch, R.G. Feltbower, C.P. Gale, D.T. Bowen,
S.E. Oliver, A. Glaser. (2011). Cardiovascular sequelae in long term survivors
of childhood and young adult cancer. European Heart Journal 32:544-544.
Conference Abstract.
3 van Laar, M., R.J. Birch, C.P. Gale, A. Glaser, D.T. Bowen, S.E. Oliver, R.G.
Feltbower. (2010). Cardiovascular sequelae in long term survivors of childhood
and young adult cancer. Pediatric Blood & Cancer 55:825-825. Conference
Abstract.
8.1 Introduction
As described in Chapter 2, survival rates for CYA cancer are high, thus there is an
increasing focus on improving the quality of that survival and the possible long term
effects of treatment. This chapter describes the risk of cardiovascular late effects (LEs)
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amongst survivors of CYA cancer using linked cancer registry and HES data. Details of
the data sources and methodology used are provided in Chapter 4. Preliminary descriptive
analysis of the cohort are given in §5.2.2.1, Chapter 5. The results in this chapter begin
with a description of cardiovascular LEs (§8.2), followed by two main results sections
focusing on the risk of cardiovascular LEs amongst survivors of CYA cancer compared to
the general population (§8.2.1) and predictors of cardiovascular LEs (§8.2.2).
8.2 Cardiovascular Hospital Admissions
There were a total of 3247 survivors of CYA cancer (n=1367; 42% and n=1880; 58%
for 0-14 and 15-29 year olds respectively) diagnosed between 1991 and 2006 who
successfully linked to at least one inpatient HES record (see §5.2.1 for linkage rate
details). There were 119 (3.6%) individuals with at least one cardiovascular LE (n=40 and
79 for 0-14 and 15-29 year olds respectively). The cumulative incidence of cardiovascular
LEs was 7.5% (95% CI 5.3%-10.3%) and 14.0% (95% CI 9.9%-18.8%) for 0-14 and 15-
29 year olds respectively at 20 years from diagnosis (see Figure 8.1). The majority of
cases experienced one distinct cardiovascular LE (64%), 18% experienced two and the
remainder experienced between 3 and 12 distinct cardiovascular LEs (Figure 8.2). The
median time to a cardiovascular LE was 10.2 years (IQR = 6.8 to 13.4 years) from cancer
diagnosis. The time to cardiovascular LE did not vary by cardiovascular event (see Figure
8.3).
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Figure 8.1: Cumulative incidence of cardiovascular late effects amongst cancer survivors
by age group at diagnosis, for cancer diagnosis between 1991-2006 and hospital
admissions between 1996-2011
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11 12
P
e
rc
e
n
ta
g
e
 o
f 
c
a
s
e
s
 w
it
h
 c
a
rd
io
v
a
s
c
u
la
r 
la
te
 e
ff
e
c
ts
 
Number of distinct cardiovascular events 
Figure 8.2: Bar graph showing the percentage of distinct cardiovascular late effects for
119 long term survivors of childhood and young adult cancer in Yorkshire, for cancer
diagnosis between 1991-2006
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Figure 8.3: Box and whisker plot showing the time from diagnosis to first cardiovascular
late effect by cardiovascular diagnosis amongst 119 long term survivors of childhood and
young adult cancer in Yorkshire, for cancer diagnosis between 1991-2006
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8.2.1 Comparison of Cancer Cohort to the General Population
Table 8.1 contains the number and crude incidence of cardiovascular LEs per 10,000
person-years (pys) amongst cancer survivors and the general population by age group.
There were 181 cardiovascular LEs (counting each type of diagnosis once per person)
amongst the cancer survivor cohort, compared to 112,118 events in the general population.
Overall, the incidence was higher amongst cancer survivors than the general population
(51.3 vs. 35.2 per 10,000 pys respectively). Hypertension was the most common type of
cardiovascular event for the survivors cohort and the general population (13.3 and 9.9 per
10,000 pys respectively), except amongst the childhood survivor cohort, amongst which
cardiomyopathy was most common (8.4 per 10,000 pys) and hypertension second most
common (7.8 per 10,000 pys). Overall, the survivor cohort had notably higher incidence
of hypertension (13.3 vs. 9.9 per 10,000 pys), cardiomyopathy and heart failure (7.4 vs.
1.8 per 10,000 pys), conduction disorders (6.5 vs. 5.0 per 10,000 pys), cerebrovscular
disease (4.5 vs. 2.5 per 10,000 pys), pulmonary heart disease (4.3 vs. 1.8 per 10,000 pys)
and pericardial disease (3.1 vs. 0.8 per 10,000 pys) compared to the general population.
However, when assessing incidence according to age group, the incidence of hypertension
and cerebrovascular disease was only increased compared to the general population for
the childhood survivor cohort (7.6 vs. 2.8 per 10,000 pys for hypertension and 5.8 vs. 0.9
per 10,000 pys for cerebrovascular disease), but not the young adult survivor cohort (17.7
vs. 16.8 for hypertension and 3.5 vs. 3.2 for cerebrovascular disease). The incidence
of cardiovascular operations and procedures (7.0 vs. 6.8 per 10,000 pys) and valvular
heart disease (1.1 vs. 1.3 per 10,000 pys) was similar amongst the survivor cohort and
general population, however, the incidence of coronary artery disease was lower amongst
the survivor cohort compared to the general population (4.0 vs. 5.4 per 10,000 pys).
Figure 8.4a shows the excess risk of cardiovascular events amongst the cancer survivor
cohort compared to the general population represented as hospitalisation rate ratios
(HRRs). The rate of cardiovascular hospitalisations was higher for the survivor cohort
compared to the general population overall (HRR = 1.4, 95% CI 1.2-1.7). Furthermore,
there was a significant increase in the risk of hospitalisation for hypertension (HRR
= 2.1, 95% CI 1.6-2.8), operations and procedures (HRR = 1.6, 95% CI 1.1-2.3),
cardiomyopathy and heart failure (HRR = 5.9, 95% CI 4.0-8.6), pulmonary heart disease
(HRR = 3.4, 95% CI 2.0-5.7), pericardial disease (HRR = 5.1, 95% CI 2.8-9.3),
conduction disorders (HRR = 1.9, 95% CI 1.3-2.9) and cerebrovascular disease (HRR
= 2.8, 95% CI 1.2-1.7).
Results by age group, Figure 8.4b, show that the rate of cardiovascular hospitalisations
was higher for the childhood cohort compared to the general population overall (HRR =
2.6, 95% CI 1.9-3.6), but not for the young adult cohort (HRR = 1.2, 95% CI 0.91.5).
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Amongst the younger cohort, there was a significant increased risk of cardiomyopathy
and heart failure (HRR=12.7, 95% CI 7.4-21.9), cerebrovascular disease (HRR=7.9, 95%
CI 4.1-15.2), pericardial disease (HRR=7.9, 95% CI 3.3-19.0), hypertension (HRR=4.0
95% CI 2.3-7.1), valvular heart disease (HRR=3.2, 95% CI 1.0-10.0) and operations and
procedures (HRR=2.2, 95% CI 1.0-4.5). Despite no significant increased hospitalisation
rate for young adults overall, there was a significant increase in the hospitalisation rate
of pericardial disease (HRR=4.0, 95% CI 1.8-8.8), cardiomyopathy and heart failure
(HRR=3.8, 95% CI 2.2-6.6), pulmonary heart disease (HRR=3.5, 95% CI 2.0-6.4),
conduction disorders (HRR=2.0, 95% CI 1.2-3.2) and hypertension (HRR=1.8, 95% CI
1.3-2.5) in this age group.
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Figure 8.4: Hospitalisation rate ratios and 95% confidence intervals comparing
cardiovascular late effects amongst cancer survivors to the general population overall (a)
and by age group (b), 1996-2011
8.2.2 Predictors of Cardiovascular LEs
There was significant evidence of an increased risk of cardiovascular LEs for those
diagnosed aged 15-29 years compared to those diagnosed aged 0-14 years in the
unadjusted analysis (HR=1.69, 95% CI 1.16-2.48 P -value=0.007) and a significant
8. LONG TERM EFFECTS AMONGST SURVIVORS OF CANCER 215
reduced risk of cardiovascular LEs by 4% on average over the study period (HR=0.94,
95% CI 0.88-0.99, P -value=0.020); no further differences in demographic and clinical
variables were observed (Table 8.2).
Table 8.3 gives the excess hazard ratios (EHR) for the risk of cardiovascular LEs adjusting
for the rate of cardiovascular events in the background population. The EHR of age
at diagnosis was 1.19 (95% CI 0.89-1.60), however, this effect was not significant.
Furthermore, the EHR for year of diagnosis was very close to 1 and not significant
(EHR=1.02, 95% CI 0.96-1.08), implying that although rates of cardiovascular LEs
were decreasing for the cancer survivor cohort, this was mirrored by a decrease in
cardiovascular events for the background population. The risk of cardiovascular LEs for
those diagnosed with leukaemia (EHR=1.37, 95% CI 0.92-2.04), lymphoma (EHR=1.23,
95% CI 0.81-1.87) and CNS tumours (EHR=1.28, 95% CI 0.81-2.02) were all higher
when compared to other solid tumours, however, non of the effects were statistically
significant. In addition, despite large EHR for sex (EHR=1.19, 95% CI 0.89-1.60) there
was no significant difference in cardiovascular LEs according to sex. Subgroup analysis
model (i) including only survivors who received chemotherapy to assess the impact of the
number of anthracyline drugs administered is given in Table 8.4. There was no significant
difference in the risk of cardiovascular LEs according to the number of anthracycline
drugs administered (EHR=0.77, 95% CI 0.53-1.12, P -value=0.171). Furthermore, there
were no significant effects for age at diagnosis or year of diagnosis as in the main
analysis (Table 8.3). However, there was borderline significant evidence at the 10% level
of females having a higher risk of cardiovascular LEs compared to males (EHR=1.37,
95% CI 0.94-1.99). Subgroup analysis model (ii) including only survivors who received
radiotherapy is given in Table 8.5. There was borderline significant evidence of an
increased the risk of cardiovascular LEs (excluding cerebrovascular disease) for those
who received radiotherapy to the chest (EHR=7.36, 95% CI 0.97-55.7, P -value=0.053).
Furthermore, there was borderline significant evidence at the 10% level of a large
increased risk in cardiovascular LEs for females compared to males (EHR=12.21, 95%
CI 0.80-187.19, P -value=0.072) as in the chemotherapy subgroup analysis. The wide CIs
surrounding both of these estimates were a reflection of the small number of cases in this
subgroup analysis, which included 812 cases of whom 31 had a cardiovascular LE. Of
those with a cardiovascular LE, there were 7 cases who received radiotherapy to the chest
and 20 were female.
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Table 8.2: Number of cases with and without cardiovascular late effects (LEs) and
unadjusted hazard ratios (HRs) obtained from univariable Cox proportional hazards
models for the time to cardiovascular LEs amongst survivors of childhood and young
adult cancer, diagnosed between 1991 and 2006
N HR (95% CI) P -valueLate Effect No Late Effect Total
Sex
Male 69 1857 1926 1
Female 50 1271 1321 1.02 (0.71-1.46) 0.933
Age at cancer diagnosis
0-14 years 40 1327 1367 1
15-29 years 79 1801 1880 1.69 (1.16-2.48) 0.007
Diagnostic Groupa
I: Leukaemia 23 564 587 1
II: Lymphoma 32 681 713 1.10 (0.65-1.89) 0.719
III: CNS tumours 16 474 490 0.83 (0.44-1.57) 0.567
IV-XII: Other solid tumours 48 1409 1457 0.87 (0.53-1.43) 0.583
Year of Diagnosis 119 3128 3247 0.94 (0.88-0.99) 0.020
Treatment
Chemotherapy (± Surgery) 41 1201 1242 1
Radiotherapy (± Surgery) 9 312 321 0.70 (0.34-1.45) 0.340
Chemo & Radiotherapy (±
Surgery)
27 464 491 0.86 (0.52-1.41) 0.543
Surgery only or no treatment 42 1151 1193 0.87 (0.57-1.34) 0.532
Number of Anthracyclines
Zero 88 2089 2177 1
One 21 835 856 0.70 (0.43-1.12) 0.137
Two 10 199 209 1.52 (0.79-2.93) 0.209
Three 0 5 5 - -
Radiation to the Chest
No 112 3026 3138 1
Yes 7 102 109 1.64 (0.76-3.52) 0.204
Cranial Radiation
No 108 2905 3013 1
Yes 11 223 234 0.98 (0.53-1.83) 0.956
Radiation to the Neck
No 111 2951 3062 1
Yes 8 177 185 1.00 (0.49-2.06) 0.994
Deprivation Fifthsb
Most Deprived (5) 45 1062 1104 1
4 19 653 672 0.72 (0.42-1.24) 0.230
3 24 587 611 1.02 (0.62-1.69) 0.484
2 25 500 525 1.19 (0.73-1.96) 0.927
Least Deprived (1) 9 326 335 0.64 (0.31-1.33) 0.235
Total 119 3128 3247
aInternational classification of childhood cancer; bIndex of Multiple Deprivation 2007
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Table 8.3: Excess hazard ratios (EHR) and 95% confidence intervals (CI) obtained from a
Royston-Parmar relative survival model (probit scale and 1 degree of freedom), modelling
the risk of a cardiovascular late effects for long term survivors of cancer diagnosed
between 1991 and 2006 aged 0-14 and 15-29 years inclusive
Variable EHR 95% CI P -valuelower upper
Sex
Male 1
Female 1.19 0.89 1.60 0.234
Age at cancer diagnosis
0-14 years 1
15-29 years 1.09 0.79 1.51 0.610
Year of Diagnosis 1.02 0.96 1.08 0.508
Diagnostic Groupa
IV-XII: Other solid tumours 1
I: Leukaemia 1.37 0.92 2.04 0.122
II: Lymphoma 1.23 0.81 1.87 0.337
III: CNS tumours 1.28 0.81 2.02 0.284
Treatment
Surgery only or no treatment 1
Chemotherapy (± Surgery) 1.10 0.78 1.54 0.592
Radiotherapy (± Surgery) 0.73 0.30 1.72 0.463
Chemo & Radiotherapy (± Surgery) 0.93 0.57 1.50 0.763
Deprivationb 0.99 0.99 1.00 0.577
aInternational classification of childhood cancer; bIndex of Multiple
Deprivation 2007 included as a continuous score
Table 8.4: Excess hazard ratios (EHR) and 95% confidence intervals (CI) obtained from a
Royston-Parmar relative survival model (probit scale and 1 degree of freedom), modelling
the risk of a cardiovascular late effects for long term survivors of cancer who received
chemotherapy treatment and were diagnosed between 1991 and 2006
Variable EHR 95% CI P -valuelower upper
Sex
Male 1
Female 1.37 0.94 1.99 0.096
Age at cancer diagnosis
0-14 years 1
15-29 years 0.93 0.62 1.39 0.731
Year of Diagnosis 1.02 0.97 1.08 0.834
Number of Anthracyclinesa 0.77 0.53 1.12 0.221
aNumber of distinct anthracycline drugs administered modelled as
a continuous variable
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Table 8.5: Excess hazard ratios (EHR) and 95% confidence intervals (CI) obtained from
a Royston-Parmar relative survival model, modelling the risk of a cardiovascular late
effects for long term survivors of cancer who received radiotherapy treatment and were
diagnosed between 1991 and 2006
Variable EHR 95% CI P -valuelower upper
Sex
Male 1
Female 12.21 0.80 187.19 0.072
Age at cancer diagnosis
0-14 years 1
15-29 years 0.49 0.10 2.32 0.368
Year of Diagnosis 0.98 0.83 1.17 0.834
Chest Radiation
No 1
Yes 7.36 0.97 55.70 0.053
8. LONG TERM EFFECTS AMONGST SURVIVORS OF CANCER 219
8.3 Model Assessments
Methods for model assessment are described in §4.4.5. As the flexible parametric RP
survival models rely on cubic splines to estimate the baseline hazard function, the scale
and the complexity of the splines need to be determined. Models were compared using
the AIC and BIC for the proportional hazards (PH) model, proportional odds (PO) model
and probit model between 1 and 5 degrees of freedom (df) (Table 8.6). For the PH model
and the PO model, the AIC is lowest using 2 df and the BIC is lowest model using 1
df. For the probit model, the AIC and BIC are lowest for the simplest model with 1 df.
Overall, the probit model had the lowest AIC and BIC, although the difference in AIC and
BIC for PH and PO models compared to the probit model were very small. The probit
model was chosen as the most appropriate model, further confirmed by a violation of the
PH assumption §8.3.1. In general, BIC values were more sensitive to changes in df when
compared to AIC, as differences between AIC values at each degree of freedom were
much smaller compared differences in BIC. This is because as the df increase, there is
increased model complexity, and BIC has a stronger penalty for model complexity when
compared to AIC.
Table 8.6: Choice of baseline complexity based on the number of degrees of freedom (df)
for the proportional hazards (PH) model, the proportional odds (PO) model and probit
model. The optimal (lowest) AIC and BIC values are underlined for each model.
df PH Model PO Model probit ModelAIC BIC AIC BIC AIC BIC
1 1330.35 1403.37 1330.15 1403.17 1328.23 1401.25
2 1329.74 1408.85 1329.72 1408.83 1329.66 1408.76
3 1331.37 1416.56 1331.34 1416.53 1331.40 1416.60
4 1332.51 1423.78 1332.51 1423.78 1332.62 1423.90
5 1332.63 1430.00 1332.62 1429.99 1332.54 1429.90
8.3.1 Proportional hazards assumption
The PH assumption of the PH model with 1 df was checked using log cumulative hazard
plots for each variable in the model (Figure 8.5). Overall, there did not appear to be
a serious violation of the PH assumption except for the variable sex, in which the log
cumulative hazard plot crossed at the mid-point on the time axis and thereby violating
the PH assumption. This supports the choice of probit model based on the AIC and BIC
which does not require a PH assumption (§8.3).
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Figure 8.5: Log cumulative hazard plot for the proportional hazards Royston-Parmar
survival model by sex, age group, year of diagnosis, diagnostic group, treatment group
and Index of Multiple Deprivation
8.3.2 Sensitivity to Model Complexity and Scale
Differences in AIC and BIC shown in §8.3 were minimal, and the log cumulative hazard
plots to assess the PH assumption are subjective. Sensitivity to the choice of model was
assessed. Figure 8.6 shows there was little to no difference in the relative survival curves
between using a 1 or 2 df model for the PH, PO or probit models with all confidence
intervals overlapping. Figure 8.7 highlights there was very little difference in relative
survival using 1 df between the PH, PO or probit models. Therefore, the models were
robust to the choice of scale and df.
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Figure 8.6: Relative survival curves for time to cardiovascular event obtained from
multivariate Royston-Parmar relative survival models comparing models with 1 and 2
degrees of freedom (df) using the proportional hazards (PH), proportional odds (PO) and
probit scales
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Figure 8.7: Relative survival curves for time to cardiovascular event obtained from
multivariate Royston-Parmar relative survival models comparing the proportional hazards
(PH), proportional odds (PO) and probit scales with 1 degree of freedom (df)
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8.4 Conclusion
The results presented in this chapter provide the first population-based evidence of
increased cardiovascular morbidity in a cohort of survivors of CYAs with cancer in
Yorkshire through the use of cancer registry data linked to routinely collected inpatient
HES data.
There was a significant increase in cardiovascular morbidity in survivors of childhood
cancer compared with the general population. For TYAs, this increased burden on
survivors was limited to pericardial disease, cardiomyopathy and heart failure, pulmonary
heart disease, conduction disorders and hypertension compared to the general population.
There was a significant increased risk of cardiovascular LEs for those who received chest
radiation, however increases in the risk of cardiovascular LEs according to the use and
number of anthracyclines were not observed. The rate of cardiovascular events decreased
by 6% on average per year for survivors of CYA cancer, however, this was mirrored by a
decreasing trend amongst the general population.
Although survival rates are improving (Chapter 6), the results presented here highlight an
ongoing need for survivors of CYA cancer to receive continued monitoring. Awareness
of the potential long term effects of cancer need to be raised not only with the survivors
themselves, but also to potential future health carers.
Chapter 9 concludes the thesis with a detailed discussion of all the work presented in this
thesis, alongside the novel contributions of the work, the study implications, limitations
and recommended areas for future research.
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Chapter 9
Discussion
9.1 Introduction
Cancer is the leading cause of death amongst CYAs in the UK, and improving outcomes
from cancer remains a key national priority [22, 23]. Despite this, there is a paucity of
research on CYA outcomes which take into account vital data on the severity of disease
at diagnosis. Furthermore, missing data are often ignored, resulting in few conclusive
results.
This study set out to improve upon the quality of research addressing variation in cancer
outcomes amongst CYAs, and has identified key survival inequalities for a population of
CYAs with cancer in Yorkshire. The novel application of multiple imputation to CYA
cancer research enabled the first comprehensive population-based study of CYA cancer
survival trends over time and in relation to ethnic group whilst adjusting for disease
severity. The study has also sought to determine whether inequalities in disease severity
according to age, ethnicity and deprivation exist for CYAs with cancer for the first time in
the UK. Furthermore, despite a growing population of long term survivors of childhood
and TYA cancer, the literature on late effects of cancer has largely overlooked the TYA
population of survivors and has relied on self reported outcomes in retrospective cohort
studies. This study therefore aimed to objectively quantify the burden of long term health
effects, focusing on cardiovascular disease, for long term survivors of cancer for both
children and TYAs in Yorkshire based on a unique data linkage approach.
The empirical and novel findings which have arisen from this thesis are summarised
below. A detailed discussion and synthesis of these results is given in §9.2, §9.3, §9.4
and §9.5. The chapter concludes with the implications of the study, the strengths and
limitations as well as recommendations for future research and an overall conclusion.
The empirical and novel findings arising from this thesis are as follows:
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Missing Data and Multiple Imputation
For the first time, the high proportion of missing staging and ethnicity data has been
quantified, and trends over time described, for CYAs with cancer in Yorkshire (Chapter
6). Complete case analysis resulted in biased estimates which lacked precision and power
when compared to multiple imputation to correct for missingness. Improvements in
survival of cancer over time were only evident after the use of multiple imputation.
Variation in Cancer Survival
CYA cancer survival has been described by age group, ethnic group and disease severity
for the first time in a comprehensive analysis using appropriate methods to account
for missingness. Survival was significantly poorer for TYAs compared to children, for
those with advanced stage disease and for other compared to white ethnicity. There was
significant improvement in survival over time for CNS tumours and leukaemia, but not
GCTs.
Inequalities in Disease Severity at Diagnosis
Differences in disease severity at diagnosis were described for the first time for CYAs with
cancer. Despite poorer survival of TYAs compared to children, there was no significant
difference in the disease severity at diagnosis between these two age groups. Furthermore,
ethnicity and deprivation did not influence the disease severity at diagnosis. Despite
no significant improvements in survival over time for GCTs, the number of later stage
diagnoses of GCTs decreased by 4% on average per year between 1990 and 2009.
Cardiovascular Late Effects amongst Long Term Survivors of CYA Cancer
In the first study assessing late effects amongst survivors of childhood and TYA cancer,
a significant increase in cardiovascular morbidity was observed for childhood and
subgroups of the TYA population compared with the general population. The rate of
cardiovascular events decreased by 6% on average per year for survivors of CYA cancer,
however, this was mirrored by a decreasing trend amongst the general population.
9.2 Missing Data and Multiple Imputation
The Yorkshire register’s database system included only a single field for recording stage,
and as such, a large number of recorded stage values were invalid when compared to
existing staging mechanisms for CYA cancers, which contributed to an already low level
of complete and accurate stage data. Further missing stage data could have arisen from
doctors failing to record stage within medical notes or due to poor understanding of the
information recorded within medical notes by data extractors. Importantly, this study
showed that there was no improvement in the completeness of stage data within the
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Yorkshire register over the 20 year study period for all cancers. This was in spite of the
Department of Health’s recognition in 2007, albeit towards the end of the study period,
that stage data was a key gap in national cancer intelligence and was recommended as an
important area for improvement [1, 22, 33].
This study identified that, in contrast to missing stage data, there was a significant
improvement in the level of completeness of ethnicity data obtained from linked HES
data records. This trend was primarily a consequence of the availability of HES data from
1996 onwards, with increased missing data at the beginning of the study period being due
to a higher likelihood of non-linkage for these cases. However, despite this feature of the
study design, data completeness of ethnic group continued to improve to the end of the
study period.
In spite of an increase in the number of publications relating to advanced multiple
imputation techniques in recent years, many applied health researchers fail to realise
the potential problems of adopting inadequate ad-hoc techniques or simply ignoring
missing data. There is a wealth of research focusing on survival of cancer across all
ages worldwide, however, between 1997 and 2014, just 60 studies implemented MICE.
In particular, of the 18 UK studies of childhood and TYA cancer survival identified from
a systematic review, none adopted adequate methods for handling missing data, with the
majority either performing a CCA or simply neglecting to mention any missing data. The
novel application of two advanced multiple imputation techniques, MICE and SMC-FCS,
highlighted for the first time in CYA cancer outcomes research the serious implications
of ignoring missing data through comparisons with a CCA.
An analysis based on complete cases resulted in biased estimates, reduced power to
identify significant effects and reduced precision. In particular, the study identified
important survival inequalities according to age at diagnosis, year of diagnosis, diagnostic
subgroup and ethnicity which only became apparent after the use of imputation
techniques. Furthermore, multiple imputation avoided discarding non-missing stage data,
and allowed for the inclusion of this prognostic factor within the analysis. This was
in contrast to many previous studies of survival for CYA cancers that neglected to use
any measure of disease severity, despite its importance in determining the prognosis
of a patient. Imputation and inclusion of disease severity measures showed that key
inequalities in survival remained evident for certain subgroups of society, even after
adjustment for disease severity. These findings are discussed in detail in §9.3.
In summary, the comparison of CCA and imputation methods presented in this thesis
show that failure to apply adequate missing data techniques can reduce statistical power
and thereby the ability to identify potentially important factors related to CYA cancer
outcomes. Furthermore, it can result in invalid and imprecise estimates and reinforces
228 9. DISCUSSION
the message that in most instances, complete case analysis is not an acceptable method
in the presence of missing data. The use of CCA can have serious consequences should
the results be subsequently used to determine clinical practice. These conclusions are not
limited to CYA cancer outcomes research, but have wider applicability to other diseases.
9.3 Variation in Cancer Survival
Chapter 2 identified a key gap in the knowledge of the variation of survival amongst
children and TYAs, in particular, there was a paucity of survival analysis studies which
adjusted for disease severity. There was just one study in which the survival of TYAs was
compared to survival rates amongst children [42], and the results, although covering the
whole of England, did not adjust for year of diagnosis, ethnicity or stage which have all
been identified as having significant effects on survival. Furthermore, although the authors
acknowledged stage as an important factor, they excluded it from the analysis because of
missing data. In addition, none of the identified studies on CYA cancer survival in the
UK used adequate methods to handle missing data. The findings in this thesis relate to
a novel population-based study examining survival trends over time and in relation to
ethnic group encompassing the childhood and TYA age range whilst adjusting for disease
severity. The key original findings according to ethnicity, deprivation, age group, sex,
year of diagnosis and disease severity are discussed in detail below.
9.3.1 Ethnicity
Survival was poorer for other ethnicity compared to white ethnicity amongst those with
CNS tumours, and marginally, but not significantly, poorer for Asian and other ethnicity
compared to white ethnicity for those with leukaemia and GCTs.
Four previous studies have assessed ethnic differences for childhood leukaemia in the
UK [52, 55, 56, 57], two of which also looked at ethnic differences for childhood CNS
tumours [55, 56]. To date, no study has looked at ethnic differences amongst CYAs with
GCTs or TYAs with any cancer in the UK.
Studies by McKinney et al. [55] and Stiller et al. [56] showed increased HRs of death for
Asian compared to non-Asian children with leukaemia after adjusting for WBC count,
however, the former studies effect was not significant, and the latter national study showed
only a borderline significant effect (P=0.057). Stiller et al. [56] also observed that
survival differences became more apparent after 5-years post diagnosis. The results in
this thesis were consistent with these previous studies as no significant effects of Asian
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or other ethnicity was observed compared to white ethnicity for those with leukaemia for
diagnoses between 1990 and 2009, despite large effect sizes indicating poorer survival. It
is possible that due to the rarity of the disease, the overall high level of survival and the
small number of Asian and other ethnic minorities this study and previous research by
McKinney et al. [55] and Stiller et al. [56] lack power to identify significant differences,
despite consistent evidence of increased HRs for these ethnic groups. This is in contrast
to studies by Powell et al. [57] and Oakhill and Mann [52] in which poorer survival for
south Asians compared to non-south Asians with leukaemia was observed after adjusting
for WBC count. However, differences were restricted to 1980s when overall survival of
leukaemia was poorer, which may now be obsolete and could have led to increased study
power due to a larger number of observed deaths. Furthermore, missing data was not
accounted for in these studies.
This study was the first to identify a significant difference between other ethnicity and
white ethnicity for CNS tumours in Yorkshire. The non-significant effect of Asian
ethnicity for CNS tumours was consistent with previous studies [55, 56] for the CNS
tumour group as whole. This study has identified that despite no difference for Asian
ethnicity in terms of CNS tumour survival, the minority other ethnic group had poorer
prognosis compared to those of white ethnicity. Although Stiller et al. [56] identified
evidence of poorer survival for non-white children compared to white children for CNS
tumours, this finding was restricted to the astrocytoma subgroup of CNS tumours, the
early 1980s, did not include TYAs and did not adjust for grade of tumour. The novel
contribution of this study, therefore, was the identification of a two-fold increase risk
of death from CNS tumours for those of non-white and non-Asian ethnicity despite
adjustment for disease severity at diagnosis through use of a more detailed breakdown of
ethnicity based on routinely collected data rather than relying on name analysis programs
as used in previous studies.
In addition, this study was the first to identify possible survival disadvantages from GCTs
for non-white ethnic groups, although these results were not significant, they warrant
further investigation.
9.3.2 Deprivation
There was no evidence of an effect on survival of deprivation for CNS tumours, leukaemia
or GCTs. For CNS tumours, this was consistent with a study by Tseng et al. [60] in
2006 after adjustment for WHO grade, although the authors performed a CCA and did
not provide details of the amount of missing data. Evidence from an earlier study in
Yorkshire showed that children from middle affluent areas with CNS tumours were at an
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increased risk of death compared to those from affluent areas, however, the results were
not adjusted for WHO grade [55]. Therefore, it was not possible to ascertain whether
these effects were truly due to deprivation, or whether children from middle affluent areas
were more likely to be diagnosed with advanced grade tumours.
For leukaemia, the study by Lightfoot et al. [65] in 2012 showed that children from
more deprived areas had poorer survival compared to children from more affluent areas,
however, there was no adjustment for disease severity in this study, nor was missing data
taken into account. Therefore, the results may be unreliable as deprivation effects could
be confounded by disease severity and missing data could have led to biased estimates.
For GCTs, the study by Birch et al. [44] focusing on TYAs with cancer showed no effect
of deprivation on survival. This is consistent with the results presented in this thesis,
which have now extended this observation to childhood GCTs.
The results presented in this thesis provide evidence that deprivation does not affect
survival of CNS tumours, leukaemia or GCTs for children and TYAs after adjustment
for disease severity, in contrast to earlier studies which did not adjust for disease severity.
9.3.3 Age Group
The results show, in the first comprehensive study of childhood and TYA cancer survival
adjusting for disease severity, that survival was significantly poorer for TYAs compared
to children for CNS tumours, GCTs and leukaemia.
For CNS tumours, survival was 34% poorer for TYAs compared to children. One previous
study comparing children and TYAs with CNS tumours showed a significant improvement
in survival for TYAs compared to 0-14 year olds in contrast to our study [42], however,
TYAs were defined as 15-24 year olds, rather than the definition of 15-29 year olds used
here. O’Hara et al. [42] also provided a comparison with 25-49 year olds, and showed
significantly poorer survival for this group compared to children under the age of 15. It is
possible therefore that the effect of the 25-29 year olds included in the definition of TYAs
for this thesis outweighed the positive effect of 15-24 year olds observed by O’Hara et al.
[42]. Further differences in the results were likely to arise due to adjustment for WHO
grade, year of diagnosis, ethnicity and diagnostic subgroup, which were not taken into
account by O’Hara et al. [42]. Arguably, these adjustments were likely to have a much
greater impact on the results than the choice of upper age boundary. There was some
evidence from the TYA literature to indicate that older age was associated with poorer
survival for CNS tumours, which was consistent with our results, however, the evidence
was limited to the astrocytoma subgroup of CNS tumours, results were not compared to
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children with CNS tumours, disease severity was not taken into account and a CCA was
performed [44].
For leukaemia, the effects of age were consistent when compared to separate studies of
childhood [4] and TYA [44] cancer. The increased risk of death for TYAs compared
to children with ALL could be due to differences in disease biology, for example, the
t(12,21) translocation seen in 25% of children with B-cell ALL is only seen in 3% of adult
cases [76], and TYAs have a higher ratio of T-cell compared to B-cell ALL compared to
children which is associated with poorer prognosis [77, 78]. The results in this thesis also
confirm earlier childhood specific studies highlighting the poor survival rates of children
diagnosed under the age of 1 [53, 64, 65]. Although it has been suggested that differences
in presenting white cell count between TYAs and children could have resulted in poorer
TYA survival compared to children with ALL [44], the results in this thesis show that
the difference in survival between children and TYAs remained significant even after
adjustment for presenting white cell count. Moreover, the results showed that there were
no significant differences in presenting white cell count between children and TYAs.
For GCTs, there was a 4-fold increase in the risk of death for TYAs compared to children,
which was in contrast to a TYA study by Birch et al. [44] indicating higher survival of
GCTs for those aged 17-20 years (87%) and 21-24 years (90%) compared to 13-16 year
olds (80%). However, the study by Birch et al. [44] did not include the full childhood
age range in addition to the TYA age range, only included diagnoses up to 2001, did not
adjust for stage and used a CCA. Furthermore, the 5-year survival rate for TYAs with
GCTs within this thesis was 94%, which was higher than the 5-year survival shown for
TYAs by Birch et al. [44].
Poorer survival of TYAs with cancer compared to children could be a result of differences
in the biological or molecular characteristics of cancers occurring amongst TYAs, such
as those described for leukaemia, or due to differences in access to clinical trials between
children and TYAs. In 2006/2007, 19% of TYA patients were reported to be enrolled
onto clinical trials, compared to 51% of children with cancer for the same time period.
Specifically, enrolment to clinical trials for TYAs with CNS tumours was particularly low
[87]. Similar evidence of clinical trial enrolment in the US highlights that only a small
proportion of those aged 15-25 years were enrolled onto clinical trials compared to the
majority of children diagnosed with cancer [293]. Detailed data on clinical trials for all
children and TYAs in this study were not available to study the effects of trial enrolment
on survival, however, information was available for the leukaemia subgroup, ALL, and a
separate analysis of survival for ALL according to clinical trial era has been conducted
using Yorkshire register data (van Laar et al, 2015 in press). In addition to clinical trial
enrolment, it is possible that TYAs have poorer survival compared to children due to
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the use of adult treatment protocols rather than more effective paediatric protocols, and
the resulting differences in treatment toxicity could have impacted on survival. Data on
treatment protocols and compliance of treatment for children and TYAs diagnosed with
cancer were not available and could therefore not be studied here. Previous work has
provided evidence to suggest that teenagers with CNS tumours, leukaemia and GCTs
were amongst the diagnostic groups with the lowest referral rates to paediatric oncology
centres [294]. Efforts are underway in the UK to ensure all TYAs have the opportunity
to enter trials where appropriate and are treated within principal treatment centres so that
individuals can be treated and followed-up within an environment with appropriate age
and/or site-specific expertise [43].
9.3.4 Sex
For children and TYAs with CNS tumours, leukaemia and GCTs, sex was not a significant
predictor of survival after adjustment for year of diagnosis, age group, ethnicity and
disease severity. For CNS tumours, there was some evidence of poorer survival in
the univariable analysis, however, this effect was no longer present after adjustment of
covariates. For leukaemia, there were no univariable or multivariable effects of sex on
survival. For GCTs, there was borderline significant evidence of poorer survival amongst
females compared to males, however, this effect did not remain after adjustment for other
covariates. This is in contrast to an earlier study of TYA cancers which has shown females
have improved survival for most types of cancer [44], however, the authors conclude that
a possible explanation could include earlier presentation of cancer for females compared
to males although they were unable to explicitly assess this in their study. The analysis in
this thesis covers a more recent study period (1990 to 2009 compared to 1979-2003 for
Birch et al. [44]) and includes a more comprehensive analysis covering the childhood and
TYA age range, in addition to adjustments for disease severity and ethnic group and the
application of advanced missing data methods.
9.3.5 Year of Diagnosis
Importantly, survival rates showed a consistent improvement over the study period for
CNS tumours and leukaemia. However, such an improvement was not observed for GCTs.
Previous work focusing on TYAs in England [44] and the North of England [59] did show
improvements in survival for GCTs, however, both studies covered earlier periods, with
improvements seen from 80% to 94% between 1979 and 2001 [44] and 37% to 86%
between 1968 and 1997 [59]. The analysis within this study included diagnoses between
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1990 and 2009, and survival was already high (91%) at the start of this period, therefore,
there was less opportunity for observing further improvements in this study. Further work
should therefore focus on minimising the complications of treatment for GCTs to improve
the quality of survival.
9.3.6 Disease Severity at Diagnosis
There were large and significant decreases in survival for advanced stage CNS tumours,
leukaemia and GCTs. This was not unexpected due to the definition of disease severity
relating strongly to survival, however, the results highlight the importance of including
this prognostic variable within survival analysis. Previously reported differences in
deprivation and gender were not evident within the analysis in this thesis, however,
despite adjustment of disease severity, key survival disadvantages for ethnic minorities
and TYAs were evident. The analyses adjusting for disease severity provided in this
thesis covering the childhood and TYA age range provide an important benchmark for
future larger studies of childhood and TYA cancer, in particular, focus should be directed
towards other tumour groups, such as lymphoma, once data on stage and disease severity
improves in completeness as well as quality.
9.4 Inequalities in Disease Severity at Diagnosis
In order to improve survival for all CYAs with cancer and to further determine the reasons
for survival inequalities, it is important to understand whether potential inequalities in
disease severity at diagnosis exist, and where possible, eliminate these through raising
awareness of the importance of a timely diagnosis of cancer. To date, there were
no previously reported studies assessing the effects of age at diagnosis, ethnicity and
deprivation on the stage of cancer at diagnosis for CYAs, despite evidence of such effects
amongst the adult cancer population.
Importantly, this study provides the first reported evidence showing that, despite
significant survival disadvantages for TYAs compared to children, there were no
differences in the likelihood of being diagnosed with advanced stage disease between
children and TYAs for CNS tumours and leukaemia. Furthermore, the majority of CNS
tumours and leukaemias were low grade and standard risk respectively at diagnosis. For
GCTs, despite a two-fold increase in the proportion of late stage diagnoses amongst
children compared to TYAs, the effect of age group on the severity of disease was
not significant within the multivariable analysis. The increased proportion of children
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with late stage tumours could simply be an artifact of this diagnostic group, in which
the majority of cases are TYAs. However, further larger scale studies are required to
ascertain whether children with GCTs are more likely to be diagnosed with late stage
disease compared to TYAs. Importantly, despite no improvements in survival over time
for GCTs, 5-year survival rates were around 75% to 80% even for late stage tumours,
and the proportion of late stage diagnoses was shown to decrease over time by 4% on
average over the study period. Furthermore, despite indications that children were more
likely to be diagnosed with advanced stage disease, survival for TYAs was almost four-
fold poorer compared to children. The reasons for continued inequalities in survival for
TYAs compared to children do not appear to be due to inequalities in disease severity.
Other reasons, as described in more detail in §9.3.3, could be differences in the biological
characteristics of cancers between children and TYAs, differences in enrollment onto
clinical trials or differences in the treatment protocols available. Further research is
warranted in these areas to ascertain why TYAs have poorer survival compared to children
diagnosed with the same disease of the same severity. Furthermore, the study showed that
there were no differences in the likelihood of being diagnosed with more advanced stage
tumours for different ethnic groups or levels of deprivation. In spite of this, CYAs of non-
white and non-Asian ethnicity had a significant survival disadvantage from CNS tumours
compared to those of white ethnicity. The results presented here indicate that ethnicity
or deprivation were unlikely to have created barriers to receiving a timely diagnoses of
cancer for CYAs in contrast to that observed for adults with cancer. Recent work by
Lightfoot et al. [65] in 2012, focusing specifically on children with leukaemia, concluded
that the observed deprivation gap in survival from leukaemia was more likely a result of
differences in treatment adherence according to deprivation rather than a difference in
access to healthcare. The lack of inequality in disease severity for leukaemia observed
in this study is consistent with the conclusion by Lightfoot et al. [65], which was based
on the premise that the deprivation gap arose when chemotherapy treatment moved from
in-hospital to at home administration. However, these results were not adjusted for the
severity of disease, and therefore it was unclear whether the deprivation gap observed in
that study was partly or wholly accountable for by the severity of disease at diagnosis.
9.5 Cardiovascular Late Effects amongst Long Term
Survivors of CYA Cancer
The systematic literature review in Chapter 2 revealed a paucity of timely research
relating to objective population-based research on the long term effects of childhood
cancer. Furthermore, research on the same topic was lacking even more so for the TYA
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cancer survivor population. The work provided in this thesis sought to fill this gap in
the knowledge by presenting the first population-based study of cardiovascular LEs in
survivors of childhood and TYA cancer using linked Yorkshire register and routinely
collected inpatient HES data.
There was evidence of a significant increase in cardiovascular LEs in survivors of
childhood cancer compared with the general population, whilst for TYAs the increased
risk of cardiovascular LEs were not observed overall, but did occur for pericardial disease,
cardiomyopathy and heart failure, pulmonary heart disease, conduction disorders and
hypertension compared to the general population. Subgroup analysis for those who
received chest radiation as part of their cancer treatment were at a significant increased
risk of developing one or more cardiovascular LE compared to children and TYAs who
did not receive chest radiation which was consistent with previous studies [112, 113].
However, the use and number of anthracyclines was not associated with a significant
increase in the risk of cardiovascular LEs in the analysis presented here.
9.6 Implications of the Study
Despite the use of advanced statistical techniques, the large amount of missing data
had the important implication that survival patterns could not be studied for all CYA
cancers, with imputations being limited to cancers with less that 60% of missing data.
Therefore the improvement in data completeness and quality of staging for CYA cancers
is of key importance. As part of this study, a comprehensive guide of CYA cancer
staging mechanisms has been developed for all ICCC diagnostic groups that can be used
to implement a tailored data entry mechanism for stage and disease severity within the
Yorkshire registers database; the implementation of this is currently underway. The new
system will encourage more accurate capturing of staging data due to automatic validation
procedures to ensure increased validity of recorded stage data in future. In addition, data
on the staging mechanism which was used will also be captured. It is anticipated that
completeness will also be improved after implementation of this system as it may be
easier to identify stage or disease severity within the medical notes with the availability of
the names of all relevant staging mechanisms for CYA cancers on the registers database
system. Continued training and awareness of the importance of complete and accurate
staging data is required to ensure the improvement of future research into the outcomes
of cancer as well as research into factors which affect late diagnosis.
Previously reported inequalities in survival from cancer amongst CYAs should be
interpreted and acted upon with care due to their lack of adjustments for disease severity
and lack of appropriate missing data methods. This study has provided contrasting
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evidence of some previously identified survival inequalities which were not apparent in
the comprehensive analysis within this thesis. For example, Birch et al. [44] previously
reported poorer survival for females compared to males for most cancers amongst TYAs,
however, sex did not significantly affect survival for any tumour group within this thesis.
In addition, the national study by O’Hara et al. [42] showed poorer survival for children
compared to TYAs with GCTs, which was the opposite effect observed within this thesis.
Although the work presented in this thesis only focused on survival variation for CNS
tumours, leukaemia and GCTs diagnosed within the Yorkshire region, the analysis was
more comprehensive in terms of adjustment for disease severity as well as the use of
multiple imputation, lack of which has been shown to produce biased estimates. Previous
work has shown that Yorkshire is representative of the UK in terms of its demographic
profile, therefore, results from this study are generalisable outside of the Yorkshire region
[12]. Although large scale national studies are useful in providing more study power and
confidence of UK wide applicability, more in depth and comprehensive research using
appropriate and advanced statistical techniques are arguably more valuable to unpick real
inequalities in survival.
Despite improvements in survival rates, survival for TYAs with cancer remains poor
compared to children. This observation is in spite of evidence showing that the disease
severity at presentation is the same for TYAs as children. Continued efforts should
therefore be made to ensure TYAs have equal access to clinical trials in addition
to improved treatment protocols to drive further improvements in survival for TYAs
diagnosed with cancer. Furthermore, the two-fold increased risk of death for non-white
and non-Asian CYAs with CNS tumours needs to be addressed, although the reasons for
this survival inequality remain unclear. Importantly, the inequality cannot be explained
by presentation with higher grade tumours at diagnosis compared to white children.
Finally, there is an ongoing need for survivors of both childhood and TYA cancer
to receive continued monitoring for potential long term effects of cancer. This study
quantified a 3-fold increased risk of cardiovascular LEs for survivors of childhood cancer,
and although effects were not seen overall for TYAs, they remained at increased risk of
many cardiovascular disease subgroups. It is important that those at risk of developing
cardiovascular LEs are supported with strategies to maximise cardiovascular health and
given access to appropriate health surveillance. Therefore, awareness of the potential long
term effects of cancer need to be raised not only with the survivors themselves, but also
to potential future health carers. Furthermore, surveillance of long term survivors should
not only be targeted to survivors of childhood cancer, but should also include survivors of
TYA cancer.
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9.7 Strengths and Limitations of the Study
This study has provided comprehensive and original findings for a population of CYAs
with cancer in Yorkshire relating to variation in cancer survival, inequalities in disease
severity at diagnosis and the burden of cardiovascular disease for survivors of cancer.
In addition to the strengths of this study in comparison to previous work, there were a
number of limitations which need to be considered.
The initial survival analysis for this thesis was restricted to data between 1990 and 2005,
and implemented multiple imputation of stage for all cancers combined (published in
van Laar et al. [263] in 2012). There were several limitations of this preliminary work,
including the large overall amount of missing stage data (two-thirds missing stage data),
the lack of consideration of different staging mechanisms for specific cancers and the
use of name analysis to identify ethnicity which limited the analysis to only two broad
ethnic groups being studied (south Asian and non-south Asian). The work in this thesis
built upon the preliminary published work by extending the time period to 2009, using
linked HES data to identify more detailed ethnicity groupings (white, Asian and other)
and analysing missing data more rigorously taking into account the validity of recorded
values for specific diagnostic groups prior to analysis. This enhancement resulted in
a more detailed analysis of novel and population-based findings of survival trends for
both the childhood and TYA cohort. However, on the basis of the current multiple
imputation literature, it was decided that missing data occurring in more than 60% of
cases should be avoided due to an increased chance of errors within the imputation process
leading to increased inaccuracies of the results. This meant that detailed survival analysis
was restricted to CNS tumours, leukaemia and GCTs. Therefore, the survival patterns
according to age group, ethnic group and deprivation after adjustment for disease severity
remain unclear for other CYA cancers.
Furthermore, the preliminary work only focused on MICE, whereas a recent and
more advanced imputation technique, SMC-FCS, was implemented for the final results
assessing trends in survival for CYAs with cancer. Although Bartlett et al. [149]
suggest that SMC-FCS offers a substantial advantage compared to MICE when imputing
non-linear models including Cox PH models, the results in this thesis showed that
differences in the analysis results between MICE and SMC-FCS methods were negligible.
Simulations for n=100 and n=1000 subjects by Bartlett et al. [149] showed that FCS
resulted in biased estimates, with a larger bias for continuous variables compared to binary
variables, which was not observed for SMC-FCS. The simulations were restricted to data
which were MCAR, and the true effect sizes, β, were small (β=1). Within the thesis,
data were assumed to be MAR and estimates for disease severity were large, although the
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true effect sizes were not known. The fact that there were no differences between MICE
and SMC-FCS indicated that the imputation model was likely to be specified correctly,
as the stated advantage of SMC-FCS over MICE was to avoid mis-specification of the
imputation model.
This study was based on a detailed population-based register of CYA cancers in Yorkshire.
Although previous work has shown that Yorkshire is representative of the UK in terms
of its demographic profile, thereby making the study results generalisable outside of the
Yorkshire region [12], the main disadvantage of focusing only on the Yorkshire region was
a lack of study power for some analyses. For example, in depth analyses of interaction
terms, to explore how the effects disease severity on survival varied between diagnostic
subgroups was not possible. In addition, it was not possible to study the cardiovascular
LEs amongst survivors of CYA cancer according to individual tumour group, therefore,
we were unable to determine whether the overall risk was the same for all diagnostic
groups. Data on cause specific mortality or relapse deaths were not available in this study
and therefore only overall survival was assessed. Cause-specific death data is available
from the Office of National Statistics, however, such data has been shown to be unreliable
for cancer, and the cost of such data far outweigh its benefit [295, 296]. An alternative
method to overall survival which does not require cause-specific mortality data, is relative
survival [297], which accounts for the mortality in an age and sex matched background
population. This method is important for elderly populations in which the underlying
mortality rates are high, however, the benefits of relative survival compared with overall
survival for childhood and TYA studies are limited. Furthermore, despite availability of a
detailed ethnicity breakdown within HES records, there were too few non-white and non-
Asian cases to assess further individual ethnic categories, which may have been avoided
if the study had been performed on a national level. Nonetheless, linkage with HES data
allowed for an additional ‘other’ ethnic group to be included compared to previous studies
which were limited to south Asian and non-south Asian on the basis of name analysis.
Despite detailed data on ethnicity, there were some limitations to the accuracy of ethnicity
data recorded in HES and multiple ethnicity codes were associated with one person. This
is a known problem within HES data, and could lead to misclassification of ethnicity
[298]. The most commonly recorded value of ethnicity was used to classify patients
into ethnic categories, which will have resulted in fewer misclassifications of ethnicity
compared to a simpler approach of using the latest recorded ethnicity value. Furthermore,
individual review of 8 cases was required to determine their ethnicity as there was no
unique ethnicity code which occurred most commonly. For these cases in particular, the
likelihood of misclassification of ethnicity was greater, which ultimately could have led
to some bias in the estimates.
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In addition to data on ethnicity, the linkage of Yorkshire register data with HES data
allowed the long term cardiovascular burden for survivors of CYAs to be quantified in
an objective manor, rather than previous studies which relied on self-reported long term
effects [135]. Despite this improvement upon previous studies, some methodological
limitations remained. Firstly, the study was based in Yorkshire and the overall number
of cardiovascular admissions identified for survivors of CYA cancer was n=119 (3.6%).
As the number of survivors with cardiovascular LEs was small, it was not possible
to perform subgroup analysis and determine whether the risk of LEs varied between
diagnostic groups. In addition, the study did not provide evidence to show that the use
and number of anthracyclines were significant predictors of cardiovascular LEs. Whereas
other studies, which focused on childhood survivors, show a clear dose-dependent effect
[109, 111, 116, 118]. It was not possible to explore a dose-dependent effect within this
study due to the lack of data on cumulative anthracycline doses within the Yorkshire
register’s database. It was likely that the number of different anthracycline agents
administered (the only information available for this thesis) was a poor surrogate for
cumulative dose effects.
The overall linkage rate for the study was 98%, which although high, meant that 2% of the
cohort of survivors of CYA cancer did not link to any hospital record. It is not possible
to determine whether these cases did not link due to data errors or whether or not 2%
of cases simply did not have any hospital admissions. The latter is possible, although
unlikely for a cohort of CYAs diagnosed with cancer. In addition to non-linkage of 2%
of cases, there could also be a certain degree of misclassification caused by errors in the
identifiers used to perform the linkage. This would have to effect of matching hospital
records to an incorrect diagnosis of cancer which could bias results. Nonetheless, 98% of
cases matched on the combination of exact NHS number, gender and date of birth, thus
mismatching would be unlikely for the majority of cases. For the remaining 2% of cases,
matches were made on exact NHS number, gender, postcode and partial date of birth or
on exact date of birth, postcode and gender but not NHS number. There could have been
a small number of mismatches in these 2% of cases, which could have resulted in some
biases in the estimates.
Finally, the overall burden of cardiovascular disease for long terms survivors of CYAs
with cancer was likely to be underestimated. The data provided in the present study
include only those cardiovascular LEs which were severe enough to warrant a hospital
admission, or which were discovered at the same time of an admission for a non-
cardiovascular related reason. Although the Yorkshire register was successfully linked
to outpatient HES data in addition to inpatient data, the former dataset could not be used
for identification of cardiovascular LEs due to the poor quality of this dataset. In addition,
further cardiovascular events could have been recorded within primary care records which
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were not available for the current study. Nonetheless, the results presented in this thesis
show a significant increased burden of cardiovascular disease amongst survivors of CYA
cancer compared to an age-sex matched general population in Yorkshire by considering
only part of the patient pathway post cancer diagnosis. The true burden of cardiovascular
disease amongst survivors could therefore be even greater.
One of the main strengths of this thesis is the use of multiple imputation techniques rather
than ignoring missing data or using CCA. However, ultimately, availability of accurate
and complete data is the gold standard, and imputation methods are only as good as
the partially observed data it is based on. Without comparison to the gold standard of
complete and accurate data, it is not possible to determine whether, even after imputation,
some bias has remained. Nevertheless, the use of multiple imputation has minimised the
level of bias compared to a method which simply ignores missing data, and has made
the best use of all the available recorded data. In addition, there are likely to be further
unknown or unmeasured confounders which were excluded from the analysis which may
result in further bias. However, a comprehensive set of possible confounders given the
available data were included in the analysis based on a systematic literature review in
addition to clinical input.
9.8 Future Research Recommendations
This study has shown that despite clear disadvantages of using inadequate missing data
techniques, the use of multiple imputation within cancer epidemiology remains rare.
Future studies should ensure the use of detailed multiple imputation techniques, as
described in this thesis, are applied as standard in order to minimise the effects of missing
data. More importantly, the recording of disease severity in both the medical records and
cancer registries needs to be improved.
Increased severity of disease at diagnosis results in poorer prognosis for patients, however,
the factors affecting disease severity at diagnosis remain unclear. This study has shown
that sociodemographic factors, including ethnicity and deprivation, which are thought to
affect disease severity at diagnosis through inequalities in access to healthcare for adults
with cancer, do not determine disease severity for CYAs with cancer. In order to improve
survival outcomes for all CYAs with cancer, further research into possible predictors of
late stage diagnoses is required for the CYA population.
The burden of cardiovascular disease amongst survivors of CYA cancer which warrant
submission to hospital has been quantified for the first time in the UK using data linkage
methods. The work by Woodward et al. [133], in addition to a paucity of data on LEs
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amongst survivors of TYA cancer, also identified a need to characterise survivors into
risk groups to ensure appropriate screening programs could be developed. Further work
should therefore focus on expanding the current study to a larger geographical area to
determine whether the risk of cardiovascular LEs differs between diagnostic subgroups.
However, despite additional study power offered by a national project, there may be a
compromise in the level of detailed case information when using data from the national
cancer registration service compared to the specialist register. Nonetheless, ongoing
changes to national cancer registration system may make this a viable option for future
research. In addition, cardiovascular LEs form only a small part of the overall burden
of disease in survivors of CYAs and the methods presented within this study should be
applied to quantify the burden of other long term effects amongst survivors of cancer
including secondary tumours and respiratory late effects. In addition, further linkages to
other electronic health records, such as primary care datasets should be sought to evaluate
the burden of late effects on survivors of CYA cancer which occur outside of inpatient
hospital admissions.
9.9 Future planned publications
In addition to the already published papers arising from this thesis (van Laar et al. [263]
and van Laar et al. [299]), the results from Chapter 7 will be submitted for a publication
entitled: ‘Poorer TYA survival for GCTs is not due to increased stage at diagnosis in a
population based sample’ to the British Journal of Cancer.
9.10 Conclusion
Ignoring missing data can have serious consequences on the conclusions drawn from
applied research. In spite of this, many researchers continue to ignore missing data.
This study has identified contrasting findings to earlier studies which reported inequalities
in survival, which due to the lack of adjustment for disease severity at diagnosis and
inappropriate methods of handling missing data, could be incorrect.
Survival rates continue to improve over time for CNS tumours and leukaemia, and the
number of advanced stage GCTs at diagnoses has decreased significantly between 1990
and 2009. However, those under the age of 1 year and diagnosed with leukaemia, TYAs
compared to children with CNS tumours, leukaemia and GCTs and those of non-white
and non-Asian ethnicity diagnosed with CNS tumours remain at a significant survival
disadvantage. Continued efforts should be made to ensure that TYAs have equal access to
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clinical trials and improved treatment protocols to drive further improvements for TYAs
diagnosed with cancer. In addition, the long term cardiovascular effects of cancer have
been shown, in the first population based study, to exist not only for children, but also
for TYAs surviving their cancer. Continued efforts must therefore be made to monitor
both children and TYAs for early signs of cardiovascular disease in order to maximise
cardiovascular health in this growing population of survivors.
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A International Classification of Childhood Cancer
Table 1: The International Classification of Childhood Cancer, Third Edition [7].
Diagnostic Group
ICD-O-3 code(s)1
Morphology Topography
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases
a. Lymphoid leukemias 9820, 9823, 9826, 9827,
9831-9837, 9940, 9948
b. Acute myeloid
leukemias
9840, 9861, 9866, 9867,
9870-9874, 9891, 9895-9897,
9910, 9920, 9931
c. Chronic
myeloproliferative diseases
9863, 9875, 9876, 9950,
9960-9964
d. Myelodysplastic
syndrome and other
myeloproliferative diseases
9945, 9946, 9975, 9980,
9982-9987, 9989
e. Unspecified and other
specified leukemias
9800, 9801, 9805, 9860, 9930
II. Lymphomas and reticuloendothelial neoplasms
a. Hodgkin lymphomas 9650-9655, 9659, 9661-9665,
9667
1International Classification of Diseases for Oncology, Third Edition [30]
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b. Non-Hodgkin
lymphomas (except Burkitt
lymphoma)
9591, 9670, 9671, 9673,
9675, 9678-9680, 9684,
9689-9691, 9695, 9698-
9702, 9705, 9708, 9709,
9714, 9716-9719, 9727-
9729, 9731-9734, 9760-9762,
9764-9769, 9970
c. Burkitt lymphoma 9687
d. Miscellaneous
lymphoreticular neoplasms
9740-9742, 9750, 9754-9758
e. Unspecified lymphomas 9590, 9596
III. CNS2 and miscellaneous intracranial and intraspinal neoplasms
a. Ependymomas and
choroid plexus tumor
9383, 9390-9394c
b. Astrocytomas 93803
9384, 9400-9411, 9420,
9421-9424, 9440-9442c
C72.3
c. Intracranial and
intraspinal embryonal tumors
9470-9474, 9480, 9508c
9501-9504c C70.0-C72.9
d. Other gliomas 9380c C70.0-C72.2, C72.4-C72.9,
C75.1-C75.3
9381, 9382, 9430, 9444,
9450, 9451, 9460c
e. Other specified
intracranial and intraspinal
neoplasms
8270-8281, 8300, 9350-
9352, 9360-9362, 9412,
9413, 9492, 9493, 9505-
9507, 9530-9539, 9582c
f. Unspecified intracranial
and intraspinal neoplasms
8000-8005c C70.0-C72.9, C75.1-C75.3
IV. Neuroblastoma and other peripheral nervous cell tumors
a. Neuroblastoma and
ganglioneuroblastoma
9490, 9500
b. Other peripheral
nervous cell tumors
8680-8683, 8690-8693, 8700,
9520-9523, 9501-9504
2Central Nervous System
3Tumors with non-malignant behaviour are included for all morphology codes on the line
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9501-9504 C00.0-C69.9, C73.9-C76.8,
C80.9
V. Retinblastoma 9510-9514
VI. Renal Tumours
a. Nephroblastoma and
other nonepithelial renal
tumors
8959, 8960, 8964-8967 C64.9
8963, 9364
b. Renal carcinomas 8010-8041, 8050-8075, 8082,
8120-8122, 8130-8141, 8143,
8155, 8190-8201, 8210,
8211, 8221-8231, 8240,
8241, 8244-8246, 8260-
8263, 8290, 8310, 8320,
8323, 8401, 8430, 8440,
8480-8490, 8504, 8510,
8550, 8560-8576, 8311,
8312, 8316-8319, 8361
C64.9
c. Unspecified malignant
renal tumors
8000-8005 C64.9
VII. Hepatic tumors
a. Hepatoblastoma 8970
b. Hepatic carcinomas 8010-8041, 8050-8075,
8082, 8120-8122, 8140,
8141, 8143, 8155, 8190-
8201, 8210, 8211, 8230,
8231, 8240, 8241, 8244-
8246, 8260-8264, 8310,
8320, 8323, 8401, 8430,
8440, 8480-8490, 8504,
8510, 8550, 8560-8576,
8160-8180
C22.0, C22.1
c. Unspecified malignant
hepatic tumors
8000 - 8005 C22.0, C22.1
VIII. Malignant Bone Tumours
a. Osteosarcoma 9180-9187, 9191-9195, 9200 C40.0-C41.9, C76.0-C76.8,
C80.9
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b. Chondrosarcoma 9210, 9220, 9240 C40.0-C41.9, C76.0-C76.8,
C80.9
9221, 9230, 9241-9243
c. Ewing tumor and
related sarcomas of bone
9260 C40.0-C41.9, C76.0-C76.8,
C80.9
9363-9365 C40.0-C41.9
d. Other specified
malignant bone tumors
8810, 8811, 8823, 8830,
8812, 9250, 9261, 9262,
9270-9275, 9280-9282,
9290, 9300-9302, 9310-
9312, 9320-9322, 9330,
9340-9342, 9370-9372
C40.0-C41.9
e. Unspecified malignant
bone tumors
8000-8005, 8800, 8801,
8803-8805
C40.0-C41.9
IX. Soft tissue and other extraosseous sarcomas
a. Rhabdomyosarcomas 8900-8905, 8910, 8912,
8920, 8991
b. Fibrosarcomas,
peripheral nerve sheath
tumors, and other fibrous
neoplasms
8810, 8811, 8813-8815,
8821, 8823, 8834-8835,
8820, 8822, 8824-8827,
9150, 9160, 9491, 9540-
9571, 9580
C00.0-C39.9, C44.0-C76.8,
C80.9
c. Kaposi sarcoma 9140
d. Other specified soft
tissue sarcomas
8587, 8710-8713, 8806,
8831-8833, 8836, 8840-
8842, 8850-8858, 8860-
8862, 8870, 8880, 8881,
8890, 9040-9044, 9120-
9125, 9130-9133, 9135,
9136, 9141, 9142, 9161,
9170-9175, 9231, 9251,
9252, 9373, 9581
8830 C00.0-C39.9, C44.0-C76.8,
C80.9
8963 C00.0-C39.9, C65.5-C69.9,
C73.9-C76.8, C80.9
9180, 9210, 9220, 9240 C49.0-C49.9
9260 C00.0-C39.9, C47.0-C75.9
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9364 C00.0-C39.9, C47.0-C75.9
C00.0-C39.9, C47.0-C63.9,
C65.9-C69.9, C73.9-C76.8,
C80.9
9365 C00.0-C39.9, C47.0-C63.9,
e. Unspecified soft tissue
sarcomas
8800-8805 C00.0-C39.9, C44.0-C76.8
X. Germ cell tumors, trophoblastic tumors, and neoplasms of gonads
a. Intracranial and
intraspinal germ cell tumors
9060-9065, 9070-9072,
9080-9085, 9100, 9101c
C70.0-C72.9, C75.1-C75.3
b. Malignant extracranial
and extragonadal germ cell
tumors
9060-9065, 9070-9072,
9080-9085, 9100-9105
C00.0-C55.9, C57.0-C61.9,
C63.0-C69.9, C73.9-C75.0,
C75.4-C76.8, C80.9
c. Malignant gonadal
germ cell tumors
9060-9065, 9070-9073,
9080-9085, 9090, 9091,
9100, 9101
C56.9, C62.0-C62.9
d. Gonadal carcinomas 8010-8041, 8050-8075,
8082, 8120-8122, 8130-
8141, 8143, 8190-8201,
8210, 8211, 8221-8241,
8244-8246, 8260-8263,
8290, 8310, 8313, 8320,
8323, 8380,8384, 8430,
8440, 8480-8490, 8504,
8510, 8550, 8560-8573,
9000, 9014, 9015,
C56.9, C62.0-C62.9
8441-8444, 8451, 8460-8473
e. Other and unspecified
malignant gonadal tumors
8590-8671 C56.9, C62.0-C62.9
8000-8005
XI. Other malignant epithelial neoplasms and malignant melanomas
a. Adrenocortical
carcinomas
8370-8375
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b. Thyroid carcinomas 8010-8041, 8050-8075, 8082,
8120-8122, 8130-8141, 8190,
8200, 8201, 8211, 8230,
8231, 8244-8246, 8260-8263,
8290, 8310, 8320, 8323,
8430, 8440, 8480, 8481,
8510, 8560-8573
C73.9
8330-8337, 8340-8347, 8350
c. Nasopharyngeal
carcinomas
8010-8041, 8050-8075, 8082,
8120-8122, 8130-8141, 8190,
8200, 8201, 8211, 8230,
8231, 8244-8246, 8260-8263,
8290, 8310, 8320, 8323,
8430, 8440, 8480, 8481,
8200-8576
C11.0-C11.9
d. Malignant melanomas 8720-8780, 8790
e. Skin carcinomas 8010-8041, 8050-8075,
8078, 8082, 8090-8110,
8140, 8143, 8147,8190,
8200, 8240, 8246, 8247,
8260, 8310, 8320, 8323,
8390-8420, 8430, 8480,
8542, 8560, 8570-8573,
8940, 8941
C44.0-C44.9
f. Other and unspecified
carcinomas
8010-8084, 8120-8157,
8190-8264, 8290, 8310,
8313-8315, 8320-8325,
8360, 8380-8384, 8430-
8440, 8452-8454, 8480-
8586, 8588-8589, 8940,
8940, 8941, 8983, 9000,
9010-9016, 9020, 9030
C00.0-C10.9, C12.9-C21.8,
C23.9-C29.9, C48.8, C50.0-
C55.9, C57.0-C61.9, C63.0-
C63.9, C65.9-C72.9, C75.0-
C76.8, C80.9
XII. Other and unspecified malignant neoplasms
a. Other specified
malignant tumors
8930-8936, 8950, 8951,
8971-8981, 9050-9055, 9110
9363 C00.0-C39.9, C47.0-C75.9
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b. Other unspecified
malignant tumors
8000-8005 C00.0-C21.8, C23.9-C39.9,
C42.0-C55.9, C57.0-C61.9,
C63.0-C63.9, C65.9-C69.9,
C73.9-C75.0, C75.4-C80.9
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B Classification Scheme for Cancers in 15-24 year olds
Table 2: Classification Scheme for Cancers in 15-24 year olds
GROUP 1 - Leukaemias
1.1. Acute lymphoid leukaemia (ALL)
1.2. Acute myeloid leukaemia (AML)
1.3. Chronic myeloid leukaemia (CML)
1.4. Other and unspecified leukaemia (Other Leuk)
1.4.1. Other and unspecified lymphoid leukaemias
1.4.2. Other and unspecified myeloid leukaemias
1.4.3. Other specified leukaemias, NEC
1.4.4. Unspecified leukaemia
GROUP 2 - Lymphomas
2.1. Non-Hodgkin lymphoma (NHL)
2.1.1. Non-Hodgkin lymphoma, specified subtype
2.1.2. Non-Hodgkin lymphoma, subtype not specified
2.2. Hodgkin lymphoma (HL)
2.2.1. Hodgkin lymphoma, specified subtype
2.2.2. Hodgkin lymphoma, subtype not specified
GROUP 3 - Central Nervous System & other Intracranial
& Intraspinal Neoplasms (CNS tumours)
3.1. Astrocytoma
3.1.1. Pilocytic astrocytoma
3.1.2. Other low grade astrocytoma
3.1.3. Glioblastoma and anaplastic astrocytoma
3.1.4. Astrocytoma not otherwise specified
3.2. Other gliomas
3.2.1. Oligodendroglioma
3.2.2. Other specified glioma
3.2.3 Glioma NOS
3.3. Ependymoma
3.4 Medulloblastoma and other primitive neuroectodermal tumours
3.4.1 Medulloblastoma
3.4.2 Supratentorial PNET
3.5. Other specified intracranial and intraspinal neoplasms (Other CNS)
3.5.1 Craniopharyngioma
3.5.2 Pituitary tumours
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3.5.3 Pineal tumours
3.5.4 Choroid plexus tumours
3.5.5 Meningioma
3.5.6 Nerves sheath tumour of the brain
3.5.7 Other specified tumours
3.6 Unspecified intracranial and intraspinal neoplasms tumours
3.6.1. Unspecified malignant intracranial and intraspinal neoplasms
3.6.2. Unspecified non-malignant intracranial and intraspinal neoplasms
GROUP 4 - Osseous and Chondromatous Neoplasms, Ewing tumour
and other Neoplasms of Bone (Bone Tumours)
4.1. Osteosarcoma
4.2. Chondrosarcoma
4.3. Ewing sarcoma
4.3.1. Ewing sarcoma of bone
4.3.2. Extraskeletal Ewing sarcoma
4.3.3. Ewing sarcoma of unknown site
4.4. Other specified and unspecified bone tumours (Other bone tumours)
4.4.1. Other specified bone tumours
4.4.2. Unspecified bone tumours
GROUP 5 - Soft Tissue Sarcomas (STS)
5.1. Fibromatous neoplasms (Fibrosarcoma)
5.1.1. Fibrosarcoma
5.1.2. Malignant fibrous histiocytoma
5.1.3. Dermatofibrosarcoma
5.2. Rhabdomyosarcoma
5.3. Other specified soft tissue sarcomas
5.3.1. Liposarcoma
5.3.2. Leiomyosarcoma
5.3.3. Synovial sarcoma
5.3.4. Clear cell sarcoma
5.3.5 Blood vessel tumours
5.3.6 Nerve sheath tumours
5.3.7 Alveolar soft part sarcoma
5.3.8 Miscellaneous specified soft tissue sarcoma
5.4 Unspecified soft tissue sarcomas
GROUP 6 - Germ Cell & Trophoblastic Neoplasms (Germ cell tumours)
6.1 Gonadal germ cell & trophoblastic neoplasms
6.2 Germ cell & trophoblastic neoplasms of non-gonadal sites
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6.2.1. Intracranial germ cell and trophoblastic tumours
6.2.2. Other non-gonadal germ cell and trophoblastic tumours
GROUP 7 - Melanoma and Skin Carcinoma
7.1. Melanoma
7.2. Skin carcinoma
GROUP 8 - Carcinomas (except of skin)
8.1. Carcinoma of thyroid
8.2. Other carcinoma of head and neck
8.2.1. Nasopharyngeal carcinoma
8.2.2. Carcinoma of other sites in lip oral cavity and pharynx
8.2.3. Carcinoma of nasal cavity, middle ear, sinuses, larynx and other ill-
defined sites in head and neck
8.3. Carcinoma of trachea, bronchus, lung and pleura
8.4. Carcinoma of breast
8.5. Carcinoma of genito-urinary (GU) tract
8.5.1. Carcinoma of kidney
8.5.2. Carcinoma of bladder
8.5.3. Carcinoma of ovary
8.5.4. Carcinoma of cervix
8.5.5. Carcinoma of other and ill-defined sites in GU
8.6. Carcinoma of gastro-intestinal (GI) tract
8.6.1. Carcinoma of colon and rectum
8.6.2. Carcinoma of stomach
8.6.3. Carcinoma of liver and intrahepatic bile ducts
8.6.4. Carcinoma of pancreas
8.6.5. Carcinoma of other and ill-defined sites in GI tract
8.7. Carcinomas of other & ill-defined sites not elsewhere classified (NEC)
8.7.1. Adrenocortical carcinoma
8.7.2. Other carcinomas NEC
GROUP 9 - Miscellaneous Specified Neoplasms NEC
9.1. Embryonal tumours NEC
9.1.1. Wilms tumour
9.1.2. Neuroblastoma
9.1.3. Other embryonal tumours NEC
9.2 Other rare miscellaneous specified neoplasms
9.2.1. Paraganglioma and glomus tumours
9.2.2. Other specified gonadal tumours NEC
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9.2.3. Myeloma, mast cell tumours and miscellaneous reticuloendothelial
neoplasms NEC
9.2.4. Other specified neoplasms NEC
GROUP 10 - Unspecified Malignant Neoplasms NEC
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C Literature Review on Survival of Cancer Amongst
Children and Young Adults in the UK
Table 3: Medline and Web of Science Search Strategy, 1980-2014, English Language
Articles only
Index Search Terms Results (N)
1 survival OR survival analys* OR survival rate* OR prognos* 1,446,307
2 child* OR pediatric* OR paediatric* OR teenage* or young
adult* OR adolescen* or TYA or AYA or CYA or CTYA
3,055,665
3 neoplasm* OR cancer* OR cancer regist* OR tumor* OR
tumour*
4,776,978
4 England OR English OR UK OR United Kingdom OR GB OR
Great Britain
46,125
5 1 and 2 and 3 and 4 1276
6 Title and Abstract Review 18
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D WHO Grading of Tumours of the Central Nervous
System
Figure D.1: WHO Grading of Tumours of the Central Nervous System. Reprinted from
Louis et al. [6]
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E The Expectation-Maximization (EM) Algorithm
within the Medical Literature
Table 4: Medline and Web of Science Search Strategy, 1925-present, English Language
Articles only
Index Search Terms Results (N)
1 EM Algorithm 953
2 Expectation-Maximization Algorithm 480
3 Expectation-Maximisation Algorithm 17
4 maximum likelihood estimation 1042
5 MLE 604
6 1 or 2 or 3 or 4 or 5 2894
7 missing data 3494
8 missing values 751
9 missing cases 61
10 incomplete data 938
11 incomplete cases 35
12 incomplete values 0
13 missing completely at random 90
14 MCAR 94
15 missing at random 238
16 MAR 2658
17 (missing not at random) 32201
18 MNAR 59
19 non response 1341
20 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
or 19
36451
21 6 and 20 179
22 Remove duplicates from 21 169
23 Remove non-relevant articles 98
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F Inverse Probability Weighting within the Medical
Literature
Table 5: Medline and Web of Science Search Strategy, 1946-present, English Language
Articles only
Index Searches Results
1 (inverse adj probability adj weighting) 76
2 (IPW not Prader–Willi) 39
3 (IPW not inferior-posterior) 36
4 (missing adj values) 749
5 (missing adj data) 3431
6 (missing adj cases) 65
7 (incomplete adj values) 0
8 (incomplete adj cases) 34
9 (incomplete adj data) 955
10 MCAR 84
11 (missing adj completely adj at adj random) 87
12 MAR 2684
13 (missing adj at adj random) 241
14 MNAR 57
15 (non adj response) 1347
16 1 or (2 and 3) 76
17 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 9036
18 16 and 17 8
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G Multiple Imputation and Cancer Survival within the
Medical Literature
Table 6: Medline and Web of Science Search Strategy, 1978-present, English Language
Articles only
Index Search Terms Results (N)
1 (multiple adj2 imputation) 588
2 (multiple adj2 imputa*) 618
3 exp Neoplasms/ 2097627
4 neoplasms 1767329
5 cancer 804104
6 (cancer adj regist*) 10073
7 Survival Analysis/ or Survival/ or Survival Rate/ 190152
8 Treatment Outcome/ 497985
9 (survival adj analysis) 91658
10 survival 635694
11 (survival adj rate) 140627
12 1 or 2 622
13 3 or 4 or 5 or 6 2384201
14 7 or 8 or 9 or 10 or 11 1051097
15 12 and 13 and 14 40
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H Kaplan-Meier curves for multiply imputed variables
in Stata
The following Stata code was used to create K-M plots for ethnic group by imputation
(Figure 6.8):
set more off
#delimit ;
sts graph if _mj!=0, by(eth_grp _mj) scheme(sol)
addplot(line survivor_eth _t if eth_grp==1, sort c(J) lcolor(black) ||
line survivor_eth _t if eth_grp==2, sort c(J) lcolor(red) ||
line survivor_eth _t if eth_grp==3, sort c(J) lcolor(blue)
legend(order(121 "White" 122 "Asian" 123 "Other"))) ;
#delimit cr
In the graph editor, select “record” and then manually change 1 line to a different colour.
Save the grec file. Locate the grec file and open it as a text file, then edit the file by adding
in line colour changes for all lines required. For a graph with 3 groups (i.e. ethnicity:
white, asian, other), imputed 40 times, you need to colour 3 times 40 lines as follows:
//plot1 color
plotregion1.plot1.style.editstyle line(color(gray)) editcopy
// plot2 color
plotregion1.plot2.style.editstyle line(color(gray)) editcopy
//repeat until plot number 40
// plot41 color
plotregion1.plot41.style.editstyle line(color(erose)) editcopy
// plot42 color
plotregion1.plot42.style.editstyle line(color(erose)) editcopy
//repeat until plot number 90
// plot81 color
plotregion1.plot81.style.editstyle line(color(eltblue)) editcopy
// plot82 color
plotregion1.plot82.style.editstyle line(color(eltblue)) editcopy
//repeat until plot number 120
Once the grec file has been amended with the above, save the edited text file with
extension .grec. Return to graph editor, with your original graph, and “play” the .grec
file to colour lines accordingly.
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I Staging of Childhood and Young Adult Cancer
Figure I.2 contains details of all prognostic staging mechanisms recommended for
implementation into the cancer registry database for the Yorkshire Specialist Register of
Cancer in Children and Young People based on a detailed description of missing staging
data given in Chapter 5.
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p
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